

**CIRCULATION, REASSORTMENT AND TRANSMISSION OF NGARI AND BUNYAMWERA
VIRUSES IN NORTHERN KENYA.**

by

Odhiambo Collins Otieno

Submitted in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy

In the Faculty of Health Sciences
Department of Medical Virology

University of Pretoria

Supervisors:

Prof. Marietjie Venter

Prof. Robert Swanepoel

Dr. Rosemary Sang

Ethics

THIS STUDY HAS BEEN APPROVED BY UNIVERSITY OF PRETORIA RESEARCH ETHICS COMMITTEE, PROTOCOL NUMBER **299/2013**.

Declaration

I declare that the thesis, which I hereby submit for the degree of Doctor of Philosophy (Medical Virology) at the University of Pretoria, is my own original work and has not been previously submitted by me for a degree at this or any other tertiary institution.

SIGNED:

DATE:

Acknowledgements

The completion of this study would not have been possible without the assistance of the following institutions and individuals. Your contribution is highly appreciated.

- My supervisors, Professor Marietjie Venter, Professor Robert Swanepoel and Dr Rosemary Sang for their extensive knowledge in Virology and sage advice that promoted an interactive learning environment and added value to this project.
- The financial assistance from the Swedish International Development Agency (SIDA) through the African Region Postgraduate Program in Insect Science program (ARPPIS) administered by the Capacity building department of the International Centre of Insect Physiology and Ecology (ICIPE).
- The logistic support of staff of ICIPE including Dr Baldwin Torto, Lilian Igweta, Margeret Ochanda, Lisa Omondi, Elias Aosa, Dolarosa Osogo, David Marangu, Gerald Rono, Martin Mbaya, Felix Odhiambo, Joash Lago, Jackson Kimani and Richard Ochieng.
- Fellow scholars who contributed to my knowledge and provided perspective whenever required including Dr David Tchouassi, Dr Olivia Lwande, Edith Chepkorir, Samuel Arum, Caroline Tigoi, Purity Ngina among others.
- Staff of the Kenya Medical Research Institute's (KEMRI) Viral Hemorrhagic Fever Laboratory for their support in training and guidance on various techniques necessary to run this study. These include Joel Lutomia, Victor Ofulla, Dr Limbaso Konongoi, Albina Makio, Sophia Mbaika, Samuel Owaka, Albert Nyunja, Caroline Ochieng, Gilbert Rotich, Reuben Lugalia and Caroline Wasonga. I would also like to thank Samuel Ogutu, the head of the KEMRI animal house for assistance in rearing experimental mice. Special thanks to Benedict Orindi of ICIPE and Felix Humwa of KEMRI for assistance in statistical analysis.
- Staff of the Zoonoses Research unit of the University of Pretoria including Stephanie VanNiekerk and Voula Stivaktas.
- My current employer, the KEMR/CDC HIV-Research Branch especially Dr Clement Zeh for

his mentorship, support and flexibility in giving me time off during my studies.

- Lastly, I would like to thank my loving family; Susan, Nicolette and Brett, for being patient and understanding during my long absence from home in pursuit of my dream. I also extend a hand to my mother, Betty Opar, for taking care of my family in my absence. And to my late father, Dr John Opar, for providing me a strong foundation, this PhD is dedicated to you.
- Finally, to God for protection during frequent travels and the potential dangers while carrying out these studies.

Table of Contents

Ethics.....	ii
Declaration	iii
Acknowledgements.....	iv
List of Figures	x
List of Tables	xiv
List of Abbreviations	xvi
Summary	xx
1. Chapter 1	1
LITERATURE OVERVIEW.....	1
1.1 INTRODUCTION.....	1
1.2 Arbovirus Classification.....	4
1.4 The family <i>Bunyaviridae</i>	6
1.4.1 Virion structure	7
1.4.4 <i>Orthobunyavirus</i>	15
1.4.5 Epidemiology of selected <i>Orthobunyavirus</i> serogroups.....	16
1.4.6 Clinical manifestations of Orthobunyaviruses.....	17
1.5 Evolutionary diversity	19
1.6 Phenotypic diversity.....	20
1.7 Vector competence	21
1.7.1 Transmission barriers.....	22
1.8 Vectors of Orthobunyavirus	24
1.9 Transovarial transmission.....	25
1.10 Seroprevalence of Orthobunyaviruses.....	26
1.11 Conclusion.....	29
1.12 Hypothesis	30
1.13 Objective	30
1.13.1. Specific objectives	30
PHYLOGENETIC ANALYSIS OF BUNYAMWERA AND NGARI VIRUSES (FAMILY BUNYAVIRIDAE; GENUS ORTHOBUNYAVIRUS) ISOLATED IN KENYA	32
2.1 INTRODUCTION.....	32
2.2 METHODS.....	33
2.2.1 Cells and viruses	33
2.2.2 Propagation of virus	34
2.2.3 RNA isolation and cDNA synthesis.....	35

2.3	RESULTS.....	39
2.4	DISCUSSION	53
Chapter 3.....		57
GENOME SEQUENCE ANALYSIS OF <i>IN VITRO</i> AND <i>IN VIVO</i> PHENOTYPES OF BUNYAMWERA AND NGARI VIRUS ISOLATES FROM NORTHERN KENYA.....		57
3.1	INTRODUCTION.....	57
3.2	METHODS.....	58
3.2.1	Ethics statement	58
3.2.2	Virus stock preparation	59
3.2.3	Plaque assay and purification.....	60
3.2.4	<i>Invitro</i> growth kinetics	61
3.2.5	Molecular characterization of plaque purified phenotypes	61
3.2.6	Clinical disease in mice.....	62
3.3	RESULTS.....	64
3.3.1	Isolation and Purification of Plaque phenotypes.....	64
3.3.2	<i>In vitro</i> growth curves	65
3.3.3	Genetic characterization of plaque phenotypes	71
3.3.4	Mice pathogenesis.....	76
3.4	Discussion	78
Chapter 4.....		82
VECTOR COMPETENCE OF SELECTED MOSQUITO SPECIES IN KENYA FOR NGARI AND BUNYAMWERA VIRUSES.....		82
4.1	INTRODUCTION.....	82
4.2	MATERIALS AND METHODS	84
4.2.1	Mosquitoes	84
4.2.2	Viruses	85
4.2.3	Vector competence.....	85
4.2.4	Oral transmission	87
4.3	RESULTS.....	89
4.3.1	Oral Transmission.....	91
4.4	DISCUSSION	92
Chapter 5.....		95
TRANSOVARIAL TRANSMISSION OF NGARI AND BUNYAMWERA VIRUS ISOLATES IN NORTHERN KENYA.....		95
5.1	INTRODUCTION.....	95

5.2	MATERIALS AND METHODS	96
5.2.1	Mosquitoes	96
5.2.2	Viruses	96
5.2.3	Transovarial transmission	97
5.3	RESULTS.....	99
5.4	DISCUSSION	100
Chapter 6		102
SEROPREVALENCE OF ORTHOBUNYAVIRUSES IN SELECT PARTS OF RIFT VALLEY AND NORTH EASTERN KENYA		102
6.1	INTRODUCTION.....	102
6.2	METHODS.....	103
6.2.1	Study site.....	103
6.2.2	Viruses	104
6.2.3	Study population	105
6.2.4	Ethical consideration.....	106
6.2.5	Neutralizing antibody prevalence	106
6.2.6	Statistical analysis	107
6.3	RESULTS.....	108
6.3.1	PRNT antibody seroprevalence and risk factors.....	108
6.3.3	Malaria diagnosis	115
6.4	DISCUSSION	115
Chapter 7		118
Concluding Remarks		118
Chapter 8		121
REFERENCES		121
Appendices		137
Appendix 1; Nucleotide and amino acid sequences determined in this study aligned against selected Bunyamwera and Ngari virus isolates from GenBank		137
Appendix 1A: Ngari virus S segment nucleotide sequence alignment.....		137
Appendix 1B: Bunyamwera virus S segment nucleotide sequence alignment.....		138
Appendix 1C: Ngari virus M segment nucleotide sequence alignment		140
Appendix 1D: Bunyamwera virus M segment nucleotide sequence alignment		147
Appendix 1E: Ngari virus L segment nucleotide sequence alignment.....		152
Appendix 1F: Bunyamwera virus L segment nucleotide sequence alignment.....		164
Appendix 1G: Ngari virus NSs protein amino acid sequence alignment		172

Appendix 1H: Ngari virus N protein amino acid sequence alignment	172
Appendix 1I: Ngari virus M protein amino acid sequence alignment.....	173
Appendix 1J: Ngari virus L protein amino acid sequence alignment.....	175
Appendix 1K: Bunyamwera virus NSs protein amino acid sequence alignment	180
Appendix 1L: Bunyamwera virus N protein amino acid sequence alignment	180
Appendix 1M: Bunyamwera virus M protein amino acid sequence alignment	181
Appendix 1N: Bunyamwera virus L protein amino acid sequence alignment	183
Appendix 2: Primers used in sequencing of Kenyan Bunyamwera and Ngari virus isolates	186
Appendix 3A	187
Informed Consent Agreement	188
Appendix 3B.....	192
Assent Form for Individuals above 5 through 17 Years of Age.....	192
Appendix 3C.....	196
Parent/Guardian Permission Form for Individuals above 5 through 17 Years of Age	196
Appendix 4	200
QUESTIONNAIRE ON HUMAN EXPOSURE TO CRIMEAN-CONGO HEMORRHAGIC FEVER	200
Appendix 5: Permission to uses figures	203

List of Figures

Figure 1: Arboviral transmission cycle (Ellis B.R and Wilcox B.A 2009)	3
Figure 2: Structure of Bunyavirus virion. The three RNA segments are individually encapsidated by the N protein and the RNA-dependent RNA polymerase associates with the RNA-N complex to form ribonucleoprotein. http://viralzone.expasy.org/viralzone/all_by_species/250.html	8
Figure 3: Coding strategies of <i>Bunyaviridae</i> S genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot, 2000)	9
Figure 4: Coding strategies of <i>Bunyaviridae</i> M genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot R.M et al. 2000)	10
Figure 5: Coding strategies of <i>Bunyaviridae</i> L genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot R.M et al. 2000)	11
Figure 6: Terminal consensus sequences of the S, M and L genome segments of each.....	13
Figure 7: Hypothesizes transmission barriers to arbovirus infection (Hardy J.L et al. 1983).	24
Figure 8: Geographic distribution of Orthobunyaviruses in Africa (Wertheim HFL et al. 2012).	28
Figure 9: Geographic regions of Bunyamwera and Ngari virus isolations in Kenya	35
Figure 10: Geographic regions of Bunyamwera and Ngari virus isolations in Africa	36

Figure 11: RT-PCR gel showing amplified S genome fragments of Bunyamwera and Ngari virus isolates in the current study.....	38
Figure 12: Bayesian analysis of the coding region of the S segment of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All <i>Orthobunyavirus</i> abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus	41
Figure 13: Bayesian analysis of the M polyprotein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All <i>Orthobunyavirus</i> abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus	43
Figure 14: Bayesian analysis of the L protein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All <i>Orthobunyavirus</i> abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus	45
Figure 15: Picture showing intraperitoneal inoculation of 1-4 day old suckling mice with experimental virus diluted in maintenance media.....	63
Figure 16: Photograph of crystal violet-stained virus infected Vero cell monolayer showing plaque phenotypes.	64
Figure 17: Growth kinetics of wild type parental and plaque purified phenotypes of Bunyamwera virus isolate GSA/S4/11232. There was a significant difference between the WT and the plaque	

phenotypes by day 3 post-inoculation.....	66
Figure 18: Growth kinetics of wild type parental and plaque purified phenotypes of Bunyamwera virus isolate MGD/S1/12060. There was a significant difference between the WT and the plaque phenotypes by day 3 post-inoculation.....	67
Figure 19: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate TND/S1/19801. There was no significant difference between the WT and plaque phenotypes at any time point.....	68
Figure 20: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate GSA/TS7/5170. There was no significant difference between the WT and plaque phenotypes at any time point.....	69
Figure 21: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate ISL/TS2/5242. There was no significant difference between the WT and plaque phenotypes at any time point.....	70
Figure 22: Alignment of 5' non-coding region of S, M and L genome segments of Kenyan Ngari virus isolates.....	73
Figure 23: Alignment of 5' non-coding region of S, M, and L genome segments of Kenyan Bunyamwera virus isolates.	74
Figure 24: Alignment of 3' non-coding region of S, M, and L genome segments of Kenyan Bunyamwera virus isolates.	75
Figure 25: Picture showing comparison between control mice (left) and virus inoculated mice (right). The virus infected mice is showing right hind limb paralysis.	76
Figure 26: Survival curve comparison of wild type parental and Plaque purified phenotypes of Bunyamwera and Ngari virus isolate infection in mice.	77
Figure 27: Survival curve comparison of wild type parental and Plaque purified phenotypes of Ngari virus isolate TND/S1/19801 infection in mice.	78
Figure 28: Mosquito feeding experimentation using Hematok membrane feeder.....	86

Figure 29: Picture showing ovicup with moist filter paper for mosquito oviposition.	87
Figure 30: Mosquito virus transmission experiment showing mosquito feeding on immobilized mice.	88
Figure 31: Photograph showing mosquito feeding on anesthetized mice to stimulate oviposition. .	98
Figure 32: Photograph showing filter papers with mosquito eggs placed in distilled water to allow for hatching.	98
Figure 33: Photograph showing mosquito rearing container and shelves for adult mosquito containment.....	99
Figure 34: A map showing study sites in Garissa and Nakuru Counties, Kenya.	105
Figure 35: Picture showing comparative Plaque Reduction Neutralizing Test performed on a 24-well plate	107
Figure 36: Bunyamwera virus seroprevalence by age groups in health facilities in Kotile, Sangailu and Naivasha health facilities 2009-2012.	110
Figure 37: Ngari virus seroprevalence by age groups in health facilities in Kotile, Sangailu and Naivasha health facilities 2009-2012.	111

List of Tables

Table 1: World Health Organization (WHO) list of Neglected Tropical Diseases	5
Table 2: Pattern of <i>Bunyaviridae</i> protein sizes (kDa) (Elliott R.M 2001).....	12
Table 3: Selected arboviruses belonging to the genus <i>Orthobunyavirus</i> of the family <i>Bunyaviridae</i> . host, vectors and distribution.	18
Table 4: Bunyamwera and Ngari virus isolates included in phylogenetic analysis of the full coding sequences of selected orthobunyaviruses.....	34
Table 5: Table Ss protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete S segment (Kenyan isolates in this study are bolded).	48
Table 6: N protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete S segment (Kenyan isolates in this study are bolded).	49
Table 7: M polyprotein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete M segment (Kenyan isolates in this study are bolded).	50
Table 8: L protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete L segment (Kenyan isolates in this study are bolded).	51
Table 9: Between group mean distance for selected virus isolates included in this study.	52
Table 10: Virus isolates obtained from diverse geographical regions and species in Kenya.	59
Table 11: Nucleotide differences between wild type parental and Plaque purified phenotypes of	

Bunyamwera and Ngari virus isolates.	71
Table 12: Infection and dissemination rates for mosquitoes orally exposed to Bunyamwera and Ngari viruses (infectious dose= 10^{10} PFU/ml).	90
Table 13: Transmission rates for mosquitoes with disseminated infection after oral exposure to Bunyamwera and Ngari virus isolates	92
Table 14: Comparison between ovarian cycle and vertical transmission rates of Bunyamwera virus isolate GSA/S4/11232 among <i>Aedes aegypti</i> and <i>Anopheles gambiae</i> colonies.	99
Table 15: Endpoint titers of serum samples collected from persons in North Eastern Kenya and analyzed using comparative PRNT	109
Table 16: Demographic characteristics of persons with positive PRNT for Bunyamwera and Ngari viruses in Kenya.....	112
Table 17: Bivariable analysis of risk factors associated with <i>Orthobunyavirus</i> infections in Kenya.	113
Table 18: Multivariable analysis of risk factors associated with <i>Orthobunyavirus</i> infections in Kenya	114
Table 19: Primers used in sequencing of Kenyan Bunyamwera and Ngari virus isolates.	186

List of Abbreviations

AA:	Amino acid
BATV:	Batai virus
BI:	Bayesian inference
BUNV:	Bunyamwera virus
CCHF:	Crimean Congo hemorrhagic fever
cDNA:	Complementary DNA
CPE:	Cytopathic effects
CVV:	Cache Valley virus
DUGV:	Dugbe virus
FBS:	Fetal bovine serum
HTNV:	Hantavirus
ILEV:	Ilesha virus
JEEV:	Japanese equine encephalitis virus
LACV:	Lacrosse virus
LP:	Large plaque
MEGA:	Molecular Evolutionary Genetics Analysis
NRIV:	Ngari virus
PCR:	Polymerase chain reaction
PFU:	Plaque forming units
PRNT:	Plaque reduction neutralization test
RVF:	Rift Valley fever
SP:	Small plaque
VEEV:	Venezuelan equine encephalitis virus
WHO:	World Health Organization
WNV:	West Nile virus

WT:	Wild type
YF:	Yellow fever

Abbreviations of amino acids

A:	Alanine
C:	Cysteine
D:	Aspartic acid
E:	Glutamic acid
F:	Phenylalanine
G:	Glycine
H:	Histidine
I:	Isoleucine
K:	Lysine
L:	Leucine
M:	Methionine
N:	Asparagine
P:	Proline
Q:	Glutamine
R:	Arginine
S:	Serine
T:	Threonine
V:	Valine
W:	Tryptophan
Y:	Tyrosine

Presentations and Publications Related to this Work

Presentations

Collins Odhiambo and Rosemary Sang. Phenotypic and Genotypic Diversity of Bunyamwera Virus. Second Medical Veterinary and Virus Symposium, 8-9 September 2012, Silver Springs Hotel, Nairobi, Kenya.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Circulation, evolution and transmission of ngari and bunyamwera orthobunyaviruses in Northern Kenya. The 62nd Annual Meeting of the American Society of Tropical Medicine and Hygiene, 13-17 November 2013, Marriot Hotel, Washington DC, USA.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Circulation, evolution and transmission of Ngari and Bunyamwera orthobunyaviruses in Northern Kenya. The 16th International Congress on Infectious Diseases, 2-5 April 2014, Cape Town, South Africa.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Seroprevalence of Ngari and Bunyamwera viruses in selected parts of Rift Valley and North Eastern Kenya. 3rd Medical Veterinary and Virus Symposium, 16-17 October 2014, Hilton Hotel, Nairobi, Kenya.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Seroprevalence of Ngari and Bunyamwera viruses in selected parts of Rift Valley and North Eastern Kenya. 5th International Meeting on Emerging Diseases and Surveillance, 31 October- 3 November 2014, Vienna, Austria.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Seroprevalence of Ngari and Bunyamwera viruses in selected parts of Rift Valley and North Eastern Kenya. The 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene, 2-6 November 2014, Marriot Hotel, New Orleans, USA.

Manuscripts

Collins Odhiambo, Marietjie Venter, Olivia Lwande, Robert Swanepoel, Rosemary Sang. Phylogenetic analysis of Bunyamwera and Ngari viruses (Family *Bunyaviridae*; Genus *Orthobunyavirus*) isolated in northern Kenya. Manuscript submitted to journal of Epidemiology and Infection. Assigned manuscript number HYG-OM-6173.

Collins Odhiambo, Marietjie Venter, Limbaso Konongoi, Robert Swanepoel, Rosemary Sang. Genome sequence analysis of *in vitro* and *in vivo* phenotypes of Bunyamwera and Ngari virus isolates from northern Kenya (2014). PLoS ONE 9(8): e105446.

Collins Odhiambo, Marietjie Venter, Edith Chepkorir, Sophia Mbaika, Joel Lutomiah, Robert Swanepoel, Rosemary Sang. Vector competence of selected mosquito species in Kenya for Ngari and Bunyamwera viruses (2014). Journal of Medical Entomology 51(6): 1248–1253.

Collins Odhiambo, Marietjie Venter, Robert Swanepoel, Rosemary Sang. Seroprevalence of Ngari and Bunyamwera viruses in select parts of Rift Valley and North Eastern Kenya. Manuscript submitted to journal of Vector-Borne and Zoonotic Diseases. Assigned manuscript number VBZ-2014-1760.R1

CIRCULATION, REASSORTMENT AND TRANSMISSION OF NGARI AND BUNYAMWERA VIRUSES IN NORTHERN KENYA.

By

Odhiambo Collins Otieno

Supervisors:

Prof. Marietjie Venter

Prof. Robert Swanepoel

Dr. Rosemary Sang

Department: Medical Virology

Degree: Doctor of Philosophy (Medical Virology)

Summary

Kenya has experienced severe arboviral outbreaks of public health concern in the recent past, including yellow fever (YF), Crimean Congo hemorrhagic fever (CCHF), chikungunya, and Rift Valley fever (RVF) among others. Most of these infections are under diagnosed and hence neglected due to non-specific nature of their symptoms. Often they are mistaken for endemic tropical diseases such as malaria and typhoid infections and are only recognized during major outbreaks which result in adverse public health and economic consequences to the affected communities. Ongoing inter-epidemic surveillance in RVF virus hotspots in Kenya has indicated continued intense transmission of Bunyamwera virus (BUNV) in the absence or under low level activity of RVF virus. BUNV belongs to the genus *Orthobunyavirus* of the family *Bunyaviridae*. These are segmented RNA viruses whose members have the potential for genetic reassortment and/or drift. Recently, Ngari virus (NRIV), a natural reassortant virus associated with hemorrhagic fever was documented to have emerged from BUNV, which previously was not associated with such symptoms. However, the vectors that are involved in the maintenance and transmission of BUNV and NRIV are diverse and their role in virus maintenance/dynamics is poorly known. It is thus important to investigate the dynamics of BUNV and NRIV in selected transmission foci in an

effort to understand their circulation better in order to be able to control and predict outbreaks.

In this study, we determined the evolutionary and phenotypic diversity of BUNV and NRIV isolates previously obtained from vectors in parts of Kenya. We have provided genetic sequences of two BUNV and three NRIV isolates which contribute to addressing paucity of genetic sequences associated with this group of viruses. Phylogenetic analysis of these sequences in addition to other sequences in GenBank revealed evidence of geographic/temporal clustering that requires further investigation. Next, we demonstrated that plaque purified phenotypes of selected BUNV and NRIV isolates differ in *in vivo* growth kinetics and pathogenicity in mice, possibly related to specific mutations within the genome. The phenotypic changes and identification of mutations possibly associated with these changes support further investigation of specific mutations using site directed mutagenesis. In addition, we determined the competence of some of the mosquito species implicated in their transmission, *Anopheles gambiae*, *Aedes aegypti* and *Culex quinquefasciatus* and evaluated the dynamics of their transmission in these vectors. We conclude that *Anopheles gambiae* is likely a more competent vector for NRIV than *Aedes aegypti* and is a moderately competent vector for BUNV, which has implications for animal movement in malaria endemic areas where the vector is present. We also report evidence of BUNV transovarial transmission in both *Aedes aegypti* and *Anopheles gambiae* with the prevalence of transmission related to the ovarian cycle. Finally, we determined the level of human exposure to these viruses in the transmission foci. Orthobunyavirus-specific antibodies were detected by plaque reduction neutralization test in 89 (25.8%) of 345 persons tested. Multivariable analysis revealed age and residence in North Eastern Kenya as risk factors. In conclusion, we propose that acute febrile disease surveillance needs to be implemented in North Eastern Kenya. This study helps identify the virus strains/populations and the vector species that play a critical role in sustenance and transmission of BUNV and NRIV in different ecosystems in the country. All these are important in understanding virus circulation, potential for emergence and risk to populations in areas of circulation, and will help in making decisions for intervention and management. Generated sequence data in this study contributes to global phylogenetic

characterization of Orthobunyaviruses worldwide and their molecular epidemiology. The study also shed light/improve our knowledge on the genetic stability or diversity and evolutionary trends of *Orthobunyavirus* strains in Kenya.

1. Chapter 1

LITERATURE OVERVIEW

1.1 INTRODUCTION

Arthropod-borne viruses (arboviruses), which are RNA viruses except African swine fever virus which is a DNA virus, constitute animal viruses transmitted to vertebrate hosts through blood-sucking arthropod vectors. According to the World Health Organization (WHO), an arbovirus is characterised by, replication in both arthropod and animal host, viral transmission to the vertebrate host by an arthropod vector and the vertebrate host demonstrating viremia and in addition, possible direct and/or transovarial transmission (Kuno and Chang 2005). Arboviruses remain a major public health and veterinary problem in Kenya and worldwide.

While most arboviruses primarily exploit birds and animals, with human infection as a result of a spill-over from zoonotic replication cycles, some like dengue virus, have evolved to exploit humans as primary reservoirs (Forshey et al. 2010). Humans are usually dead-end hosts because they are incapable of transmitting the virus and cannot function as reservoirs for mosquito re-infection (Weaver and Barrett 2004). Human infections may be asymptomatic or result in clinical disease which can range from mild to moderate febrile illness to severe hemorrhagic manifestations and neurological disease. Human exposure worldwide is likely to expand given the increase in activities that encroach on wild arboviral habitat (Forshey et al. 2010). The tropics provide an environment that can support arboviral emergence as significant human pathogens given that arthropods prefer hot and humid conditions and that virus transmission is also enhanced as a result of shortened incubation periods in vectors. Global warming has influenced the emergence and re-emergence of arboviral diseases by providing an enabling environment to mosquito species that were previously restricted to the tropics. Arboviruses exhibit considerable evolution potential with distinct geographical genotypes and enhanced transmissibility, and disease severity may be associated with a particular genotype. A single mutation on the chikungunya virus envelope protein gene resulted in efficient transmission by a less competent vector (*Aedes albopictus*), believed to have resulted

in severe chikungunya fever disease in Reunion island (Tsetsarkin et al. 2007).

1.1 Arboviral transmission cycle

Arboviruses survive in nature through transmission from infected arthropods to susceptible vertebrate host (Weaver and Barrett 2004). Arboviruses require a host in which they replicate, and a vector, such as a mosquito, for transmission to other organisms. Viruses replicate in the invertebrate host, accumulating in the salivary glands and are transmitted to the vertebrate host during blood feeding and are able to transmit the virus to another animal through saliva during a second round of blood feeding (Gray and Banerjee 1999). Three components are necessary for maintaining this transmission cycle: the virus, vertebrate host and invertebrate host (Pfeffer and Dobler 2010). All these three components must be available at the same time and place. Factors influencing transmission include competence of the vector, vertebrate host susceptibility and level of viremia in the infecting host. Changes in viral genetics, host or vector composition and/or dynamics can result in amplification of arboviral population to epidemic levels (Weaver and Reisen 2010). Arboviral outbreaks can be associated with relatively small viral genetic changes or introduction of new strains with increased virulence or amplification potential. These changes may also enhance vector competence and hence increase transmission potential. Environmental change may also affect vector abundance, survival and pathogen replication hence increasing vector contact rate and subsequently enhancing transmission.




Figure 1: Arboviral transmission cycle (Ellis and Wilcox 2009)

Birds followed by other wild and domestic vertebrates are the most common arbovirus hosts, while humans are usually dead-end hosts, incapable of transmitting the infection and cannot function as reservoirs for re-infection of the vector. However, infection can result in clinical disease. A majority of arboviruses are maintained in enzootic transmission cycles involving birds, rodents or non-human vertebrates as reservoir hosts (Soldan and Gonzalez-Scarano 2005). The enzootic transmission cycles can occur in sylvatic habitats, oscillating between wild animals and the vector e.g. Venezuelan equine encephalitis virus (VEEV) and yellow fever (YF) virus, while others like dengue virus, chikungunya virus and YF virus can cycle in urban or domestic habitats involving domestic animals and the vectors (Figure 1). Human infection and epidemics can result from direct spillover of these enzootic transmission cycles when amplification levels result in tangential transmission or due to human activity in sylvatic enzootic habitats (Gubler 1996, Weaver and Barrett 2004). This spillover transmission may involve the participation of enzootic and bridge vectors.

Mosquitoes are the main transmission vector although other biting arthropods, sand flies, midges

and ticks can also transmit viruses. The arthropod vectors develop a life-long infection and in some cases, infected females can transovarially transmit the virus to their progeny. Alternatively, transmission may result by contamination of the ovum through the micropyle apparatus. Even though transovarial transmission is inefficient, it provides a maintenance survival mechanism for the virus during unfavourable conditions for its vertebrate and vector host (Sang and Dunster 2001). However, transovarial transmission has been documented to be highly efficient for the California serogroup of viruses (Kuno and Chang 2005).

1.2 Arbovirus Classification

Arboviruses including those of medical relevance mainly belong to six families; Togoviridae, Flaviviridae, Rhabdoviridae, Orthomyxoviridae, Reoviridae and Bunyaviridae (van Regenmortel et al. 2000, Weaver and Reisen 2010) and are transmitted by arthropods, mainly mosquitoes and ticks. The most prominent examples of arboviruses that have emerged in recent times include dengue virus, WNV, Japanese equine encephalitis virus (JEEV), CCHF virus and chikungunya virus. Arboviruses are classified according to antigenic relationships, morphology, and replicative mechanisms (Alatoom and Payne 2009). The ability of arboviruses to cause epidemics and disease depends on a wide range of factors including viral genetics, vector competence and epidemiology (Weaver and Reisen 2010).

1.3 Arbovirus Disease Burden

Majority of arboviral infections remain undiagnosed due to symptom similarity with other tropical diseases, including malaria, typhoid and other bacterial infections like brucellosis and leptospirosis, the public health threat to the population is greatly underestimated (Sang and Dunster 2001). Currently, there are suggestions to include arboviral infections under the WHO neglected tropical diseases (Table 1). These are diseases that do not receive considerable attention in international public health programs despite their global burden being similar to HIV, malaria and tuberculosis infections (LaBeaud 2008). In 2010, the WHO included dengue fever under this category (WHO,

2010).

Table 1: World Health Organization (WHO) list of Neglected Tropical Diseases (WHO, 2010)

CAUSATIVE PATHOGENS	DISEASE
Virus	Dengue/Severe dengue
	Rabies
Protozoa	Chagas disease
	Human African trypanosomiasis (sleeping sickness)
	Leishmaniasis
Helminth	Cysticercosis/Taeniasis
	Dracunculiasis (guinea-worm disease)
	Echinococcosis
	Foodborne trematodiasis
	Lymphatic filariasis
	Onchocerciasis (river blindness)
	Schistosomiasis
	Soil-transmitted helminthiasis
Bacteria	Buruli ulcer
	Leprosy (Hansen disease)
	Trachoma
	Yaws

There has been resurgence in arboviral infections worldwide over the past two decades (Jones et al. 2008). The tropics have been affected most with multiple arboviruses causing epidemics frequently. This resurgence has been driven by a number of factors, including an explosion in population growth leading to unplanned urbanization which has resulted in poor conditions of living that

promote the expansion of mosquito densities. Compounding this problem is the lack of an effective mosquito control program as well as human agricultural practices that have provided suitable larval habitats. International travel and trade has also impacted on the spread of arboviruses and vectors to new habitats (Pfeffer and Dobler 2010). Despite these reports, the actual cumulative impact of arboviral infections on the global diseases burden has not been fully estimated (LaBeaud et al. 2011). Arboviral diseases are characterized by sequelae ranging from asymptomatic infections and undifferentiated fever to encephalitis and hemorrhagic manifestations that can result in significant morbidity and mortality. The East African region is a hotspot for arboviral diseases with epidemics occurring frequently and expected to increase with time. Kenya has had multiple arboviral disease outbreaks within the past two decades resulting in economic losses due to animal trade restrictions and public health distress. These include YF outbreak in 1992 and 1995 (Okello et al. 1993), chikungunya fever outbreak in 2004 (Sergon et al. 2008), and RVF outbreak in 1997 and 2006 (Woods et al. 2002, CDC 2007). The abundance of mosquitoes infected with arboviruses in Kenya has been reported with evidence of simultaneous arboviral circulations (Sang and Dunster 2001, Crabtree et al. 2009, LaBeaud et al. 2011). It is thus probable that cases of arboviral diseases could remain undetected given that during outbreaks suspected cases are attributed to the epidemic arbovirus. Entomological arbovirus surveillance during RVF outbreaks has demonstrated co-circulation of arboviruses including BUNV (Traore-lamizana et al. 2001, Crabtree et al. 2009). It is thus of paramount importance to understand the transmission dynamics of such arboviruses in order to estimate the true disease burden during such outbreaks, improve existing prevention mechanisms, management plans and prevent introduction to new habitats.

1.4 The family *Bunyaviridae*

The Bunyaviridae is the largest of the arbovirus families. It is a diverse group of RNA viruses comprising over 300 viral species including 97 species, 81 possible species, and a large number of isolates, encompassing 19 viruses in seven groups of related viruses and dozens of ungrouped viruses (Briese et al. 2013). The family is divided into five genera; *Orthobunyavirus*, *Nairovirus*,

Tospovirus, *Phlebovirus* and *Hantavirus* (Calisher 1996). The family was characterized in 1975 to classify viruses with diverse lifecycles yet similar morphology and structure (Schmaljohn 1996). Distinction between genera is based on antigenic, serological, molecular and structural differences between the viruses (Calisher 1996). Members of the *Bunyaviridae* family are found all over the world and some are significant animal pathogens while some like the genus *Tospovirus* infect plants (Elliott 2001). A majority are spread through sylvatic transmission cycles between susceptible vertebrate hosts and hematophagous arthropods such as mosquitoes, phlebotomine flies and ticks. The genus *Hantavirus* comprises viruses that do not infect insect vectors and are maintained (Soldan and Gonzalez-Scarano 2005) in nature through persistent, benign infection of their rodent hosts (Tsai, 1987). Others like RVF and CCHF can also be transmitted through a non-vectorial route such as through contact with infected animal tissue or body fluids (Al-Hazmi et al. 2003). The *Bunyaviridae* family is associated with significant human infections globally with diverse clinical manifestations such as severe pediatric encephalitis, associated with La Crosse virus (*Orthobunyavirus*), hemorrhagic, retinal, encephalitic and hepatic disease, associated with RVF virus (*Phlebovirus*) and hemorrhagic fever associated with CCHF virus (*Nairovirus*) (Lambert and Lanciotti 2009).

1.4.1 Virion structure

BUNV was the first virus in this family to be sequenced completely and has a total size of 12294 nucleotides, of which 95.3% encodes amino acids (Elliott 1989). The BUNV genome consists of three negative-sense RNA segments that involve a variety of coding strategies that lead to generation of a limited set of structural and non-structural proteins (Elliot et al. 2000, Schmaljohn and Hooper 2001) (Figure 2-5). The large (L) segment encodes a large protein that consists of the RNA-dependent RNA polymerase activity for replication and transcription of genomic RNA segments. The medium (M) segment encodes a precursor polypeptide which yields the viral surface glycoproteins Gn and Gc and a nonstructural protein NSm, and the S (small) segment encodes the nucleocapsid (NC) and a nonstructural protein NSs in overlapping reading frames (Nunes et al.

2005). The lengths of the S, M and L segments vary among genera, ranging from 0.8-2.9 kb for the S segment, 3.5-5 kb for the M segment and 6.3-13 kb for the L segment (Figure 3-5). The size and coding strategy of proteins encoded by viruses within a genus is similar while the terminal nucleotide sequences at the 3' and 5' ends of the three RNA segments are conserved within a genus but differ from those of other genera demonstrating a molecular basis for the extraordinary diversity of species within the family (Table 2).




Figure 2: Structure of Bunyavirus virion. The three RNA segments are individually encapsidated by the N protein and the RNA-dependent RNA polymerase associates with the RNA-N complex to form ribonucleoprotein. ViralZone, SIB Swiss Institute of Bioinformatics.

http://viralzone.expasy.org/viralzone/all_by_species/250.html




Figure 3: Coding strategies of *Bunyaviridae* S genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot et al. 2000)




Figure 4: Coding strategies of *Bunyaviridae* M genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot et al. 2000)




Figure 5: Coding strategies of *Bunyaviridae* L genome segment. Genomic RNAs are represented by purple boxes, black boxes indicate 3'/5' NCR, mRNAs are shown as green boxes, red boxes indicate host-derived primer sequence at 5' end, and arrowheads indicate truncated 3' end, and nt indicates nucleotides. Gene products, with their size in kilodaltons (kDa) are represented by light and dark blue boxes. (Elliot et al. 2000)

The size and coding strategy of proteins encoded by viruses within a genus is similar while the terminal nucleotide sequences at the 3' and 5' ends of the three RNA segments are conserved within a genus but differ from those of other genera demonstrating a molecular basis for the extraordinary diversity of species within the family (Table 2).

Table 2: Pattern of Bunyaviridae protein sizes (kDa) (Elliott 2001)

RNA	protein	Genus				
		Orthobunyavirus	Hantavirus	Nairovirus	Phlebovirus	Tospovirus
L segment	L	259-263	246-247	459	238-241	330-332
M segment	Gn	29-41	68-76	30-45	50-70	52-58
	Gc	108-120	52-58	72-84	55-75	72-78
	NSm	15-18	none	78-85, 92-115	None or 78	34
S segment	N	19-25	50-54	48-54	24-30	52
	Ns	10-13	none	none	29-31	29

In most of the orthobunyaviruses, the terminal 11 bases of the S, M and L segment are complementary except a mismatch at positions 9 and -9 which facilitate circularization within the ribonucleocapsid (Figure 6) (Elliott 1990).

<i>Orthobunyavirus</i>	3' UCAUCACAU--- 5' AGUAGUGUG---
<i>Hantavirus</i>	3' AUCAUCAUCUG--- 5' UAGUAGUAUGC---
<i>Nairovirus</i>	3' AGAGUUUCU--- 5' UCUCAAAGA---
<i>Phlebovirus</i>	3' UGUGUUUC--- 5' ACACAAAG---
<i>Tospovirus</i>	3' UCUCGUUA--- 5' AGAGCAAU---

Figure 6: Terminal consensus sequences of the S, M and L genome segments of each genus of the family *Bunyaviridae* (Elliott and Wilkie 1986).

1.4.2 Functionality of encoded proteins

1.4.2.1 S segment proteins

The N protein is the most abundant and the first to be expressed in virus-infected cells. The N protein has conserved regions that may be associated with complement fixation antibodies which may cross-react among viruses in the same genus (Calisher 1996). The N protein is used to encapsidate the genomic and antigenomic RNA to form ribonucleoproteins (Jin and Elliott 1991). On the other hand, the NSs protein may contribute to viral pathogenesis by acting as an interferon antagonist that blocks the transcriptional activation of interferons (Weber et al. 2002). The protein also inhibits host cell protein synthesis (Bridgen et al. 2001) and may delay early stage cell death by inhibiting IFN regulatory factor 3 mediated apoptosis (Kohl et al. 2003). Moreover, the NSs protein has been demonstrated to counteract RNA silencing directed against cellular and viral RNA (Soldan et al. 2005).

1.4.2.2 M segment proteins

The M polyprotein has not been detected in infected cells, suggesting that it is co-translationally cleaved to give the mature Gc, Gn and NSm proteins (Lappin et al. 1994). The gene order of the M segment is 5'-Gn-NSm-Gc-3' in the genome-complementary sense (Figure 4) (Fuller and Bishop 1982, Fazakerley et al. 1988, Nakitare and Elliott 1993). There are 2-3 potential glycosylation sites relatively rich in Cysteine and conserved N and C terminal hydrophobic domains that may act as neutralising and protective epitopes (Wang et al. 1993). Conserved regions in the Gn glycoprotein contain type-specific antigenic determinants for hemagglutinating and neutralizing antibodies and are used to classify the viruses into serogroups (Cheng et al. 2000). The Gn glycoprotein contains the Golgi targeting and/or retention signals which may be needed for the Gc-Gn interaction to localize to the Golgi compartment (Lappin et al. 1994, Bupp et al. 1996, Shi et al. 2004, Pollitt et al. 2006). It has also been demonstrated that the N terminal domain of NSm plays a role in virus growth (Pollitt et al. 2006). Additionally, the NSm contains some hydrophobic and non-hydrophobic domains that may be necessary for virus assembly (Shi et al. 2006). On the other hand, the Gc glycoprotein plays a role in fusion activity and may be a major determinant for viral attachment to mammalian cells (Pobjecky et al. 1986, Pekosz et al. 1995). The Gc glycoprotein has also been determined to play a significant role in virulence (Gonzalez-Scarano et al. 1985, Elliott 1990).

1.4.2.3 L segment protein

The L segment encodes the L protein (RNA-dependent RNA polymerase) in a negative-sense coding strategy (Figure 5). Only a small amount of the L protein is detectable in virus-infected cells. The mRNA synthesized from the L segment contains a 5' cap and host derived-primer sequence necessary for transcription, indicating that the L protein has endonuclease activity to mediate the 'cap-snatching' process (Jin and Elliott 1993). The L protein may also have a role in neurovirulence and neurovasiveness as demonstrated in mice infected with California serogroup viruses, but the mechanism has not been elucidated (Endres et al. 1991).

1.4.3 Virus evolution

Co-circulation of these viruses and segmented nature of their genomes provides opportunities for genetic reassortment and recombinations. While reassortment of orthobunyaviruses has been experimentally confirmed to occur between genetically related viruses, natural reassortments have been infrequently described. Segment reassortment of BUNV has recently been associated with human disease outbreaks especially within the East African region (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). NRIV, a natural reassortant virus, was associated with haemorrhagic fever outbreak in Kenya and Somalia. Through sequence analysis, it was determined that the S and L segments of this virus were closely related to BUNV, while the M segment was similar to that of the Batai virus (BATV), an *Orthobunyavirus* first isolated in Malaysia and previously not isolated in humans (Bowen et al. 2001, Briese et al. 2006). This suggests that BATV or a closely related virus is the donor of the NRIV M segment sequence and may have been co-circulating with BUNV.

1.4.4 *Orthobunyavirus*

The *Orthobunyavirus* is the largest genus of the *Bunyaviridae* family with over 172 individual viruses grouped into 18 serogroups (Calisher 1996, Gonz alez-Scarano et al. 1996). These include Anopheles A, Anopheles B, Bakau, Bunyamwera, Bwamba, Capim, California, Gamboa, Guama, Group C, Koongol, Minatitlan, Nyando, Olifanstlei, Patois, Simbu, Tete and Turlock (Calisher 1996). A majority of the viruses in this genus are transmitted by mosquitoes (Table 3). The majority of human pathogens within this genus are distributed among three serogroups; California serogroup, predominantly in North America and Europe, New World Group C viruses and the Bunyamwera serogroup, predominantly in Africa, Central and South America (Calisher and Karabatsos 1988, Elliot et al. 2000). BUNV is the type member of the *Orthobunyavirus* genus (Yanase et al. 2006). It was first isolated from *Aedes* mosquitoes in Uganda in 1943 (Smithburn et al. 1946) and subsequently from viremic humans in Africa (Karabatsos 1985).

1.4.5 Epidemiology of selected *Orthobunyavirus* serogroups

1.4.5.1 Bunyamwera serogroup

Aside from Lokern and Main Drain viruses that have been isolated from *Culicoides*, majority of viruses within this serogroup are transmitted by mosquitoes (Karabatsos 1985). Some viruses including BUNV, NRIV, Ilesha virus, Tensaw virus, Germiston virus, Guaroa virus, BATV, Shokwe virus, Wyeomyia virus and Xingu virus have been isolated from human and are associated with disease (Karabatsos 1985). Main Drain virus has been associated with encephalitis in horses. BUNV was the first isolate discovered in 1943 from *Aedes* mosquitoes in Uganda and has also been isolated from viremic humans in Africa (Smithburn et al. 1946, Karabatsos 1985). Antibodies to BUNV have been detected in humans, livestock, primates, birds and rodents (Gonzalez and Georges 1988).

1.4.5.2 California serogroup

California encephalitis virus is the prototype virus of this serogroup, and was first isolated in North America from mosquitoes in 1943 (Hammon et al. 1952). Members of the serogroup are widely distributed globally including Africa, Asia, North and South America and Europe (Calisher 1983). Members of the serogroup have also been isolated from rodents and other animals. Members include California encephalitis, James Canyon, La Crosse, Inkoo, Snowshoe, Tahyna and Trivittatus viruses and may be associated with encephalitis in humans.

1.4.5.3 Group C serogroup

Group C viruses have mainly been isolated from mosquitoes, rodents and marsupials in South and North America (Pinheiro 1981, Karabatsos 1985). Some of the viruses like Carapayu, Oriboca, Itaquí, Nepuyo, Apeu, Marituba, Ossa and Madrid virus are associated with human disease with symptoms including self-limited and dengue-like illness with fever, headache, myalgia, nausea, vomiting and weakness (Nunes et al. 2005).

1.4.5.4 Bwamba serogroup

Most members of this serogroup have been isolated from humans with febrile illness and are

geographically restricted to Africa (Karabatsos 1985). The prototype of this group, Bwamba virus was first isolated in 1937 from an infected human in Uganda. Antibodies to these viruses have been detected in humans, livestock animals, and avian sera in Africa (Bishop and Shope 1979). Bwamba serogroup viruses are serologically related to the California serogroup (Casals 1963).

1.4.5.5 Simbu serogroup

Members of this serogroup, vectored by culicoids and mosquitoes, are widely distributed globally with presence in Asia, Australia, Africa, North and South America (Karabatsos 1985). Isolates have been recovered from birds, cattle and pigs among other vertebrates. Some are human pathogens such as Oropouche and Shuni viruses while others like Akabane and Aino viruses are significant veterinary pathogens (Karabatsos 1985, Bishop 1996). Serological surveys have also revealed that these viruses may also infect monkeys, birds and rodents (Bishop 1996).

1.4.6 Clinical manifestations of Orthobunyaviruses

Clinical manifestations associated with *Orthobunyavirus* genus infections include a nondescript febrile illness with myalgia and arthralgia, and encephalitis. BUNV is associated with febrile illness with headache, arthralgia, rash and infrequent central nervous system involvement (Gonzalez and Georges 1988, Nichol et al. 2005). Oropouche virus (Bowen et al. 2001) causes Oropouche fever, an acute febrile dengue-like illness mainly in South America (Pinheiro et al. 1981). La Crosse virus has been implicated in pediatric encephalitis in the United States (Kappus et al. 1983, Alatoon and Payne 2009) while Cache Valley Virus (CVV) is responsible for a majority of meningitis cases in humans within the same region (Sexton et al. 1997, Campbell et al. 2006).

Table 3: Selected arboviruses belonging to the genus *Orthobunyavirus* of the family *Bunyaviridae*. host, vectors and distribution.

VIRUS SPECIES	DISEASE	PRINCIPAL VECTOR	GEOGRAPHIC DISTRIBUTION
Akabane	Cattle	Mosquito, midge	Africa, Asia, Australia
Bakau	Cattle	Mosquito	Asia
Batai	Human	Mosquito	Africa
Birao	Human	Mosquito	Africa
Bozo	Human	Mosquito	Africa
Bunyamwera	Human	Mosquito	Africa
Bwamba	Human	Mosquito	Africa
Cache Valley	Sheep, cattle	Mosquito	North America
Fort Sherman	Human	Mosquito	South America
Germiston	Human	Mosquito	Africa
Ilesha	Human	Mosquito	Africa
Iquitos	Human	Unknown	South America
La Crosse	Human	Mosquito	North America
Maguari	Human	Mosquito	South America
Mboke	Human	Mosquito	Africa
Ngari	Human	Mosquito	Africa
Nyando	Human	Mosquito	Africa
Oropouche	Human	Midge	South America
Pongola	Human	Mosquito	Africa
Schmallenberg	Cattle, Sheep, Goat	Mosquito, Midge, Tick	Europe
Shamonda	Human	Midge	Africa
Shokwe	Human	Mosquito	Africa
Simbu	Human	Mosquito, Midge	Africa
Tahyna	Human	Mosquito	Europe

Additionally, these viruses also affect livestock for example, Akabane virus and Aino virus are associated with abortions, congenital defects and stillbirths in cattle, sheep and goats, resulting in a devastating economic impact due to their wide distribution (Inaba et al. 1975). CVV is also associated with similar pathogenesis in sheep in the United States, Canada and Mexico (Edwards et

al. 1989). While viruses of the *Orthobunyavirus* genus are known to cause human disease, they were previously not associated with haemorrhagic fevers. However, BUNV reassortant has been implicated in recent outbreaks of haemorrhagic fevers in Kenya and Somalia (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). This is thought to have arisen through genetic reassortment between two segmented viruses co-circulating in the same environment demonstrating that genetic reassortment can profoundly increase viral pathogenicity (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006).

1.5 Evolutionary diversity

Arboviruses are principally transmitted horizontally between arthropod vectors and vertebrate reservoir/susceptible hosts. The majority of arboviruses are RNA viruses that lack polymerases with proofreading activity and thus exhibit error frequencies of 1 mutation in 10^3 – 10^5 nucleotides per round of replication (Drake and Holland 1999). Their high mutation frequencies, rapid replication, intense transmission and large population sizes allow these viruses to produce variants that can rapidly adapt to fluctuating environments (Ciota and Kramer 2010). Despite this potential for sequence change in RNA viruses, consensus sequences of most arboviruses have remained conserved. This has been attributed to the different selective pressures encountered in the different vertebrate and invertebrate hosts (Woolhouse et al. 2001). Thus, only those mutations that are beneficial to the virus or neutral in either host are maintained, consequently, arboviruses sacrifice the ability to be host specific (Kassen 2002). However, modest variation in terms of number of mutations is not always synonymous with phenotypic outcome of the change. A single mutation can have a major effect in viral replicative ability or infectivity in particular hosts (Ciota and Kramer 2010). The genotype associated with VEEV outbreaks has a single mutation in the E2 gene that increases vector competence or VEEV virulence (Anishchenko et al. 2006). Similarly, the recent chikungunya virus outbreak in the Indian Ocean islands were associated with emergence of a viral strain that shared a single common substitution in the E1 gene and a variable second mutation that resulted in increased competence of *Aedes albopictus* vector (Tsetsarkin et al. 2007, Tsetsarkin et

al. 2009). These examples indicate that even with slower than expected evolutionary rates, arboviruses still retain the capacity to produce variants that can be exploited in new settings.

Given that many of the viruses of the family *Bunyaviridae* use the same arthropod and vertebrate hosts and have segmented genomes, there is a greater possibility for the emergence of both reassortant and recombinant viruses that could result in altered pathogenesis or host range. A large hemorrhagic fever outbreak occurred in Kenya, Tanzania, and Somalia between 1997 and 1998 and was thought to be associated with RVF virus infections (Woods et al. 2002). However, a previously unidentified virus was subsequently isolated from two hemorrhagic fever cases. Moreover, acute infection with this unidentified virus was detected in a quarter of the hemorrhagic fever cases tested. Genetic analysis of the S, M and L segments of the genome revealed that the S and L segments were similar to those of BUNV, while the M segment sequence differed from that of other genetically characterized members of the *Orthobunyavirus* genus, suggesting that the virus was a case of genetic reassortment (Bowen et al. 2001). Known diseases caused by viruses of the *Orthobunyavirus* genus range from uncomplicated febrile illness to fatal encephalitis (Kokernot et al. 1957, Nichol 2001) hence the suggestion that the novel pathogenesis properties of the NRIV is due to the unique nature of the M genomic segment (Zeller et al. 1996).

Borucki et al. demonstrated experimentally that segment reassortment can occur in transovarially infected mosquitoes using LaCrosse virus and snowshoe hare virus both belonging to the California serogroup bunyaviruses (Borucki et al. 1999).

1.6 Phenotypic diversity

Plaque phenotypes of RNA viruses have been implicated in virulence (Davis et al. 2004). Small plaque variants of WNV have been characterized to exhibit attenuated properties both *in vivo* and *in vitro*. Small plaque variants of WNV were shown to exhibit low replication efficiency compared to the wild type (Jia et al. 2007). Small plaque variants of other arboviruses such as dengue are known to be temperature sensitive and attenuated in suckling mice (Eckels et al. 1976). Contrary, a small plaque variant of JEEV showed neurovirulence and neuroinvasiveness similar to the parent strain

(Wu et al. 1997). Small plaque variants of YF virus have been shown to be defective in cell penetration, cell to cell spread and reduced growth characteristics (Vlaycheva and Chambers 2002, Vlaycheva et al. 2004, 2005). This was attributed to an amino acid substitution at two positions in the envelope protein.

1.7 Vector competence

Vector competence is the ability or capacity of a vector to acquire, maintain, and transmit a virus to a vertebrate host after an appropriate extrinsic incubation period. Vector competency is determined by isolation of an arbovirus from a naturally infected vector, laboratory demonstration of vector infection following feeding on viremic blood, laboratory evidence of viral transmission during blood feeding and evidence of contact between vector and vertebrate host in nature. Vector competence refers to intrinsic factors such as internal physiological factors that control vector infection and ability to transmit virus as well as behavioral traits including host preference (DeFoliart et al. 1987). Vector competency is further affected by extrinsic factors like rainfall, vertebrate host population, humidity and temperature. Temperature and humidity affect vector development and longevity. In addition, these two factors influence the rate of virus multiplication in the vector and the time necessary for completion of viral incubation that ultimately results in the ability of the vector to transmit by bite. High virus doses have also been determined to increase vector competence by overcoming barriers to infection for different vector species and viruses (Chamberlain et al. 1959, Jupp et al. 1981, Kramer et al. 1981, Sardelis et al. 2001, Mahmood et al. 2006). Other factors include vector age and strain for example, young *Aedes aegypti* were found to have a higher survival probability compared to older mosquitoes hence more likely to complete the extrinsic incubation period necessary for virus transmission. Duration of the extrinsic incubation period is important in the epidemiology of arboviruses since it determines the length of time a vector must survive after infection for it to efficiently transmit the virus. Thus higher vector population densities or prolonged survival times may be required to maintain transmission cycles of vectors with long extrinsic incubation periods and vice versa (Hardy et al.

1983).

Species of mosquitoes from different geographic regions differ in biological trait and morphologic characteristics (Beams 1985, DeFoliart et al. 1987). *Culex pipiens* has been implicated in RVF outbreak in Egypt (Hoogstraal et al. 1979), *Aedes vexans* in west Africa (Zeller et al. 1997, Traore-lamizana et al. 2001) and Saudi Arabia (Jupp et al. 2002), *Aedes caspius* in Egypt as an enzootic vector (Gad et al. 1999). A competent arboviral vector must be susceptible to infection, abundant, long lived and able to blood feed on and become infected by both amplification and dead-end host. Short-lived mosquitoes rarely serve as competent vectors because they do not have sufficient time to complete the extrinsic incubation period. Laboratory assessment of vector competence can provide an insight on the potentiality of field collected mosquitoes as disease vectors. Such competency studies have been performed for RVF virus (Turell et al. 2007, Moutailler et al. 2008, Turell et al. 2008), WNV (Turell et al. 2001, Balenghien et al. 2008, Reisen et al. 2008, Doyle et al. 2011), California encephalitis virus (Kramer et al. 1992) and VEEV (Turell et al. 2006) among others. Laboratory experiments have shown that several mosquito species can be orally infected with viruses and can subsequently transmit the infection through blood feeding (Turell et al. 1996). These studies, some which use mosquito species not implicated in transmission cycles, have shown the potential for local transmission in the event that the virus is introduced into the environment (Turell and Kay 1998). Given that mosquito control methods differ for different species, it is of public health importance to identify which species of mosquitoes are competent vectors that may be involved in the natural transmission cycle so that appropriate control measures can be applied.

1.7.1 Transmission barriers

Previous studies have documented the existence of a midgut (mesenteron) infection barrier associated with refractoriness when some arboviruses are ingested by certain mosquito species (Chamberlain and Sudia 1961, Murphy 1975). More recent studies have shown the existence of other barriers to infection apart from the midgut barrier. Hardy et al proposed that a series of barriers prevent or reduce further dissemination of virus at various times between its appearance in

the lumen of the midgut and its eventual shedding into the salivary glands (Hardy et al. 1983) (Figure 7). The mosquito lumen is separated from the hemocoel by a single epithelial layer of cells surrounded by a porous multilayered membrane, the basal lamina. The first virus proliferation occurs in the epithelial cells if a sufficient viral dose is ingested. However, infection fails to establish or may be established only at very high viral dose if a mosquito is refractory to a given arbovirus. The second barrier is posed by the basal lamina and is termed the "mesenteron escape" barrier. A third barrier is the salivary gland infection barrier. Both were experimentally demonstrated with Western equine encephalitis virus in *Culex tarsalis* (Kramer et al. 1981). In 20--30% of infected *C. tarsalis*, the virus did not multiply to normal levels in the mesenteron and did not disseminate into the hemolymph regardless of the length of time. In another 20-45% of infected mosquitoes, the virus multiplied normally and disseminated into the hemolymph, but failed to infect the salivary glands. However, the salivary gland infection barrier in some of these mosquitoes was overcome after an extended incubation period showing that this barrier is both time and dose dependent. Individuals of some species are unable to transmit the virus during blood feeding even at optimal conditions for highly competent vector species (Chamberlain and Sudia 1961, Jupp et al. 1981). This might be related in part to the infecting dose of virus. Studies have shown that a reduction in the infective dose of virus reduces arboviral transmission (Jupp 1974, Watt et al. 1976).




Figure 7: Hypothesizes transmission barriers (bold) to arbovirus infection (Adapted from Hardy et al. 1983).

1.8 Vectors of Orthobunyavirus

BUNV was first isolated from *Aedes* mosquitoes in the Semliki forest in Uganda (Smithburn et al. 1946). However, it was not possible to identify the particular *Aedes* species from which the isolation was made. A second strain of the virus was isolated in 1955 from *Aedes circumluteolus* in

Tongaland, South Africa (Kokernot et al. 1957). Arthropod vectors of medical importance flourish in many parts of Kenya (Linthicum et al. 1985, Sang and Dunster 2001) hence the need for continuous surveillance. Entomological surveys during RVF outbreaks in the recent past have demonstrated co-circulation of arboviruses including BUNV (Traore-lamizana et al. 2001, Crabtree et al. 2009). Ongoing inter-epidemic surveillance has indicated continued intense transmission of BUNV in the absence of or under low level activity of RVF virus. Knowledge on the vectors involved in their transmission is scanty or absent. The surveillance activities incriminated a range of mosquito species associated with BUNV through isolation from field sampled mosquitoes including *Aedes argenteocephalus*, *Aedes dalzieli*, *Aedes vittatus*, *Aedes furcifer-taylori* and *Mansonia africana* and *Mansonia uniformis* as new vectors for this virus in Senegal (Traore-lamizana et al. 2001). In Kenya, BUNV has been isolated from *Aedes ochraceus*, *Aedes mcintoshi* and *Anopheles funestus* mosquitoes while a related virus, Pongola virus, was isolated from *Aedes mcintoshi* and *Aedes circumluteolus* (Traore-lamizana et al. 2001, Crabtree et al. 2009, Ochieng et al. 2013). The virus has also been isolated from *Aedes quasiunivittatus* (Logan et al. 1991). Pongola virus was first isolated in South Africa in 1957 from *Aedes circumluteolus* (Kokernot et al. 1957). NRIV has been detected previously in West Africa from a wide diversity of mosquito species including *Anopheles gambiae*, *Anopheles pharoensis*, *Culex antennatus*, *Culex poicillipes* and *Culex tritaeniorhynchus* (Gordon et al. 1992, Zeller et al. 1996). Some of these mosquito species are predominant in different regions of Kenya including *Anopheles gambiae*, *Anopheles pharoensis* and *Culex antennatus* (Lutomiah et al. 2013). However, the actual role of the associated mosquito species in the maintenance and transmission of the virus in the environment remains unclear. Surveillance for the vector-borne pathogen and identification of the arthropod vectors that transmit these agents are critical components in estimating the risk of human exposure and understanding the transmission and maintenance mechanism.

1.9 Transovarial transmission

The frequency of transovarial transmission is generally low for most arboviruses (<1%), while

unusually high for some bunyaviruses belonging to the California serogroup (Kuno and Chang 2005). Watts et al. demonstrated transovarial transmission of Lacrosse virus (LACV) experimentally using *Aedes triseriatus* and concluded that this was a mechanism of overwintering (Watts et al. 1973, Watts et al. 1974). This finding in addition to demonstrations in other members of the California serogroup suggests an important mechanism in the maintenance of these arboviruses. Transovarial transmission has also been demonstrated in several tropical bunyaviruses of other serogroups and genera. RVF virus has been isolated from field collected larvae of *Aedes lineatopennis* in Kenya (Linthicum et al. 1985). This mechanism is credited for the long-term survival of RVF virus in the absence of suitable vertebrate hosts, high densities of competent mosquito species and suitable environmental conditions (Moutailler et al. 2008).

1.10 Seroprevalence of Orthobunyaviruses

Diagnostic laboratories rarely test for infections caused by Orthobunyaviruses hence the true prevalence of these viruses remain undetermined (Blitvich et al. 2012). Currently, there is no data on the seroprevalence of Orthobunyaviruses in Kenya. Bunyamwera serogroup viruses associated with human disease have been isolated in Africa and include BUNV, NRIV, Shokwe virus, Ilesha virus and Germiston virus and have overlapping geographic distribution across Africa as shown in Figure 8. Virus transmission usually peak during the rainy season when mosquitoes are abundant and persons of all age groups can be affected. BUNV has been observed to be active in the riverine forests of Nigeria and the Central African Republic (Gonzalez and Georges 1988). For example, all adults living in tropical rain forests of the Democratic Republic of Congo are seropositive for BUNV. Ilesha virus on the other hand, has a higher seropositivity rate in persons living in the Savvanah compared to persons living in the rain forests (Gonzalez and Georges 1988). Germiston virus is endemic in Southern African countries and to date has not been associated with any major outbreak of human disease and is thus considered of minor public health importance (Gonzalez and Georges 1988). All these viruses have also been isolated in Kenya (Johnson et al. 1977, Lwande et al. 2013, Ochieng et al. 2013). Since these viruses comprise a neglected but potentially deadly

group of viruses as evidenced by the implication of NRIV in hemorrhagic fever outbreaks within northern Kenya (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006), there is need to investigate whether these viruses commonly infect humans within this region. BUNV serosurveys suggest wide distribution within sub-Saharan Africa (Gerrard et al. 2004). A previous study on hemorrhagic fever patients during the 1997/1998 RVF outbreak demonstrated NRIV acute infection in 27% of cases (Bowen et al. 2001).




Figure 8: Geographic distribution of Orthobunyaviruses in Africa (Wertheim et al. 2012). Dots represent countries where viruses have been isolated.

1.11 Conclusion

The evolutionary success of some viruses, especially in the *Bunyaviridae* family, is thought to be facilitated by their ability to adapt to varying conditions via genetic drift involving intramolecular genetic changes, and shifts which involve genomic segment reassortment. Genetic drift occurs due to the poor fidelity of the RNA polymerase and lack of proofreading capability resulting in multiple genetic variants or quasispecies. NRIV is a newly emergent reassortant virus thought to be associated with severe disease epidemics within Africa (Gerrard et al. 2004, Briese et al. 2006). Genetic analysis reveals that its S and L RNA segments are derived from BUNV while the M segment is derived from BATV, an *Orthobunyavirus* first isolated in Malaysia. Although genetic drift and reassortment seem to occur in the *Bunyaviridae* family, the epidemiological consequences of these evolutionary events are poorly understood. Because no specific medical treatment exists for arboviral diseases, it is important to continually carry out surveillance in order to understand their transmission trends and dynamics in real time. Genetic reassortments/recombinations are bound to compromise surveillance when new variants and/or genotypes emerge, evading existing diagnostic/detection and management tools. Additionally, entomological arbovirus surveillance during RVF outbreaks has demonstrated co-circulation of RVF virus and other arboviruses including BUNV. In addition, ongoing inter-epidemic surveillance has indicated continued intense transmission of BUNV in the absence of or under low level activity of RVF virus. However, knowledge on the vector competence of mosquito species involved in virus transmission is scanty or absent. The surveillance activities incriminated a range of mosquito species that are associated with BUNV and NRIV through isolation from field sampled mosquitoes but the actual role of the associated mosquito species in the maintenance and transmission of the virus in the environment remains unclear. Efforts to bring these infections under control would not be successful unless we have a full understanding of how these viruses are being maintained and moved in the environment. Moreover, it is necessary to determine whether these viruses represent an unrecognized cause of disease in humans.

The present study was undertaken to extend the currently available full sequencing data on the S, M and L RNA segments of BUNV and NRIV. Generating sequencing data on the three segments of these two viruses from disparate historic, host and geographic origins will further contribute to phylogenetic characterization and molecular epidemiology of these viruses, including tracking their movement, identification of the sources of outbreaks, and aid investigations of reassortment events. We also characterize and monitor emergent arboviral genotypes of BUNV and NRIV from previous surveillance exercises in Kenya, determine their seroprevalence among patients presenting with febrile illness within selected regions of Kenya and determine the vector competence of selected mosquito species that may mediate transmission in order to design effective detection and control measures.

1.12 Hypothesis

1. Bunyamwera and Ngari viruses are genetically stable in spite of isolation from different mosquito host, time or space, implicated mosquito species are not efficient vectors of these viruses and human exposure to the two viruses is minimal among febrile patients in the northern Kenya region.

1.13 Objective

To understand the dynamics of Ngari and Bunyamwera virus circulation and transmission in northern Kenya.

1.13.1. Specific objectives

1. To investigate the genotypic diversity and reassortments of Bunyamwera and Ngari virus isolates in the northern Kenya ecozone with respect to vector, time and space.
2. To evaluate the growth characteristics and virulence of Bunyamwera and Ngari virus isolates obtained from diverse geographic region, time and vector species in Kenya.

3. To determine the infection, dissemination and transmission rates of *Aedes*, *Culex* and *Anopheles* mosquito species exposed to Bunyamwera and Ngari virus infected-blood meal and identify transmission barriers.
4. To determine transovarial transmission of Bunyamwera and Ngari viruses in selected mosquito vectors as a mechanism of virus maintenance in nature
5. To determine the seroprevalence of Bunyamwera and Ngari viruses in febrile patients in northern Kenya from 2009 to 2012.

Chapter 2

PHYLOGENETIC ANALYSIS OF BUNYAMWERA AND NGARI VIRUSES (FAMILY BUNYAVIRIDAE; GENUS ORTHOBUNYAVIRUS) ISOLATED IN KENYA

2.1 INTRODUCTION

The Bunyaviridae family is divided into five genera; *Orthobunyavirus*, *Phlebovirus*, *Nairovirus*, *Hantavirus* and *Tospovirus* (Calisher 1996). The genus *Orthobunyavirus* is composed of over 172 viruses that infect humans and are transmitted by mosquitoes, midges and ticks from reservoir animals like rodents and livestock. Members of the *Orthobunyavirus* genus are tri-segmented, negative-sense, single-stranded RNA viruses responsible for mild to severe human and animal diseases. The L segment encodes a large protein that consists of the RNA-dependent RNA polymerase activity for replication and transcription of genomic RNA segments. The M segment encodes a precursor polypeptide which yields the virion surface glycoproteins Gn and Gc and a nonstructural protein NSm, and the S segment encodes the nucleocapsid (NC) and a nonstructural protein (NSs) in overlapping reading frames (Soldan and Gonzalez-Scarano 2005). BUNV is the prototype virus of the *Orthobunyavirus* genus as well as the *Bunyaviridae* family of arboviruses. BUNV is associated with febrile illness with headache, arthralgia, rash and infrequent central nervous system involvement (Gonzalez and Georges 1988). Viruses of the *Orthobunyavirus* genus were previously not associated with haemorrhagic symptoms until NRIV was implicated in haemorrhagic fever outbreaks in Kenya and Somalia, and retrospectively in Sudan (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). NRIV was determined to be a reassortment between two segmented viruses (BUNV and BATV) co-circulating within the same environment. Subsequent analysis of isolate sequences from outbreak samples showed that the L and S segment sequences closely matched those of BUNV while the M segment was identical to that of BATV (Briese et al. 2006).

Surveillance activities during RVF outbreaks have demonstrated co-circulation of arboviruses including BUNV (Crabtree et al. 2009). Additionally, ongoing inter-epidemic surveillance activities

have indicated continued intense transmission of BUNV (Lutomiah et al. 2014). During a RVF outbreak in Kenya and Somalia in 1997/1998, NRIV was isolated from the blood of two patients and antibody detected in several others with hemorrhagic fever (Briese et al. 2006). Retrospectively, two isolations were made from the blood of two patients during an earlier outbreak in the Sudan with IgM and IgG detected in 7% and 61% of patients (Nashed et al. 1993).

Co-circulation of viruses within the same serogroup is likely to provide opportunities for genetic reassortments. Efforts to bring these infections under control and predict their emergence would not be successful unless we have a full understanding of how these viruses are being maintained and moved in the environment. However, characterization of these emergent arboviral species has been hampered by paucity of full genome sequences in the Genbank that in turn make it impossible to accurately estimate their evolutionary trend and public health burden. Moreover, an in depth study of the transmission and evolutionary history of BUNV and NRIV in Kenya has not been reported. We have recently isolated BUNV and NRIV from surveillance exercises in Kenya based on short diagnostic sequences (Ochieng et al. 2013, Lutomiah et al. 2014). Our main objective was to provide complete coding sequence of some of these isolates as well as, in addition to sequences already deposited in the GenBank, investigate their genetic diversity with respect to time, geographic location and vector species of isolation.

2.2 METHODS

2.2.1 Cells and viruses

Vero cells (African green monkey kidney) (ATCC® CCL-81™) were used for growing virus stocks for quantification by plaque assay. The cells were maintained in Eagles Minimum Essential Media (Sigma) supplemented with 10% fetal bovine serum (Sigma) and 2 mM L-glutamine (Invitrogen). BUNV and NRIV isolates were obtained from previous surveillance exercises in Kenya. The virus isolates used in this study are listed in Table 4 along with their geographical origin (Figure 9 and 10), host source and year of isolation.

Table 4: Bunyamwera and Ngari virus isolates included in phylogenetic analysis of the full coding sequences of selected orthobunyaviruses.

Virus	Specimen code	Site of isolation	Collection date	Isolation source
Bunyamwera	BUNV_GSA/S4/11232	Kenya (Garissa)	2009	<i>Aedes Mcintoshi</i>
	BUNV_MGD/S1/12060	Kenya (Magadi)	2010	<i>Anopheles Funestus</i>
	BUNV prototype	Uganda	1943	<i>Aedes</i>
	BUNV_ArB29051	Central African Republic	1994	<i>Mansoni uniformis</i>
	BUNV_(AF325122)	Australia	2000	
	BUNV_ArB28215	Central African Republic	1992	<i>Anopheles sp</i>
	BUNV_(JF961341)	Kenya (Garissa)	2011	<i>Aedes Mcintoshi</i>
	BUNV_PE-7.0014	Peru	1997	<i>Mosquito</i>
Ngari	NRIV_TND/S1/19801	Kenya (Tana-delta)	2011	<i>Anopheles Funestus</i>
	NRIV_GSA/TS7/5170	Kenya (Garissa)	2009	<i>Amblyomma gemma</i>
	NRIV_ISL/TS2/5242	Kenya (Isiolo)	2009	<i>Rhipicephalus pulchellus</i>
	NRIV_DakArD28542	Senegal (Dakar)	1979	<i>Aedes simsoni</i>
	NRIV_9800535	Kenya	1998	<i>Homo sapiens</i>
	NRIV_9800521	Somalia	1998	<i>Homo sapiens</i>
	NRIV_SUD-HKV141	Sudan	1988	<i>Homo sapiens</i>
	NRIV_SUD-HKV66	Sudan	1988	<i>Homo sapiens</i>
	NRIV_Adrar	Mauritania	2010	<i>Small ruminant</i>

* Isolates sequenced in this study are bolded

2.2.2 Propagation of virus

Freshly confluent Vero cells (ATCC® CCL-81™) grown in 75 cm² flasks were infected with 1 ml of each isolate to make virus stock for the study. The cultures were observed daily for cytopathic effects (CPE) and harvested when more than 75% cells showed CPE. The virus was harvested by freezing and thawing of the cultures followed by centrifugation at 880 *g* for 10 min at 4°C to remove the cell debris/lysate. The supernatant was aliquoted into 500µl each into cryotubes and stored at -70°C, until use. Final virus isolates sequenced were low passage (Vero 3).




Figure 9: Geographic regions of Bunyamwera and Ngari virus isolations in Kenya

2.2.3 RNA isolation and cDNA synthesis

For RNA extraction, we used the MagNA Pure LC RNA Isolation Kit I (Roche Applied Science, Indianapolis, IN). Complementary DNA (cDNA) was synthesised using Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN) with 2 µl Random hexamers followed by PCR using Phusion High-Fidelity PCR Kit (Finnzyme OY, Espoo, Finland) and appropriate primers. Primers (Appendix 2, Table 19) for each segment were either designed based on sequences of BUNV, BATV and NRIV available in GenBank or obtained from previous publications (Yanase et al. 2006, Jost et al. 2011).




Figure 10: Geographic regions of Bunyamwera and Ngari virus isolations in Africa

Reactions were performed in thin-walled 0.5 ml tubes (Thermo Scientific™) using a Bio-Rad thermal cycler with heated lid. The total volume per reaction mixture was 20µl.

Phusion PCR reaction:

5× PCR reaction buffer.....4µl

dNTPs (10 mM each).....0.4µl
 Template DNA 2µl
 Primer F (10µM).....1µl
 Primer R (10µM).....1µl
 DMSO (Fisher Scientific).....0.6µl
 Polymerase (1U/ µl).....0.2µl
 dH₂O..... 10.8µl

PCR programme:

Initial denaturing.....98°C.....30s	} 40-45 cycles
Strand separation.....98°C.....10 s	
Annealing.....57-65°C.....15s	
Elongation..... 72°C.....45s	
Final extension.....68°C.....7 mins	

PCR products were mixed with 6X loading buffer (0.4% orange G, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll® 400, 10mM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8.0) (Promega)) and loaded in the wells of the agarose gel. An electric current was applied to the gel (70-130 volts) for approximately 45 minutes in order to separate different fragments of nucleic acids. As a size marker, two different DNA ladders were used; 1 Kb and 100 bp ladders (Promega). Amplified DNA fragments were visualized by electrophoresis on a 1.5% agarose gel (Figure 9). The Amplified DNA was purified and prepared for sequencing using ExoSAP-IT PCR clean-up kit (USB Corp, Cleveland, OH) according to the manufacturer's instructions and stored at -20°C.




Figure 11: RT-PCR gel showing amplified S genome fragments of Bunyamwera and Ngari virus isolates in the current study. wt; wild type, sp: small plaque, lp: large plaque, +: Bunyamwera virus control, -: no template added.

2.2.4 Sequencing and phylogenetic analysis

Sequencing was performed using different sets of primers for S, M and L segments as defined above using Big Dye V3.1 kit (Applied biosystems) according to manufacturer's instructions and run on the 3500XL genetic analyser (Applied Biosystems, Foster city, California, USA). Purification of sequencing products before injection was done with the Zymo research sequencing clean-up kit. The sequences obtained were cleaned and edited using Bioedit software, USA for both the reads from the forward and reverse primers. Sequences obtained were subjected to BLAST searches in NCBI GenBank (<http://www.ncbi.nlm.nih.gov/blast/Blast>) to identify similar sequences. The clean sequences of each segment were aligned against a selection of corresponding segment sequences of Bunyamwera serogroup virus including BUNV, BATV and NRIV using MAFFT sequence alignment program (Standley 2013). MrModeltest version 2.3 (Nylander 2004) in cooperation with PAUP*4b10 (Swofford 2002) using the Akaike information criterion (AIC) (Akaike 1973) was used to predict the best parameters in reconstructing Bayesian trees. The MrModeltest predicted that the general time reversible (GTR) evolutionary model would be the best for the set of sequences for the three segments (L, M, S) in the Bayesian phylogenies' analyzing the relationships among all BUNV and NRIV isolates whose sequence was determined. However, only data for S segment were subject to a gamma distribution with a proportion of invariable sites. The

MrBayes software package 3.1.2 (Ronquist and Huelsenbeck 2003) was then used to run MCMC Bayesian inference (BI). The program was set to run for 10,000,000 generations with sampling every 1,000 generations. A 50% majority rule consensus tree was created from the trees remaining after a 10% burn-in removal. The included Bayesian sets of trees were sampled after likelihood scores reached convergence and the mean split difference values were almost 0.01. Trees were visualized using Figtree v 1.4.0 (Rambaut 2006-2012) with nodal support evaluated by posterior probabilities (PP) for the BI. La Crosse virus of the California serogroup was used as outgroup for the phylogenetic analysis of all the three segments of BUNV and NRIV. Nucleotide and amino acid similarity and genetic distance between the Kenyan isolates and selected isolates from diverse regions (Table 5) were computed in MEGA v5.20 using the p-distance method (Tamura et al. 2011).

2.2.4 Nucleotide sequence accession numbers


The genome sequences determined in this study were deposited in GenBank under the following accession numbers (S segment, M segment, and L segment): KM507344, KM507340 and KM507338 (BUNV_MGD_S1_12060_WT); KM507345, KM507339 and KM507337 (BUNV_GSA_S4_11232_WT); KM507343, KM514679 and KM507335 (NRIV_TND_S1_19801_WT); KM507341, KM514677 and KM507336 (NRIV_GSA_TS7_5170_WT); KM507342, KM514678 and KM507334 (NRIV_ISL_TS2_5242_WT).

2.3 RESULTS

To support the molecular characterization efforts (Chapters 2 and 3), 15 full length S, M and L coding nucleotide and amino acid sequences of the 5 viruses sequenced in this study and their alignment with other viruses from GenBank are presented (Appendix 1) As previously reported by Groseth et al, the S segment of the NRIV and BUNV isolates formed entirely separate phylogenetic


branches (Groseth et al. 2012). The Kenyan NRIV isolates sequenced in the current study, regardless of the vector species of origin, geographic region and year of isolation, formed a monophyletic group with strong bootstrap support (98%), distinct from the other NRIV isolates from Sudan and Senegal and were more closely related to the NRIV isolates associated with the 1997/1998 hemorrhagic fever outbreak in East Africa, NRIV_9800535 and NRIV_9800521 (Figure 12). The Kenyan BUNV isolates sequenced in the current study, (MGD_S1_12060WT and GSA_S4_11232WT) clustered together with the Central African Republic isolate, BUNV_ArB29051 (AM709778) and with the Kenyan BUNV_AMH001130 (JF961342) isolated in 2011 but all these isolates were divergent from the prototype virus isolated from Uganda, BUNV (NC_001925) which is ancestral to all the NRIV isolates. The Australian BUNV isolate, BUNV_M11852 (AF325122) clustered more closely with BATV and Calovo virus isolates distinct from the African BUNV isolates. Likewise, BUNV isolate BUNV_ArB28215 (AM711130) was divergent from the African isolates despite isolation from Central African Republic and was closest to Nyando and Bozo virus isolates (Figure 12).

Phylogenetic analysis of the M and L segments followed a similar pattern as the S segment with the Kenya NRIV isolates sequenced in the current study forming a monophyletic group with 100% bootstrap support (Figure 13 and 14). The Kenyan isolates clustered closest to the two isolates associated with the 1997/1998 hemorrhagic fever outbreak in the Kenya Somali border, NRIV_9800521 and NRIV_9800535 as well as NRIV_Adrar, recently isolated from a small ruminant in Mauritania. Phylogenetic analysis of the L segment indicated that the Kenyan BUNV isolates were divergent from the prototype virus from Uganda (NC.001925). The two BUNV isolates in the current study clustered closest with the 2011 Kenyan isolate BUNV_AMH001130 (JF961341) but distinct from the prototype virus from Uganda (Figure 14).




Bayesian analysis of the coding region of the S segment of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus

Figure 12: Bayesian analysis of the coding region of the S segment of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. Kenyan isolates sequenced in this study are indicated by solid dots. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). Batai virus, BIRV: Birao virus, BOZOV: Bozo virus, BUNV: Bunyamwera virus, CVV: Cache Valley virus, CVOV: Calovo virus, FSV: Fort Shernan virus, GERV: Germiston virus, ILEV: Ilesha virus, KIRV: Kairi virus, LACV: La Crosse virus, NDOV: Nyando virus, NOLAV: Nola virus, NRIV: Ngari virus, PGAV: Pongola virus, POTV: Potosi virus, SHOV: Shokwe virus, TSV: Tensaw virus, WYOV: Wyomyia virus, XINV: Xingu virus. S segment accession numbers; Abbey_lake_orthobunyavirus_Cu20_XJ (KJ710424), BATV_Chittoor_IG_20217 (JX846598), BATV_MM2222 (JX846595), BATV_MS50 (JX846604), BATV_NM_12 (KJ187040), BATV_UgMP_6830 (JX846601), BATV_XQ_B (KJ398936), BIRV_ArB2198 (AM711131), BOZOV_ArB13529 (AM711132), BUNV_BLCNNS (D00353), BUNV_Pe7_0014 (AJ697960), BUNV_ArB29051(AM709778), BUNV_NC (NC_001927), BUNV_ArB28215(AM711130), BUNV_M11852 (AF325122), BUNV_AMH1130 (JF961342), CVOV_134 (KJ542624), CVOV_138_pool_468 (KC608157), CVOV_8020 (KJ542630), CVOV_8040 (KJ542633), CVOV_JAn_MS3 (KJ542627), CVV_MNZ_92011 (KC436108), FSV_86MSP18 (EU564829), GERV_BLCSA (M19420), ILEV_ArB16282 (AM709780), ILEV_HB80P125 (AM709779), ILEV_ILESHA_8e (KC608151), ILEV_R5964 (KF234073), KRIV_Mex07 (EU879063), LACV_Dallas_TX_2009 (GU591164), NDOV_ArB16055 (AM709781), NOLAV_ArB2882 (AM711134), NRIV_9800521_Somalia_1998 (JX857325), NRIV_9800535 (JX857328), NRIV_Adrar (KJ716848), NRIV_D28542/4e (KC608154), NRIV_DakArD28542 (JX857316), NRIV_HKV141(JX857322), NRIV_HKV66 (JX857319), PGAV_SAAr1 (EU564828), POTV_AY729652_1 (AY729652), SHOV_SAAr_4042 (EU564831), TSV_TSV_FL06 (FJ943507), WYOV_JN572082 (JN572082), XINV_BeH388464_e (EU564830)



Bayesian analysis of the M polyprotein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus

Figure 13: Bayesian analysis of the M polyprotein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. Kenyan isolates sequenced in this study are indicated by solid dots. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). Batai virus, BIRV: Birao virus, BOZOV: Bozo virus, BUNV: Bunyamwera virus, CVV: Cache Valley virus, CVOV: Calovo virus, FSV: Fort Shernan virus, GERV: Germiston virus, ILEV: Ilesha virus, KIRV: Kairi virus, LACV: La Crosse virus, NDOV: Nyando virus, NOLAV: Nola virus, NRIV: Ngari virus, PGAV: Pongola virus, POTV: Potosi virus, SHOV: Shokwe virus, TSV: Tensaw virus, WYOV: Wyomyia virus, XINV: Xingu virus. M segment accession numbers: BATV_ON_7_B_01 (AB257765), BATV_ON_1_E_94 (AB257764), BATV_NM_12 (KJ187039), TSV_FE3_66FB (FJ943508), CVV_AF082576 (AF082576), TSV_FL06 (FJ943506), GERV_BLCMPOLY (M21951), CVV_MI80_1_450 (AF186241), ILEV_KO_2 (AY859372), CVV_807270 (AF186243), CVV_CK102 (AF186242), BUNV_BLCMA (M11852), MAGV_AY286443 (AY286443), MAGV_ts8 (AY286444), CVV_082576 (AF082576), ILEV_R5964 (KF234074), POTV_89_3380 (EU004189), NRIV_Dakar_D28542/4e (KC608153), ILEV_ILESHA_8e (KC608150), NRIV_Adrar (KJ716849), BATV_XQ+B (KJ398937), Abbey_lake_orthobunyavirus_Cu20_XJ (KJ710423), BATV_MS50 (JX846605), BATV_UgMP_6830 (JX846602), BATV_Chittoor_IG_20217 (JX846599), BATV_MM2222 (JX846596), NRIV_9800521 (JX857326), NRIV_9800535 (AY593725), NRIV_DakArD28542 (JX857317), NRIV_HKV141 (JX857323), NRIV_HKV66 (JX857320), CHLV_CHLV_Mex07 (JN808310), CVOV_138_pool_468 (KC608156) GROV_BeH22063 (AY380581), CVV_MNZ_92011 (KC436107), BATV_Italy_2009 (KC168047), IACOV_BeAn314206 (JN572066), LACV_Human_78 (AF528166), BUNV_NC (NC_001926), BUNV_AMH001130 (JF961341), CVOV_JAnMS3 (KJ542628), CVOV_134 (KJ542625), CVOV_184 (DQ334335)



Bayesian analysis of the L protein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). BUNV: Bunyamwera virus, NRIV: Ngari virus, BATV: Batai virus

Figure 14: Bayesian analysis of the L protein of Bunyamwera and Ngari virus isolates from diverse regions. Branch lengths are proportional to distance (the number of nucleotide changes), and the distance scale at the bottom of the tree represents the number of expected substitutions per site. Values indicate the probability for each partition or clade in the tree. Kenyan isolates sequenced in this study are indicated by solid dots. All Orthobunyavirus abbreviations are used according to (ICTV, 2005). Batai virus, BIRV: Birao virus, BOZOV: Bozo virus, BUNV: Bunyamwera virus, CVV: Cache Valley virus, CVOV: Calovo virus, FSV: Fort Shernan virus, GERV: Germiston virus, ILEV: Ilesha virus, KIRV: Kairi virus, LACV: La Crosse virus, NDOV: Nyando virus, NOLAV: Nola virus, NRIV: Ngari virus, PGAV: Pongola virus, POTV: Potosi virus, SHOV: Shokwe virus, TSV: Tensaw virus, WYOV: Wyomyia virus, XINV: Xingu virus. L segment accession numbers: Abbey_lake_orthobunyavirus_Cu20_XJ (KJ710425), NRIV_Dakar_D28542/4e (KC608152), ILEV_ILESHA_8e (KC608149), BUNV_AMH001130 (F961340), NRIV_9800521 (JX857327), NRIV_9800535 (JX857330), NRIV_DakArD28542 (JX857318), NRIV_HKV141 (JX857324), NRIV_HKV66 (JX857321), ILEV_R5964 (KF234075), LACV_Human_78 (AF528165), BATV_NM_12 (KJ187038), BATV_MS50 (JX846606), BATV_UgMP_6830 (JX846603), CVOV_138-pool_468 (JX846600), BATV_MM2222 (JX846597), BATV_Italy_2009 (KC168048), CVOV_8040 (KJ542635), CVOV_8020 (KJ542632), CVOV_JAn_MS3 (KJ542629), CVOV_134 (KJ542626), TSV_TSV_FE3_66FB (FJ943510), TSV_TSV_FL06 (FJ943509), CVV_MNZ_92011 (KC436106), BUNV_14383 (X14383), NRIV_Adrar (KJ716850), BUNV_NC_Uganda (NC001925)

The Kenyan NRIV isolates sequenced in the current study were closely related with nucleotide sequence identity of over 98% for all segments and nucleotide diversity no more than 2.7% (Tables 5-8). When comparing with other NRIV isolates from the Kenya-Somali border, Sudan and Senegal nucleotide sequence identities ranged from 98.5-99.3, 98.5-99.3 and 97.3-98.0% for the S, M and L segments respectively. Similarly, the Kenyan BUNV isolates in the current study were closely related with nucleotide sequence identity of over 99.6% for all segments. However, Comparing the Kenyan BUNV isolates to other Bunyamwera viruses, nucleotide sequence identity ranged from 82.2-96.4 , 96.0-99.4 and 96.6% for the S, M and L segments respectively. Similarly, nucleotide diversity was no more than 3.8%, 6.3% and 3.4% for the S, L and M segments except isolates BUNV_ArB29051 from Central African Republic and BUNV_M11852 from Australia which were more than 17% divergent in the S segment. This was confirmed by p-distance analysis of nucleotide and amino acid sequences which reveal that these two viruses are closer to Nyando and Colovo viruses respectively (Table 9)

The encoded proteins were highly conserved among the Kenyan NRIV isolates with similarity not less than 99.5% for the N protein, Ns protein, M polyprotein, and L protein (Tables 5-8). The NSs protein was the most conserved when compared among NRIV isolates from the different geographic regions (Table 6). For BUNV, amino acid similarity among the Kenyan isolates were no less than 99.0% for the N protein, NS protein, M polyprotein and L protein (Tables 5-8). The least amino acid similarity was observed with the two BUNV isolates, the Central African Republic BUNV_ArB28215 and the Australian BUNV_M11852 which were less than 93% identical in the N and Ns proteins (Tables 5 and 6).

Table 5: Table Ss protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete S segment (Kenyan isolates in this study are bolded).

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
1	GSA/TS7/5170_WT		100	100	100	100	100	100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
2	ISL/TS2/5242/WT	100		100	100	100	100	100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
3	TND/S1/19801/WT	100	100		100	100	100	100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
4	NRIV_DakArD28542	99.6	99.6	99.6		100	100	100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
5	NRIV_SUD-HKV141	99.6	99.6	99.6	99.3		100	100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
6	NRIV_SUD-HKV66	99.6	99.6	99.6	99.3	100.0		100	100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
7	NRIV_9800521	100	100	100	99.6	99.6	99.6		100	100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
8	NRIV_9800535	100	100	100	99.6	99.6	99.6	100		100	99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
9	MGD/S1/12060/WT	100	100	100	99.6	99.6	99.6	100	100		99.0	100	100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
10	GSA/S4/11232/WT	99.6	99.6	99.6	99.3	99.3	99.3	99.6	99.6	99.6		99.0	99.0	99.0	85.1	92.0	94.0	88.1	88.1	87.1	87.1	87.1	87.1	93.0
11	BUNV_(NC_001927)	100	100	100	99.6	99.6	99.6	100	100	100	99.6		100	100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
12	BUNV_BLCNNS_	100	100	100	99.6	99.6	99.6	100	100	100	99.6	100		100	86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
13	BUNV_ArB29051	100	100	100	99.6	99.6	99.6	100	100	100	99.6	100	100		86.1	93.0	95.0	89.1	89.1	88.1	88.1	88.1	88.1	94.0
14	BUNV_(AF325122)	92.7	92.7	92.7	93.0	93.0	93.0	92.7	92.7	92.7	92.4	92.7	92.7	92.7		83.1	84.1	95.0	93.0	94.0	94.0	94.0	94.0	84.1
15	BUNV_ArB28215_	94.3	94.3	94.3	94.0	94.0	94.0	94.3	94.3	94.3	94.0	94.3	94.3	94.3	88.7		91.0	85.1	84.1	84.1	84.1	84.1	84.1	89.1
16	BATV_MS50_	95.7	95.7	95.7	95.3	95.3	95.3	95.7	95.7	95.7	95.3	95.7	95.7	95.7	89.4	92.7		85.1	87.0	86.0	86.0	86.0	86.0	93.0
17	BATV_UgMP-6830	93.0	93.0	93.0	93.3	93.3	93.3	93.0	93.0	93.0	92.7	93.0	93.0	93.0	97.6	89.1	89.4		98.0	99.0	97.0	99.0	99.0	85.1
18	BATV_Chittoor/IG-20217	92.0	92.0	92.0	92.4	92.4	92.4	92.0	92.0	92.0	91.7	92.0	92.0	92.0	96.0	88.4	90.3	98.3		99.0	97.0	99.0	99.0	87.0
19	BATV_MM2222	91.4	91.4	91.4	91.7	91.7	91.7	91.4	91.4	91.4	91.0	91.4	91.4	91.4	96.0	88.7	90.3	98.3	99.3		98.0	100.0	100	86.0
20	BATV_Italy-2009	91.0	91.0	91.0	91.4	91.4	91.4	91.0	91.0	91.0	90.7	91.0	91.0	91.0	95.0	89.1	89.6	96.6	97.6	97.6		98.0	98.0	86.0
21	BATV_ON-7/B/01	91.7	91.7	91.7	92.0	92.0	92.0	91.7	91.7	91.7	91.4	91.7	91.7	91.7	96.3	88.4	90.0	98.6	99.6	99.6	98.0		100	86.0
22	BATV_ON-1/E/94	92.4	92.4	92.4	92.7	92.7	92.7	92.4	92.4	92.4	92.0	92.4	92.4	92.4	96.6	88.4	90.6	98.6	99.0	99.0	97.3	99.3		86.0
23	ILEV_ILESHA/8e	95.7	95.7	95.7	95.3	95.3	95.3	95.7	95.7	95.7	95.3	95.7	95.7	95.7	90.0	91.4	94.6	90.0	91.0	90.3	90.0	90.6	90.6	

Table 6: N protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete S segment (Kenyan isolates in this study are bolded).

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23
1	GSA/TS7/5170_WT		100	100	99.5	100	100	99.5	99.5	100	100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
2	ISL/TS2/5242/WT	100		100	99.5	100	100	99.5	99.5	100	100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
3	TND/S1/19801/WT	100	100		99.5	100	100	99.5	99.5	100	100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
4	NRIV_DakArD28542	99.1	99.1	99		99.5	99.5	99.1	99.1	99.5	99.5	99.5	99.5	99.1	93.1	91.4	90.1	93.1	92.7	92.2	93.1	92.7	93.1	93.9
5	NRIV_9800535	99.1	99.1	99	99.7		100	99.5	99.5	100	100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
6	NRIV_9800521	98.9	98.9	99	99.5	99.8		99.5	99.5	100	100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
7	NRIV_SUD-HKV141	98.9	98.9	99	99.2	99.2	99.1		100	99.5	99.5	99.5	99.5	99.1	93.1	91.4	90.1	93.1	92.7	92.2	93.1	92.7	93.1	93.9
8	NRIV_SUD-HKV66	98.5	98.5	99	99.1	99.1	98.9	99.5		99.5	99.5	99.5	99.5	99.1	93.1	91.4	90.1	93.1	92.7	92.2	93.1	92.7	93.1	93.9
9	MGD/S1/12060/WT	98.2	98.2	98	98.2	98.2	98.1	97.8	97.7		100	100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
10	GSA/S4/11232/WT	97.9	97.9	98	97.9	97.9	97.8	97.5	97.4	99.7		100	100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
11	BUNV_(NC_001927)	95.8	95.8	96	95.5	95.5	95.7	95.7	95.5	96.4	96.4		100	99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
12	BUNV_BLCNNS	95.8	95.8	96	95.5	95.5	95.7	95.7	95.5	96.4	96.4	100		99.5	92.7	91.8	90.5	92.7	92.2	91.8	92.7	92.2	92.7	94.4
13	BUNV_ArB29051_	98.1	98.1	98	98.1	98.1	97.9	97.7	97.5	99.5	99.5	96.5	96.5		92.2	91.8	90.1	92.2	91.8	91.4	92.2	91.8	92.2	93.9
14	BUNV_(AF325122)	86.4	86.4	86	85.9	85.6	85.5	86.1	85.6	85.9	85.9	85.9	85.9	86.1		87.9	89.2	98.2	97.8	97.4	97.4	97.8	97.8	90.9
15	BUNV_ArB28215_	86.9	86.9	87	86.8	87.1	87.2	86.5	86.8	87.5	87.5	87.8	87.8	87.5	83.5		86.6	87.9	87.5	87.9	88.8	87.5	87.9	88.8
16	BATV_MS50_	85.6	85.6	86	85.1	85.1	84.9	85.4	85.4	85.2	84.9	85.8	85.8	85.1	90.5	82.6		88.8	88.4	88.8	87.9	88.4	88.8	88.4
17	BATV_UgMP-6830	86.6	86.6	87	86.5	86.8	86.9	86.4	86.4	86.9	86.9	86.8	86.8	86.8	83.9	84.6	84.1		99.5	99.1	98.2	99.5	99.1	90.5
18	BATV_Chittoor/IG-20217	85.5	85.5	86	85.5	85.5	85.4	85.8	85.8	85.1	84.8	84.8	84.8	84.9	89.9	82.4	95.5	83.9		99.5	97.8	100	99.5	90.1
19	BATV_MM2222	85.2	85.2	85	84.9	84.9	84.8	85.2	85.2	84.5	84.2	83.8	83.8	84.1	89.5	82.4	94.7	83.4	97.5		97.4	99.5	99.1	89.6
20	BATV_Italy-2009	84.6	84.6	85	84.4	84.4	84.5	84.4	84.4	84.5	84.2	84.8	84.8	84.1	89.4	83.8	93.2	84.4	92.9	92.9		97.8	97.4	90.5
21	BATV_ON-7/B/01	85.1	85.1	85	85.4	85.4	85.2	85.4	85.1	84.6	84.4	84.2	84.2	84.2	90.1	82.4	94.7	83.5	97.7	97.2	92.8		99.5	90.1
22	BATV_ON-1/E/94	85.9	85.9	86	85.9	85.9	85.8	86.2	86.2	85.8	85.5	84.9	84.9	85.4	89.6	82.5	94.4	84.4	96.5	97.2	92.7	95.8		89.6
23	ILEV_ILESHA/8e	89.8	89.8	90	89.8	90.1	90.2	89.9	90.1	89.2	89.2	88.9	88.9	89.4	83.4	86.5	84.2	83.9	83.1	82.8	82.6	82.2	82.6	

Table 7: M polyprotein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete M segment (Kenyan isolates in this study are bolded).

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21
1	GSA/TS7/5170_WT		100.0	99.9	98.8	98.7	98.6	98.7	98.6	63.8	63.8	63.5	63.5	61.2	95.2	97.8	95.0	94.9	63.6	95.3	93.1	68.6
2	ISL/TS2/5242_WT	99.9		99.9	98.8	98.7	98.6	98.7	98.6	63.8	63.8	63.5	63.5	61.2	95.2	97.8	95.0	94.9	63.6	95.3	93.1	68.6
3	TND/S1/19801_WT	99.9	99.9		98.7	98.6	98.5	98.6	98.5	63.7	63.7	63.4	63.4	61.1	95.1	97.7	94.9	94.9	63.6	95.2	93.0	68.6
4	NRIV_DakArD28542	97.4	97.4	97.4		99.7	99.6	98.7	98.6	63.7	63.7	63.5	63.5	61.1	95.4	98.6	95.5	95.3	63.8	95.7	93.4	68.9
5	NRIV_SUD-HKV141	96.9	96.9	96.9	99.0		99.7	98.6	98.5	63.8	63.8	63.5	63.5	61.2	95.5	98.7	95.6	95.4	63.9	95.8	93.5	69.0
6	NRIV_SUD-HKV66	96.9	97.0	96.9	99.1	99.5		98.5	98.3	63.7	63.7	63.4	63.4	61.0	95.2	98.4	95.3	95.1	63.8	95.5	93.2	68.8
7	NRIV_9800521	97.7	97.7	97.7	97.9	97.4	97.4		99.5	63.8	63.8	63.4	63.4	61.2	94.9	97.7	95.1	94.8	63.6	95.3	93.1	68.6
8	NRIV_9800535	97.6	97.6	97.6	97.8	97.3	97.4	99.3		63.9	63.9	63.5	63.5	61.2	94.8	97.6	94.9	94.8	63.6	95.1	93.2	68.6
9	MGD/S1/12060_WT	64.0	64.0	63.9	64.0	63.9	63.9	63.9	63.8		99.9	98.1	98.1	95.4	64.6	63.9	64.4	64.6	78.6	64.3	64.4	63.3
10	GSA/S4/11232_WT	64.0	64.0	64.0	64.0	63.9	63.9	64.0	63.9	99.9		98.2	98.2	95.5	64.6	63.9	64.4	64.6	78.6	64.3	64.4	63.2
11	BUNV_(NC_001926)	63.9	63.9	63.9	63.9	63.7	63.7	63.7	63.7	95.7	95.7		100.0	94.4	64.2	63.7	64.0	64.2	78.5	63.9	64.1	62.8
12	BUNV_(M11852)	63.9	63.9	63.9	63.9	63.7	63.7	63.7	63.7	95.7	95.7	100.0		94.4	64.2	63.7	64.0	64.2	78.5	63.9	64.1	62.8
13	BUNV_(JF961341)	61.7	61.7	61.7	61.6	61.5	61.5	61.6	61.5	95.3	95.3	91.7	91.7		61.9	61.3	61.7	61.9	76.1	61.7	61.9	61.0
14	BATV_MM2222	88.9	88.9	88.8	89.5	89.2	89.3	88.7	88.6	64.6	64.6	64.1	64.1	62.0		96.0	98.1	97.1	64.3	98.1	93.3	69.2
15	BATV_UgMP-6830	94.7	94.7	94.7	96.4	96.0	96.1	95.0	94.9	64.0	64.1	63.8	63.8	61.5	90.3		95.8	95.8	64.1	96.2	93.8	68.9
16	BATV_ON-1/E/94	88.1	88.1	88.0	88.8	88.5	88.4	88.0	87.9	64.2	64.3	63.9	63.9	61.8	94.9	89.1		96.4	64.5	97.3	93.3	69.2
17	BATV_ON-7/B/01	88.0	88.0	87.9	88.6	88.5	88.6	87.9	88.0	64.2	64.3	64.0	64.0	61.7	93.5	89.3	91.9		64.0	98.1	93.1	68.8
18	BATV_MS50	63.8	63.8	63.8	63.8	63.8	63.8	63.8	63.7	72.8	72.8	72.7	72.7	70.0	64.4	63.9	64.2	64.4		64.0	64.5	64.3
19	BATV_Chittoor/IG-20217	88.7	88.7	88.7	89.5	89.2	89.3	88.7	88.7	64.4	64.4	64.1	64.1	61.9	95.4	89.9	93.4	96.4	64.5		93.3	68.8
20	BATV_Italy-2009	84.1	84.1	84.1	84.7	84.5	84.4	84.2	84.3	64.5	64.5	64.1	64.1	62.0	84.7	84.8	84.6	84.0	64.7	84.2		68.9
21	ILEV_ILESHA/8e	68.7	68.7	68.7	68.6	68.7	68.7	68.6	68.6	65.0	65.0	64.9	64.9	62.9	68.2	68.2	67.9	68.2	65.3	68.4	68.1	

Table 8: L protein nucleotide/amino acid sequence identities among selected Bunyamwera serogroup viruses. Nucleotide and amino acid sequence identities are shown below and above the diagonal, respectively. Comparison of nucleotide sequences is based on the complete L segment (Kenyan isolates in this study are bolded).

		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
1	GSA/TS7/5170_WT		99.8	100	99.4	99.1	99.3	99.4	99.3	99.1	99.2	99	99	81.8	81.5	82.7	81.8	81.5	91.8
2	ISL/TS2/5242_WT	99.5		99.8	99.3	99.1	99.2	99.3	99.2	98.9	99.1	98.8	98.8	81.9	81.6	82.7	81.9	81.5	91.7
3	TND/S1/19801_WT	100	99.5		99.4	99.1	99.3	99.4	99.3	99.1	99.2	99	99	81.8	81.5	82.7	81.8	81.5	91.8
4	NRIV_DakArD28542	97.7	97.7	97.7		99.4	99.5	99.6	99.5	99.4	99.5	99.3	99.3	81.6	81.4	82.6	81.6	81.3	91.6
5	NRIV_SUD-HKV141	97.3	97.3	97.3	98.6		99.6	99.2	99.1	99	99.1	99	99	81.6	81.4	82.7	81.6	81.3	91.8
6	NRIV_SUD-HKV66	97.3	97.4	97.3	98.7	99.4		99.3	99.2	99.1	99.2	99.1	99.1	81.8	81.5	82.7	81.8	81.5	91.7
7	NRIV_9800521	97.8	98	97.8	98.5	97.9	97.9		99.8	99.1	99.2	99	99	81.7	81.4	82.7	81.7	81.4	91.7
8	NRIV_9800535	97.7	97.9	97.7	98.4	97.8	97.8	99.6		99	99.1	98.9	98.9	81.6	81.3	82.6	81.6	81.3	91.7
9	MGD/S1/12060_WT	94.9	94.4	94.9	95.7	95.2	95.2	94.8	94.8		99.8	99.5	99.5	81.7	81.5	82.7	81.7	81.5	91.7
10	GSA/S4/11232_WT	95	94.5	95	95.7	95.3	95.3	94.9	94.9	99.9		99.6	99.6	81.7	81.4	82.7	81.7	81.5	91.8
11	BUNV_(NC_001925)	96	95.9	96	97.3	96.8	96.9	96.4	96.3	96.5	96.5		100	81.5	81.4	82.7	81.5	81.4	91.5
12	BUNV_(X14383)	96	95.9	96	97.3	96.8	96.9	96.4	96.3	96.5	96.5	100		81.5	81.4	82.7	81.5	81.4	91.5
13	BATV_MM2222	73.5	73.6	73.5	73.5	73.6	73.7	73.4	73.3	73.6	73.6	73.6	73.6		98.1	81.3	99.1	96.6	81.4
14	BATV_UgMP-6830	73.5	73.7	73.5	73.5	73.6	73.7	73.6	73.5	73.5	73.5	73.3	73.3	90.5		81.2	98.2	96.1	80.9
15	BATV_MS50	73.8	73.9	73.8	74.1	74.1	74.1	74	74	74	74	74.1	74.1	72.7	72.7		81.2	81	81.8
16	BATV_Chittoor/IG-20217	73.4	73.4	73.4	73.5	73.5	73.7	73.3	73.3	73.5	73.4	73.5	73.5	95.7	90.4	72.7		96.6	81.1
17	BATV_Italy-2009	73.6	73.7	73.6	73.6	73.6	73.7	73.5	73.5	73.8	73.8	73.7	73.7	85.9	86.1	72.8	85.8		80.9
18	ILEV_ILESHA/8e	81.4	81.3	81.4	81.6	81.5	81.4	81.3	81.3	81.3	81.3	81.6	81.6	73.7	73.9	74.5	73.5	74.3	

Table 9: Between group mean distance comparisons for the S segment of selected virus isolates included in this study.

	Virus Isolate	1	2	3	4	5	6	7	8	9	10	11	12	13	14
1	Batai		0.352	0.341	0.400	0.684	0.383	0.231	0.160	0.336	0.308	0.377	0.308	0.350	0.693
2	Batai_MS50	0.163		0.269	0.327	0.684	0.316	0.327	0.324	0.265	0.281	0.311	0.283	0.301	0.694
3	Bunyamwera	0.152	0.130		0.217	0.654	0.274	0.311	0.338	0.056	0.082	0.238	0.085	0.237	0.670
4	Bozo	0.196	0.177	0.109		0.653	0.255	0.398	0.401	0.240	0.265	0.278	0.263	0.240	0.663
5	Bunyamwera_PE-7.0014	0.351	0.371	0.353	0.364		0.679	0.684	0.715	0.671	0.684	0.675	0.676	0.679	0.189
6	Bunyamwera_ARB28215	0.175	0.153	0.123	0.123	0.354		0.347	0.353	0.270	0.281	0.256	0.291	0.199	0.663
7	BUNV_M11852	0.098	0.159	0.139	0.196	0.363	0.163		0.243	0.311	0.301	0.346	0.310	0.337	0.689
8	Calovo	0.072	0.156	0.151	0.193	0.361	0.162	0.106		0.340	0.335	0.385	0.338	0.328	0.709
9	Bunyamwera_(this_study)	0.152	0.129	0.021	0.117	0.356	0.123	0.139	0.151		0.051	0.242	0.058	0.250	0.686
10	Ngari_(this_study)	0.145	0.131	0.031	0.126	0.363	0.129	0.134	0.150	0.019		0.237	0.019	0.255	0.689
11	Ilesha	0.175	0.168	0.113	0.153	0.375	0.139	0.170	0.178	0.113	0.110		0.234	0.233	0.665
12	Ngari	0.147	0.133	0.034	0.126	0.361	0.130	0.141	0.151	0.022	0.012	0.108		0.253	0.691
13	Nyando	0.160	0.156	0.101	0.127	0.361	0.099	0.153	0.147	0.104	0.106	0.113	0.109		0.658
14	Wyeomyia	0.363	0.384	0.366	0.370	0.069	0.353	0.371	0.365	0.371	0.371	0.375	0.373	0.364	

NB: Mean distances in bold represent lowest mean distance between virus groups

2.4 DISCUSSION

In this chapter, we present phylogenetic analysis of full coding sequences of three NRIV and two BUNV isolates originating from diverse regions of Kenya and from different vector and potential host species (Ochieng et al. 2013, Lutomiah et al. 2014). We also investigate whether genetic diversity is correlated with year, geographic location and vector species of isolation.

Our data seems to support the hypothesis of a geographic/temporal association among NRIV isolates evidenced by phylogenetic analyses of the three genomic segments generally grouping isolates from the same region and collection year together, although there were some exceptions to this grouping. We observed a temporal/geographic variation in the rate of evolution of the L and M segment between the NRIV isolates. The 1979 NRIV_DakArD28542 prototype virus from Senegal was closest to the last common ancestor followed by the 1988 Sudan isolates (NRIV_SUD_HKV141 and NRIV_SUD_HKV66), the 1998 Kenya-Somali isolates (NRIV_9800521 and NRIV_9800535) which also mimics the geographical distance between these regions (Figure 10). The temporal/geographic clustering rather than by source of isolation is further supported by the observation of the 1988 NRIV isolates from Sudan (SUD-HKV66 and SUD-HKV141) and the 1998 Kenya-Somali border isolates (NRIV_9800535 and NRIV_9800521) clustering separately for all segments despite isolation from human hosts. However, we do not have information on how these humans, who are likely dead end hosts, acquired these infections. Temporal clustering is further supported by the 2011 Mauritania isolate (NRIV_Adrar) clustering closely with the NRIV isolates in the current study despite being isolated from diverse regions. However, it is possible this isolate may have been introduced into Mauritania from the East African region through infected livestock. Modelling of Rift Valley fever infections suggest movement of Rift Valley fever virus (RVF) virus from the East African region to Senegal and Mauritania possibly due to animal trade (Soumare et al. 2012).

The S segment did not display a similar pattern as observed for the L and M segments and this may be related to difference in mutation rates between the various segments. The slow evolution of the S

segment is corroborated by the highly conserved amino acid sequences observed for the N and Ns protein in the current study. NRIV isolates from different regions; Kenya, Kenya-Somali border, Sudan and Senegal clustered separately, distinct for each region of isolation. The Kenyan NRIV isolates in the current study clustered closest to the 1998 NRIV isolates (NRIV_9800521 and NRIV_9800535) from the Kenya-Somali border indicating that the current Kenyan NRIV isolates may have been introduced into the various regions in Kenya from the Kenya-Somali border. The amino acid positions with substitutions unique to the Kenyan isolates in both the M polyprotein and L protein may represent geographical/temporal motifs. This is given further credence by unique substitutions identified for the Kenyan NRIV isolates in the current study and the two 1998 NRIV isolates mentioned above and confirmed by phylogenetic analysis.

Phylogenetic analyses of BUNV isolates were hampered by the lack of complete sequences for all segments. However, there was evidence of geographic clustering for example the Kenyan BUNV isolates in the current study shared unique amino acid substitutions with the previously isolated 2011 Kenyan BUNV isolate (BUNV_AMH001130 (JF961341) from the same region when compared with the BUNV prototype from Uganda. The current Kenyan BUNV isolates in the current study clustered closest to the 1994 Central African Republic BUNV_ArB29051 but divergent from the Australian isolate BUNV_M11852. Similar observations have been made for BATV in which correlation between geographic and genetic diversity has been suggested (Jost et al. 2011, Huhtamo et al. 2013). BATV isolates from Europe, Asia and Africa generally cluster independently within strongly supported groups with country specific viruses clustering closely (Huhtamo et al. 2013). This was more or less similar for the BUNV isolates where the S segment of the Australian isolate BUNV_M11852, was divergent from the Kenyan, Central African Republic and Ugandan BUNV isolates and clustered more closely with BATV and Calovo virus isolates. An exception was the 1992 Central African Republic isolate BUNV_ARB28215 which was divergent from the other African isolates and clustered closest to Nyando and Bozo virus isolates. Similar observation for this isolate has been reported in a previous study (Yandoko et al. 2007) suggesting

that it may have been erroneously named BUNV since, unlike the other African isolates, BUNV_ARB28215 has a shorter non-coding region and may probably be a different virus. Similarly, for the M segment, the Kenyan BUNV isolates sequenced in the current study formed a monophyletic clade with the 2011 Kenyan isolate, BUNV_AMH001130, divergent from the prototype virus from Uganda. The 1979 NRIV prototype virus NRIV_DakArD28542 from Senegal is at the base of all other NRIV isolates in all three genomic segments. BUNV_PE-7.0014 isolate from Peru clusters closest to Wyeomyia virus of the California serogroup as previously reported by Mores et al (Mores et al. 2009), distinct from the African BUNV isolates analyzed in the current study. This is further supported by the short distance observed between the two viruses in the p-distance analysis of both nucleotide and amino acid sequences.

Our data did not support the existence of distinct virus isolates circulating in specific host species, for example, we did not find any major differences in the NRIV isolates from mosquito and tick vectors indicating that the same virus strain may be circulating within northern Kenya in both ticks and mosquitoes and diverse vertebrate host species. Similarly, we did not identify significant differences in the BUNV isolates from different mosquito genus and species. While RNA viruses have the potential to undergo sequence changes due to their plasticity and high error rate of their RNA polymerases (Woolhouse et al. 2001, Kassen 2002), our isolates may represent the consensus genotype of the virus. Such consensus genotypes arise from the different selective pressures encountered within the different host systems. Alternatively, ticks, (from which NRIV was isolated) may have fed on viremic host and may not be competent vectors for NRIV. This calls for tick vector competence studies for NRIV to be undertaken.

In summary, our analysis suggests a rough geographic/temporal association of NRIV isolates and does not support any evolutionary clustering of viral isolates based upon the host source of isolation of the virus; viral isolates from mosquitoes, ticks or humans sources did not group together. Data from this study therefore do not support the existence of distinct virus isolates circulating in specific host species. There is a need to sequence all three segments of available isolates to correctly

categorize them. It is likely that BATV_MS50 (JX846604) is misclassified as a BATV as observed by recent studies (Dilcher et al. 2013, Huhtamo et al. 2013). It would be of interest to also re-look at the BUNV isolate from Central African Republic, BUNV ArB28215 (AM711130) which is distinct from the prototype virus in our study as well as Yandoko et al, (Yandoko et al. 2007), where it clustered more closely with Bozo virus. Likewise, the Australian BUNV isolate, BUNV_M11852 and Peru isolate BUNV_PE-7.0014 need to be re-considered given their association with BATV and Wyeomyia virus, respectively.

Despite the relative slow rate of evolution of these viruses, the possibility of genetic shift and drift remains real with continued isolation of orthobunyaviruses from previously unknown vectors and hosts such as ticks (Lwande et al. 2013) and birds (Tauro et al. 2009). While there was evidence of a geographic/temporal correlation with genetic diversity, a more in depth analysis including identification of signature motifs that might be representative of a given geographic clade is restricted by limited full length sequences of these viruses. Furthermore there is need for more studies on pathogenesis and wider distribution of these viruses. While public health efforts have focused on well characterized viruses such as RVF, WNV, chikungunya and dengue viruses, the emergence of Orthobunyaviruses such as NRIV and Schmallerbergvirus as human and veterinary pathogens emphasizes there is need for in-depth characterization of these viruses and determination of their true public health impact.

Chapter 3

GENOME SEQUENCE ANALYSIS OF *IN VITRO* AND *IN VIVO* PHENOTYPES OF BUNYAMWERA AND NGARI VIRUS ISOLATES FROM NORTHERN KENYA.

3.1 INTRODUCTION

BUNV is the prototype virus of the *Orthobunyavirus* genus of the *Bunyaviridae* family of arboviruses. The virus is associated with febrile illness with headache, arthralgia, rash and infrequent central nervous system involvement (Gonzalez and Georges 1988). While viruses of the *Orthobunyavirus* genus are known to cause human disease, they were previously not associated with hemorrhagic manifestations. However, NRIV has been implicated in recent outbreaks of hemorrhagic fevers in Kenya and Somalia (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). NRIV is thought to have arisen through genetic reassortment between bunyaviruses co-circulating in the same environment (Gerrard et al. 2004).

Like other viruses within the *Bunyaviridae* family, the BUNV genome consists of three negative-sense RNA segments that employ a variety of coding strategies leading to generation of a limited set of structural and non-structural proteins (Elliot et al. 2000, Schmaljohn and Hooper 2001). The L (large) segment encodes a large protein that comprises the RNA-dependent RNA polymerase for replication and transcription of genomic RNA segments. The M (medium) segment encodes a precursor polypeptide which yields the viral surface glycoproteins Gn and Gc and a nonstructural protein NSm, and the S (small) segment encodes the nucleocapsid (NC) and a nonstructural protein (NSs) in overlapping reading frames (Schmaljohn and Hooper 2001). The prevalence of members of the *Bunyaviridae* family are likely underestimated because of lack of detection tools arising partly from their high level of diversity, limited phenotypic and genetic characterization and segmented nature of their genome.

Orthobunyaviruses are mostly isolated and amplified in interferon defective African green monkey kidney epithelial Vero cell line that may result in mutations yielding substrains that are

phenotypically different from the parental wild type virus (Sundstrom et al. 2011). Such observations have been reported among other viruses of the family *Bunyaviridae*, including Puumala virus where the large plaque (LP) grows to higher titers than the small plaque (SP) and the parental wild type (WT) virus in interferon defective cells but no difference in growth when interferon competent cells were used (Sundstrom et al. 2011). Genome sequencing analysis revealed differences at two positions in the NC protein and two positions in the L protein (Sundstrom et al. 2011). Attenuation both *in vivo* and *in vitro* has also been observed for the SP phenotype of West Nile virus (WNV) (Davis et al. 2004). Attenuated pathogenesis has also been reported for dengue and Japanese encephalitis virus in mice experiments (Eastman and Blair 1985, Blaney Jr et al. 2001, Blaney Jr et al. 2002, Blaney Jr et al. 2003). Thus, understanding the mutation distribution in a heterogeneous arbovirus population is important, given that any variant can be favored by selection which ultimately affects fitness. We hypothesize that natural mutations may accumulate during passage of BUNV and NRIV isolates, obtained from entomological surveillance exercises in Kenya (Ochieng et al. 2013). Such mutations may yield substrains with genotypic and phenotypic differences between each other and with the parental WT strains (likely composed of several different substrains). In analyzing the viral phenotypes, we studied the kinetics of replication following infection of Vero cells. Additionally, we studied pathogenesis of viral strains after peritoneal inoculation of mice. We also sequenced the coding regions of the three RNA segments to determine whether difference in phenotype is associated with particular mutations in the genome. We report that BUNV and NRIV substrains compared to each other and to the parental wild type display contrasting phenotypes.

3.2 METHODS

3.2.1 Ethics statement

The study protocol (number SSC 2677) was approved by the Animal Care and Use Committee of the Kenya Medical Research Institute and by the Animal Ethics Committee of the University of Pretoria (Protocol number H012-13). All animal experiments were carried out in accordance with

the regulations and guidelines of the Kenya Medical Research Institute and University of Pretoria Animal Ethics Committees.

3.2.2 Virus stock preparation

The site in Kenya and vector species from which the 5 virus isolates used in the study were obtained is summarized in Table 10.

Table 10: Virus isolates obtained from diverse geographical regions and species in Kenya.

Specimen identity	Specimen code	Isolation site	Isolation date	Mosquito/tick species	Passage history
Bunyamwera viruses	GSA/S4/11232	Garissa	2009	<i>Aedes mcintoshi</i>	Vero 3
	MGD/S1/12060	Magadi	2010	<i>Anopheles funestus</i>	Vero 3
Ngari viruses	TND/S1/19801	Tana-delta	2011	<i>Anopheles funestus</i>	Vero 3
	GSA/TS7/5170	Garissa	2009	<i>Amblyomma gemma</i>	Vero 3
	ISL/TS2/5242	Isiolo	2009	<i>Rhipicephalus pulchellus</i>	Vero 3

Vero cells (ATCC® CCL-81™) were grown in T-75 culture flasks containing Eagle's minimum essential medium (Sigma) supplemented with 10% fetal bovine serum (Gibco-BRL), 2% L-glutamate (Sigma) and 2% penicillin/streptomycin (Gibco-BRL). Confluent cells were rinsed with sterile phosphate buffered saline, and 0.1 mL clarified homogenate of field collected mosquitoes were added followed by incubation at 37°C for one hour to allow virus adsorption with constant rocking. After incubation, maintenance medium (MEM with Earle's salts, 2% FBS, 2% glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1 µL/mL amphotericin B) was added and cells

incubated at 37°C and observed daily for CPE. Each isolate was grown individually to avoid cross-contamination and supernatants were harvested when approximately 75% of the cells exhibited CPE. The culture supernatants were aliquoted and stored at -80°C until used. The stock concentrations were determined by plaque assay titration as described below.

3.2.3 Plaque assay and purification

Vero cells were seeded on 6 well plates and incubated in a humidified CO₂ incubator at 37°C overnight before use. The cells were used when they attained 75–90% confluence. Ten-fold dilutions of the virus isolates were made in maintenance media. Media was carefully aspirated from the cells on the 6-well plates using sterile transfer pipettes and 100 µl of the appropriate viral dilution added to each of duplicate wells of 6-well plates with gentle rocking to evenly distribute the virus. Plates were incubated at 37°C for 1 hour after which media was carefully aspirated and 3 ml of 1.25% methylcellulose solution gently added to each plate. Plates were placed in a CO₂ humidified incubator and incubated for 5 days. Development of plaques was monitored by visualization under an inverted microscope (Leica DM IL LED). To facilitate visualization of plaques, methylcellulose solution (Sigma Aldrich) was carefully aspirated using transfer pipette followed by fixation in 10% formaldehyde (Sigma Aldrich) after which plates were stained with crystal violet solution (Sigma Aldrich).

Plaque purification

The LP and SP phenotypes of isolates GSA/S2/11232WT and TND/S4/19801WT (previously passaged 3 times on Vero cells) with a titer of 1×10^9 PFU/ml were diluted in maintenance media to approximately 10 PFU/ml. Then, confluent Vero cells in 24-well plates were infected with 100 µl of diluted virus per well. After adsorption for 1 h at 37°C, the cells were overlaid with 1 ml of 1.25% methylcellulose. Five days later, the methylcellulose medium was aspirated and pasture pipettes used to pick plaques from wells with single plaques and placed in 500ul of maintenance media, then propagated on Vero cells and the procedure was repeated twice more, without intermediate

amplification, for each of the plaque isolates. The purified isolates were then amplified by propagation on confluent Vero cells and then frozen at -80°C until use.

3.2.4 *Invitro* growth kinetics

Our viral isolates including the parental WT, i.e. mixture of SP and LP, were used to infect 90% confluent monolayers of Vero cells at a multiplicity of infection of 0.01 and incubated for one hour to allow virus adsorption. Infected monolayers were washed twice with sterile PBS and overlaid with maintenance medium and incubated at 37°C. An aliquot of tissue culture fluid (0.5 ml) was collected every 12 hours for the first 2 days and once on day 3 of infection, mixed 1:10 with maintenance media and frozen at -80°C until use. Daily samples were titrated by plaque assay as described above (Section 3.2.3). The statistical package R (R Development Core Team 2008) was used for fitting exponential growth data using the Kruskal–Wallis test (Kruskal and Wallis 1952). The detection of correlated error structure in the growth curve data was carried out as follows; the log-transformed data was fit to linear mixed effects models using R, and an AR1 model was found to fit the data better than a repeated measures model.

3.2.5 Molecular characterization of plaque purified phenotypes

RNA isolation and cDNA synthesis

For RNA extraction, we used the MagNA Pure LC RNA Isolation Kit I (Roche Diagnostics, Indianapolis, IN). Complementary DNA (cDNA) was synthesised using Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN) with Random hexamers followed by PCR using Phusion High-Fidelity PCR Kit (Finnzyme OY, Espoo, Finland) and appropriate primers as described in section 2.2.3. Primers for each segment were either designed based on sequences of BUNV, BATV and NRIV available in GenBank or obtained from publications (Yanase et al. 2006, Jost et al. 2011) (Appendix 2). Amplified DNA fragments were visualized by electrophoresis on a 1.5% agarose gel. The Amplified DNA was purified and prepared for

sequencing using ExoSAP-IT PCR clean-up kit (USB Corp, Cleveland, OH) according to the manufacturer's instructions and stored at -20°C.

Sequence analysis of viral genomes

Sequencing was performed using different sets of primers for the S, M and L segments as defined in section 2.2.3 above using Big Dye V3.1 kit (Applied biosystems) and injection on a 3500XL genetic analyser (Foster city, California, USA). The sequences obtained were cleaned and edited using Bioedit software (www.mbio.ncsu.edu/BioEdit/BioEdit.html, USA) for both the reads from the forward and reverse primers. Sequences obtained were compared to those in the gene bank using the Basic Local Alignment Search tool (BLAST) (Altschul et al. 1990) in NCBI GenBank (<http://www.ncbi.nlm.nih.gov/blast/Blast>) to identify similar sequences. The clean sequences of each segment of each phenotype were aligned against the corresponding segment sequences of the wild type virus isolate using Bioedit.

3.2.6 Clinical disease in mice

Pathogenicity of the plaque phenotypes was evaluated in Swiss Albino suckling (1-4 days old) and 6 week old mice obtained from the KEMRI animal house. To obtain the required sample size for the mice experiments, we assumed that equal sample sizes are required for BUNV and NRIV, respectively. Then to calculate the minimum number of mice required for each viral arm, the base sample size was estimated using the formula (Kirkwood and Sterne 2003):

$$n = \frac{(Z_{1-\alpha/2} \sqrt{2\bar{p}(1-\bar{p})} + Z_{1-\beta} \sqrt{p_n(1-p_n) + p_b(1-p_b)})^2}{(p_n - p_b)^2}$$

Such that:

$$\bar{p} = (p_n + p_b)/2$$

n = minimum mice required per group

p_n & p_b = expected proportion of mice dying due to NRIV and BUNV infection, respectively.

$Z_{1-\alpha/2}$ & $Z_{1-\beta}$ = Z statistic for a level of significance and power, respectively.

Preliminary work as recorded in the international catalogue of arboviruses (<http://wwwn.cdc.gov/arbocat/catalog-listing.asp?VirusID=79&SI=1>) has shown that NRIV and BUNV can lead to 100% and 50% mortality of infected mice, respectively by day two of infection. Considering a critical value of 1.96 and a power of 84% the base sample size becomes $10.5 \approx 11$ mice per group or viral treatment.

Mice were inoculated intraperitoneally with 100 μ l of 10^9 PFU/ml of wild type or amplified plaque purified virus isolates (LP and SP) in maintenance media (Figure 15). As control, mice were injected with an equal volume of maintenance media. All mice were carefully observed twice daily up to 14 days for clinical disease which included characteristic tremors and hind-limb paralysis. Survival functions were graphed for the two sets of viruses. Pairwise comparisons of survival curves were made using the Wilcoxon-Breslow test to test for equality of survivor functions



Figure 15: Picture showing intraperitoneal inoculation of 1-4 day old suckling mice with experimental virus diluted in maintenance media.

3.3 RESULTS

3.3.1 Isolation and Purification of Plaque phenotypes

Plaque titration of NRIV and BUNV yielded plaques of two significantly distinct phenotypes, LP (Range: 0.88-1.21 mm) and SP (Range: 0.47-0.66 mm) (Figure 16). Each plaque phenotype was sub-cloned twice and purified each time by inoculation onto new Vero cells. The plaque phenotypes retained their plaque size after amplification by single passage in cell culture to generate viral stocks with high titers for onward experimentation. The cloned LP substrain produced larger plaques than the SP suggesting that the former was more efficiently replicated in Vero cells than the latter.




Figure 16: Photograph of crystal violet-stained Bunyamwera virus infected Vero cell monolayer showing plaque phenotypes.

3.3.2 *In vitro* growth curves

In general, the LP phenotype of BUNV isolates grew at a faster rate and to a significantly higher titre ($p=0.009$) than the SP phenotype by day 3 of infection (Figures 17 and 18). The BUNV WT phenotype reached approximately 5-logs higher than the virus titre of the SP and LP phenotypes by day 3 post-infection. However, the difference in growth of the SP and LP phenotypes was insignificant. BUNV WT isolates generally grew to a higher titre than NRIV WT isolates.

For the NRIV isolates (Figure 19-21), the difference in titre between the WT and plaque phenotypes at 3 days post-infection was not more than 1 log except for isolate GSA/TS7/5170 (Figure 20). However, the difference in titer between the WT and plaque variants was not significant.




Figure 17: Growth kinetics of wild type parental and plaque purified phenotypes of Bunyamwera virus isolate GSA/S4/11232. There was a significant difference between the WT and the plaque phenotypes by day 3 post-inoculation.




Figure 18: Growth kinetics of wild type parental and plaque purified phenotypes of Bunyamwera virus isolate MGD/S1/12060. There was a significant difference between the WT and the plaque phenotypes by day 3 post-inoculation.




Figure 19: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate TND/S1/19801. There was no significant difference between the WT and plaque phenotypes at any time point.




Figure 20: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate GSA/TS7/5170. There was no significant difference between the WT and plaque phenotypes at any time point.




Figure 21: Growth kinetics of wild type parental and plaque purified phenotypes of Ngari virus isolate ISL/TS2/5242. There was no significant difference between the WT and plaque phenotypes at any time point.

3.3.3 Genetic characterization of plaque phenotypes

Comparison of the full genome nucleotide and amino acid sequences of low passage NRIV isolates revealed little or no divergence within the S segments (Table 11).

Table 11: Nucleotide differences between wild type parental and Plaque purified phenotypes of Bunyamwera and Ngari virus isolates.

Specimen identity	Virus Phenotype	Passage history	Nucleotide (amino acid) substitution in indicated Bunyamwera/Ngari virus segment		
			S	M	L
Bunyamwera viruses		Vero 7	G320C (G79R)	A1503G (K485E) C2009T	No changes
	GSA/S4/11232SP				
		Vero 7	T244C C559T	G3593A	G129A (A27T) T1523C C2623T (T858I)
	GSA/S4/11232LP				
		Vero 7	A803T C915T	C82T (A11V) G1503A (E485K) T2601C (S853P) G3423A (E1127K) T4229C	G278T A6099C (Q217K)
	MGD/S1/12060SP				
		Vero 7	A803T C915T	C1319T G1503A (E485K) T4229C	A6099C (Q217K)
	MGD/S1/12060LP				
Ngari viruses	TND/S1/19801SP	Vero 7	No changes	No changes	No changes
	TND/S1/19801LP	Vero 7	No changes	No changes	G300A (D84N)
	GSA/TS7/5170SP	Vero 7	No changes	T3272C	No changes
	GSA/TS7/5170LP	Vero 7	No changes	No changes	No changes
	ISL/TS2/5242SP	Vero 7	No changes	No changes	G869A G2741A G2993A
	ISL/TS2/5242LP	Vero 7	No changes	G3839A	No changes

* LP = large plaque; SP =small plaque

The N and NSs proteins of NRIV isolates were 100% conserved between the phenotypes. However, all BUNV isolate phenotypes exhibited nucleotide substitutions in all segments compared

to the WT except the L segment of isolate GSA/S4/11232SP. There was a single nucleotide change in the M segment of isolate GSA/TS7/5170SP and ISL/TS2/5242LP and three changes on the L segment of isolate ISL/TS2/5242SP. All these single nucleotide changes were synonymous. There were no changes in the nucleotide sequences of L segments of other NRIV isolates except isolate TND/S1/19801LP which had one nucleotide substitution resulting in a non-synonymous change in the amino acid sequence (D84N).

For the BUNV isolates, there were more transversions than transitions resulting in several non-synonymous codons. The 5' and 3' genome ends of the BUNV and NRIV phenotypes were highly conserved for all the three segments (Figures 22-24). All NRIV phenotypes were identical for the 5' non-coding region of the S and M segments while for the L segment, isolate ISL/TS2/5242 phenotypes differed from the other two NRIV isolates at 4 positions (Figure 22). Isolate TND/S1/19801 WT and TND/S1/19801SP phenotype differed from the two NRIV isolates at a single position. Similarly, there were only two nucleotide differences in the 5' non-coding region of the S segment between isolate MGD/S1/12060WT and all the other phenotypes of all BUNV isolates and none for the M and L segments (Figure 23). However, there was a 5' nucleotide deletion at positions 6815-6817 in the non-coding region of the L segment of isolate GSA/S4/11232LP (Figure 23).

The 3' non-coding region for all the BUNV and NRIV isolates were identical for all three segments except 1 nucleotide difference for the former in the L segment (Figure 24).

5' NCR S segment Ngari

```

ISL/TS2/5242/WT      GCAGGGGAGCATTTTAAATCGGGCTAAATCATCAGTTTTAATTTGGCTAAAAGGGTTGTTTCAACCCACAAAATAACAGCTGTTTGGGTGGGTGGTGGGGACAGAAAG 110
ISL/TS2/5242/SP      ..... 110
ISL/TS2/5242/LP      ..... 110
GSA/TS7/5170_WT      ..... 110
GSA/TS7/5170_SP      ..... 110
GSA/TS7/5170_LP      ..... 110
TND/S1/19801/WT      ..... 110
TND/S1/19801/SP      ..... 110
TND/SA/19801/LP      ..... 110

ISL/TS2/5242/WT      ACAGCGGACTAAATTAAACATTACATTATTAATGGTATTTTAAGTTTATAGGTGGAGCACACTACT 174
ISL/TS2/5242/SP      ..... 174
ISL/TS2/5242/LP      ..... 174
GSA/TS7/5170_WT      ..... 174
GSA/TS7/5170_SP      ..... 174
GSA/TS7/5170_LP      ..... 174
TND/S1/19801/WT      ..... 174
TND/S1/19801/SP      ..... 174
TND/SA/19801/LP      ..... 174

```

5' NCR M segment Ngari

```

ISL/TS2/5242_WT      TTTTTTAAGAAATCATCATTTTAGTTTTAAAAATTTTATATGTTAGCCTTAGGGCAAATTAGCTGTTATTATATCGGTAGCACACTACT 89
ISL/TS2/5242_SP      ..... 89
ISL/TS2/5242_LP      ..... 89
GSA/TS7/5170_WT      ..... 89
GSA/TS7/5170_SP      ..... 89
GSA/TS7/5170_LP      ..... 89
TND/S1/19801_WT      ..... 89
TND/S1/19801_SP      ..... 89
TND/S1/19801_LP      ..... 89

```

5' NCR L segment Ngari

```

ISL/TS2/5242_WT      AGCATATCTTCATTGGTTTATTTAATTGGACATTCCAAAAGCCACTATGTGGCAAAATGATGACAGCATCAAAAAAGTACAATTTTCTTATGTAGGAGCACACTACT 109
ISL/TS2/5242_SP      ..... 109
ISL/TS2/5242_LP      ..... 109
GSA/TS7/5170_WT      .A. .... .A. .... .TC. .... 109
GSA/TS7/5170_SP      .A. .... .A. .... .TC. .... 109
GSA/TS7/5170_LP      .A. .... .A. .... .TC. .... 109
TND/S1/19801_WT      .A. .... .A. .... .TC. .... 109
TND/S1/19801_SP      .A. .... .A. .... .TC. .... 109
TND/S1/19801_LP      .A. .... .A. .... .TC. .... 109

```

Figure 22: Alignment of 5' non-coding region of S, M and L genome segments of Kenyan Ngari virus isolates.

5' NCR S segment Bunyamwera

MGD/S1/12060/WT	GCAGGGAAGCATTTTAAATCGGGCTAAATCATCAGTTTAAATTTGGCTAAAGGGTTGTTTCAACCCACAAATTAACAGCTGTTTGGGTGGGTGGTTGG	100
MGD/S1/12060/SP	T.....	100
MGD/S1/12060/LP	T.....	100
GSA/S4/11232/WT	T.....	100
GSA/S4/11232/SP	T.....	100
GSA/S4/11232/LP	T.....	100
MGD/S1/12060/WT	GGACAGAAAGACAGCGGACTAAATTAACTTACATTATTAATGGTATTTTAAGTTTtaggtggagCACACTACT	174
MGD/S1/12060/SP	T.....	174
MGD/S1/12060/LP	T.....	174
GSA/S4/11232/WT	T.....	174
GSA/S4/11232/SP	T.....	174
GSA/S4/11232/LP	T.....	174

5' NCR M segment Bunyamwera

MGD/S1/12060_WT	AAATTAGACGGTTATTAAATTCATTATTATATACATTCAAATTCATATTGACACATTGTGTCAAAAACAAGGCTGTTTTGTTATCGGTAGCACACTACT	100
MGD/S1/12060_SP		100
MGD/S1/12060_LP		100
GSA/S4/11232_WT		100
GSA/S4/11232_SP		100
GSA/S4/11232_LP		100

5' NCR L segment Bunyamwera

MGD/S1/12060_WT	AACATATCTTCATTGGTTTATTTAATTGGACATCCAAAAGCACTATGTGGCAAAAATGATGACAGCATCAAAAAAGTACAATTTTCTTATGTAGGAGCACACTACT	108
MGD/S1/12060_SP		108
MGD/S1/12060_LP		108
GSA/S4/11232_WT		108
GSA/S4/11232_SP		108
GSA/S4/11232_LP		108

Figure 23: Alignment of 5' non-coding region of S, M, and L genome segments of Kenyan Bunyamwera virus isolates.

3' NCR Bunyamwera S segment

GSA/S4/11232/WT	AGTAGTGACTCCACACTACAAACTTGCTATTGTTGAAAATCGCTGTGCTATCAAATCTAACAGAAAGTCATTAAAGGCTCTTTA	85
GSA/S4/11232/SP		85
GSA/S4/11232/LP		85
MGD/S1/12060/WT		85
MGD/S1/12060/SP		85
MGD/S1/12060/LP		85

3' NCR Bunyamwera M segment

MGD/S1/12060_WT	AGTAGTGACTACCGATACATCACAAACCTTTCAGAGACACATCTTTATTTTCAAG	56
MGD/S1/12060_SP		56
MGD/S1/12060_LP		56
GSA/S4/11232_WT		56
GSA/S4/11232_SP		56
GSA/S4/11232_LP		56

3' NCR Bunyamwera L segment

MGD/S1/12060_WT	AGTAGTGACTCCTACATATAGAAAATTTAAAAACATAACCAGTAGGAGT	50
MGD/S1/12060_SP		50
MGD/S1/12060_LP		50
GSA/S4/11232_WT	C.....	50
GSA/S4/11232_SP		50
GSA/S4/11232_LP		50

Figure 24: Alignment of 3' non-coding region of S, M, and L genome segments of Kenyan Bunyamwera virus isolates.

3.3.4 Mice pathogenesis

We selected the wild type and plaque phenotypes of isolates GSA/S2/11232 and TND/S7/19801 for the mice pathogenesis experiments. Six-week old mice were not susceptible to infection by either virus isolate. However, newborn mice were susceptible to infection with both BUNV and NRIV isolates and displayed clinical symptoms such as hind limb paralysis, tremors, disorientation and mortality beginning 2-3 days post inoculation. Figure 25 shows a picture of virus inoculated newborn mouse displaying partial paralysis of the hind limb compared to control mouse.



Figure 25: Picture showing comparison between control mice (left) and virus inoculated mice (right). The virus infected mice is showing right hind limb paralysis.

Mice inoculated with isolate GSA/S4/11232SP all died 3 days post inoculation compared to only 50% of mice inoculated with the LP phenotype (Figure 26). However, the rest of the mice died by day 4 post inoculation. The difference in mortality rate between the SP phenotype and the WT and LP was significant ($p = 0.0110$). The converse was true for mice inoculated with NRIV isolate TND/S1/19801 where the LP phenotype was more lethal than the SP phenotype (Figure 27). Mice inoculated with the SP phenotype were alive 4 days post inoculation whereas all mice inoculated with the LP were dead. The difference in mortality was not significant ($p = 0.3579$).




Figure 26: Survival curve comparison of wild type parental and Plaque purified phenotypes of Bunyamwera and Ngari virus isolate infection in mice.




Figure 27: Survival curve comparison of wild type parental and Plaque purified phenotypes of Ngari virus isolate TND/S1/19801 infection in mice.

3.4 Discussion

In the current chapter we evaluate the genetic diversity of plaque purified phenotypes of BUNV and NRIV isolates by full genome sequencing. We also determine the rate of *in vivo* growth in Vero cells and evaluate pathogenesis of the viral phenotypes in Swiss Albino mice. Difference in growth was more pronounced in BUNV than NRIV isolates. This may be explained by the more mutations observed for the former possibly due to the extra passages which the SP and LP phenotypes underwent compared to the WT. In contrast, NRIV phenotypes had fewer mutations despite undergoing extra passages than the WT during the purification and amplification

processes. As expected, the LP phenotypes grew to a higher titer than the SP phenotypes for both BUNV and NRIV isolates. Previous studies of other viruses have correlated plaque size to replication rate with the LP phenotypes displaying faster replication rates than SP phenotypes (Ramsingh et al. 1995, Zhang et al. 1995, Kanno et al. 1998). The LP phenotypes were generally more virulent than SP phenotypes and this would be expected to be the same both *in vitro* and *in vivo* on the assumption that LP phenotypes would produce larger foci of cell destruction (Kanno et al. 1999). However, inoculation of mice with selected BUNV and NRIV isolate phenotypes resulted in discordant observations in the present study. While mice inoculated with the SP phenotype of NRIV isolate, TND/S1/19801, survived longer than the LP phenotype, the reverse was true for BUNV isolate GSA/S4/11232 in which mice inoculated with the SP phenotype died 3 days post-inoculation compared to 4 days post-inoculation for the LP phenotype and this difference in mortality rate was significant. This difference in neurovirulence for phenotypes of BUNV isolate GSA/S4/11232 in mice cannot fully be accounted for by the rate of replication as shown in the one-step growth curves. Previous neurovirulence studies of viruses within the *Orthobunyavirus* genus have mapped such differences to the L segment (Endres et al. 1991). The study by Endres et al., was designed to identify molecular determinants responsible for attenuation of a variant California serogroup virus. Another study investigating the biological function of BUNV L protein demonstrated that mutations in the polymerase genome affect the ability of BUNV to replicate in different cells (Shi and Elliott 2009). Thus, the discordant observed in the current study may have resulted from the unusual deletion observed in the 5' non-coding region of the L segment of the LP phenotype. The non-coding regions are known to play a role in viral RNA and protein synthesis, nucleocapsid formation and virion assembly (Mazel-Sanchez and Elliott 2012). However, reverse genetic studies have shown that non-

conserved sequences of the non-coding region result in attenuation only when large sections are excised (Lowen and Elliott 2005, Mazel-Sanchez and Elliott 2012). This is corroborated by the observed higher growth rate of the GSA/S4/11232 virus isolate LP phenotype compared to the SP phenotype. Moreover, the deletion did not occur between the terminal nucleotides, 20 and 33 where the important packaging elements have been mapped (Kohl et al. 2006). Hence, it is more likely that pathogenesis may have been dependent on the single nucleotide substitutions that were present in the different segments of the BUNV isolate.

It is interesting that all the nucleotide substitutions on the M segment while resulting in non-synonymous amino acid changes, involved substitution of amino acids with the same properties thus a significant difference in protein function would be unexpected. The M segment substitutions resulted in exchange of positively charged amino acids, glutamic acid for lysine. However, two mutations in the L segment of the LP phenotype involved substitution of amino acids with different properties which are likely to alter the functionality of the L protein. Thus for isolate GSA/S4/11232, the LP attenuated pathogenesis may be mapped to any of the 2 non-synonymous mutations on the L segment. The T858I mutation resulting in amino acid substitution of a polar for a non-polar amino acid, occurring within the predicted catalytic site of the L protein (AA 597-1330) seems the most plausible cause of the observed attenuation in pathogenesis. Mutation within the catalytic site of the L protein has been demonstrated to abolish polymerase activity in a previous study (Shi and Elliott 2009).

With regard to isolate TND/S1/19801SP phenotype which was attenuated in mice but genetically similar to the WT virus, it is likely that the SP phenotype was present in a higher quantity in the WT virus, which is a mixture of both LP and SP phenotypes, and could have preferentially been sequenced. However, in the mice pathogenesis experiment, it is likely that the LP phenotype in

the WT grew at a faster rate as expected and resulted in earlier death of mice compared to the SP phenotype. However, we did not isolate the infecting virus from mice to confirm this observation. Another limitation was the use of interferon defective Vero cells for the one step growth curve analysis which may have limited our comparison with mice pathogenesis as the GSA/S4/11232 SP phenotype may have been better at counteracting the interferon response.

In summary, we have identified a mutation in the L segment of BUNV isolate GSA/S4/11232 LP phenotype which may be associated with decreased pathogenesis in suckling mice and virus replication in Vero cells. In addition, we have identified other natural mutations whose role in viral growth and pathogenesis should be determined. Site directed mutagenesis studies may clarify the exact mutation involved in the observed phenotypic changes.

Chapter 4

VECTOR COMPETENCE OF SELECTED MOSQUITO SPECIES IN KENYA FOR NGARI AND BUNYAMWERA VIRUSES.

4.1 INTRODUCTION

BUNV is the type species on the *Orthobunyavirus* genus, the largest of the 7 genera within the *Bunyaviridae* family with 18 different serogroups (Calisher and Karabatsos 1988, Gonzalez-Scarano and Nathanson 1996, Yanase et al. 2006). However, the majority of human pathogens within the genus are distributed among three serogroups; California serogroup, predominantly in North America and Europe, New World Group C viruses and the Bunyamwera serogroup, predominantly in Africa, Central and South America (Calisher and Karabatsos 1988, Elliot et al. 2000). The majority of viruses within the Bunyamwera serogroup are transmitted by mosquitoes.

The clinical manifestations associated with BUNV infection include febrile illness with headache, arthralgia, rash and infrequent central nervous system involvement (Gonzalez and Georges 1988). While viruses of the *Orthobunyavirus* genus are known to cause human disease, they were previously not associated with hemorrhagic manifestation. However, during recent outbreaks of hemorrhagic fevers in Kenya and Somalia, NRIV, a reassortant virus was suspected to have contributed to part of the human hemorrhagic cases (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). Genetic characterization of NRIV revealed that the medium (M) segment was similar to that of BATV, an *Orthobunyavirus* first isolated in Malaysia and not associated with human infection, while the S and L segment were related to BUNV (Traore-

lamizana et al. 2001). This was thought to have occurred due to segment reassortment as a result of co-circulation of BATV and BUNV.

Arthropod borne viruses flourish in many parts of Kenya (Linthicum et al. 1985, Sang and Dunster 2001) and entomological surveys during hemorrhagic fever outbreaks have demonstrated co-circulation of arboviruses, including BUNV (Traore-lamizana et al. 2001, Crabtree et al. 2009). BUNV has been isolated from a range of mosquito species in surveys including *Aedes mcintoshi*, *Aedes ochraceus* and *Aedes quasiunivittatus* (Logan et al. 1991, Crabtree et al. 2009, Ochieng et al. 2013). However, the actual role of these mosquito species in the maintenance and transmission of the virus remains unclear. The identification of mosquito species that are efficient in transmitting these viruses is critical components in estimating the risk of human exposure and understanding the transmission and maintenance mechanism. Additionally, while there is evidence that genetic reassortment can profoundly increase viral pathogenicity (Bowen et al. 2001, Briese et al. 2006); there is lack of data on how this may affect mosquito vector competence. Even a single nucleotide mutation can have a major effect on viral infectivity or replication in particular hosts (Ciota and Kramer 2010). For example, a single mutation in the E2 gene of VEEV can increase vector competence or virulence to cause outbreaks (Anishchenko et al. 2006). Similarly, the recent chikungunya virus outbreak in the Indian Ocean islands was associated with emergence of a virus strain that shared a single common substitution in the E1 gene and a variable second mutation that resulted in increased competence of *Aedes albopictus* as a vector (Tsetsarkin et al. 2007, Tsetsarkin et al. 2009). Likewise, the RVF vaccine, MP-12 virus, is an attenuated virus resulting from accumulation of mutations in its L and M segments (Caplen et al. 1985).

Laboratory assessment of vector competence can provide an insight into the potential of field collected mosquitoes as disease vectors. These studies are intended to assess variations in vector ability to transmit viruses (Hardy et al. 1983). Given that mosquito control methods differ depending on the species type, it is of public health importance to identify which species of mosquitoes are competent vectors that may be involved in the natural transmission cycle so that appropriate measures can be applied. Thus, we set out to determine the vector competence of, *Aedes aegypti*, *Culex quinquefasciatus* and *Anopheles gambiae* for transmission of recent Kenyan isolates of BUNV and NRIV because they are the most abundant mosquito species in many ecological zones in Kenya. Secondly, we determined the possible effect of genetic reassortment on vector competence in the selected mosquito species.

4.2 MATERIALS AND METHODS

4.2.1 Mosquitoes

Mosquitoes tested included established laboratory colonies of *Aedes aegypti* (F>35), *Anopheles gambiae* (F>36) and *Culex quinquefasciatus* (F>40) selected because of their abundance in Kenya, ease of laboratory rearing as well as being sources of previous isolations of BUNV and NRIV (Karabatsos 1985). Additionally, we used field collected *Aedes aegypti* from Rabai, in the Kenyan coastal region to establish a low generation colony (F4-8). Mosquitoes were maintained in 4-liter plastic cages in the biological safety level-2 insectary at 28°C, relative humidity 75-80% and a 12:12 (light: dark) hour photoperiod. They were provided with 10% sucrose solution on cotton pads as a carbohydrate source until used in the study. The selected mosquito species were evaluated for their susceptibility to, and competence in transmitting the two viruses to newborn mice.

4.2.2 Viruses

The viruses used in the study were isolated during previous surveillance exercises in the northeastern Kenya ecozone (Ochieng et al. 2013). Viral stocks were prepared by inoculating the viruses on confluent monolayers of Vero cells and harvested when showing over 75% cytopathic effects. The culture fluids were clarified by centrifugation at 5000g and the supernatants stored frozen at -70°C, after determination of the PFU/mL titers by plaque assay titration on Vero cells, until used (Gargan 2nd et al. 1983).

4.2.3 Vector competence

The selected viral isolates were diluted in defibrinated rabbit blood to a final concentration of approximately 10^{10} PFU/mL. Female mosquitoes, starved for 24 hours, were allowed to feed on infected blood through a Hematok membrane feeder (Discovery Workshops, Accrington, the United Kingdom) (Figure 28). After 1 hour, engorged mosquitoes were separated from unfed mosquitoes and placed into new cages while non-engorged mosquitoes were destroyed. The engorged mosquitoes were maintained for up to 14 days at 28°C, 12:12 (Light: Day) hour and provided 10% sucrose as a carbohydrate source until assayed for infection and dissemination, and transmission potential.



Figure 28: Mosquito feeding experimentation using Hematok membrane feeder.

At days 7 and 14, a subset of mosquitoes was sampled and the extent of virus infection determined by plaque assay of triturated leg and abdomen on Vero cells as previously described (Turell et al. 1984). Thus, detection of virus in the mosquito abdomen only was considered as a non-disseminated infection limited to its midgut while detection in both abdomen and leg was considered a disseminated infection (Turell et al. 1984).

Moist paper in ovicups was placed in the different cages to stimulate oviposition (Figure 29).



Figure 29: Picture showing ovicup with moist filter paper for mosquito oviposition.

4.2.4 Oral transmission

For the transmission experiments, fully engorged day 14 infected mosquitoes (infection dose, approx. 10^{10} PFU/mL) were selected from the pool of fed mosquitoes and placed in cages either singly (Figure 30) or in groups of 2-5 as described by Turell et al (Turell et al. 2007) and allowed to feed on Swiss Albino suckling mice (1-4 days old) . The study protocol (number SSC 2677) was approved by the Animal Care and Use Committee of the Kenya Medical Research

Institute.




Figure 30: Mosquito virus transmission experiment showing mosquito feeding on immobilized mice.

Immediately after the transmission assay, mosquitoes were sampled and their feeding status determined. The legs and abdomen of engorged mosquitoes were separated and assayed by plaque assay as described in section 3.2.3 above. The development of clinical symptoms or death in exposed mice was an indication of successful transmission.

4.2.5 Statistical analysis

Sample size for the vector competence studies was calculated as follows;

A priori power analyses based on chi-square analyses was conducted to determine the appropriate sample sizes required to detect significant differences in mosquito infection and dissemination rates among virus treatment groups using G power software (GPower, <http://www.psych.uni-duesseldorf.de/aap/projects/gpower/>) (Faul et al. 2007). Cohen's effect size w , a measure of the size of the difference between the null and alternative hypotheses (Cohen 1992), was applied. Based on this, we calculated the sample sizes necessary to detect a small to medium difference ($w = 0.2$) of effect size with 99% power (Richards et al. 2007). Thus, for the effect of geographical region, dose, phenotype and species ($P = 0.05$, degrees of freedom [df] = 3), a total sample size of about 589 mosquitoes was required.

The infection rate was determined for each mosquito species as the percentage of mosquitoes with virus in the abdomen, dissemination rate as the percentage of infected mosquitoes with a disseminated infection (virus in the legs), and the transmission rate as the percentage of infected mosquitoes that refed on newborn mice and transmitted virus by bite. Statistical analyses were performed using the R statistical software (R Development Core Team 2008). The Fisher exact test was used to compare virus infection and dissemination rates among mosquito species. Significance was tested at a level of $\alpha \leq 0.05$.

4.3 RESULTS

All the mosquito species tested ingested virus-infected blood. However, different barriers were present in different species (Table 12). This was dependent on the virus species and the infection and dissemination rates were dependent on intrinsic incubation period. We did not observe any difference in infection rates between established laboratory colony of *Aedes aegypti* and the newly established colony hence these data were combined. *Aedes aegypti* was moderately susceptible to BUNV with infection rates of 30.1% and 44.1% at day 7 and day 14 respectively,

developing a midgut infection. The infection rate was similar regardless of the incubation period. Over 60% of *Aedes aegypti* with a midgut infection developed disseminated infection at both time points. Approximately, 17% more mosquitoes developed a disseminated infection at day 14 compared to day 7 and this was statistically significant ($p=0.004$). However, the picture was completely different when *Aedes aegypti* was fed on blood infected with NRIV, with under 4.2% of exposed mosquitoes developing a midgut infection regardless of the intrinsic incubation period (Table 12). None of the few mosquitoes with a midgut infection developed disseminated infection.

Table 12: Infection and dissemination rates for mosquitoes orally exposed to Bunyamwera and Ngari viruses (infectious dose= 10^{10} PFU/ml).

Virus	Mosquito species	Incubation period (days post-infection)	Number tested	Midgut infection N (%)	p-value	Disseminated infection N (%)	P value
Bunyamwera GSA/S1/11232	<i>Aedes aegypti</i>	7	103	31 (30.1)	0.33	19 (18.4)	0.004
		14	143	63 (44.1)		51 (35.7)	
	<i>Anopheles gambiae</i>	7	96	24 (25.0)	0.76	15 (15.6)	0.137
		14	84	32 (38.1)		21 (25.0)	
	<i>Culex quinquefasciatus</i>	7	72	1 (1.4)	ND	ND	ND
		14	80	0		ND	
Ngari TND/S4/19801	<i>Aedes aegypti</i>	7	58	2 (3.4)	1.0	0	ND
		14	96	4 (4.2)		0	
	<i>Anopheles gambiae</i>	7	96	32 (33.3)	0.611	8 (8.3)	0.032
		14	63	24 (38.1)		13 (20.6)	
	<i>Culex quinquefasciatus</i>	7	102	0	ND	ND	ND
		14	87	0		ND	

ND: Not done

In contrast, *Anopheles gambiae* was moderately susceptible to both viruses with 25.0% and 38.1% developing a midgut infection at day 7 and day 14 with BUNV. A similar rate was observed for NRIV with 33.3% and 38.1% of blood fed mosquitoes developing a midgut

infection at day 7 and day 14 respectively. The dissemination rate was 15.6% and 25.0% for BUNV at both day 7 and day 14 time points and was not significantly influenced by the incubation period. However, for NRIV, dissemination rate was 8.3% at day 7 and more than doubled to 20.6% by day 14 (Table 12). This difference in dissemination rate was statistically significant ($p=0.032$). *Culex quinquefasciatus* was refractory to both BUNV and NRIV with only one (1.4%) mosquito developing a midgut infection with BUNV at day 7 which was not disseminated (Table 12). Since, infection rate for NRIV was zero, we did not perform any dissemination experiments for *Culex quinquefasciatus* at days 7 and 14.

4.3.1 Oral Transmission

Twelve fully engorged ‘infected’ mosquitoes at day 14 intrinsic incubation, previously starved for 24 hours, were allowed to feed on 12 singly restrained suckling mice separately for one hour. Eight mice (80%) among those fed on by 10 *Aedes aegypti* mosquitoes (83.3%) with a disseminated infection of BUNV isolate, GSA/S4/11232, developed clinical symptoms characterized by tremors and partial paralysis by day 2 post-transmission (Table 13).

Likewise, 5 (41.7%) mice exposed to BUNV isolate and 5 (100%) exposed to NRIV isolate, TND/S1/19801 infection through bite by *Anopheles gambiae* with disseminated infection developed clinical symptoms by day 2 post-infection. There was no significant difference in dissemination or transmission rates between the mosquito and viral species ($p>0.05$). The mice recovered fully by day 5 post-infection and remained healthy throughout the 14 days of observation. However, for mice exposed to groups of mosquitoes, mortality was observed by day 4 post-infection whenever two or more mosquitoes with a disseminated infection fed.

Table 13: Transmission rates for mosquitoes with disseminated infection after oral exposure to Bunyamwera and Ngari virus isolates

Virus isolate	Mosquito species	No of mosquito tested	No with disseminated infection	Percent Transmission
GSA/S1/11232	<i>Aedes aegypti</i>	12	10 (83.3)	8 (80.0)
GSA/S1/11232	<i>Anopheles gambiae</i>	12	7 (58.3)	5 (71.4)
TND/S4/19801	<i>Anopheles gambiae</i>	12	5 (41.7)	5 (100%)

4.4 DISCUSSION

Implication of a particular mosquito species as a vector of a particular virus requires demonstration of mosquito vector competence and transmission in addition to detection of virus in field collected mosquitoes (Kramer et al. 1992). This is the first report on the ability of mosquitoes in Kenya to transmit NRIV and BUNV. In this study we examined the vector competence of three common mosquito species in Kenya for field isolated BUNV and NRIV. All mosquito species tested ingested blood but different barriers were observed per species with midgut barrier associated with low infection rates and midgut escape barrier associated with a small percentage of infected mosquitoes developing a disseminated infection as described by Turell et al. (Turell et al. 2008). The results indicate that *Anopheles gambiae* is a potentially efficient vector of NRIV. Most isolations of NRIV have been obtained from *Anopheles gambiae* as a single species (Karabatsos 1985), although one of the study isolates (GSA/S4/11232) was obtained from *Anopheles funestus* (Ochieng et al. 2013). *Anopheles gambiae* was moderately susceptible for both viruses with *Aedes aegypti* moderately competent for BUNV. Although

Anopheles gambiae may be a potential vector of NRIV and BUNV, other factors including feeding preference and abundance, need to be considered in implicating the species rather than merely transmission by bite (Turell et al. 2001). Additionally, other mosquito species need to be tested for their competence for NRIV which has been detected previously in West Africa from a wide diversity of mosquito species (Gordon et al. 1992, Zeller et al. 1996). NRIV was the most common isolate from various mosquito species that normally feed on both humans and domestic ungulates including *Anopheles gambiae*, *Anopheles pharoensis*, *Culex antennatus*, *Culex poicillipes* and *Culex tritaeniorhynchus* which suggests that humans and domestic animals may be involved in the ecology of this virus (Gordon et al. 1992). Moreover, NRIV has also been isolated from sick sheep in southern Mauritania and in a survey conducted to monitor RVF virus following the outbreak of 1987 in West Africa. Some of these mosquito species are predominant in different regions in Kenya including *Anopheles gambiae*, *Anopheles pharoensis* and *Culex antennatus* (Lutomiah et al. 2013) hence a risk in case NRIV is introduced in those regions through movement of infected persons, vectors or animals. For instance, RVF outbreak in the Kenyan coast region was attributed to movement of infected animals from the Northern part of Kenya (Nguku et al. 2010). As previously determined, *Aedes aegypti* was a competent vector for BUNV and most isolations have been made from *Aedes* species (Karabatsos 1985). *Culex quinquefasciatus* was incompetent for either virus. This species has been reported to be poorly susceptible to RVF virus, a member of the family *Bunyaviridae* (McIntosh et al. 1980, Turell and Kay 1998). This was attributed to the existence of a major midgut infection barrier (Turell et al. 2008) and which we confirmed as there was almost non-existent mosquito midgut infection for either virus. Moreover, *Culex quinquefasciatus* has a preference for avian species (Elizondo-Quiroga et al. 2006, Garcia-Rejon et al. 2010) from which no NRIV has been isolated although a

recent study has documented the presence of BUNV antibodies in birds in Argentina (Tauro et al. 2009). For a mosquito to be an efficient vector, it must primarily feed on the susceptible host or be a general feeder to act as a bridging vector. However, it is possible that with continuous exposure of these viruses to avian immune system may in future result in mutations that alter vector competence of the vector species for these viruses.

Although *Aedes aegypti* and *Anopheles gambiae* varied in their susceptibility to NRIV and BUNV, over 70% of mosquitoes that developed a disseminated infection transmitted virus by bite. This suggests that midgut infection and escape barriers may be the principal factors controlling vector competence with these viruses (Kramer et al. 1981). One limitation of our study is that we did not use low or moderate viremia that may represent natural viremia in animals. Additionally, we did not test field collected mosquitoes, however, we did not observe a significant difference in infection, dissemination and transmission rates between low and high generation *Aedes aegypti*.

In conclusion, the study suggests that *Anopheles gambiae* is a more competent vector for NRIV than *Aedes aegypti* possibly due to the indirect contribution of genetic reassortment. In addition, *Anopheles gambiae* is also moderately competent for BUNV. This has major implication in the light of continued animal trade and travel especially into malaria endemic regions where *Anopheles gambiae* is more prevalent. In the likely event of introduction of the viruses in such regions, it would pose a challenge to public health authorities due to symptom similarities with other tropical illnesses including malaria. Public health authorities should continually monitor emergent arboviral genotypes circulating within particular regions as well as identify vectors mediating these transmissions in order to preempt and prevent their adverse effects.

Chapter 5

TRANSOVARIAL TRANSMISSION OF NGARI AND BUNYAMWERA VIRUS ISOLATES IN NORTHERN KENYA

5.1 INTRODUCTION

NRIV (family *Bunyaviridae*, genus *Orthobunyavirus*) emerged as a significant human pathogen during previous RVF outbreaks in Africa (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). NRIV was isolated from two hemorrhagic patients and antibodies detected in several others with hemorrhagic fever during the RVF outbreak of 1997/1998 in the Kenya-Somali border region (Gerrard et al. 2004, Briese et al. 2006). Similar observations were made when NRIV was retrospectively isolated from samples of hemorrhagic patients from the 1987/1988 RVF outbreak in the Sudan (Nashed et al. 1993). NRIV is a reassortant composed of the S and L segments of BUNV and the M segment of BATV (Bowen et al. 2001), the latter viruses not associated with hemorrhagic symptoms.

Arthropod-borne viruses flourish in many parts of Kenya (Linthicum et al. 1985, Sang and Dunster 2001) and entomological surveys during hemorrhagic fever outbreaks have demonstrated co-circulation of arboviruses, including BUNV (Traore-lamizana et al. 2001, Crabtree et al. 2009). BUNV has been isolated from a range of mosquito species in surveys including *Aedes mcintoshi*, *Aedes ochraceus* and *Aedes quasiunivittatus* (Logan et al. 1991, Traore-lamizana et al. 2001, Crabtree et al. 2009, Ochieng et al. 2013). Likewise, NRIV has been detected previously in West Africa from a wide diversity of mosquito species including *Anopheles gambiae*, *Anopheles pharoensis*, *Culex antennatus*, *Culex poicillipes* and *Culex tritaeniorhynchus* (Gordon et al. 1992, Zeller et al. 1996). Some of these mosquito species are predominant in different regions of Kenya including *Anopheles gambiae*, *Anopheles pharoensis* and *Culex antennatus* (Lutomiah et al. 2013). However, the actual role of these mosquito species in the maintenance and transmission of the virus in the environment remains unclear. Surveillance for the vector-borne pathogen and identification

of the arthropod vectors that transmit these agents are critical components in estimating the risk of human exposure and understanding the transmission and maintenance mechanism.

Vertical transmission, a means of viral persistence in nature, is important not only for viral survival in nature but also for their role in the establishment of biological transmission. Some Orthobunyaviruses within the California serogroup are known to be maintained in nature through vertical transmission and is unusually high ranging from 20% to over 90% (Turell and Kay 1998, Kuno and Chang 2005). However, there is paucity of data regarding vertical transmission in Bunyamwera serogroup viruses. We have recently determined the vector competence of selected mosquito species (*Aedes aegypti*, *Culex quinquefasciatus* and *Anopheles gambiae*) for BUNV and NRIV isolates in Kenya (Chapter 4). *Aedes aegypti* and *Anopheles gambiae* were determined to be competent vectors for BUNV while the later was competent for NRIV. In this study we assess the ability of competent mosquito species, as determined in the preceeding chapter (Chapter 4), to transmit BUNV and NRIV transovarially to their progeny.

5.2 MATERIALS AND METHODS

5.2.1 Mosquitoes

Mosquitoes tested included established laboratory colonies of *Aedes aegypti* (F>4-8), and *Anopheles gambiae* (F>36). Mosquitoes were maintained in 4-liter plastic cages in the biological safety level-2 insectary at 28°C, relative humidity 75-80% and a 12:12 (light: dark) hour photoperiod. They were provided with 10% sucrose solution on cotton pads as a carbohydrate source until used in the study.

5.2.2 Viruses

The viruses used in the study were isolated during previous surveillance exercises in northeastern Kenya (Ochieng et al. 2013). Two Kenyan isolates were employed; these were the BUNV isolate GSA/S1/11232, from a pool of *Aedes mcintoshi* and NRIV isolate TND/S1/19801 obtained from a pool of *Anopheles funestus*. Viral stocks were prepared by inoculating the viruses on confluent

monolayers of Vero cells and harvested when showing over 75% cytopathic effects. The culture fluids were clarified by centrifugation at 5000g and the supernatants stored frozen at -70°C, after determination of the PFU/mL titers by plaque assay (Section 3.2.3) titration on Vero cells, until used (Gargan 2nd et al. 1983).

5.2.3 Transovarial transmission

The selected viral isolates were diluted in defibrinated rabbit blood to a final concentration of approximately 10^{10} PFU/mL. Female mosquitoes, starved for 24 hours, were allowed to feed on infected blood through a Hematok membrane feeder (Discovery Workshops, Accrington, the United Kingdom) (Figure 28). After 1 hour, engorged mosquitoes were separated from unfed mosquitoes and placed into new cages while non-engorged mosquitoes were destroyed. The engorged mosquitoes were maintained at 28°C, 12:12 (L: D) hour for 6-7 days and provided 10% sucrose as a carbohydrate source. Moist paper in ovicups was placed in the different cages to stimulate oviposition (Figure 29). After oviposition, mosquitoes were fed on uninfected mice to stimulate egg production and fresh ovicups placed into the cages (Figure 31). This was repeated again to achieve the third ovarian cycle. All egg rafts on filter paper were collected and allowed to hatch in distilled water (Figure 32). Pupae were removed, washed in water, and placed for emergence in 1-liter cardboard containers with netting secured over the open end. Emerged adult mosquitoes were contained in a mosquito rearing container (Figure 33) and maintained for 4-8 days at 26°C and then triturated in pools of 25 mosquitoes each in 1 ml of diluent. These were frozen at -70°C until assayed by plaque assay on Vero cell monolayers.



Figure 31: Photograph showing mosquito feeding on anesthetized mice to stimulate oviposition.



Figure 32: Photograph showing filter papers with mosquito eggs placed in distilled water to allow for hatching.



Figure 33: Photograph showing mosquito rearing container and shelves for adult mosquito containment

5.3 RESULTS

Using plaque assay to identify infected mosquito pools, 12 pools comprising 291 orally infected *Aedes aegypti* mosquitoes, 9 pools (75.0%) were positive for BUNV during the first ovarian cycle (Table 14)

.Table 14: Comparison between ovarian cycle and vertical transmission rates of Bunyamwera virus isolate GSA/S4/11232 among *Aedes aegypti* and *Anopheles gambiae* colonies.

Ovarian cycle	Number of infected pools/total pools (%)	
	<i>Aedes aegypti</i>	<i>Anopheles gambiae</i>
1	9/12 (75.0%)	3/9 (33.3%)
2	3/12 (25.0%)	3/6 (50.0%)

There was a drastic reduction during the second ovarian cycle with only 3 pools (25.0%) of adult mosquitoes being positive. For *Anopheles gambiae* mosquitoes however, 3 pools (33.3%) out of 9 pools in the first ovarian cycle were positive for BUNV while 3 pools (50%) of adult mosquitoes were positive in the second ovarian cycle.

5.4 DISCUSSION

Our study confirms that *Aedes aegypti* and *Anopheles gambiae* mosquitoes are able to vertically transmit BUNV in contrasting fashion. The efficiency of Bunyavirus transovarial transmission is thought to result from direct infection of ovarian tissues hence ova are already infected before oviposition as opposed to virus infecting eggs during oviposition in other viruses (Beaty and Thompson 1978, Rosen 1988, Rosen et al. 1989, Dohm et al. 2002). The higher transovarial transmission rates in our study are thus not unexpected as determined previously (Turell et al. 1982a). Transovarial transmission of BUNV by *Anopheles gambiae* was consistent with previous studies that indicate vertical transmission inefficiency during the first ovarian cycle after oral exposure (Miller et al. 1979). However, *Aedes aegypti* displayed a different picture with transovarial transmission more efficient during the first ovarian cycle and subsequently reduced in the second and third ovarian cycles. This is similar to a previous study of vertical transmission of California encephalitis virus by two *Aedes* mosquito species where filial infection rate was highest in the first ovarian cycle progeny and declined with increasing ovarian cycles (Turell et al. 1982a). Both mosquito species displayed transovarial transmission in the first ovarian cycle and the rates were reflective of the infection and dissemination rates determined in the preceeding chapter (Chapter 4) where *Aedes aegypti* had a more permissive midgut infection and escape barrier for BUNV compared to *Anopheles gambiae*. The same transmission barriers have been implicated in the vector competence of *Aedes aegypti* and *Aedes albopictus* species for La Crosse virus (Hughes et al. 2006). Transovarial transmission to the first ovarian cycle progeny may be attributed to the development of a stabilized infection in these mosquito species, where nearly all cells are infected including the germinal tissue as determined for some California serogroup viruses (Tesh and

Shroyer 1980, Turell et al. 1982b). The difference in vertical transmission rate in the different mosquito species needs to be investigated to determine the exact mechanism.

Our study was not devoid of limitations, including the use of long colonized laboratory strains of the vectors (*Anopheles gambiae*). Hence, these results need confirmation using newly colonized strains. Our efforts to determine the rate of vertical transmission of NRIV was frustrated by the inability to obtain adult mosquitoes from the larvae which died during experimentation. This may be attributed to retardation of larval development by the infecting virus. This warrants further investigation to identify the exact cause of larval retardation. Additionally, we did not attempt to isolate virus from the larvae as confirmation of successful transovarial transmission.

In conclusion, *Aedes aegypti* and *Anopheles gambiae* are competent vector of BUNV with contrasting vertical transmission rates depending on the ovarian cycle. Additionally, our results suggest that BUNV may persist longer in *Anopheles gambiae* mosquito species, making it a more competent vector in sustaining the virus during dry periods.

Chapter 6

SEROPREVALENCE OF ORTHOBUNYAVIRUSES IN SELECT PARTS OF RIFT VALLEY AND NORTH EASTERN KENYA

6.1 INTRODUCTION

BUNV and NRIV have recently been isolated from mosquitoes and ticks in the north eastern pastoral zones of Kenya (Lwande et al. 2013, Ochieng et al. 2013). Likewise, Ilesha and Germiston viruses have been previously isolated from mosquitoes in western Kenya (Johnson et al. 1977). These viruses belong to the *Orthobunyavirus* genus of the family *Bunyaviridae* and possess a tripartite, single-stranded, negative-sense RNA genome. Some members of the genus including these four viruses are known to cause clinical disease in humans with diverse pathological consequences. BUNV, the prototype member of the family, is associated with febrile illness with headache, arthralgia, rash and infrequent central nervous system involvement (Gonzalez and Georges 1988, Grimstad 1988). Ilesha virus has been associated with febrile illness and erythema, and in some cases, fatal meningoencephalitis and hemorrhagic fever (Morvan et al. 1994). Germiston virus is characterized by mild disease with fever, rash and headache (Karabatsos 1985). Genetic reassortments between members of serogroups within the *Orthobunyavirus* genus are known to occur in nature leading to emergence of new viruses with altered pathogenesis (Bowen et al. 2001, Saeed et al. 2001, Gerrard et al. 2004, Aguilar et al. 2011, Blitvich et al. 2012). NRIV, a reassortant of BUNV and BATV, has been implicated in recent outbreaks of hemorrhagic fevers in Kenya and Somalia (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006). NRIV genome comprises the L and S segment of BUNV and the M segment of BATV, the two viruses not associated with hemorrhagic manifestations (Briese et al. 2006).

While BUNV, NRIV, Ilesha virus and Germiston virus have been isolated from mosquito and/or tick vectors during surveillance exercises in Kenya, no clear evidence exists for incidence of human

infection with these viruses as diagnostic laboratories seldom test for *Orthobunyavirus* infections. The actual disease burden of these viruses in Kenya remains to be determined. Moreover, viruses of the genus comprise a neglected but potentially deadly group of viruses as evidenced by the recent outbreak of Schmallenberg virus in Europe that resulted in malformations in ruminants (Lutomiah et al. 2013) and the implication of NRIV in hemorrhagic fever outbreaks within northern Kenya (Bowen et al. 2001, Gerrard et al. 2004, Briese et al. 2006, Lutomiah et al. 2013).

The International Centre of Insect Physiology and Ecology (ICIPE) is conducting a project entitled; An Integrated Response System for Emerging Infectious Diseases in East Africa, also known as Arbovirus Infection and Diversity (AVID) project. The project brings together a consortium of implementing institutions consisting of health, veterinary, wildlife and vector experts to take an integrated approach to arbovirus surveillance and research. The main aim of the project is to improve the prediction and prevention of RVF and other emerging arboviruses (CCHF, YF, Dengue, Onyong-nyong, WN, CHIK, Semliki Forest viruses etc.) and hoping to develop a model for response that could be expanded to other emerging diseases in the East African region. The project is interested in the discovery of both known and unknown viruses causing Emerging Infectious Diseases. The present analysis that uses samples from the AVID project aims to determine 1) the prevalence of *Orthobunyavirus* antibodies among febrile patients randomly selected from an ongoing febrile surveillance in three different regions of Kenya, as an indication of past clinical or subclinical infections and, 2) the demographic risk factors associated with exposure to these viruses.

6.2 METHODS

6.2.1 Study site

The study was conducted in Ijara District, Garissa County of northern Kenya (Figure 34). The region is an arid to semi-arid region with a majority of inhabitants practicing nomadic pastoralism with cattle, goats, sheep, donkeys and camels. Human whole blood specimens were drawn from febrile patients attending Sangailu Dispensary and Ijara Health Centre, the main health facilities that

serve most of the inhabitants. Additionally, blood specimens were drawn from Naivasha, a town within the Rift Valley Province of Kenya where these viruses have not been previously isolated, but a known RVF endemic region (Lutomiah et al. 2013).

6.2.2 Viruses

The BUNV (GSA/S4/11232) and NRIV (TND/S1/19801) strains used in this study were isolated from *Aedes mcintoshi* and *Anopheles funestus* respectively, during surveillance in the northern Kenya pastoral zone (Ochieng et al. 2013). Ilesha and Germiston viruses were obtained from the Centers of Disease Control and Prevention, Fort Collins, Colorado.




Figure 34: A map showing study sites in Garissa and Nakuru Counties, Kenya.

6.2.3 Study population

This was a retrospective study utilizing randomly selected 345 serum specimens collected from febrile patients in Sangailu Dispensary (n=94), Kotile Health Centre (n=118) and Naivasha health centre (n=133). The surveillance was conducted from January 2009 through April 2012. Blood

blood specimens were obtained from patients presenting with acute febrile illness, including symptoms like chills, cough, headache, joint aches, general body weakness, and any hemorrhagic signs. Inclusion criteria included patients greater than 5 years of age, referred for laboratory blood test by clinicians and consented to participate in the study. Demographic data was obtained from participants during the consenting process using a standard questionnaire (Appendix 4).

6.2.4 Ethical consideration

The samples used in this study were drawn from consenting patients and were de-identified. A signed consent form was obtained from participants 18 years and above while for patients younger than 18, a written assent was obtained from the parent or guardian (Appendix 3A-C). The human use protocol was approved by the Ethical Review Committees of the Kenya Medical Research Institute, Kenya (Protocol 2677) and the University of Pretoria, South Africa (Protocol 299/2013).

6.2.5 Neutralizing antibody prevalence

Each serum specimen was screened for anti-viral antibodies using the plaque reduction neutralization test (PRNT) as previously described (Rodrigues et al. 2011, Blitvich et al. 2012). Briefly, virus isolates were diluted to a standard concentration yielding 20-50 plaques. Sera were heat-inactivated at 56° for 30 minutes and diluted at 1:20 concentration in maintenance media (minimum essential media) (Sigma) with Earle's salts, 2% fetal bovine serum, 2% glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1 µL/mL amphotericin B). The serum dilutions were added to microcentrifuge tubes containing the standard concentration of the diluted virus and incubated for 1 hour at 37⁰C. The virus–antibody mixtures were then added to a 24-well plate with confluent Vero cell monolayer and incubated for 1 hour for un-neutralized virus adsorption after which an overlay of 1.25% methylcellulose (Sigma Aldrich) was added and incubated for 5 days. The plates were stained with 0.25% crystal violet (Sigma Aldrich) in absolute ethanol (Sigma Aldrich) and plaques counted. All reactive sera from the initial screening were further serially diluted to determine the endpoint titer, highest dilution that neutralizes 90% or greater of the virus

relative to a serum-free control (Figure 35). For serum specimens that were reactive with more than one virus, a four-fold or higher PRNT₉₀ antibody titer difference was required to determine the infecting virus.




Figure 35: Picture showing comparative Plaque Reduction Neutralizing Test performed on a 24-well plate

6.2.6 Statistical analysis

Statistical analysis was performed using R statistical package (R Development Core Team 2008). The proportions of reactive specimens ($\text{PRNT} \geq 20$) were calculated with their respective 95% confidence intervals. Proportions were compared using Pearson Chi Square or Fischer exact tests where cell counts were less than 5. Bivariate analysis was done and variables that had a $p \leq 0.25$ were included in the final multivariate model. Variables that fit in the final model were age, occupation and district. Associations were reported using odds ratios. Variables that had a $p \leq 0.05$ in the final model were reported as significant.

6.3 RESULTS

6.3.1 PRNT antibody seroprevalence and risk factors

Overall, 89/345 (25.8%) febrile patients had neutralizing antibody to at least one of the four orthobunyaviruses with prevalences of 11.9%, 15.9%, 8.7% and 3.2% for BUNV, NRIV, Ilesha virus and Germiston virus respectively. Thirty three patients (9.6%) had neutralizing antibodies to more than one virus with majority of cross-neutralization between Ilesha virus and BUNV (Table 15). These 33 specimens were titrated and analyzed by comparative PRNT to identify the *Orthobunyavirus* responsible for the seropositivity. Eight specimens were resolved based on this analysis while 25 specimens remained undetermined (Table 15). Patients with neutralizing antibodies against any *Orthobunyavirus* in this study were significantly older than those without neutralizing antibodies; BUNV (35 versus 25 years; Chi Square test; $P < 0.0001$), NRIV (30 versus 25 years Chi Square test; $P = 0.033$), Ilesha virus (46 versus 28 years; $p=0.000$) and Germiston virus (41 versus 30 years; $p=0.019$).

Seroprevalence were significantly higher in Sangaila district for both BUNV and NRIV followed by Kotile district (25.5% vs 12.7% and 33.0% vs 20.8% respectively) (Table 16) while Naivasha district had the least prevalence with 1.5% for BUNV and no evidence of exposure to NRIV (Figures 36 and 37). However, for Ilesha virus, seroprevalence was relatively similar between Sangailu and Kotiel districts (14.9% versus 13.6%) while higher in the latter for Germiston virus (2.1% versus 7.6%).

Table 15: Endpoint titers of serum samples collected from persons in North Eastern Kenya and analyzed using comparative PRNT

	Demographic characteristics				PRNT ₉₀ titers				
Patient ID	Collection year	Residence	Age (y)	Sex	BUNV	NRIV	ILEV	GERV	Diagnosis
HSA010062	2009	Sangailu	50	M	160	160	160	80	UND
HSA010005	2009	Sangailu	50	F	160	-	20	-	BUNV
HSA010010	2009	Sangailu	60	M	-	40	40	-	UND
HSA010074	2010	Sangailu	30	M	20	160	-	-	NRIV
HSA010094	2010	Sangailu	20	F	160	80	-	-	UND
HSA010109	2010	Sangailu	60	F	40	20	-	-	UND
HSA010303	2010	Sangailu	60	M	40	-	40	-	UND
HSA010312	2010	Sangailu	20	F	40	80	320	160	UND
HSA010314	2010	Sangailu	20	F	80	-	40	-	UND
HSA010389	2010	Sangailu	47	M	80	40	-	-	UND
HSA010395	2010	Sangailu	60	M	80	-	20	-	UND
HSA010752	2011	Sangailu	16	M	20	160	-	-	NRIV
HSA010779	2011	Sangailu	30	F	20	40	-	-	UND
HSA010780	2011	Sangailu	50	F	80	40	40	-	UND
HSA010856	2011	Sangailu	80	F	40	-	20	-	UND
HSA010888	2011	Sangailu	29	M	80	-	40	-	UND
HSA010918	2011	Sangailu	30	M	20	160	40	-	NRIV
HSA010947	2011	Sangailu	90	F	20	80	40	-	UND
HSA010988	2012	Sangailu	38	M	-	160	40	-	NRIV
HSA050018	2011	Kotile	17	M	80	-	20	-	BUNV
HSA050075	2011	Kotile	37	M	40	40	-	20	UND
HSA050083	2011	Kotile	35	M	80	-	80	40	UND
HSA050102	2011	Kotile	36	M	80	160	40	80	UND
HSA050124	2011	Kotile	30	M	-	≥640	160	-	NRIV
HSA050137	2011	Kotile	24	F	160	20	160	40	UND
HSA050146	2011	Kotile	19	M	20	80	-	-	NRIV
HSA050220	2011	Kotile	76	M	-	80	80	40	UND
HSA050222	2011	Kotile	73	M	-	80	80	160	UND
HSA050225	2011	Kotile	30	M	80	320	160	160	UND
HSA050286	2012	Kotile	37	F	80	160	160	80	UND
HSA050308	2012	Kotile	8	F	40	20	20	-	UND
HSA050388	2012	Kotile	55	F	20	-	40	-	UND
HSA050399	2012	Kotile	50	F	20	40	-	-	UND

*PRNT, plaque reduction neutralization test; BUNV, Bunyamwera virus; NRIV, Ngari virus; ILEV, Ilesha virus; GERV, Germiston virus; –, titer <20; UND, undetermined orthobunyavirus.

Neutralizing antibody prevalence for both BUNV and NRIV was similar among males and females (12.7% versus 11.4% and 15.7% versus 16.1%, respectively; $p < 0.05$) (Table 16). However, seroprevalence was more than twice higher in males for Ilesha and Germiston viruses (12.7% versus 6.2% and 6.0% versus 1.4%, respectively). Seroprevalence was significantly higher in participants above 50 years of age for BUNV and Ilesha viruses while for NRIV and Germiston viruses, seroprevalence peaked in participants of ages between 30 and 49 years. Participants 19 years and below had the lowest seroprevalence of either virus (3.0%).




Figure 36: Bunyamwera virus seroprevalence by age groups in health facilities in Kotile, Sangailu and Naivasha health facilities 2009-2012.




Figure 37: Ngari virus seroprevalence by age groups in health facilities in Kotile, Sangailu and Naivasha health facilities 2009-2012.

Table 16: Demographic characteristics of persons with positive PRNT for Bunyamwera and Ngari viruses in Kenya.

Characteristic	BUNV PRNT ₉₀	NRIV PRNT ₉₀	ILEV PRNT ₉₀	GERV PRNT ₉₀	
District	N (%)	N (%)			Total
Sangailu	24 (25.5)	31 (33.0)	14 (14.9)	2 (2.1)	94
Naivasha	2 (1.5)	0 (0)	0 (0)	0 (0)	133
Kotile	15 (12.7)	24 (20.3)	16 (13.6)	9 (7.6)	118
Gender					
male	17 (12.7)	21 (15.7)	17 (12.7)	8 (6.0)	134
female	24 (11.4)	34 (16.1)	13 (6.2)	3 (1.4)	211
Age					
5-19	3 (4.1)	10 (13.5)	2 (2.7)	0 (0)	74
20-29	13 (10.5)	13 (10.5)	6 (4.8)	2 (1.6)	124
30-39	8 (10.5)	17 (22.4)	7 (9.2)	6 (7.9)	76
40-49	1 (5.6)	4 (22.2)	0 (0)	0 (0)	18
≥50	16 (30.2)	11 (20.8)	15 (28.3)	3 (5.7)	53
Occupation					
Farmer	6 (14.0)	5 (11.6)	7 (16.3)	2 (4.7)	43
Herdsmen	7 (21.2)	9 (27.3)	6 (18.2)	1 (3.0)	33
Housewife	17 (13.7)	25 (20.2)	7 (5.6)	2 (1.6)	124
Student	4 (12.1)	5 (15.2)	1 (3.0)	0 (0)	33
Businessman	1 (1.9)	3 (5.7)	3 (5.7)	3 (5.7)	53
Formal employment	2 (10.0)	2 (10)	0 (0)	1 (5.0)	20

In terms of occupation, seroprevalence was highest among herdsmen for BUNV, NRIV and Ilesha viruses (21.2%, 27.3% and 18.2% respectively). Businessmen had the lowest seroprevalence for BUNV and NRIV (1.9% vs 5.7% respectively).

Univariate and Multivariate logistic regression indicated that age and location were significantly associated with *Orthobunyavirus* seroprevalence (Table 17 and 18). The odds of *Orthobunyavirus* infections increased by approximately 1.0 for a 1-year increase in age after controlling for other factors. The odds of BUNV seropositivity were higher in Sangailu than Kotile (OR 3.76, 95% CI 1.45, 9.73). Similarly, the odds for NRIV seropositivity were higher in Sangailu compared to Kotile (OR 2.83, 95% CI 1.27, 6.33). Further analysis revealed that occupation and gender of patients was not significantly associated with BUNV and NRIV seropositivity. However, gender was associated with Ilesha and Germiston virus seropositivity with males more than twice likely to have antibodies against the two viruses.

Table 17: Bivariable analysis of risk factors associated with *Orthobunyavirus* infections in Kenya.

	Bunyamwera virus		Ngari virus		Ilesha virus		Germiston virus	
Variable	OR [95% CI]	p-value	OR [95% CI]	p-value	OR [95% CI]	p-value	OR [95% CI]	p-value
Gender		0.7145		0.9129				
Females	<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	
Males	1.13 [0.58 – 2.20]	0.714	0.967 [0.535- 1.750]	0.913	2.23(1.04-4.76)	0.037	4.42(1.15-17.00)	0.03
Age (years)	1.04 [1.02 - 1.06]	< 0.0001	1.017 [0.9999 - 1.0342]	0.052	1.06[1.03 - 1.08]	0.000	1.04[1.00 - 1.07]	0.025
Age Category (Years)		0.0006		0.1427		0.000		0.053
5 - 19	<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	
20 - 29	2.77 [0.76 - 10.07]	0.121	0.750 [0.311 - 1.807]	0.521	0.58(0.11 - 3.03)	0.523	0.20(0.03-1.26)	0.087
30 - 39	2.78 [0.71 - 10.94]	0.142	1.844 [0.782 - 4.347]	0.162	1.60(0.31 - 8.13)	0.574	1.43(0.34-6.00)	0.63
40 - 49	1.39 [0.14 -14.23]	0.78	1.829 [0.500 -6.681]	0.361			1	
≥ 50	10.23 [2.80 -37.39]	< 0.0001	1.676 [0.654 -4.294]	0.282	6.12(1.30 - 28.82)	0.022	1	
Location		< 0.0001		0.004		0.782		0.060
Sangailu	2.35 [1.15-4.80]	0.019	1.927 [1.036- 3.587]	0.038	1.12[0.51 - 2.42]	0.782	<i>ref.</i>	
Naivasha	0.10 [0.02-0.47]	0.003						
Kotile	<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		3.80(0.80-18.02)	0.090
Occupation		0.0794		0.077		0.008		
Businessman	0.17 [0.02- 2.03]	0.162	0.54 [0.083- 3.499]	0.518	64[2.83 - 1446.88]	0.009	1.14[0.11-11.65]	0.912
Farmers	1.46 [0.27- 7.96]	0.662	1.184 [0.209- 6.7]	0.848	1.92[0.19 - 19.27]	0.579	0.93[0.08-10.86]	0.952
Herdsmen	2.42 [0.45- 13.03]	0.303	3.375 [0.648- 17.566]	0.148	6.22[0.73 - 53.35]	0.095	0.59[0.04-10.05]	0.718
Housewife	1.43 [0.30- 6.72]	0.651	2.273 [0.494- 10.447]	0.291	7.11[0.81 - 62.79]	0.078	0.31[0.03-3.60]	0.350
Student	1.24 [0.21- 7.48]	0.813	1.607 [0.281- 9.188]	0.594	1.91[0.23 - 16.13]	0.550		
Formal employment	<i>ref.</i>		<i>ref.</i>		<i>ref.</i>		<i>ref.</i>	

Table 18: Multivariable analysis of risk factors associated with *Orthobunyavirus* infections in Kenya

	Bunyamwera virus		Ngari virus		Ilesha virus		Germiston virus	
Variable	AOR [95% CI]	p-value	AOR [95% CI]	p-value	AOR [95% CI]	p-value	AOR [95% CI]	p-value
Gender								
Females					<i>ref</i>		<i>ref</i>	
Males					2.61(0.74 - 9.29)	0.137	8.00(1.89-33.74)	0.005
Age (years)								
Age Category (Years)								
5 - 19	<i>ref.</i>				<i>ref</i>		<i>ref</i>	-
20 - 29	2.16 [0.22 - 21.57]	0.513	0.636 [0.183 - 2.21]	0.476	0.15(0.02 - 1.25)	0.080	0.35(0.05-2.30)	0.272
30 - 39	2.21 [0.19 - 26.21]	0.531	1.877 [0.532 - 6.628]	0.328	0.37(0.04 - 3.18)	0.368	2.49(0.53-11.84)	0.250
40 - 49	8.57 [0.71- 103.03]	0.0910	0.981 [0.183- 5.253]	0.9820			1	-
≥ 50	31.56 [2.96- 336.12]	0.0040	0.700 [0.171 - 2.868]	0.6200	0.74(0.09 - 6.15)	0.778	1	-
Location								
Sangailu	3.76 [1.45- 9.73]	0.006	2.829 [1.265- 6.326]	0.011			<i>ref</i>	
Naivasha	0.04 [0.01- 0.37]	0.004	--				-	
Kotile	<i>ref.</i>						5.77[1.13 - 29.61]	0.036
Occupation								
Businessman	0.11 [0.01 - 1.75]	0.118	0.869 [0.080- 9.479]	0.908	2.98[0.20 - 44.89]	0.430		
Farmers	0.24 [0.03 - 2.11]	0.196	0.577 [0.063 - 5.268]	0.626	7.23[0.53 - 98.53]	0.138		
Herdsmen	0.18 [0.02 -1.61]	0.126	0.534 [0.063 - 4.539]	0.565	6.53[0.4 - 92.98]	0.166		
Housewife	0.12 [0.02- 0.86]	0.035	0.396 [0.0538 - 2.915]	0.363	4.60[0.31 - 68.28]	0.267		
Student	2.39 [0.15 - 38.46]	0.54	0.722 [0.065 - 8.014]	0.728	<i>ref.</i>			
Formal employment	<i>ref.</i>		<i>ref.</i>		-			

6.3.3 Malaria diagnosis

Of 87 patients with at least one *Orthobunyavirus* seropositivity, only 43 (49.4) patients had a confirmatory laboratory test performed for malaria diagnosis. Of these 43 laboratory diagnostic tests, only 8 (18.6%) were positive. Forty-one patients had a presumptive malaria diagnosis based on the clinical symptoms and the clinician's judgement.

6.4 DISCUSSION

In this chapter, we determine the prevalence of four orthobunyaviruses, BUNV, NRIV, Ilesha and Germiston viruses, in febrile patients attending health facilities in three different regions of Kenya. The overall seroprevalence for either of BUNV, NRIV, Ilesha virus and Germiston virus was 25.8%, indicative of significant circulation of these viruses among the Kenyan population. The lowest seroprevalence was against Germiston virus which suggests that human exposure is low and may be attributed to the feeding preference of the implicated mosquito vector, *Culex rubinotus*, which feeds primarily on rodents, to a moderate degree on domestic ungulates and rarely on humans (Jupp et al. 1976).

It is interesting to note that majority of infections occurred in persons greater than 15 year old indicating that this may represent exposure to these viruses during the last RVF outbreak in 1997/98 in which NRIV was isolated from hemorrhagic fever patients and antibodies detected in others (Briese et al. 2006). The prevalence of antibodies against BUNV, NRIV, Ilesha virus and Germiston virus increased with age suggesting endemicity of these viruses in Sangailu and Kotile districts. Seroprevalence was highest in persons aged ≥ 50 years for BUNV and Ilesha virus whereas NRIV and Germiston virus seroprevalence was higher in persons ≥ 30 years. About 27% of patients with hemorrhagic fever investigated in the 1997/1998 outbreak had evidence of acute NRIV infection (Briese et al. 2006). Thus, it is possible that some of the cases in the present study may be persons with IgG antibodies acquired in previous exposure during the previous outbreak.

There was a high degree of cross-neutralization between the BUNV and Ilesha virus assays which could not be distinguished by comparative PRNT. This was unexpected given there is little cross-neutralization between the two viruses (Hunt and Calisher 1979, Karabatsos 1985). Additionally, 12 patients had neutralizing antibodies to BUNV and NRIV and likewise could not be distinguished by comparative PRNT suggesting that these may represent persons doubly infected many years ago and as such, trace amounts of antibody remaining were insufficient to yield a 4-fold or greater titer between the implicated viruses. Alternatively, in the absence of virus isolation, there could be other yet to be identified orthobunyaviruses circulating within the same region. Although we did not screen for Shokwe virus, previously isolated in Kenya, antibodies against the virus do not neutralize any of the viruses tested in the current study (Hunt and Calisher 1979, Nashed et al. 1993). Additionally, it is possible that some of the patients seropositive for NRIV may have been infected with Batai virus (Nashed et al. 1993) although this virus has not been isolated in Kenya. We also did not have a virus from a different serogroup as a control for our neutralization assays.

The failure of public health system to identify those infected with these viruses may be attributed to the non-specific nature of their clinical presentation making it difficult to differentiate them from other diseases that present with febrile illness including malaria, typhoid and brucellosis. Additionally, this may be compounded by the unavailability of laboratory assays that can be used to detect these viruses in such remote and poor settings and this can explain why about half the patients seropositive for at least one *Orthobunyavirus* had a presumptive malaria diagnosis. In many settings, malaria is generally ascribed to all febrile illnesses unless confirmation is made by laboratory diagnosis. However, malaria-like symptoms are also observed for arbovirus infections and as such, presumptive malaria diagnosis by the clinicians may be inappropriate. Additionally, only approximately 18% of patients tested had confirmed malaria infection indicating that there are likely other causes of febrile illness than malaria alone. More importantly, once a smear is positive to malaria, public health laboratories rarely test for alternative causes of disease. While all patients in this study sought care for unspecified fever, we could not determine whether any of these febrile

illnesses resulted from infection by either of the four viruses because there was no follow up to obtain convalescent sample for determination of rise in antibody titer.

The seroprevalence of BUNV, NRIV, Ilesha and Germiston viruses in Sangailu district was significantly higher than that in Kotile and lowest in Naivasha while Germiston seroprevalence was higher in Kotile. The difference in arbovirus prevalence between different locations has been reported in other arboviral prevalence studies within Kenya (Mease et al. 2011, Lwande et al. 2012) and can be explained by the different climatic conditions within these regions that influence economic activities of residents. The nomadic nature of inhabitants of North Eastern Kenya may result in spread of the viruses due to their close interaction with domestic animals and possible interaction of their animals with wild animals, which may be reservoirs of these viruses, during grazing (Lwande et al. 2012).

Although not statistically significant, herdsmen were at higher risk of infection by all orthobunyaviruses than housewives, farmers, students and businessmen. This may be so because of their close proximity to animal herds that may expose them to bites from mosquitoes and or ticks that have previously fed on infected animals as determined for RVF virus (Anyangu et al. 2010). Housewives were the second most affected, possibly through taking care of small livestock like sheep and goats in addition to milking (Lwande et al. 2012).

In conclusion, the present study demonstrates serological evidence of *Orthobunyavirus* activity in Sangailu and Kotile districts of Garissa County in northern Kenya. Age and location are all risk factors for BUNV and NRIV exposure. Orthobunyaviruses, among other arboviruses, should be considered when investigating etiologies of fever illnesses in North Eastern Kenya especially during seasons of high mosquito abundance.

Chapter 7

Concluding Remarks

BUNV is the prototype virus of the *Bunyaviridae* family and *Orthobunyavirus* genus. These viruses with segmented RNA genomes have the potential for genetic reassortment and and/or drift. While these viruses can cause human disease, they were not associated with hemorrhagic fever symptoms until NRIV, a natural reassortant virus of BUNV and BATV, was isolated from hemorrhagic fever patients and antibodies detected in several others during the 1997/1998 RVF outbreak in East Africa and retrospectively in the 1987/1988 outbreak in Sudan. While genetic drift and reassortment are known to occur frequently in the *Bunyaviridae* family, the epidemiological consequences of these evolutionary events are poorly understood and further hampered by lack of complete genome sequences. Additionally, BUNV and NRIV have been isolated in different mosquito species in surveillance exercise in northern Kenya but the role of these vectors in the maintenance and transmission of these viruses are poorly known. Moreover, actual disease burden of these viruses in Kenya remains to be determined since diagnostic laboratories seldom test for these infections. Thus, in this study we investigated the dynamics of these viruses in selected transmission foci in order to understand their circulation in an effort to provide knowledge that can be applied by public health authorities to bring these infections under control and also to predict their emergence.

In Chapter 2, we obtain complete gene sequences of two BUNV and three NRIV isolates from recent surveys in Kenya and investigate their genetic diversity with respect to time, location and vector species of origin. The Kenyan BUNV and NRIV isolates clustered distinctly from other BUNV and NRIV isolates from different geographic regions with insignificant differences with respect to time, region and vector species of isolation. However, the Kenyan isolates sequenced in this study were closest to the NRIV isolates from the 1997/1998 Kenya-Somalia hemorrhagic fever outbreak. Phylogenetic analyses reveal a rough geographic/temporal association of NRIV isolates,

but no clustering by source of the isolate. Our data did not support any evolutionary clustering of viral isolates based upon the source of isolation hence does not support the hypothesis of distinct virus isolates circulating in different host species.

In chapter 3, we presented genotypic and phenotypic characteristics of BUNV and NRIV isolates. In this chapter, we compare growth characteristics of purified plaque-isolated biological substrains of the two viruses in cell culture and evaluated pathogenesis in suckling mice. The LP substrains grew to a higher titer on Vero cells than the SP phenotype. However, the SP phenotype of BUNV was more neurovirulent than the LP phenotype contrary to our expectation. We attributed the observed phenotype to a non-synonymous mutation in the predicted active site of the L protein and propose further mutagenesis studies to confirm this observation.

In chapter 4, we determined the vector competence of, *Aedes aegypti*, *Culex quinquefasciatus* and *Anopheles gambiae* for transmission of BUNV and NRIV. Our results indicated that *Aedes aegypti* was moderately susceptible to BUNV infection but was incompetent for NRIV. However, *Anopheles gambiae* was moderately susceptible to both BUNV and NRIV viruses, while *Culex quinquefasciatus* was refractory to both viruses. In chapter 5, we investigated the role of vertical transmission in the maintenance of BUNV in nature. We determined that both *Aedes aegypti* and *Anopheles gambiae* transovarially transmitted BUNV to their progeny and that the prevalence of vertical transmission was related to ovarian cycle. We thus underscore the need to continually monitor emergent arboviral genotypes circulating within particular regions as well as vectors mediating these transmissions in order to preempt and prevent their adverse effects. We recommend that the genetic mechanism for species specificity/vector competence due to reassortment needs further investigation.

Finally, in chapter 6, we report findings from a retrospective serosurvey of febrile patients attending three health facilities located in Sangailu, Kotile (in Garissa, North Eastern Kenya) and Naivasha (in Rift Valley) of Kenya. BUNV and NRIV specific antibodies were detected in 84 (24.3%) of 345

persons tested; Prevalences were 11.9% for BUNV and 15.9% for NRIV. We determined that age and location were risk factors for BUNV and NRIV infections. We propose that in future these infections should be considered when investigating etiologies of febrile illness in patients reporting to health facilities in such endemic areas especially during seasons of high mosquito abundance.

While public health efforts have focused on well characterized viruses such as RVF, WNV, chikungunya and dengue viruses, the emergences of orthobunyaviruses such as NRIV and Schmallenberg virus as human and veterinary pathogens emphasize the need for in-depth characterization of these viruses and determination of their true public health impact. Additionally, we propose re-analysis of all three segments of available *Orthobunyavirus* isolates for correct identification of circulating viruses. The findings of this research thesis also underscore the need to continually monitor emergent arboviral genotypes circulating within particular regions as well as vectors mediating their transmissions to enable appropriate and timely intervention by public health authorities in the event of an outbreak. Finally, our work provides evidence of exposure of residents of North Eastern province of Kenya to Orthobunyaviruses and underscores the need to design and validate testing tools for use in febrile patients within such regions in order to diagnose and effectively treat these infections.

Chapter 8

REFERENCES

- Aguilar, P. V., Barrett A.D, Saeed M.F, Watts D.M, Russell K, Guevara C, Ampuero J.S, Suarez L, Cespedes M, Montgomery J.M, Halsey E.S, and Kochel T.J. 2011.** Iquitos Virus: A Novel Reassortant Orthobunyavirus Associated with Human Illness in Peru. *PLoS Negl Trop Dis* 5: e1315.
- Akaike, H. 1973.** Information theory as an extension of the maximum likelihood principle. , Budapest, Hungary.
- Al-Hazmi, M., Ayoola E.A, Abdurahman M, Banzal S, Ashraf J, El-Bushra A, Hazmi A, Abdullah M, Abbo H, Elamin A, Al-Sammani el T, Gadour M, Menon C, Hamza M, Rahim I, Hafez M, Jambavalikar M, Arishi H, and Aqeel A. 2003.** Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans. *Clin Infect Dis* 36: 245–252.
- Alatoom, A., and D. Payne. 2009.** An Overview of Arboviruses and Bunyaviruses. *LabMed*. 40: 237-240.
- Altschul, S. F., Gish W, Miller W, Myers E.W, and Lipman D.J. 1990.** Basic local alignment search tool. *J Mol Biol.*, 215: 403-410.
- Anishchenko, M., Bowen R.A, Paessler S, Austgen L, Greene I.P, and Weaver S.C. 2006.** Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation. *Proc Natl Acad Sci U S A* 103: 4994–4999.
- Anyangu, A. S., Gould L.H, Sharif S.K, Nguku P.M, Omolo J.O, Mutonga D, Rao C.Y, Lederman E.R, Schnabel D, Paweska J.T, Katz M, Hightower A, Njenga M.K, Feikin D.R, and Breiman R.F. 2010.** Risk factors for severe Rift Valley fever infection in Kenya, 2007. *Am. J. Trop. Med. Hyg.* 83: 14–21.
- Balenghien, T., Vazeille M, Grandadam M, Schaffner F, Zeller H, Reiter P, Sabatier P, Fouque F, and Bicout D.J. 2008.** Vector Competence of Some French *Culex* and *Aedes* Mosquitoes for West Nile Virus. . *Vector-borne Zoonotic Dis*. 8.
- Beams, B. F. 1985.** Analysis of mosquito control agency public education programs in the United States. *J. Am. Mosq. Control Assoc.* 1: 212-219.
- Beaty, B. J., and W. H. Thompson. 1978.** Tropisms of La Crosse virus in *Aedes triseriatus* (Diptera: Culicidae) following infective blood meals. *J. Med. Entomol.* 14: 499-503.
- Bishop, D. H. L. 1996.** Biology and Molecular Biology of Bunyaviruses, pp. 19-53. *In* e. R.M. Elliott [ed.], *The Bunyaviridae*. Plenum Press, New York.
- Bishop, D. H. L., and R. E. Shope. 1979.** Bunyaviridae. *Compr Virology* 14: 1-156.

- Blaney Jr, J. E., Manipon G.G, Murphy B.R, and Whitehead S.S. 2003.** Temperature sensitive mutations in the genes encoding the NS1, NS2A, NS3, and NS5 nonstructural proteins of dengue virus type 4 restrict replication in the brains of mice 4. *Arch Virol.* 148: 999–1006.
- Blaney Jr, J. E., Johnson D.H, Firestone C.Y, Hanson C.T, Murphy B.R, and Whitehead S.S. 2001.** Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice. *J.Virol.* 75: 9731–9740.
- Blaney Jr, J. E., Johnson D.H, Manipon G.G, Firestone C.Y, Hanson C.T, Murphy B.R, and Whitehead S.S. 2002.** Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. *Virol.* 300: 125–139.
- Blitvich, B. J., Saiyasombat R, Talavera-Aguilar L.G, Garcia-Rejon J.E, Farfan-Ale J.A, Machain-Williams C, and Loroño-Pino M.A. 2012.** Orthobunyavirus Antibodies in Humans, Yucatan Peninsula, Mexico *EID* 18: 1629-1632.
- Borucki, M. K., Chandler L.J, Parker B.M, Blair C.D, and Beaty B.J. 1999.** Bunyavirus superinfection and segment reassortment in transovarially infected mosquitoes. . *J Gen. Virol.* 80: 3173-3179.
- Bowen, M. D., Trappier S.G, Sanchez A.J, Meyer R.F, Goldsmith C.S, Zaki S.R, Dunster L.M, Peters C.J, Ksiazek T.G, and Nichol S.T. 2001.** A reassortant bunyavirus isolated from acute hemorrhagic fever cases in Kenya and Somalia. *Virol.* 291: 185-90.
- Bridgen, A., Weber F, Fazakerley J.K, and Elliott R.M. 2001.** Bunyamwera bunyavirus nonstructural protein NSs is a nonessential gene product that contributes to viral pathogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 98: 664-669.
- Briese, T., Calisher C.H, and Higgs S. 2013.** Viruses of the family Bunyaviridae: are all available isolates reassortants?. *Virol.* 446: 207-216.
- Briese, T., Bird B, Kapoor V, Nichol S.T, and Lipkin W.I. 2006.** Batai and Ngari viruses: M segment reassortment and association with severe febrile disease outbreaks in East Africa. *J Virol* 80: 5627-30.
- Bupp, K., Stillmock K, and Gonzalez-Scarano F. 1996.** Analysis of the intracellular transport properties of recombinant La Crosse virus glycoproteins. *Virol.* 220: 485-490.
- Calisher, C., and N. Karabatsos. 1988.** Arbovirus serogroups: definition and geographical distribution. CRC Press, Boca Raton.
- Calisher, C. H. 1983.** Taxonomy, classification, and geographic distribution of California serogroup bunyaviruses. *Progress in clinical and biological research* 123: 1-16.
- Calisher, C. H. 1996.** History, classification, taxonomy of viruses in the family bunyaviridae.

Plenum Press, New York.

- Campbell, G. L., Mataczynski J.D, Reisdorf E.S, Powell J.W, Martin D.A, Lambert A.J, Haupt T.E, Davis J.P, and Lanciotti R.S. 2006.** Second human case of Cache Valley virus disease. *Emerg. Infect. Dis.* 12: 854-856.
- Caplen, H., Peters C.J, and Bishop D.H. 1985.** Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. *J. Gen Virol.* 66: 2271-2277.
- Casals, J. 1963.** Relationships among Arthropod-Borne Animal Viruses Determined by Cross-Challenge Tests. *Am J Trop Med Hyg.* 12: 587-596.
- CDC. 2007.** Rift Valley fever outbreak—Kenya, November 2006–January 2007, pp. 73–76, *MMWR Morb Mortal Wkly Rep.*
- Chamberlain, R. W., and W. D. Sudia. 1961.** Mechanism of transmission of viruses by mosquitos. *Ann. Rev. Entomol.* 6: 371-390.
- Chamberlain, R. W., Sudia W.D, and Gillett J.D. 1959.** St. Louis encephalitis virus in mosquitoes. *Am J Hyg* 70 :221-36..
- Cheng, L., Schultz KT, Yuill TM, and Israel BA. 2000.** Identification and localization of conserved antigenic epitopes on the G2 proteins of California serogroup Bunyaviruses. *Viral immunol.* 13: 201-213.
- Ciota, A. T., and L. D. Kramer. 2010.** Insights into Arbovirus Evolution and Adaptation from Experimental Studies. *Viruses* 2: 2594-2617.
- Cohen, J. 1992.** A power primer. *Psychol. Bull.* 111: 155–159.
- Crabtree, M., Sang R, Lutomiah J, Richardson J, and Miller B. 2009.** Arbovirus surveillance of mosquitoes collected at sites of active Rift Valley Fever virus transmission: Kenya, 2006-2007. *J Med.Entomol.* 46: 961-964.
- Davis, C. T., Beasley D.W, Guzman H, Siirin M, Parsons R.E, Tesh R.B, and Barrett A.D. 2004.** Emergence of attenuated West Nile virus variants in Texas, 2003. *Virol.* 330: 342–350.
- DeFoliart, G. R., Grimstad P.R, and Watts D.M. 1987.** Advances in mosquito-borne arbovirus/vector research. *Ann. Rev. Entomol.* 32: 479-505.
- Dilcher, M., Sall A.A, Hufert F.T, and Weidmann M. 2013.** Clarifying Bunyamwera virus riddles of the past. . *Virus Genes* 47: 160-163.
- Dohm, D. J., Sardelis M.R, and Turell M.J. 2002.** Experimental Vertical Transmission of West Nile Virus by *Culex pipiens* (Diptera: Culicidae). *J Med.Entomol.* 39: 640-644.
- Doyle, M. S., Swope B.N, Hogsette J.A, Burkhalter K.L, Savage H.M, and Nasci R.S. 2011.** Vector Competence of the Stable Fly (Diptera: Muscidae) for West Nile Virus. *J Med.Entomol.* 48: 656-668.

- Drake, J. W., and J. J. Holland. 1999.** Mutation rates among RNA viruses. *Proc. Natl. Acad. Sci. U. S. A* 96: 13910–13913.
- Eastman, P. S., and C. D. Blair. 1985.** Temperature-sensitive mutants of Japanese encephalitis virus. *J Virol.* 55: 611–616.
- Eckels, K. H., Brandt W.E, Harrison V.R, McCown J.M, and Russell P.K. 1976.** Isolation of a temperature-sensitive dengue-2 virus under conditions suitable for vaccine development. *Infect Immun* 14: 1221–1227.
- Edwards, J. F., Livingston C.W, Chung S.I, and Collisson E.C. 1989.** Ovine arthrogryposis and central nervous system malformations associated with in utero Cache Valley virus infection: spontaneous disease. *Vet Pathol* 26: 33-39.
- Elizondo-Quiroga, A., Flores-Suarez A, Elizondo-Quiroga D, Ponce-Garcia G, Blitvich B.J, Contreras-Cordero J.F, Gonzalez-Rojas J.I, Mercado-Hernandez R, Beaty B.J, and Fernandez-Salas I. 2006.** Host-feeding preference of *Culex quinquefasciatus* in Monterrey, northeastern Mexico. *J Am Mosq Control Assoc.* 22: 654-661.
- Elliot, R. M., Bouloy M, Calisher C.H, Goldbach R, Moyer J.T, Nichol S.T, Pettersson, Plyusnin A, and Schmaljohn C.S. 2000.** Family Bunyaviridae. Academic press, San Diego.
- Elliott, R. M. 1989.** Nucleotide sequence analysis of the large (L) genomic RNA segment of Bunyamwera virus, the prototype of the family Bunyaviridae. *Virol.* 173: 426-436.
- Elliott, R. M. 1990.** Molecular biology of the Bunyaviridae. *J Gen. virol.* 71: 501-522.
- Elliott, R. M. 2001.** The continuing threat of bunyaviruses and hantaviruses. Heriot-Watt UniversityCambridge University Press.
- Elliott, R. M., and M. L. Wilkie. 1986.** Persistent infection of *Aedes albopictus* C6/36 cells by Bunyamwera virus. *Virol.* 150: 21-32.
- Ellis, B. R., and B. A. Wilcox. 2009.** The ecological dimensions of vector-borne disease research and control. *Cad. Saúde Pública, Rio de Janeiro* 25: S155-S167.
- Endres, M. J., Griot C, Gonzalez-Scarano F, and Nathanson N. 1991.** Neuroattenuation of an avirulent bunyavirus variant maps to the L RNA segment. *J Virol* 65: 5465-70.
- Faul, F., Erdfelder E, Lang A.G, and Buchner A. 2007.** G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 39: 175–191.
- Fazakerley, J. K., Gonzalez-Scarano F, Strickler J, Dietzschold B, Karush F, and Nathanson N. 1988.** Organization of the middle RNA segment of snowshoe hare Bunyavirus. *Virol.* 167: 422-432.
- Forshey, B. M., Guevara C, Laguna-Torres V.A, Cespedes M, Vargas J, Gianella A, Vallejo**

- E, Madrid C, Aguayo N, Gotuzzo, V. Suarez, Morales A, Beingolea L, Reyes N, Perez J, Negrete M, Rocha C, Morrison A.C, Russell K.L, Blair P.J, Olson J.G, and Kochel T.J. 2010. Arboviral etiologies of acute febrile illnesses in Western South America, 2000–2007. PLoS Negl Trop Dis. 4: e787.
- Fuller, F., and D. Bishop. 1982. Identification of virus-coded nonstructural polypeptides in bunyavirus-infected cells. J virol. 41: 643-648.
- Gad, A. M., Farid H.A, Ramzy R.R, Riad M.B, Presley S.M, Cope S.E, Hassan M.M, and Hassan A.N. 1999. Host feeding of mosquitoes (Diptera: Culicidae) associated with the recurrence of Rift Valley fever in Egypt. J Med Entomol. 36: 709-14.
- Garcia-Rejon, J. E., Blitvich B.J, Farfan-Ale J.A, Loroño-Pino M.A, Chi Chim W.A, Flores-Flores L.F, Rosado-Paredes E, Baak-Baak C, Perez-Mutul J, Suarez-Solis V, Fernandez-Salas I, and Beaty B.J. 2010. Host-feeding preference of the mosquito, *Culex quinquefasciatus*, in Yucatan State, Mexico. J Insect Sci. 10: 32.
- Gargan 2nd, T. P., Bailey C.L, Higbee G.A, Gad A, and El Said S. 1983. The effect of laboratory colonization on the vector pathogen interactions of Egyptian *Culex pipiens* and Rift Valley fever virus. Am J Trop Med Hyg. 32: 1154-1163.
- Gerrard, S. R., Li L, Barrett A.D, and Nichol S.T. 2004. Ngari virus is a Bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa. J Virol 78: 8922-6.
- González-Scarano, F., Bupp K, and Nathanson N. 1996. Pathogenesis of diseases caused by viruses of the bunyavirus genus, pp. 227–252, In: The Bunyaviridae, Elliott RM (ed) ed. Plenum Press, New York.
- Gonzalez-Scarano, F., and N. Nathanson. 1996. Bunyaviridae. In K. D. Fields BN, Howley PM [ed.], In Fields Virology. Lippincott–Raven, Philadelphia.
- Gonzalez-Scarano, F., Janssen R.S, Najjar J.A, Pobjecky N, and Nathanson N. 1985. An avirulent G1 glycoprotein variant of La Crosse bunyavirus with defective fusion function. J virol 54: 757-763.
- Gonzalez, J. P., and A. J. Georges. 1988. Bunyaviral fevers: Bunyamwera, Ilesha, Germiston, Bwamba and Tataguine. In T. Monath [ed.], In: The Arboviruses: Epidemiology and Ecology CRC press, Boca Raton, FL.
- Gordon, S. W., Tammariello R.F, Linthicum K.J, Dohm D.J, Digoutte J.P, and Calvo-Wilson M.A. 1992. Arbovirus isolations from mosquitoes collected during 1988 in the Senegal River basin. Am J Trop Med Hyg 47: 742-748.
- Gray, S. M., and N. Banerjee. 1999. Mechanisms of Arthropod Transmission of Plant and Animal Viruses. Microbiol. Mol. Biol. Rev. 63: 128.

- Grimstad, P. R. 1988.** California group virus disease, pp. 99–136. *In* e. In: Monath TP [ed.], The Arboviruses: Epidemiology and Ecology. CRC Press, Boca Raton, FL.
- Groseth, A., Weisend C, and Ebihara H. 2012.** Complete genome sequencing of mosquito and human isolates of Ngari virus. *J Virol.* 86: 13846-13847.
- Gubler, D. J. 1996.** The global resurgence of arboviral diseases. *Trans R Soc Trop Med Hyg* 90: 449-451.
- Hammon, W. M., Reeves W.C, and Sather G. 1952.** California encephalitis virus, a newly described agent. II. Isolations and attempts to identify and characterize the agent. *J Immunol* 69: 493-510.
- Hardy, J. L., Houk E.I, Kramer L.D, and Reeves W.C. 1983.** Intrinsic factors affecting vector competence of mosquitoes for arboviruses. *Ann. Rev. Entomol.* 28: 229-262.
- Hoogstraal, H., Meegan J.M, Khalil G.M, and Adham F.K. 1979.** The Rift Valley fever epizootic in Egypt 1977-78. 2. Ecological and entomological studies. *Trans R Soc Trop Med Hyg* 73: 624–629.
- Hughes, M. T., Gonzalez J. A, Reagan K.L, Blair C.D, and Beaty B.J. 2006.** Comparative potential of *Aedes triseriatus*, *Aedes albopictus*, and *Aedes aegypti* (Diptera: Culicidae) to transovarially transmit La Crosse virus. *J. Med. Entomol.* 43: 757-761.
- Huhtamo, E., Lambert A.J, Costantino S, Servino L, Krizmancic L, Boldorini R, Allegrini S, Grasso I, Korhonen E.M, Vapalahti O, Lanciotti R.S, and Ravanini P. 2013.** Isolation and full genomic characterization of Batai virus from mosquitoes, Italy 2009. *J Gen Virol.* 94: 1242-1248.
- Hunt, A. R., and C. H. Calisher. 1979.** Relationships of bunyamwera group viruses by neutralization. *Am J Trop Med Hyg.*, 28: 740-749.
- Inaba, Y., Kurogi H, and Omori T. 1975.** Letter: Akabane disease: epizootic abortion, premature birth, stillbirth and congenital arthrogryposis-hydranencephaly in cattle, sheep and goats caused by Akabane virus. *Aust Vet J* 51: 584-585.
- Jia, Y., Moudy R.M, Dupuis II A.P, Ngo K.A, Maffei J.G, Jerzak G.V.S, Franke M.A, Kauffman E.B, and Kramer L.D. 2007.** Characterization of a Small Plaque Variant of West Nile Virus Isolated in New York in 2000. *Virol.* 367: 339–347.
- Jin, H., and R. M. Elliott. 1991.** Expression of functional Bunyamwera virus L protein by recombinant vaccinia viruses. *J virol* 65: 4182-4189.
- Jin, H., and R. M. Elliott. 1993.** Characterization of Bunyamwera virus S RNA that is transcribed and replicated by the L protein expressed from recombinant vaccinia virus. *J virol* 67: 1396-1404.
- Johnson, B. K., Shockley P, Chanas A.C, Squires E.J, Gardner P, Wallace C, Simpson D.I,**

- Bowen E.T, Platt G.S, H Way, Chandler J.A, Highton R.B, and Hill M.N. 1977.** Arbovirus isolations from mosquitoes: Kano Plain, Kenya. *Trans R Soc Trop Med Hyg* 71: 518-521.
- Jones, K., Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, and Daszak P. 2008.** Global trends in emerging infectious diseases. *Nat* 451: 990–994.
- Jost, H., Bialonski A, Schmetz C, Gunther S, Becker N, and Schmidt-Chanasit J. 2011.** Isolation and phylogenetic analysis of Batai virus, Germany. *Am J Trop Med Hyg* 84: 241-3.
- Jupp, P. G. 1974.** Laboratory studies on the transmission of West Nile virus by *Culex* (*Culex*) *univittatus* Theobald; factors influencing the transmission rate. *J. Med. Entomol.* 11: 455-458.
- Jupp, P. G., McIntosh B.M, and Anderson D. 1976.** *Culex* (*Eumelanomyia*) *rubinotus* Theobald as vector of Banzi, Germiston and Witwatersrand viruses. IV. Observations on the biology of *C. rubinotus*. *J Med Entomol.* 12: 647-651.
- Jupp, P. G., McIntosh B.M, Dos Santos I, and de Moor P. 1981.** Laboratory vector studies on six mosquito and one tick species with chikungunya virus. *Trans. R. Soc. Trop. Med. Hyg.* 75: 15-19.
- Jupp, P. G., Kemp A, Grobbelaar A, Lema P, Burt F.J, Alahmed A.M, Al Mujalli D, Al Khamees M, and Swanepoel R. 2002.** The 2000 epidemic of Rift Valley fever in Saudi Arabia: mosquito vector studies. *Med Vet Entomol.* 16: 245-252.
- Kanno, T., Inoue T, Mackay D, Kitching P, Yamaguchi S, and Shirai J. 1998.** Viruses produced from complementary DNA of virulent and avirulent strains of swine vesicular disease viruses retain the in vivo and in vitro characteristics of the parental strain. *Arch Virol* 143: 1055-62.
- Kanno, T., Mackay D, Inoue T, Wilsden G, Yamakawa M, Yamazoe R, Yamaguchi S, Shirai J, Kitching P, and Murakami Y. 1999.** Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus. *J Virol* 73: 2710-6.
- Kappus, K. D., Monath T.P, Kaminski R.M, and Calisher C.H. 1983.** Reported encephalitis associated with California serogroup virus infections in the United States, 1963-1981. *Prog Clin Biol Res.*, 123: 31-41.
- Karabatsos, N. 1985.** International catalogue of arboviruses, including certain other viruses of vertebrates. *Am Soc Trop Med Hyg*, San Antonio.
- Kassen, R. 2002.** The experimental evolution of specialists, generalists, and the maintenance of diversity. *J Evol Biol.* 15: 173-190.
- Kirkwood, B., and J. Sterne. 2003.** *Malben:Medical Statistics.* Blackwell Science.

- Kohl, A., Lowen A.C, Léonard V.H.J, and Elliott R.M. 2006.** Genetic elements regulating packaging of the Bunyamwera orthobunyavirus genome. *J. Gen. Virol.* 87: 177–187.
- Kohl, A., Clayton RF, Weber F, Bridgen A, Randall RE, and Elliott RM. 2003.** Bunyamwera virus nonstructural protein NSs counteracts interferon regulatory factor 3-mediated induction of early cell death. *J virol.*, 77: 7999-8008.
- Kokernot, R. H., Heymann C.S, Muspratt J, and Wolstenholme B. 1957.** Studies on arthropod-borne viruses of Tongaland. V. Isolation of Bunyamwera and Rift Valley fever viruses from mosquitoes. *S. Afr. J. Med. Sci.* 22: 71-80.
- Kramer, L. D., Hardy J.L, Presser S.B, and Houk E.G. 1981.** Dissemination barriers for western equine encephalomyelitis virus in *Culex tarsalis* infected after ingestion of low viral doses. *Am. J. Trop. Med. Hyg.* 30: 90-97.
- Kramer, L. D., Reeves W.C, Hardy J.L, Presser S.B, Eldridge B.F, and Bowen M.D. 1992.** Vector competence of California mosquitoes for California encephalitis and California encephalitis-like viruses *Am. J. Trop. Med. Hyg.* 47: 562-573.
- Kruskal, W. H., and W. A. Wallis. 1952.** Use of ranks in one-criterion variance analysis. *J Amer Statist Assoc* 47: 583–621.
- Kuno, G., and G. J. Chang. 2005.** Biological transmission of arboviruses: Reexamination of and new insights into components, mechanisms, and unique traits as well as their evolutionary trends. *Clin Microbiol Rev.*, 18: 608-637.
- LaBeaud, A. D. 2008.** Why Arboviruses Can Be Neglected Tropical Diseases. *PLoS Negl Trop Dis.* 2: e247.
- LaBeaud, A. D., Sutherland L.J, Muiruri S, Muchiri E.M, Gray L.R, Zimmerman P.A, Hise A.G, and King C.H. 2011.** Arbovirus Prevalence in Mosquitoes, Kenya. *Emerg Infect Dis.* 17: 233-241.
- Lambert, A. J., and R. S. Lanciotti. 2009.** Consensus Amplification and Novel Multiplex Sequencing Method for S Segment Species Identification of 47 Viruses of the Orthobunyavirus, Phlebovirus, and Nairovirus Genera of the Family Bunyaviridae. *J Clin Microbiol.*, 47: 2398–2404.
- Lappin, D. F., Nakitare G.W, Palfreyman J.W, and Elliott R.M. 1994.** Localization of Bunyamwera bunyavirus G1 glycoprotein to the Golgi requires association with G2 but not with NSm. *J Gen Virol.* 75: 3441-3451.
- Linthicum, K. J., Davies F.G, Kairo A, and Bailey C.L. 1985.** Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera during an inter-epizootic period in Kenya. *J. Hyg.* 95: 197-209.
- Logan, T. M., Linthicum K.J, Davies F.G, Binopal Y.S, and Roberts C.R. 1991.** Isolation of

Rift Valley Fever Virus from Mosquitoes(Diptera: Culicidae) Collected During an Outbreak in Domestic Animals in Kenya. *J Med Entomol.* 28: 293-295.

- Lowen, A. C., and R. M. Elliott. 2005.** Mutational analyses of the nonconserved sequences in the Bunyamwera Orthobunyavirus S segment untranslated regions. *J Virol* 79: 12861-70.
- Lutomiah, J., Bast J, Clark J, Richardson J, Yalwala S, Oullo D, Mutisya J, Mulwa F, Musila L, Khamadi S, Schnabel D, Wurapa E, and Sang R. 2013.** Abundance, diversity, and distribution of mosquito vectors in selected ecological regions of Kenya: public health implications. *J Vector Ecol.* 38: 134-142.
- Lutomiah, J., Musila L, Makio A, Ochieng C, Koka H, Chepkorir E, Mutisya J, Mulwa F, Khamadi S, Miller B.R, Bast J, Schnabel D, Wurapa E.K, and Sang R. 2014.** Ticks and tick-borne viruses from livestock hosts in arid and semiarid regions of the eastern and northeastern parts of Kenya. *J Med. Entomol.* 51: 269-277.
- Lwande, O. W., Irura Z, Tigoi C, Chepkorir E, Orindi B, Musila L, Venter M, Fischer A, and Sang R. 2012.** Seroprevalence of Crimean Congo hemorrhagic fever virus in Ijara District, Kenya. *Vector Borne Zoonotic Dis.* 12: 727-32.
- Lwande, O. W., Lutomiah J, Obanda V, Gakuya F, Mutisya J, Mulwa F, Michuki G, Chepkorir E, Fischer A, Venter M, and Sang R. 2013.** Isolation of tick and mosquito-borne arboviruses from ticks sampled from livestock and wild animal hosts in Ijara District, Kenya. *Vector Borne Zoonotic Dis.* 13: 637-642.
- Mahmood, F., Chiles R.E, Fang Y, Green E.N, and Reisen W.K. 2006.** Effects of time after infection, mosquito genotype, and infectious viral dose on the dynamics of *Culex tarsalis* vector competence for western equine encephalomyelitis virus. *J Am Mosq Control Assoc.* 22: 272–281.
- Mazel-Sanchez, B., and R. M. Elliott. 2012.** Attenuation of bunyamwera orthobunyavirus replication by targeted mutagenesis of genomic untranslated regions and creation of viable viruses with minimal genome segments. *J Virol* 86: 13672-8.
- McIntosh, B. M., Jupp P.G, Dos Santos I, and Barnard B.J.H. 1980.** Vector studies on Rift Valley fever in South Africa. *S. Afr. Med. J.* 58: 127-132.
- Mease, L. E., Coldren R.L, Musila L.A, Prosser T, Ogolla F, Ofula V.O, Schoepp R.J, Rossi C.A, and Adungo N. 2011.** Seroprevalence and distribution of arboviral infections among rural Kenyan adults: A cross-sectional study. *Virol. J.* 8: 371.
- Miller, B. R., DeFoliart G.R, and Yuill T.M. 1979.** *Aedes triseriatus* and La Crosse virus: lack of infection in eggs of the first ovarian cycle following oral infection of females. *Am. J. Trop. Med. Hyg.* 28: 897-901.
- Mores, C. N., Turell M.J, Dyer J, and Rossi C.A. 2009.** Phylogenetic Relationships Among

Orthobunyaviruses Isolated from Mosquitoes Captured in Peru. *Vector-Borne Zoonotic Dis.* 9: 25-32.

- Morvan, J. M., Digoutte J.E, Marsan P, and Roux J.F. 1994.** Ilesha virus: a new aetiological agent of haemorrhagic fever in Madagascar. *Trans R Soc Trop Med Hyg* 88: 205.
- Moutailler, S., Krida G, Schaffner F, Vazeille M, and Failloux A. 2008.** Potential Vectors of Rift Valley Fever Virus in the Mediterranean Region. *Vector-borne Zoonotic Dis.* 8: 749-753.
- Murphy, F. A. 1975.** Cellular resistance to arbovirus infection. *Ann. NY Acad. Sci.* 266: 197-203.
- Nakitare, G. W., and R. M. Elliott. 1993.** Expression of the Bunyamwera virus M genome segment and intracellular localization of NSm. *Virology* 195: 511-520.
- Nashed, N. W., Olson J.G, and el-Tigani A. 1993.** Isolation of Batai virus (Bunyaviridae: Bunyavirus) from the blood of suspected malaria patients in Sudan. *Am. J. Trop. Med. Hyg.* 48: 676–681.
- Nguku, P. M., Shariff S.K, Mutonga D, Amwayi S, Omulo J, Mohammed O, Farmon E.C, Gould L.H, Lederman E, Rao C, Sang R, Schnabel D, Feikin D.R, Hightower A, Njenga M.K, and Breiman R.F. 2010.** An investigation of a major outbreak of Rift Valley fever in Kenya: 2006–2007. *Am. J. Trop. Med. Hyg.* 5: 5–13.
- Nichol, S., Beaty B.J, Elliot R.M, Goldbach R, Plyusnin A, Schmaljohn C.S, and Tesh R.B. 2005.** Bunyaviridae, pp. 695-716. *In* M. M. In: Fauquet CM, Maniloff J, Desselberger U, Ball LA (eds) [ed.], VIIIth Report of the International committee on Taxonomy of Viruses. Elsevier Academic Press, Amsterdam.
- Nichol, S. T. 2001.** Bunyaviruses, pp. 1603-1668. *In* W. W. Lippincott [ed.], *In: Field Virology* (D.M. Knipe and P.M. Howley,eds.).
- Nunes, M. R., Travassos da Rosa A.P, Weaver S.C, Tesh R.B, and Vasconcelos P.F. 2005.** Molecular epidemiology of group C viruses (Bunyaviridae, Orthobunyavirus) isolated in the Americas. *J Virol* 79: 10561-70.
- Nylander, J. A. A. 2004.** MrModeltest 2.3. Program distributed by the author computer program, version By Nylander, J. A. A., Uppsala University.
- Ochieng, C., Lutomiah J, Makio A, Koka H, Chepkorir E, Yalwala S, Mutisya J, Musila L, Khamadi S, Richardson J, Bast J, Schnabel D, Wurapa E, and Sang R. 2013.** Mosquito-borne arbovirus surveillance at selected sites in diverse ecological zones of Kenya; 2007 -- 2012. *Virology* 10: 140.
- Okello, G. B., Agata N, Ouma J, Cherogony S.C, Tukei P.M, Ochieng W, Den Boer J.W, and Sanders E.J. 1993.** Outbreak of yellow fever in Kenya. *Lancet*, 341: 489.
- Pekosz, A., Griot C, Nathanson N, and Gonzalez-Scarano F. 1995.** Tropism of bunyaviruses:

evidence for a G1 glycoprotein-mediated entry pathway common to the California serogroup. *Virol.* 214: 339-348.

Pfeffer, M., and G. Dobler. 2010. Emergence of zoonotic arboviruses by animal trade and migration. *Parasit vectors* 3: 35.

Pinheiro, F. P. 1981. Arboviral zoonoses in South America, pp. 159. *In* J. H. Steele and G. W. Beron (ed.) [ed.], CRC handbook series in zoonoses, section B: viral zoonoses. CRC Press, Inc., Boca Raton, Fla.

Pinheiro, F. P., Travassos da Rosa A.P, Travassos da Rosa J.F, Ishak R, Freitas R.B, Gomes M.L, LeDuc J.W, and Oliva O.F. 1981. Oropouche virus. I. A review of clinical, epidemiological, and ecological findings. *Am. J. Trop. Med. Hyg.* 30: 149-160.

Pobjecky, N., Smith J, and Gonzalez-Scarano F. 1986. Biological studies of the fusion function of California serogroup Bunyaviruses. *Microb Pathog.*, 1: 491-501.

Pollitt, E., Zhao J, Muscat P, and Elliott R.M. 2006. Characterization of Maguari orthobunyavirus mutants suggests the nonstructural protein NSm is not essential for growth in tissue culture. *Virol.* 348: 224-232.

R Development Core Team. 2008. R: A language and environment for statistical computing: statistical computing. R Foundation for Statistical Computing, Vienna, Austria.

Rambaut, A. 2006-2012. Tree Figure Drawing Tool computer program, version Version 1.4.0. By Rambaut, A.

Ramsingh, A. I., Caggana M, and Ronstrom S. 1995. Genetic mapping of the determinants of plaque morphology of coxsackievirus B4. *Arch Virol* 140: 2215-26.

Reisen, W. K., Barker C.M, Fang Y, and Martinez V.M. 2008. Does Variation in Culex (Diptera: Culicidae) Vector Competence Enable Outbreaks of West Nile Virus in California? *J. Med. Entomol.* 45: 1126-1138.

Richards, S. L., Mores C.N, Lord C.C, and Tabachnick W.J. 2007. Impact of Extrinsic Incubation Temperature and Virus Exposure on Vector Competence of Culex pipiens quinquefasciatus Say (Diptera: Culicidae) for West Nile Virus. *Vector Borne Zoonotic Dis* 7: 629–636.

Rodrigues, A. H., Santos R.I, Arisi G.M, Bernardes E.S, Silva M.L, Rossi M.A, Lopes M.B, and Arruda E. 2011. Oropouche virus experimental infection in the golden hamster (*Mesocricetus auratus*). *Virus Res* 155: 35-41.

Ronquist, F., and J. P. Huelsenbeck. 2003. MrBayes 3: Bayesian phylogenetic inference under mixed models. *Bioinformatics* 19: 1572-1574.

Rosen, L. 1988. Further observations on the mechanism of vertical transmission of flaviviruses by Aedes mosquitoes. *Am. J. Trop. Med. Hyg.* 39: 123-126.

- Rosen, L., Lien J.C, Shroyer D.A, Baker R.H, and L. LC. 1989.** Experimental vertical transmission of Japanese encephalitis virus by *Culex tritaeniorhynchus* and other mosquitoes. *Am. J. Trop. Med. Hyg.* 40: 548-556.
- Saeed, M. F., Wang H, Suderman M, Beasley D.W, Travassos da Rosa A, Li L, Shope R.E, Tesh R.B, and Barrett A.D. 2001.** Jatobal virus is a reassortant containing the small RNA of Oropouche virus. *Virus Res* 77: 25–30.
- Sang, R. C., and L. M. Dunster. 2001.** The growing threat of arbovirus transmission and outbreaks in Kenya: a review. *East Afr Med J.* 78: 655–661.
- Sardelis, M. R., Turell M.J, Dohm D.J, and O’Guinn M.L. 2001.** Vector competence of selected North American *Culex* and *Coquillettidia* mosquitoes for West Nile virus. *Infect Dis* 7: 1018–1022.
- Schmaljohn, C. S. 1996.** The viruses and their replication, pp. 1447-1471. In K. P. e. Fields BN [ed.], *Bunyaviridae*, In: *Fields virology*. 3rd edition ed. Lippincott-Raven Publishers, Philadelphia.
- Schmaljohn, C. S., and J. W. Hooper. 2001.** *Bunyaviridae: The viruses and their replication* pp. 1581-1602. In K. Fields BN, Howley PM, Griffin DE [ed.], *Bunyaviridae: The viruses and their replication*. Fields’ virology Lippincott Williams and Wilkins, Philadelphia PA.
- Sergon, K., Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi L.S, Bedno S, Burke H, Dumilla A.M, Konde J, Njenga M.K, Sang R, and Breiman R.F. 2008.** Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. *Am J Trop Med Hyg.* 78: 333-337.
- Sexton, D. J., Rollin P.E, Breitschwerdt E.B, Corey G.R, Myers S.A, Dumais M.R, Bowen M.D, Goldsmith C.S, Zaki S.R, Nichol S.T, Peters C.J, and Ksiazek T.G. 1997.** Life-threatening Cache Valley virus infection. *N Engl J Med.*, 336: 547-549.
- Shi, X., and R. M. Elliott. 2009.** Generation and analysis of recombinant Bunyamwera orthobunyaviruses expressing V5 epitope-tagged L proteins. *J Gen Virol* 90: 297-306.
- Shi, X., Lappin DF, and Elliott RM. 2004.** Mapping the Golgi targeting and retention signal of Bunyamwera virus glycoproteins. *J. Virol.* 78: 10793-10802.
- Shi, X., Kohl A, Leonard VH, Li P, McLees A, and Elliott RM. 2006.** Requirement of the N-terminal region of orthobunyavirus nonstructural protein NSm for virus assembly and morphogenesis. *J. Virol.* 80: 8089-8099.
- Smithburn, K. C., Haddow A.J, and Mahapatra A.F. 1946.** A neurotropic virus isolated from *Aedes* mosquitoes caught in the Semliki Forest. *Am. J. Trop. Med. Hyg.* 26: 189-208.
- Soldan, S. S., and F. Gonzalez-Scarano. 2005.** Emerging infectious diseases: The Bunyaviridae. *J Neurovirol.*, 11: 412-423.

- Soldan, S. S., Plassmeyer M.L, Matukonis M.K, and Gonzalez-Scarano F. 2005.** La Crosse virus nonstructural protein NSs counteracts the effects of short interfering RNA. *J. virol.* 79: 234-244.
- Soumare, P. O. L., Freire C.C.M, Faye O, Diallo M, de Oliveira J.V.C, Zanotto P.M.A, and Sall A.A. 2012.** Phylogeography of Rift Valley Fever Virus in Africa Reveals Multiple Introductions in Senegal and Mauritania. *PLoS One*, 7: e35216.
- Standley, K. 2013.** MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Molecular Biology and Evolution* 30: 772-780.
- Sundstrom, K. B., Stoltz M, Lagerqvist N, Lundkvist A, Nemirov K, and Klingström J. 2011.** Characterization of two substrains of Puumala virus that show phenotypes that are different from each other and from the original strain. *J. Virol.* 85: 1747-1756.
- Swofford, D. 2002.** PAUP: phylogenetic analysis using parsimony (*and other methods) computer program, version version 4.0b.10. By Swofford, D., Sunderland, MA.
- Tamura, K., Peterson D, Peterson N, Stecher G, Nei M, and Kumar S. 2011.** MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and 336 maximum parsimony methods. *Mol Biol Evol.*, 28: 2731-2739.
- Tauro, L. B., Diaz L.A, Almirón W.R, and Contigiani M.S. 2009.** Infection by Bunyamwera virus (Orthobunyavirus) in free ranging birds of Cordoba city (Argentina). . *Vet Microbiol.* 139: 153-155.
- Tesh, R. B., and D. A. Shroyer. 1980.** The mechanism of arbovirus transovarial transmission in mosquitoes: San Angelo virus in *Aedes albopictus*. *Am. J. Trop. Med. Hyg.* 29: 1394-1404.
- Traore-lamizana, M., Fontenille D, Diallo M, Ba Y, Zeller H.G, Mondo M, Adam F, and M. A. Thonon J. 2001.** Arbovirus surveillance from 1990 to 1995 in the Barkedji area (Ferlo) of Senegal, a possible natural focus of Rift Valley Fever virus. *J Med Entomol.* 38: 480-492.
- Tsetsarkin, K. A., Vanlandingham D.L, McGee C.E, and Higgs S. 2007.** A single mutation in chikungunya virus affects vector specificity and epidemic potential. *PLoS Pathog.* 3: e201.
- Tsetsarkin, K. A., McGee C.E, Volk S.M, Vanlandingham D.L, Weaver S.C, and Higgs S. 2009.** Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to *Aedes albopictus* and *Ae. aegypti* mosquitoes. *PLoS.One* 4: e6835.
- Turell, M. J., and B. Kay. 1998.** Susceptibility of selected strains of Australian mosquitoes (Diptera: Culicidae) to Rift Valley fever virus. *J. Med. Entomol.* 35: 132-135.
- Turell, M. J., Reeves W.C, and Hardy J.L. 1982a.** Evaluation of the efficiency of transovarial transmission of California encephalitis viral strains in *Aedes dorsalis* and *Aedes melanimon*. *Am. J. Trop. Med. Hyg.* 31: 382-388.
- Turell, M. J., Hardy J.L, and Reeves W.C. 1982b.** Stabilized infection of California encephalitis

- virus in *Aedes dorsalis*, and its implications for viral maintenance in nature. *Am. J. Trop. Med. Hyg.* 31: 1252-1259.
- Turell, M. J., Gargan T.P II, and Bailey C.L. 1984.** Replication and dissemination of Rift Valley fever virus in *Culex pipiens*. *Am J Trop Med Hyg* 33: 176–181.
- Turell, M. J., O'Guinn M.L, Dohm D.J, and Jones J.W. 2001.** Vector Competence of North American Mosquitoes (Diptera: Culicidae) for West Nile Virus. *J Med Entomol.* 38: 130-134.
- Turell, M. J., Dohm D.J, Fernandez R, Calampa C, and O'Guinn M.L. 2006.** Vector competence of Peruvian mosquitoes (Diptera: Culicidae) for a subtype IIIC virus in the Venezuelan equine encephalomyelitis complex isolated from mosquitoes captured in Peru. *J Am Mosq Control Assoc.* 22: 70-75.
- Turell, M. J., Linthicum K.J, Patrican L.A, Davies F.G, Kairo A, and Bailey C.L. 2008.** Vector Competence of Selected African Mosquito (Diptera: Culicidae) Species for Rift Valley Fever Virus. *J Med Entomol.* 45: 102-108.
- Turell, M. J., Presley S.M, Gad A.M, Cope S.E, Dohm D.J, Morrill J., and Arthur R.R. 1996.** Vector competence of Egyptian mosquitoes for Rift Valley fever virus. *Am J Trop Med Hyg* 54: 136–139.
- Turell, M. J., Lee J.S, Richardson J.H, Sang R.C, Kioko E.N, Agawo M.O, Pecor J, and O'Guinn M.L. 2007.** Vector competence of Kenyan *Culex zombaensis* and *Culex quinquefasciatus* mosquitoes for Rift Valley fever virus. *J Am Mosq Control Assoc.* 23: 378-382.
- van Regenmortel, M. H., Mayo M.A, Fauquet C.M, and Maniloff J. 2000.** Virus nomenclature: consensus versus chaos. *Arch Virol* 145: 2227-2232.
- Vlaycheva, L., Nickells M, Droll D.A, and Chambers T.J. 2004.** Yellow fever 17D virus: pseudo-revertant suppression of defective virus penetration and spread by mutations in domains II and III of the E protein. *Virol.* 327: 41–49.
- Vlaycheva, L., Nickells M, Droll D.A, and Chambers T.J. 2005.** Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein locus involved in persistent infection and its effects on virus penetration and spread. *J Gen Virol* 86: 413–421.
- Vlaycheva, L. A., and T. J. Chambers. 2002.** Neuroblastoma cell-Adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. *J Virol.* 76: 6172–6184.
- Wang, M., Pennock D.G, Spik K.W, and Schmaljohn C.S. 1993.** Epitope mapping studies with neutralizing and non-neutralizing monoclonal antibodies to the G1 and G2 envelope glycoproteins of Hantaan virus. *Virol.* 197: 757-766.

- Watt, D. M., DeFoliart G.R, and Yuill T.M. 1976.** Experimental transmission of trivittatus virus (California virus group) by *Aedes trivittatus*. *Am. J. Trop. Med. Hyg.* 25: 173-176.
- Watts, D. M., Pantuwatana S, DeFoliart G.R, Yuill T.M, and Thompson W.H. 1973.** Transovarial transmission of La Crosse virus (California encephalitis group) in the mosquito, *Aedes triseriatus*. *Science* 182: 140-141.
- Watts, D. M., Thompson W.H, Yuill T.M, DeFoliart G.R, and Hanson R.P. 1974.** Overwintering of La Crosse virus in *Aedes triseriatus*. *Am J. Trop. Med. Hyg.* 23: 694-700.
- Weaver, S. C., and A. D. T. Barrett. 2004.** Transmission cycles, host range, evolution and emergence of arboviral disease. *Nat. Rev. Microbiol.* 2: 789-901.
- Weaver, S. C., and W. K. Reisen. 2010.** Present and future arboviral threats. *Antiviral Res.*,85: 328-345.
- Weber, F., Bridgen A, Fazakerley J.K, Streitenfeld H, Kessler N, Randall R.E, and Elliott R.M. 2002.** Bunyamwera bunyavirus nonstructural protein NSs counteracts the induction of alpha/beta interferon. *J Virol.* 76: 7949-7955.
- Wertheim, H. F. L., Horby P, and Woodall J.P. 2012.** *Atlas of Human Infectious Diseases.* Oxford: Wiley Publishers.
- Woods, C. W., Karpati A.M, Grein T, McCarthy N, Gaturuku P, Muchiri E, Dunster L, Henderson A, Khan A.S, Swanepoel R, Bonmarin I, Martin L, Mann P, Smoak B.L, Ryan M, Ksiazek T.G, Arthur R.R, Ndikuyeze A, Agata N.N, and Peters C.J. 2002.** An outbreak of Rift Valley fever in northeastern Kenya, 1997–98. *Emerg Infect Dis* 8: 138–144.
- Woolhouse, M. E. J., Taylor L.H, and Haydon D.T. 2001.** Population biology of multihost pathogens. *Science* 292: 1109–1112.
- Wu, S. C., Lian W.C, Hsu L.C, and Liao M.Y. 1997.** Japanese encephalitis virus antigenic variants with characteristic differences in neutralization resistance and mouse virulence. *Virus Res.*, 51: 173–181.
- Yanase, T., Kato T, Yamakawa M, Takayoshi K, Nakamura K, Kokuba T, and Tsuda T. 2006.** Genetic characterization of Batai virus indicates a genomic reassortment between orthobunyaviruses in nature. *Arch Virol* 151: 2253-60.
- Yandoko, E. N., Gribaldo S, Finance C, Le Faou A, and Rihn B.H. 2007.** Molecular characterization of African orthobunyaviruses. *J Gen Virol.* 88: 1761-1766.
- Zeller, H. G., Fontenille D, Traore-Lamizana M, Thiongane Y, and Digoutte J.P. 1997.** Enzootic activity of Rift Valley fever virus in Senegal. *Am J Trop Med Hyg* 56: 265–272.
- Zeller, H. G., Diallo M, Angel G, Traore-Lamizana M, Thonnon J, Digoutte J.P, and Fontenille D. 1996.** [Ngari virus (Bunyaviridae: Bunyavirus). First isolation from humans in Senegal, new mosquito vectors, its epidemiology]. *Bull Soc Pathol Exot* 89: 12-16.

Zhang, H., Blake N.W, Ouyang X, Pandolfino Y.A, Morgan-Capner P, and Archard L.C.
1995. A single amino acid substitution in the capsid protein VP1 of coxsackievirus B3 (CVB3) alters plaque phenotype in Vero cells but not cardiovirulence in a mouse model. Arch Virol 140: 959-66.

Appendices

Appendix 1; Nucleotide and amino acid sequences determined in this study aligned against selected Bunyamwera and Ngari virus isolates from GenBank. Viral complementary strand sequences are presented in the 5'-3' direction.

Appendix 1A: Ngari virus S segment nucleotide sequence alignment

NRIV_DakArD28542_(JX857316)	AGTAGTGTACTCCACACTACAACTTGCTATTGTTGAAAAATCGCTGTGCTATCAAATCTAACAGAGGTCATTAAAGGCTTTTAATGATTGAGTTAGAATTTTCATGATG	110
NRIV_9800521_(JX857325)	T.....	110
NRIV_9800535_(JX857328)	T.....	110
NRIV_SUD-HKV141_(JX857322)	T.....A.....	110
NRIV_SUD-HKV66_(JX857319)	T.....A.....	110
GSA/TS7/5170_WT	T.....A.....	110
ISL/TS2/5242/WT	T.....A.....	110
TND/S1/19801/WT	T.....A.....	110
NRIV_DakArD28542_(JX857316)	TCGCTGCTAACACCAGCAGTACTTTTGACCCAGAGGTCGCATACGCTAACTTTAAGCGTGTCTACACCACTGGGCTTAGTTATGACCACATACGAATCTTCTACATTAAA	220
NRIV_9800521_(JX857325)	C.....	220
NRIV_9800535_(JX857328)	C.....	220
NRIV_SUD-HKV141_(JX857322)	C.....	220
NRIV_SUD-HKV66_(JX857319)	C.....	220
GSA/TS7/5170_WT	C.....	220
ISL/TS2/5242/WT	C.....	220
TND/S1/19801/WT	C.....	220
NRIV_DakArD28542_(JX857316)	GGACGCGAGATTAAACTAGTCTCGCAAAAAGAAGTGAATGGGAAGTTACACTTAACCTTGGGGGCTGGAAGATTACTGTATATAATACGAATTTTCCTGGCAACCGGAA	330
NRIV_9800521_(JX857325)		330
NRIV_9800535_(JX857328)		330
NRIV_SUD-HKV141_(JX857322)	G.....	330
NRIV_SUD-HKV66_(JX857319)	G.....	330
GSA/TS7/5170_WT		330
ISL/TS2/5242/WT		330
TND/S1/19801/WT		330
NRIV_DakArD28542_(JX857316)	CAACCCAGTTCCTGACGATGGTCTTACCCCTCCACCGCCTCAGTGGATTCCCTGCCAGGTACCTACTTGAGAAGATGCTAAAAGTCAGTGAACCCAGAAAAATTGATCATCA	440
NRIV_9800521_(JX857325)		440
NRIV_9800535_(JX857328)		440
NRIV_SUD-HKV141_(JX857322)		440
NRIV_SUD-HKV66_(JX857319)		440
GSA/TS7/5170_WT	C.....	440
ISL/TS2/5242/WT	C.....	440
TND/S1/19801/WT	C.....	440
NRIV_DakArD28542_(JX857316)	AATCAAAAAATAATCAATCCATTGGCTGAAAAAACGGGATCAGTTGGAATGATGGGGAGGAAGTTTACCTCTCCTTTTTTCCAGGATCAGAAATGTTCCTAGGAACTTTC	550
NRIV_9800521_(JX857325)	C.....	550

NRIV_9800535_(JX857328)		550
NRIV_SUD-HKV141_(JX857322)	T.....	550
NRIV_SUD-HKV66_(JX857319)	T.....	550
GSA/TS7/5170_WT	T.....	550
ISL/TS2/5242/WT	T.....	550
TND/S1/19801/WT	T.....	550
NRIV_DakArD28542_(JX857316)	AGATTCTATCCCTTGGCAATTGGGATCTACAAAGTCCAGCGCAAGGAAATGGAACCAAAATACCTTGAAAAGACAATGCCACAGAGGTATATGGGACTAGAAGCAGCAAC	660
NRIV_9800521_(JX857325)		660
NRIV_9800535_(JX857328)		660
NRIV_SUD-HKV141_(JX857322)	T.....A.....	660
NRIV_SUD-HKV66_(JX857319)	T.....A.....	660
GSA/TS7/5170_WT	T.....	660
ISL/TS2/5242/WT	T.....	660
TND/S1/19801/WT	T.....	660
NRIV_DakArD28542_(JX857316)	TTGGACTGTTAGTAAATTGACAGAAGTTCAGTCTGCATTAAACAGTTGTCTCCAGCTTGGGTTGGAAGAAAACTAATGTTAGTGACAGCTGCCAGGGACTTCCTTGCTAAAT	770
NRIV_9800521_(JX857325)	A.....	770
NRIV_9800535_(JX857328)	A.....	770
NRIV_SUD-HKV141_(JX857322)		770
NRIV_SUD-HKV66_(JX857319)	C.....	770
GSA/TS7/5170_WT	C.G.....	770
ISL/TS2/5242/WT	C.G.....	770
TND/S1/19801/WT	C.G.....	770
NRIV_DakArD28542_(JX857316)	TTGGAATCAACATGTAAGCAGGGAAGCATTTTAAATCGGGCTAAATCATCAGTTTTTAATTTGGCTAAAAGGGTTGTTTCAACCCACAAAATAACAGCTGTTTGGGTGGG	880
NRIV_9800521_(JX857325)		880
NRIV_9800535_(JX857328)		880
NRIV_SUD-HKV141_(JX857322)	G.....T.....	880
NRIV_SUD-HKV66_(JX857319)	G.....T.....	880
GSA/TS7/5170_WT		880
ISL/TS2/5242/WT		880
TND/S1/19801/WT		880
NRIV_DakArD28542_(JX857316)	TGGTTGGGGACAGAAAGACAGCGGACTAAATTAACATTACATTATTGATGGGTATTTTAAGTTTTAGGTGGAGCACACTACT	961
NRIV_9800521_(JX857325)	A.....	961
NRIV_9800535_(JX857328)	A.....	961
NRIV_SUD-HKV141_(JX857322)	A.....	961
NRIV_SUD-HKV66_(JX857319)	A.....	961
GSA/TS7/5170_WT	A.....	961
ISL/TS2/5242/WT	A.....	961
TND/S1/19801/WT	A.....	961

Appendix 1B: Bunyamwera virus S segment nucleotide sequence alignment

BUNV_(NC_001927)	AGTAGTGTA	CTCCACACTACAACTT	GTCTATTGTTG	AAAAATCGCTGTGCTATTAAATCC	AACAGAGGTCATTAAAGGCTCTTTAATGATTGAGTTGGAATTT	CATGATG	110
BUNV_BLCNNS_(D00353)							110

```

BUNV_ArB29051_(AM709778)      .....C..TT.....A.....A..... 110
BUNV_(AF325122)                .....A.....G...C.A.TCT.TA.-----A..C..AT.T...AA.-----A..C.....C.A....CA..... 93
BUNV_ArB28215_(AM711130)      .....C...A...GG.ATAT..A...--A...AGG.GAG..GA..AT..G.GAT.C...A.....A..... 107
MGD/S1/12060/WT                .....C...T.....A.....A..... 110
GSA/S4/11232/WT                .....C...T.....A.....A..... 110

BUNV_(NC_001927)              TCGCTGCTAAACACCAGCAGTACTTTTGACCCAGAGGTCGCATACGCTAACTTTAAGCGTGTCACACCACCTGGGCTTAGTTATGACCACATACGAATCTTCTACATTAA 220
BUNV_BLCNNS_(D00353)          ..... 220
BUNV_ArB29051_(AM709778)      ..... 220
BUNV_(AF325122)                .....T.....AT.....C..T.....T..... 203
BUNV_ArB28215_(AM711130)      .....T.....T.....CA.....C..... 217
MGD/S1/12060/WT                ..... 220
GSA/S4/11232/WT                ..... 220

BUNV_(NC_001927)              GGACGCGAGATTAAAACTAGTCTCGCAAAAAGAAGTGAATGGGAAGTTACACCTTAACCTTGGGGGCTGGAAGATTACTGTATATAATACGAATTTTCCTGGCAACCGGAA 330
BUNV_BLCNNS_(D00353)          ..... 330
BUNV_ArB29051_(AM709778)      ..... 330
BUNV_(AF325122)                .....G...G.....G.....T.....A.....G..A..... 313
BUNV_ArB28215_(AM711130)      ..GA..A.....GT.....T.....A.....G.....A..... 327
MGD/S1/12060/WT                ..... 330
GSA/S4/11232/WT                .....T..... 330

BUNV_(NC_001927)              CAACCCAGTTCTTGACGATGGTCTTACCCTCCACCGCCTCAGTGGATTCCCTGCCAGGTACCTACTTGAGAAGATGCTGAAAGTCAGTGAACCAGAGAAATTGATTATTA 440
BUNV_BLCNNS_(D00353)          ..... 440
BUNV_ArB29051_(AM709778)      .....A...C.....A.....C..C..... 440
BUNV_(AF325122)                ..GT.....A.....A.A.....A.....T.....A..A...G..A...C...A..GC...A..A..... 423
BUNV_ArB28215_(AM711130)      ..G.....T.T.....A.G.....A.....A..... 437
MGD/S1/12060/WT                .....A.....A.....C..C..... 440
GSA/S4/11232/WT                .....A.....A.....C..C..... 440

BUNV_(NC_001927)              AATCAAAAATAATCAACCCTTTGGCTGAAAAGAATGGGATCACCTTGAATGATGGAGAGGAAGTTATCTCTCTTTCTCCAGGATCAGAGATGTTCTTAGGAACTTTC 550
BUNV_BLCNNS_(D00353)          ..... 550
BUNV_ArB29051_(AM709778)      .....T..A.....A.....G.....C..T.....A.....C..... 550
BUNV_(AF325122)                .....G.....T..AC.T.....A..C..T..T.....TC...C.....A.....C.....C.....G..T..A.....G..A..... 533
BUNV_ArB28215_(AM711130)      ..GG.....AC.....A..A.....C.....T..A..G.....C..G.....T..C.....A.....C.....T..A..T..... 547
MGD/S1/12060/WT                .....T..A.....A.....G.....G.....C..T.....A.....C..... 550
GSA/S4/11232/WT                .....T..A.....A.....G.....G.....C..T.....A.....C..... 550

BUNV_(NC_001927)              AGATTCTACCCCTTAGCAATCGGGATCTACAAAGTTCAGCGCAAGGAAATGGAACCAAAATACCTTGAGAAAACAATGCGGCAGAGGTACATGGGACTAGAAGCAGCAAC 660
BUNV_BLCNNS_(D00353)          ..... 660
BUNV_ArB29051_(AM709778)      .....T.....C.....G.....A..G..... 660
BUNV_(AF325122)                .....T.....T.....T..T.....A.G..A.....T.....T.....C..A.....T.G.....CT..... 643
BUNV_ArB28215_(AM711130)      ..A.....A..G.....T.....T.....G..AA.G..A.....G.....TT...A...T..A.....C..T.....T..G..... 657
MGD/S1/12060/WT                .....T.....T.....C.....G.....A..G..... 660
GSA/S4/11232/WT                .....T.....C.....G.....A..G..... 660

BUNV_(NC_001927)              TTGGACTGTAGTAAATTGACAGAAGTTCAGTCTGCACTGACAGTTGTCTTAGCTTAGGTTGGAAGAAAACCAATGTTAGTGCAGCTGCCAGGGACTTCCTTGCTAAAT 770
BUNV_BLCNNS_(D00353)          ..... 770
BUNV_ArB29051_(AM709778)      .....C...G.....T..... 770
BUNV_(AF325122)                A...A...C...A.AC..G..C.....C..T..G..T..AG..C..T.....A...G..CAGT...T...A...A..C..... 753
BUNV_ArB28215_(AM711130)      C...A..G..C...A..T..T...A..A...T.....T...G...C...G...C..T..A...A...G..... 767
MGD/S1/12060/WT                .....C...G.....T..... 770

```

```

GSA/S4/11232/WT      .....C.....G.....T..... 770

BUNV_(NC_001927)      TCGGAATCAACATGTAAGCAGGGATGCATTTTAAATCGGGCTAAAGTCATCTGTTTAAATTTGGCTAAAAGGGTTGTTTCAACCCACAAAAT-AACAGCTGCTTGGGTGG 879
BUNV_BLCNNS_(D00353)  .....-..... 879
BUNV_ArB29051_(AM709778) .T.....T.....A.....C.....A.....A.....T..... 879
BUNV_(AF325122)      .T.....T.G.....ATGATC.GT..GAAC..GATTT.GC..A.TTAAGA.A.....A..CC.AGG.CT.A.....TCA.....TG..... 863
BUNV_ArB28215_(AM711130) .T..C.....T.....TTT..T.ATTTGAA.....T..A..CA.TT.AAAA.....CA.....T.T.GGT..A.....AT..... 876
MGD/S1/12060/WT      .T.....T.....A.....A.....A.....A.....-.....T..... 879
GSA/S4/11232/WT      .T.....T.....A.....A.....A.....-.....T..... 879

BUNV_(NC_001927)      GTGGTTGGGGACAGAAAGACAGCGGGCTAAATCAACATTATATTGTTAATGGTATTTTAAAGTTTATAGGTGGAGCACACTACT 961
BUNV_BLCNNS_(D00353)  ..... 961
BUNV_ArB29051_(AM709778) .....A.....T.....C.....A.....A..... 961
BUNV_(AF325122)      .....ATA.A.C--..T.T.TTC..GA..CA..GCA.T.C..... 943
BUNV_ArB28215_(AM711130) .....C.....CA..A..CATT..--..G.TC.TTCA.C.....C.G.T.T.GTA.A..... 956
MGD/S1/12060/WT      .....A.....T.....C.....A..... 961
GSA/S4/11232/WT      .....A.....T..T...C...A..... 961

```

Appendix 1C: Ngari virus M segment nucleotide sequence alignment

```

NRIV_DakArD28542_(JX857317) AGTAGTGTA CTACCGATACAAATCACAACTATAATTGCAAGATGTTGCTACTTCTTGCTTATTAATCCCTTGCTATGTATCAGCCTCTCCTGTAGTAACAAGATGCTTC 110
NRIV_9800521_(JX857326) .....C..... 110
NRIV_9800535_(AY593725) .....C..... 110
NRIV_SUD-HKV141_(JX857323) .....C..... 110
NRIV_SUD-HKV66_(JX857320) .....C..... 110
GSA/TS7/5170_WT .....T.....C..... 110
ISL/TS2/5242_WT .....T.....C..... 110
TND/S1/19801_WT .....T.....C..... 110

NRIV_DakArD28542_(JX857317) CATGGAGGGCAATTGATAGCAGAGAAGAAATCCCAAACAGCTGTATCAGAAATTTGCCTGAAAGATGATGTCTCTACTATTAAGTCAGAAATAACATATGAGAAGAACAA 220
NRIV_9800521_(JX857326) ..... 220
NRIV_9800535_(AY593725) ..... 220
NRIV_SUD-HKV141_(JX857323) .....C..... 220
NRIV_SUD-HKV66_(JX857320) ..... 220
GSA/TS7/5170_WT .....G..... 220
ISL/TS2/5242_WT .....G..... 220
TND/S1/19801_WT .....G..... 220

NRIV_DakArD28542_(JX857317) CACTGGTTTATTTGCCCATAGCAAAGTTTACGAAATTTGGATCATAAAAGACTGGAAAAATTGCAACCCCTGTTCCACAGCAGGGGGCAGCATAAATGTTATAGAAAGTCA 330
NRIV_9800521_(JX857326) ..... 330
NRIV_9800535_(AY593725) .....T..... 330
NRIV_SUD-HKV141_(JX857323) ..... 330
NRIV_SUD-HKV66_(JX857320) ..... 330
GSA/TS7/5170_WT ..... 330
ISL/TS2/5242_WT ..... 330
TND/S1/19801_WT ..... 330

NRIV_DakArD28542_(JX857317) ATACAGATTGTGAGCTTGACCACAAAAACATATGTGTGTAGCAGAGATTGCACAATTACAGTTGATAAAGAGGATGCTCAGATAATTTTCCAAACCGAGAAGTTGAACCAT 440

```

NRIV_9800521_(JX857326)	C.....	440
NRIV_9800535_(AY593725)	C.....	440
NRIV_SUD-HKV141_(JX857323)	C.....T.....	440
NRIV_SUD-HKV66_(JX857320)	C.....	440
GSA/TS7/5170_WT	C.....	440
ISL/TS2/5242_WT	C.....	440
TND/S1/19801_WT	C.....	440
NRIV_DakArD28542_(JX857317)	TTCTGAGGTCCTCTGGGACTACATTGAGCTCAGGCTGGTTTAAAAACCAAGCATCAGTAACATTGGACAGGACTTGTGAACATATTAAGTAACATGTGGGAAAAAGACCCCT	550
NRIV_9800521_(JX857326)	A.....T.....	550
NRIV_9800535_(AY593725)	A.....	550
NRIV_SUD-HKV141_(JX857323)	T.....	550
NRIV_SUD-HKV66_(JX857320)	T.....	550
GSA/TS7/5170_WT	..T.....T.....	550
ISL/TS2/5242_WT	..T.....T.....	550
TND/S1/19801_WT	..T.....T.....	550
NRIV_DakArD28542_(JX857317)	ACAATTCCATGCCTGCTTTAAGCACCATGTCCTGTATTAGATTCTTCCATGGCACTATTCTTCCTGGAACAATGGCTACTTCCATTTGTCAAAATATAGAACTTATAA	660
NRIV_9800521_(JX857326)	G.....A.....C.....	660
NRIV_9800535_(AY593725)	G.....T.....A.....C.....	660
NRIV_SUD-HKV141_(JX857323)	C.....	660
NRIV_SUD-HKV66_(JX857320)	C.....	660
GSA/TS7/5170_WT	G.....C.....C.....	660
ISL/TS2/5242_WT	G.....C.....C.....	660
TND/S1/19801_WT	G.....C.....C.....	660
NRIV_DakArD28542_(JX857317)	TTATAATAAGTCTGACATTGATTATCTTTATCCTGATGGTAATATTAACCAAAACCTATATATGTTATCTATTGATGCCACTATTTATGCCGATTGCATACCTTTTATGGT	770
NRIV_9800521_(JX857326)	A.....	770
NRIV_9800535_(AY593725)	A.....	770
NRIV_SUD-HKV141_(JX857323)	C.....	770
NRIV_SUD-HKV66_(JX857320)	C.....	770
GSA/TS7/5170_WT		770
ISL/TS2/5242_WT		770
TND/S1/19801_WT		770
NRIV_DakArD28542_(JX857317)	TGGTCATATAACAAAAGCTGCAAAAAATGCTCATGCTGTGGCCTAGCTTATCACCCCTTTACAAATTGTGGGTACATTGTGTATGCGGGTTAAAAATTTGAAGCATCAGA	880
NRIV_9800521_(JX857326)	T.....C.....G.....	880
NRIV_9800535_(AY593725)	T.....C.....G.....	880
NRIV_SUD-HKV141_(JX857323)	T.....G.....	880
NRIV_SUD-HKV66_(JX857320)	T.....G.....	880
GSA/TS7/5170_WT	G.....T.....T.....C.....T.....G.....	880
ISL/TS2/5242_WT	G.....T.....T.....C.....T.....G.....	880
TND/S1/19801_WT	G.....T.....T.....C.....T.....G.....	880
NRIV_DakArD28542_(JX857317)	TAGGATGAGAAATACACAGAGAATCCGGATTATGTCAAGGCTATAAAAGTCTACGTTGTGGCTAGATTGTTGTGCAAGTCAAAAGGTTTCATCTCTCATAAATCTCAATATTAT	990
NRIV_9800521_(JX857326)	T.....G.....G.....	990
NRIV_9800535_(AY593725)	T.....G.....G.....	990
NRIV_SUD-HKV141_(JX857323)		990
NRIV_SUD-HKV66_(JX857320)	T.....	990
GSA/TS7/5170_WT	G.....A.....C.....TG.....	990
ISL/TS2/5242_WT	G.....A.....C.....TG.....	990
TND/S1/19801_WT	G.....A.....C.....TG.....	990

NRIV_DakArD28542_(JX857317)	TATCTATGTTGATACTAAGCTTTGTTACACCAATAGAGGGGACATTAACCTAACCCAGAATCAAGGAAGTATGATCTGGAGGAAATTGCTGATGCTCGGAAGGATTT	1100
NRIV_9800521_(JX857326)	C.....	1100
NRIV_9800535_(AY593725)	C.....	1100
NRIV_SUD-HKV141_(JX857323)		1100
NRIV_SUD-HKV66_(JX857320)	..G.....	1100
GSA/TS7/5170_WT	A.....	1100
ISL/TS2/5242_WT	A.....	1100
TND/S1/19801_WT	A.....	1100
NRIV_DakArD28542_(JX857317)	ATTGTAGAAAAAGGGATAAAAGAATACGTAGTTTTTATACTTCTATTTTTGGGGCTTTATTCTTACTAATGGCATTAGTTATCACAAATAACACTAAATAAGGTTACAGA	1210
NRIV_9800521_(JX857326)	G.....C.....	1210
NRIV_9800535_(AY593725)	C.....A.....	1210
NRIV_SUD-HKV141_(JX857323)		1210
NRIV_SUD-HKV66_(JX857320)		1210
GSA/TS7/5170_WT	T.....A.....C.....	1210
ISL/TS2/5242_WT	T.....A.....C.....	1210
TND/S1/19801_WT	T.....A.....C.....	1210
NRIV_DakArD28542_(JX857317)	GTATCTTACAAACATCAATGTTTTTACTGTTCATGAATGTTCAATGTATCACTCAAAGAAGAATATAAAATATATTGGGGATTTTACAAATAAATGTGGCTTTTGACAT	1320
NRIV_9800521_(JX857326)	C.....C.....G.....	1320
NRIV_9800535_(AY593725)	C.....C.....T.....G.....	1320
NRIV_SUD-HKV141_(JX857323)	C.....	1320
NRIV_SUD-HKV66_(JX857320)	C.....	1320
GSA/TS7/5170_WT	C.....C.....G.....A.....	1320
ISL/TS2/5242_WT	C.....C.....G.....A.....	1320
TND/S1/19801_WT	C.....C.....G.....A.....	1320
NRIV_DakArD28542_(JX857317)	GTGGAGAGTTGGAAGATCAAGAAGGTTTAAAAATACATAAAGTTAGCAGAAAGTGCATATATAAAATATCAACTCACCTGGTCTAAAAATAATCATGACGATACTAGTGTGT	1430
NRIV_9800521_(JX857326)	A.....A.....	1430
NRIV_9800535_(AY593725)	A.....A.....A.....	1430
NRIV_SUD-HKV141_(JX857323)	T.....A.....	1430
NRIV_SUD-HKV66_(JX857320)	T.....	1430
GSA/TS7/5170_WT	G.....G.....A.....A.....	1430
ISL/TS2/5242_WT	G.....G.....A.....A.....	1430
TND/S1/19801_WT	G.....G.....A.....A.....	1430
NRIV_DakArD28542_(JX857317)	CTACTGATTGCTCAAAACACCATCCTAATAGTCGCAGCATCAGATGATTGCTGGACAAAAAATCTTTAGAGATGGGAATGTATAGGCCCTTTACAGCAAGTGGATACATG	1540
NRIV_9800521_(JX857326)	G.....	1540
NRIV_9800535_(AY593725)	G.....	1540
NRIV_SUD-HKV141_(JX857323)	C.....A.....	1540
NRIV_SUD-HKV66_(JX857320)		1540
GSA/TS7/5170_WT		1540
ISL/TS2/5242_WT		1540
TND/S1/19801_WT		1540
NRIV_DakArD28542_(JX857317)	CGACGATAAAGCAAGCAGATCTTACAGTGGGGAGGCAAAAAAGCTAGTGAGAGCATCTAAAAATATCAGACCTGGATGCAGCACAAGTGGGGCTATTAGGACCTACGATAG	1650
NRIV_9800521_(JX857326)	T.....G.....G.....A.....T.....	1650
NRIV_9800535_(AY593725)	T.....G.....G.....G.....T.....	1650
NRIV_SUD-HKV141_(JX857323)	T.....G.....	1650
NRIV_SUD-HKV66_(JX857320)	T.....G.....A.....	1650

GSA/TS7/5170_WT	T.....T.....G.....T.....T.....	1650
ISL/TS2/5242_WT	T.....T.....G.....T.....T.....	1650
TND/S1/19801_WT	T.....T.....G.....T.....T.....	1650
NRIV_DakArD28542_(JX857317)	AATCAGCAATAGCAAGCATAAAGAAAGCAGAGAACATATTCAACCATGCATCTCCTTGAATCAGTATTCCTTGGAAAGCATTGTGATTACTATAAACTTTCCGAACATAAT	1760
NRIV_9800521_(JX857326)	C.....G.....G.....	1760
NRIV_9800535_(AY593725)	T.....C.....G.....	1760
NRIV_SUD-HKV141_(JX857323)	C.....G.....	1760
NRIV_SUD-HKV66_(JX857320)	C.....G.....	1760
GSA/TS7/5170_WT	C.....T.....G.....	1760
ISL/TS2/5242_WT	C.....T.....G.....	1760
TND/S1/19801_WT	C.....T.....G.....	1760
NRIV_DakArD28542_(JX857317)	AGTGGCTACTCACAGGCAAAGTGGAGGTAAACAGCTAAAACACATCATTTTGATATTTGCTCAAGACATAGTACCCATCATTTCTGTAGATGTATCTCAGATGGGACAAA	1870
NRIV_9800521_(JX857326)	C.....	1870
NRIV_9800535_(AY593725)	C.....	1870
NRIV_SUD-HKV141_(JX857323)	C.....G.....	1870
NRIV_SUD-HKV66_(JX857320)	G.....C.....	1870
GSA/TS7/5170_WT	C.T.....T.....	1870
ISL/TS2/5242_WT	C.T.....T.....	1870
TND/S1/19801_WT	C.T.....T.....	1870
NRIV_DakArD28542_(JX857317)	GTGCCAAAATGGGGATTGGGATTTTTCAGGTTGAAATGAACCTCAACATACCAGTCAAAAAAGGACTTTTTTTGAGCATGACCTCAAGCTGTTCTGCACCCCTTGTAGAAAATG	1980
NRIV_9800521_(JX857326)	C.....T.....C.....T.....A.....T.....	1980
NRIV_9800535_(AY593725)	..T.....T.....C.....T.....C.....T.....A.....T.....	1980
NRIV_SUD-HKV141_(JX857323)	C.....T.....	1980
NRIV_SUD-HKV66_(JX857320)	C.....T.....	1980
GSA/TS7/5170_WT	A.....T.....C.....T.....T.....	1980
ISL/TS2/5242_WT	A.....T.....C.....T.....T.....	1980
TND/S1/19801_WT	A.....T.....C.....T.....T.....	1980
NRIV_DakArD28542_(JX857317)	CTTTTCCAGGCACAACAGAGTCACTTTTTTATGAAATGTTATCTAAGAAAAACACAACCTGGTGTCAAAAAGCTATTAGATAAAATAACAAGAAAATTTGGGAATAACAAT	2090
NRIV_9800521_(JX857326)	G.....A.....C.....	2090
NRIV_9800535_(AY593725)	G.....A.....C.....	2090
NRIV_SUD-HKV141_(JX857323)	G.....G.....	2090
NRIV_SUD-HKV66_(JX857320)	G.....	2090
GSA/TS7/5170_WT	T.....G.....A.....CT.....	2090
ISL/TS2/5242_WT	T.....G.....A.....CT.....	2090
TND/S1/19801_WT	T.....G.....A.....CT.....	2090
NRIV_DakArD28542_(JX857317)	ATGTTTGTAGGGATATGGAATTTGGACAGTATCTAATGTCACTGCCATATGTCAATGAAACATCATTAACCCCTGCTCAAGTTGCTAAAAATACTAGAGGTTACAGATCA	2200
NRIV_9800521_(JX857326)	T.....G.....C.....A.....T.....C.....	2200
NRIV_9800535_(AY593725)	A.T.....A.....T.....C.....	2200
NRIV_SUD-HKV141_(JX857323)		2200
NRIV_SUD-HKV66_(JX857320)		2200
GSA/TS7/5170_WT	A.....T.....T.....C.....	2200
ISL/TS2/5242_WT	A.....T.....T.....C.....	2200
TND/S1/19801_WT	A.....T.....T.....C.....	2200
NRIV_DakArD28542_(JX857317)	GCACCATCGATCTATATCTGGAAGGCAGAATCATTTGGCTAGTGCTACCCCTGGGAGTAAGTCCAAGGAATGTAGTCATGCAAAAAAGGCTCCTGCATAAGTCCTAGGT	2310
NRIV_9800521_(JX857326)	G.....G.....T.....	2310
NRIV_9800535_(AY593725)	G.....G.....T.....C.....	2310

NRIV_SUD-HKV141_(JX857323)	G.....G.....T.....	2310
NRIV_SUD-HKV66_(JX857320)	G.....G.....	2310
GSA/TS7/5170_WT	A.....G.....G..GC.....T.....C.....G.....	2310
ISL/TS2/5242_WT	A.....G.....G..GC.....T.....C.....G.....	2310
TND/S1/19801_WT	A.....G.....G..GC.....T.....C.....G.....	2310
NRIV_DakArD28542_(JX857317)	TTAGTGTTCCGATGGAAGGATTAATGGCATGTGGGGACTCACCAAAATTACAAAATTTATAAAACACCAGCAAAGCTTTATAAATCAAACAACAAGGGGGAAGTGTGGTGC	2420
NRIV_9800521_(JX857326)	G.....A.....T.....	2420
NRIV_9800535_(AY593725)	A.....T.....	2420
NRIV_SUD-HKV141_(JX857323)	T.....	2420
NRIV_SUD-HKV66_(JX857320)		2420
GSA/TS7/5170_WT	T.....G.....	2420
ISL/TS2/5242_WT	T.....G.....	2420
TND/S1/19801_WT	T.....G.....	2420
NRIV_DakArD28542_(JX857317)	TCAGGTGATGTTCATTGTCTCAGGAGCTAAGCCCAGCATCACAAGAATCTGTTGACAGGATAAAACAAATTAAGTCTTCTGACAGAACCTGAAGTAAGTGATGACGT	2530
NRIV_9800521_(JX857326)	C.....T.....	2530
NRIV_9800535_(AY593725)	C.....	2530
NRIV_SUD-HKV141_(JX857323)	C.....	2530
NRIV_SUD-HKV66_(JX857320)	C.....	2530
GSA/TS7/5170_WT	C.....A.....	2530
ISL/TS2/5242_WT	C.....A.....	2530
TND/S1/19801_WT	C.....A.....	2530
NRIV_DakArD28542_(JX857317)	TTTTTCAATTGCAATATCTACGTGCAAAGTTCAAGATAAGGGAGTATGTACAGTAAATGAAGATAGGTGGAACGTAATAAAATGTGATAGTGGGCTGATATATTATCTG	2640
NRIV_9800521_(JX857326)	G.....G.....	2640
NRIV_9800535_(AY593725)	G.....	2640
NRIV_SUD-HKV141_(JX857323)	A.....	2640
NRIV_SUD-HKV66_(JX857320)		2640
GSA/TS7/5170_WT	A.....G.....	2640
ISL/TS2/5242_WT	A.....G.....	2640
TND/S1/19801_WT	A.....G.....	2640
NRIV_DakArD28542_(JX857317)	ACCAGAGAGATGGGCAGGATACAGGCAATGATTTCCGAGAAATATTGTTTGTCCCATAGCTGCAGAAATAGAGAGGTTCCCCATAAACCCGGCAATAATTAGTGATTGTTTA	2750
NRIV_9800521_(JX857326)	G.....G.....C.....	2750
NRIV_9800535_(AY593725)	G.....G.....C.....	2750
NRIV_SUD-HKV141_(JX857323)	G.....	2750
NRIV_SUD-HKV66_(JX857320)	G.....	2750
GSA/TS7/5170_WT	A.....T.....A.....	2750
ISL/TS2/5242_WT	A.....T.....A.....	2750
TND/S1/19801_WT	CG.....A.....T.....A.....	2750
NRIV_DakArD28542_(JX857317)	TGGGAGTACCAATTCGCGGAAATCCAAATATATCACCAGCTTGGACCTAGAGAAATCTAGAAGAATTCAAAAGGGCTATTTCTGAAAAATTATCACATACTCTTATAGTTTA	2860
NRIV_9800521_(JX857326)	T.....	2860
NRIV_9800535_(AY593725)	T.....	2860
NRIV_SUD-HKV141_(JX857323)	C.....	2860
NRIV_SUD-HKV66_(JX857320)	A.....	2860
GSA/TS7/5170_WT	G.....T.....G.....	2860
ISL/TS2/5242_WT	G.....T.....G.....G.....	2860
TND/S1/19801_WT	G.....T.....G.....G.....	2860
NRIV_DakArD28542_(JX857317)	TAAATTTCAACCACAGCTAATCTTCCCCATATAAGCCGGTATACAAATATATCACAGTGCAGGGGTAGAGAATTCCTGATGGAGTAGATTACGCATATATAGCTGCTA	2970

NRIV_9800521_(JX857326)	G.....	2970
NRIV_9800535_(AY593725)	G.....	2970
NRIV_SUD-HKV141_(JX857323)	A.....	2970
NRIV_SUD-HKV66_(JX857320)	A.....	2970
GSA/TS7/5170_WT	G.....T.....	2970
ISL/TS2/5242_WT	G.....T.....	2970
TND/S1/19801_WT	G.....T.....	2970
NRIV_DakArD28542_(JX857317)	GTATGCCAGCTTTGAGCGGAACAAGTATAGGATATAATATAATGCTAGAGATAACTTTCCATTATTGATATAATTATTTATAAAAAGCGCTATTATTAAGGCAACT	3080
NRIV_9800521_(JX857326)	T..C.....T.....	3080
NRIV_9800535_(AY593725)	T..C.....T.....	3080
NRIV_SUD-HKV141_(JX857323)		3080
NRIV_SUD-HKV66_(JX857320)		3080
GSA/TS7/5170_WT	C.....C..T..C.....T.....	3080
ISL/TS2/5242_WT	C.....C..T..C.....T.....	3080
TND/S1/19801_WT	C.....C..T..C.....T.....	3080
NRIV_DakArD28542_(JX857317)	TACAATCATATATATGACACAGGCCCCACTATAGGAATCAATGTAATGCATGATGAACATTGCACAGGGCAATGCCCAACAGATATACCACATAAAGAAAAATTGGATTAC	3190
NRIV_9800521_(JX857326)	T.....T.....	3190
NRIV_9800535_(AY593725)	T.....T.....	3190
NRIV_SUD-HKV141_(JX857323)		3190
NRIV_SUD-HKV66_(JX857320)		3190
GSA/TS7/5170_WT	T.....T.....T.....	3190
ISL/TS2/5242_WT	T.....T.....T.....	3190
TND/S1/19801_WT	T.....T.....T.....	3190
NRIV_DakArD28542_(JX857317)	ATTTGCTCAAGAGAGAACTAGTCGTTGGGGATGCCAAGAAATTTGGGTGCCCTTGCTGTAATACAGGCTGTGTTTTTGGTTCTTGTTCAGGATATAATAAGGCCAGAAACAA	3300
NRIV_9800521_(JX857326)	A.....	3300
NRIV_9800535_(AY593725)	A.....	3300
NRIV_SUD-HKV141_(JX857323)		3300
NRIV_SUD-HKV66_(JX857320)		3300
GSA/TS7/5170_WT	T.....C.....A.....	3300
ISL/TS2/5242_WT	T.....A.....	3300
TND/S1/19801_WT	T.....A.....	3300
NRIV_DakArD28542_(JX857317)	AGGTGTATAGAAAAGCAGTTGAGGAGAGTGTCTTATTAAACAGTATGTATAAATTACCCAGGC AAAACATTCTGCACAGAAAATAAATGCCATAGAACCCTAAAAATCACAGAT	3410
NRIV_9800521_(JX857326)	C.G.....T.....G.....	3410
NRIV_9800535_(AY593725)	C.....T.....G.....	3410
NRIV_SUD-HKV141_(JX857323)		3410
NRIV_SUD-HKV66_(JX857320)		3410
GSA/TS7/5170_WT	C.....GC.....G.....	3410
ISL/TS2/5242_WT	C.....GC.....G.....	3410
TND/S1/19801_WT	C.....GC.....G.....	3410
NRIV_DakArD28542_(JX857317)	GAGTTAGAAATTACAGTTC AAAACAGTTGATACAAAAACATTACCCAAATATCTTAGCTGTCCAAAACCATAAAGTTATATAGTGGACAAATTAAATGATTGGGATCATTTTC	3520
NRIV_9800521_(JX857326)		3520
NRIV_9800535_(AY593725)		3520
NRIV_SUD-HKV141_(JX857323)		3520
NRIV_SUD-HKV66_(JX857320)		3520
GSA/TS7/5170_WT	C.....T.....	3520
ISL/TS2/5242_WT	C.....T.....	3520
TND/S1/19801_WT	C.....T.....	3520

NRIV_DakArD28542_(JX857317)	ACAAGGCTGTGGCAACATACAGAAAACCAATTCATCCATTATAGGCACAGGTACTGCAAAGTTTGATTATGTGTGCATGGTGCTTCCAGGAAAGATATCATTGTAAGGA	3630
NRIV_9800521_(JX857326)	T.....T.....G.....T.....	3630
NRIV_9800535_(AY593725)	T.....G.....T.....	3630
NRIV_SUD-HKV141_(JX857323)	T.....	3630
NRIV_SUD-HKV66_(JX857320)	T.....	3630
GSA/TS7/5170_WT	T.....	3630
ISL/TS2/5242_WT	T.....	3630
TND/S1/19801_WT	T.....	3630
NRIV_DakArD28542_(JX857317)	GATGTTACAATAATAACTATGAGTCATGTAAATTATTGAAGGAGGAACAATCTTTAATGTTTCGAGATAACCATGAAACTATTGACGTAGCTAATGTCAGACATCTCCTT	3740
NRIV_9800521_(JX857326)	C.....	3740
NRIV_9800535_(AY593725)	C.....	3740
NRIV_SUD-HKV141_(JX857323)	G.....T.....	3740
NRIV_SUD-HKV66_(JX857320)	G.....T.....	3740
GSA/TS7/5170_WT	G.....	3740
ISL/TS2/5242_WT	G.....	3740
TND/S1/19801_WT	G.....	3740
NRIV_DakArD28542_(JX857317)	GGAGATCTACAATTTAAATTAAATGTTGGGAGATCTAAGGTACAAGTCATTTGCAGAAAACCCAGATTTGGAATAGAGGCAAAGTGTGTTGGGTGCCCGTCATGTTTTAC	3850
NRIV_9800521_(JX857326)	G.....T.....	3850
NRIV_9800535_(AY593725)	G.....T.....T.....A.....A.....	3850
NRIV_SUD-HKV141_(JX857323)	G.....G.....A.....	3850
NRIV_SUD-HKV66_(JX857320)	G.....G.....A.....	3850
GSA/TS7/5170_WT	G.....	3850
ISL/TS2/5242_WT	G.....	3850
TND/S1/19801_WT	G.....	3850
NRIV_DakArD28542_(JX857317)	TAGTTACTCCTGCAGCTTCAAGATTGCTTCAAATATTGACACTGTATGCTCAATTGAAGGGCCTTGTAACAATTTTCATAATAGATTGATGATCACCTCTACAAAACAAG	3960
NRIV_9800521_(JX857326)	A.....A.....T.....	3960
NRIV_9800535_(AY593725)	G.....A.....T.....	3960
NRIV_SUD-HKV141_(JX857323)	T.....C.....	3960
NRIV_SUD-HKV66_(JX857320)	A.....C.....	3960
GSA/TS7/5170_WT	T.....	3960
ISL/TS2/5242_WT	T.....	3960
TND/S1/19801_WT	T.....	3960
NRIV_DakArD28542_(JX857317)	ATTATGGCATCAAAATGAGCTGTAAACCAAAGCCAAAAGAAACAGAAAGAGTCCAGATTGCAAGAAAACCTTACACAGTATTGTTTACAACAGTTGAGAAAAATGATAAA	4070
NRIV_9800521_(JX857326)	A.....	4070
NRIV_9800535_(AY593725)	A.....	4070
NRIV_SUD-HKV141_(JX857323)	T.....	4070
NRIV_SUD-HKV66_(JX857320)	T.....	4070
GSA/TS7/5170_WT	A.....A.....	4070
ISL/TS2/5242_WT	A.....A.....	4070
TND/S1/19801_WT	A.....A.....	4070
NRIV_DakArD28542_(JX857317)	ATCGAAATAAGCACAGGGGATCAAACATCCCTTTATCCAAGAGAGGGATGATAGATGCAAAACATGGTTATGCAGAGTTAGGGATGAAGGGATCAGTGTTATTTTTGAGCC	4180
NRIV_9800521_(JX857326)	T.....	4180
NRIV_9800535_(AY593725)	A.....	4180
NRIV_SUD-HKV141_(JX857323)		4180
NRIV_SUD-HKV66_(JX857320)		4180
GSA/TS7/5170_WT	T.....T.....A.....	4180

```

ISL/TS2/5242_WT      .....T.....T.....A.. 4180
TND/S1/19801_WT     .....T.....T.....A.. 4180

NRIV_DakArD28542_(JX857317) AATAAGGGCTTTCTTTGGAAGCTACTTTAGTATAGCTTTTATGTAAGTGGTCAGTATTATTGTCTATTCTAGCAATCTACATCTTCTTGCCCTATGGTGTCAAACCTTA 4290
NRIV_9800521_(JX857326) .....A..... 4290
NRIV_9800535_(AY593725) .....A..... 4290
NRIV_SUD-HKV141_(JX857323) .....A..... 4290
NRIV_SUD-HKV66_(JX857320) .....A..... 4290
GSA/TS7/5170_WT .....A..T..... 4290
ISL/TS2/5242_WT .....A..T..... 4290
TND/S1/19801_WT .....A..T..... 4290

NRIV_DakArD28542_(JX857317) GAGATGTGTTAAAAAGGAATGAATATCTATACCTTGCAGGAAATAAAGCACAGTGATTAATTAAGAAATCATCATTTTAGTTTTTAAAGAAATCATCATTTTAGTTTTTA 4400
NRIV_9800521_(JX857326) .....T..A.A..TTC..... 4376
NRIV_9800535_(AY593725) .....T..A.A..TTC..... 4376
NRIV_SUD-HKV141_(JX857323) .....T.....A..... 4376
NRIV_SUD-HKV66_(JX857320) .....T.....A..... 4376
GSA/TS7/5170_WT .....T..A..TT.....A.. 4376
ISL/TS2/5242_WT .....T..A..TT.....A.. 4376
TND/S1/19801_WT .....T..A..TT.....A.. 4376

NRIV_DakArD28542_(JX857317) AAGATAAAATTTTATATATTAGCCTTAGGGCAAATTAGCTGTTATTATATCGGTAGCACACTACT 4464
NRIV_9800521_(JX857326) .....A..... 4438
NRIV_9800535_(AY593725) ..... 4438
NRIV_SUD-HKV141_(JX857323) ..... 4440
NRIV_SUD-HKV66_(JX857320) ..... 4440
GSA/TS7/5170_WT .....G..... 4435
ISL/TS2/5242_WT .....G..... 4435
TND/S1/19801_WT .....G..... 4435

```

Appendix 1D: Bunyamwera virus M segment nucleotide sequence alignment

```

BUNV_(NC_001926) AGTAGTGTACTACCGATACATCACAACCTTTTCAGAGACACATCTTTATTTCCAAGATGAGAATTCTAATACTGCTTTTAGCAGTCACTCAACTGGCTGTGAGTAGCCCA 110
BUNV_(M11852) ..... 110
BUNV_(JF961341) ..... 1
GSA/S4/11232_WT .....T.....G.....T..A.....G..... 110
MGD/S1/12060_WT .....T.....G.....T..A.....G..... 110

BUNV_(NC_001926) GTTATCACTAGATGCTTTTCATGGTGGGCAACTGATTGCAGAAAGGAAATCCCAACATCGATTTCAGAAATTCGCATTAAAGATGACGTTTCTATGTTAAAAATCAGAGAT 220
BUNV_(M11852) ..... 220
BUNV_(JF961341) ..... 1
GSA/S4/11232_WT ...G.....A..C..... 220
MGD/S1/12060_WT ...G.....A..C..... 220

BUNV_(NC_001926) TGTCTACACAAAAAATGATACTGGGATTTTTGGCCACAGTAAAGTGTTTCGTCAGTGGACGATCACAGACTGGAAGCATGCAACCCGTGTTGTTACGGCCGGTGGTAGTA 330
BUNV_(M11852) ..... 330
BUNV_(JF961341) -----.....T.....A.....T.....A..... 102

```

GSA/S4/11232_WT T.....A.....A..... 330
MGD/S1/12060_WT T.....A.....A..... 330

BUNV_(NC_001926) TAAATGTTATAGAGGTTGATAAAAACTAAACCTTGTAACTAGAAATTATGTGTGCACAGGGGATTGCACATTAACAGTTGATAGGAAAAATGCCCAAATTATATTTTCTAG 440
BUNV_(M11852) 440
BUNV_(JF961341) G.....A.G.....G..... 212
GSA/S4/11232_WT A.G.....G..... 440
MGD/S1/12060_WT A.G.....G..... 440

BUNV_(NC_001926) ACAGACAACTTAATCATTTTGAAGTGACAGGAACACTACTATCAGCACTGGCTGGTTTAAGTCTAAAGCATCTGTTACTCTCGATAGAACATGTGAACATATAAAAGTAAG 550
BUNV_(M11852) 550
BUNV_(JF961341) G..C.....C..C..T.....C..... 322
GSA/S4/11232_WT G..G..C.....C..C..T.....C..... 550
MGD/S1/12060_WT G..G..C.....C..C..T.....C..... 550

BUNV_(NC_001926) CTGTGGAAGAAAAACATTACAATTCCATGCTTGCTTTAAGCAACACATGTCTTGTGTTTCGATTCTTACACAGGAGCATACTACCAGGGTCAATGGCAATTTTCGATCTGCC 660
BUNV_(M11852) 660
BUNV_(JF961341) T.....T..... 432
GSA/S4/11232_WT T..... 660
MGD/S1/12060_WT T..... 660

BUNV_(NC_001926) AAAATATTGAGCTGATTATAATAACAATATTGGCATTATGTATATTTATAATTATGATAATCTTAACAAAAACATACATTTGCTACGTGTTGATCCCAGTGTATTATGCCC 770
BUNV_(M11852) 770
BUNV_(JF961341) T.....A.....C.....A.....G..T.....C..... 542
GSA/S4/11232_WT T.....A.....C.....A.....G..T.....C.....A..... 770
MGD/S1/12060_WT T.....A.....C.....A.....G..T.....C.....A..... 770

BUNV_(NC_001926) ATAGCTTTTGTCTTATGGATGGGCGTACAACAGGAGTTGTAAGAAATGCACCTTGTTCGGATTGGCATATCATCCCTTTACAAACTGTGGCTCATATTGTGTCTGTGGCTC 880
BUNV_(M11852) 880
BUNV_(JF961341) A.....C..C.....C..... 652
GSA/S4/11232_WT C..C..... 880
MGD/S1/12060_WT C..C..... 880

BUNV_(NC_001926) CAAATTTGAAACATCGGACAGAATGAGGATGCACCGAGAATCAGGGTTATGTTCAGGGTTTAAAAAGCCTTGAGAGTAGCAAGAAGGCCTTGCAAATCAAAAGGCTCATCAT 990
BUNV_(M11852) 990
BUNV_(JF961341) A.....A.....G..C..... 762
GSA/S4/11232_WT A.....A.....G..C..... 990
MGD/S1/12060_WT A.....A.....G..C..... 990

BUNV_(NC_001926) TGATCATATCCATCTTACTCTCAGTGCTGATTCTATCCTTTGTAACACCCATAGAAGGGACTCTCACAACTACCCTACTGATCAGAAATATACTTTAGATGAGATAGCA 1100
BUNV_(M11852) 1100
BUNV_(JF961341) T.....T.....G.....T.....A..... 872
GSA/S4/11232_WT T.....T.....G.....T..T.....A..... 1100
MGD/S1/12060_WT T.....T.....G.....T..T.....A..... 1100

BUNV_(NC_001926) GATGTCCCTTCAAGCTAAAAACATGAAGATTCTACAAAATACTATATAATATTATATACATCACTCTTCGGTGCAGGTCTGACCATCATTTTTGCAGGAGTAGCATTGGG 1210
BUNV_(M11852) 1210
BUNV_(JF961341) C..G.....T..T.....T..T..... 982
GSA/S4/11232_WT C..G.....T..T.....T..T..... 1210
MGD/S1/12060_WT C..G.....T..T.....T..T..... 1210

BUNV_(NC_001926) GTTAACAAATTATACTAGAAGTATTAACCAAGATTAAATGTTATTTTTTCAACGAATGCAACATGTACCATAGCAAAAAATCAATCAAAATATGTAGGTGATTTCACTAATA 1320

```

BUNV_(M11852) ..... 1320
BUNV_(JF961341) A.....G.....A.....C.....G.....T.....C..... 1092
GSA/S4/11232_WT A.....G.....A.....C.....G.....T.....T.....C..... 1320
MGD/S1/12060_WT A.....G.....A.....C.....G.....T.....T.....C..... 1320

BUNV_(NC_001926) AATGTGGGTTTTGTACGTGTGGGCTGCTAGAGGATCCAGAGGGTGTGTGTGTACATAAAGCTAAAAAATCCTGTACATATTCATATCAGATTAACTGGGTCAGAGGCATC 1430
BUNV_(M11852) ..... 1430
BUNV_(JF961341) .....A.C.....A.....C.....C.G.....G.....A..T.. 1202
GSA/S4/11232_WT .....A.C.....A.....C.G.....G.....A..T.. 1430
MGD/S1/12060_WT .....A.C.....A.....C.G.....G.....A..T.. 1430

BUNV_(NC_001926) ATGATATTTGTTGCCTTTTTATTGTAAATACAGAAATACAATTATAATGGTCGCAGCAGAAGAAGACTGCTGGAAAAATGAAGAATTAAAAGAAGATTGTGTAGGGCCCTTT 1540
BUNV_(M11852) ..... 1540
BUNV_(JF961341) .....G..... 1312
GSA/S4/11232_WT .....G..... 1540
MGD/S1/12060_WT .....G.....G..... 1540

BUNV_(NC_001926) AATTGCACCTAAGGATTGTACTGATAAAGACCATAAAACCTACTTGAGTGAGGCTTCATTGTAGCAACAGCCAAAGAAAATAACTCAGGTGGATGCTGAAAAATGTGGAGA 1650
BUNV_(M11852) ..... 1650
BUNV_(JF961341) .....T.G.....C.....A..... 1422
GSA/S4/11232_WT .....T.G.....A..... 1650
MGD/S1/12060_WT .....T.G.....A..... 1650

BUNV_(NC_001926) TATTGGGGAAAACTATGGAATCAGCAATTAGAGTAATTGAAAGACAGAAGACATACCACAGAATGCACCTTGCTTGAGGCAGTATTTCTAAATAAGCACTGCGATTATTAT 1760
BUNV_(M11852) ..... 1760
BUNV_(JF961341) .....G.....G.....C.....T..... 1532
GSA/S4/11232_WT .....G.....C.....T..... 1760
MGD/S1/12060_WT .....G.....C.....T..... 1760

BUNV_(NC_001926) AAAATGTTTGAACATAACAGTGGATATTCCCAAGTAAAGTGGAGGATGATGATAAAAACACAACACTTTGATATCTGTGCCCTTACAAGCAAAATAGCCCGTTTTGTGCTCA 1870
BUNV_(M11852) ..... 1870
BUNV_(JF961341) .....C.....G.....A..... 1642
GSA/S4/11232_WT .....G.G.....A..... 1870
MGD/S1/12060_WT .....G.G.....A..... 1870

BUNV_(NC_001926) GTGCATTGCTGACAAATCTTGTGCGCAAGGTTCTTGGGAATTTGATACACATATGAATCCACATATTCAAGTAAAGTCGACAATTTTAAACATGACTTCTCTCTATTCC 1980
BUNV_(M11852) ..... 1980
BUNV_(JF961341) ...T.....A.....C.....C.....T..... 1752
GSA/S4/11232_WT ...T.....A.....C.....C.....T.....T..... 1980
MGD/S1/12060_WT ...T.....A.....C.....C.....T.....T..... 1980

BUNV_(NC_001926) TCAGAACTTTGAAGCAGCATTTCAGGCACCTGCTTATGTTCACTTGCTAACAATAATAAAAGAAAAGAAGCCCTATCAGGCAGTCAGCATGATTGAGAAAAATAAGAAG 2090
BUNV_(M11852) ..... 2090
BUNV_(JF961341) .....T.....T.....T.....T..... 1862
GSA/S4/11232_WT .....T.....T.....T..... 2090
MGD/S1/12060_WT .....T.....T..... 2090

BUNV_(NC_001926) AAGTTTCCGAATAATAAACTGCTTATTGGATATTAGATTTTGGCAAGTACTTGCTAGGCTTAAGTCATGCAAGCACATACGAGTTGCAACAGAGACAACCTAGATAAGTT 2200
BUNV_(M11852) ..... 2200
BUNV_(JF961341) .....T.....C.....A..... 1972
GSA/S4/11232_WT .....T.....C.....A..... 2200
MGD/S1/12060_WT .....T.....C.....A..... 2200

```

BUNV_(NC_001926)	ATATCAGCCAACAGAATTAAACCCGATCTGGTGGTCAACAAACATCATTAGCAAATTCCTGTAGTAGGTCAAGCAACGAAAGAATGTAAAAAGTACAAAGATGTTAGTTGCT	2310
BUNV_(M11852)		2310
BUNV_(JF961341)	C.....G.....G.....A.....	2082
GSA/S4/11232_WT	C.....G.....G.....A.....	2310
MGD/S1/12060_WT	C.....G.....G.....A.....	2310
BUNV_(NC_001926)	TAAGCCCCAAGATTTGGAATTCGCCTGGAAGATTTAATAAGCTGCTGTGACCAACCAAATTACAATATTTATAAAAAGCCAAAAAAGTCTACAAAGCTCATGACAAAGAA	2420
BUNV_(M11852)		2420
BUNV_(JF961341)	G.....T.....G.....	2192
GSA/S4/11232_WT	G.....G.....A.....	2420
MGD/S1/12060_WT	G.....G.....A.....	2420
BUNV_(NC_001926)	GAAACATGGTGCATTAAATGATCAGCATTGCCCTAGTAGACTTTGTCCCAGCTGAAGCCGATACTGTAGAAAAATTGAAACCTATGAAATGTTGGTTAGTTGACCCCTGGCAA	2530
BUNV_(M11852)		2530
BUNV_(JF961341)	T.....T.....G.....A.....C.....	2302
GSA/S4/11232_WT	T.....T.....G.....A.....	2530
MGD/S1/12060_WT	T.....T.....G.....A.....	2530
BUNV_(NC_001926)	GAATGATGATGTCTACTCTATTGCAATAAAAAATGTAGAGTGGTTGATAAGGGAGTTTGACTGTTAATTCACAAAAATGGAATATAATCAAATGTGATTCTGGTCCGC	2640
BUNV_(M11852)		2640
BUNV_(JF961341)	T.....C.....A.....C.....A.....G.....A.....T.....	2412
GSA/S4/11232_WT	T.....C.....A.....C.....A.....G.....A.....T.....	2640
MGD/S1/12060_WT	T.....C.....A.....C.....A.....G.....A.....T.....	2640
BUNV_(NC_001926)	TCTACTACAGTGACCACATACCAGGGGAAGATACAGGCAATGATATAGGACATTATTGTGTATCAGCAGGATGCAAAACTGACAGATACCCAAATTAATCCTGATGTTGTT	2750
BUNV_(M11852)		2750
BUNV_(JF961341)	TG.....A.....T.....C.....	2522
GSA/S4/11232_WT	TG.....A.....T.....C.....	2750
MGD/S1/12060_WT	TG.....A.....T.....C.....	2750
BUNV_(NC_001926)	ACTGACTGTGTGTGGGAATTTACTTCTAGGAAATCACAAATATATAGGCAAGATCTCCATGCAGTCTCTTGAAGATTACGAAAAGGCTTTAACTGACAGATTGACCCATAC	2860
BUNV_(M11852)		2860
BUNV_(JF961341)	A.....G.....A.....A.....	2632
GSA/S4/11232_WT	A.....G.....A.....A.....	2860
MGD/S1/12060_WT	A.....G.....A.....A.....	2860
BUNV_(NC_001926)	CTTGGAACCTATAGTTTTGCCCGTTAGAAAATCTCCCGCATATAAAACCAGTTTACAAATATATTACTGCACAAGGAGTCGAAAACCTCAGACGGTATAGAAGGGGCAT	2970
BUNV_(M11852)		2970
BUNV_(JF961341)	A.....A.....C.....C.....	2742
GSA/S4/11232_WT	A.....A.....C.....C.....	2970
MGD/S1/12060_WT	A.....A.....C.....C.....	2970
BUNV_(NC_001926)	TCATAACAGCCAGTATCCAGCCGCTGGGGGCACCTAGCATAGGCTACAAATGTTAGATCAAAGATGGCTTCCCACTCCTTGATCTAATAGTTTTTGTGAAGAGTGCCTGTG	3080
BUNV_(M11852)		3080
BUNV_(JF961341)	G.....T.....T.....T.....T.....G.....G.....T.....G.....A.....	2852
GSA/S4/11232_WT	T.....T.....T.....G.....G.....T.....G.....A.....	3080
MGD/S1/12060_WT	T.....T.....T.....G.....G.....T.....G.....A.....	3080
BUNV_(NC_001926)	ATAAAAAGCACATACAACCATATATATGATACTGGGCCAACAAATTAGCATAAATACAAAGCATGACGAACATTGCACTGGCCAATGTCCAAGCAATATAGAACATGAGGC	3190
BUNV_(M11852)		3190
BUNV_(JF961341)	..C.....C.....A.....C.....T.....C.....	2962

GSA/S4/11232_WT ..C.....C.....A.....C.....T.....C..... 3190
MGD/S1/12060_WT ..C.....C.....A.....C.....T.....C..... 3190

BUNV_(NC_001926) TAACTGGTTGACATTTTCACAAGAAAGAACTAGCAGATGGGGATGCGAAGAGTTTGGGTGCTTGGCTGTCAACACAGGTTGTGTGTTGGGTCTTGTCAAGATGTAATTA 3300
BUNV_(M11852) 3300
BUNV_(JF961341) ...T.....T.....T.....C..... 3072
GSA/S4/11232_WT ...T.....T.....T.....C..... 3300
MGD/S1/12060_WT ...T.....T.....T.....C..... 3300

BUNV_(NC_001926) GACCAGAAACAAAAGTTTACAGGAAAGCTGTAGATGAAGTTGTTATTTTAACAGTTTGTATTACATATCCAGGACACACTTTTTGCACAGAAATTAATGCCATAGAGCCA 3410
BUNV_(M11852) 3410
BUNV_(JF961341) A.....C..C.....G..T..C....T.....A..... 3182
GSA/S4/11232_WT A.....C..C.....G..T..C....T.....A..... 3410
MGD/S1/12060_WT A.....C..C.....G..T..C....T.....A..... 3410

BUNV_(NC_001926) AAAATAACGGAAGAAATTGAAGTCCAGTTTAAAAACAGTTGACACGAAAAACACTACCATATATAGTAGCCGTAAACAATCATAACTTTATAGTGGTCAGATAAATGATTT 3520
BUNV_(M11852) 3520
BUNV_(JF961341) A.....G.....T.....T..C.....C.....C..... 3292
GSA/S4/11232_WT A.....G.....G.....T.....T..C.....C.....C..... 3520
MGD/S1/12060_WT A.....G.....G.....T.....T..C.....C.....C..... 3520

BUNV_(NC_001926) AGGGACATTTGGGCATAATGTGCGGAAATGTCCAAAAACAAACAGCAGCATTTTAGGAACTGGGACACCAAAATTTGATTATCTTGCCATGGTGCTAGTAGGAAGGATA 3630
BUNV_(M11852) 3630
BUNV_(JF961341) T.....C...C..... 3402
GSA/S4/11232_WT G.....T.....C...C..... 3630
MGD/S1/12060_WT T.....C...C..... 3630

BUNV_(NC_001926) TCATTGTTAGGAGATGCTATAATAACAATTTTACTCCTGCAAACTTCTAAAGGAAGAAACACAGCTTATATTTAATGATGACCATGATACATAACTGTTTATAATACA 3740
BUNV_(M11852) 3740
BUNV_(JF961341) C..T.....T.....C..... 3512
GSA/S4/11232_WT C..T.....T.....C..... 3740
MGD/S1/12060_WT C..T.....T.....C..... 3740

BUNV_(NC_001926) AATCACTTAATTGGTGAGTTAGCTATAAAATTGATATTAGGGGATATCCAGTATAAAATTATTACAGAAACATTGGACCTCCAGATTGATGCGAAATGTGTTGGCTGCCC 3850
BUNV_(M11852) 3850
BUNV_(JF961341) A.....G.....T.....C..... 3622
GSA/S4/11232_WT A.....G.....T.....C..... 3850
MGD/S1/12060_WT A.....G.....T.....C..... 3850

BUNV_(NC_001926) TGATTGCTTTGAGAGCTATTCCCTGCAATTTCCAAATAGTATCAAATATAGACACAATCTGCAGCCTTGAAGGGCCTTGTGACACATTCCATAATAGGATCTCAATTAAAG 3960
BUNV_(M11852) 3960
BUNV_(JF961341) G.....A.....A.....A..A...C..G. 3732
GSA/S4/11232_WT G.....A.....A.....A..A...C..G. 3960
MGD/S1/12060_WT G.....A.....A.....A..A...C..G. 3960

BUNV_(NC_001926) CAATGCAGCAAAATTTATGCTGTAAACTCTCCTGCCAGAAGGATCCAAGACCATCAGGGACTTTTAAAAATTTGCAACAGGGAATATACTGTTGTCTTCCATACAGTAGCA 4070
BUNV_(M11852) 4070
BUNV_(JF961341) A.....G..G.....T.....A..... 3842
GSA/S4/11232_WT A.....G..G.....T.....A..... 4070
MGD/S1/12060_WT A.....G..G.....T.....A..... 4070

BUNV_(NC_001926) AAAGATGACAAAAATAGAAATAAATGTTGGAGACCAGACTTCATTCAATTAAGAGAAAGATGACAGGTGCAAAACATGGCTGTGTAGGGTCAGAGATGAAGGTATTAGTGT 4180

```

BUNV_(M11852) ..... 4180
BUNV_(JF961341) .....T..... 3952
GSA/S4/11232_WT .....T..... 4180
MGD/S1/12060_WT .....T..... 4180

BUNV_(NC_001926) AATTTTGAACCAATTAAGCCTTCTTTGGGAGTTATTTTCAGCATCTTCTTCTACATAATTGTTGTTGTAGTAGTGGGATTTTAATAATATATATTTTATGCCAATGT 4290
BUNV_(M11852) ..... 4290
BUNV_(JF961341) .....A..A.....G... 4062
GSA/S4/11232_WT .....T.....A..A.....G... 4290
MGD/S1/12060_WT .....T.....A..A.....G... 4290

BUNV_(NC_001926) TTATGAAGTTAAAGGAAGTGTGAAAGCAAATGAGAAGCTTTACTTGCAGAAATTAAGCAAAGTGAAAATTAGACGGTTATTAATTCATTGTTAAATACATTCAAAAT 4400
BUNV_(M11852) ..... 4400
BUNV_(JF961341) .....G.....G.....A.....A..T...C..... 4172
GSA/S4/11232_WT .....G.....G.....A.....A..T... 4400
MGD/S1/12060_WT .....G.....G.....A.....A..T... 4400

BUNV_(NC_001926) TCATATTGACACATTGTGTCAAAAACCAAGGCTGTTTTGTTATCGGTAGCACACTACT 4458
BUNV_(M11852) ..... 4458
BUNV_(JF961341) .....----- 4204
GSA/S4/11232_WT ..... 4458
MGD/S1/12060_WT ..... 4458

```

Appendix 1E: Ngari virus L segment nucleotide sequence alignment

```

ISL/TS2/5242_WT AGTAGTGTA CTCCACATATAGAAAATTTCAAAACATAACCAGTAAGAGTATGGAGGACCAAGTTTATGATCAATACCTGCACAGAATTC AAGCAGCTAGAACAGCCACA 110
TND/S1/19801_WT ..... 110
GSA/TS7/5170_WT ..... 110
NRIV_9800521_(JX857327) .....A.....G.....C..... 110
NRIV_9800535_(JX857330) .....A.....G.....C..... 110
NRIV_DAKAR_D28542/4E_(KC608152) .....A..T.....G.....C..... 110
NRIV_DAKARD28542_(JX857318) .....A..T.....G.....C..... 110
NRIV_SUD-HKV141_(JX857324) .....A..T.....C..... 110
NRIV_SUD-HKV66_(JX857321) .....A..T.....C..... 110

ISL/TS2/5242_WT GTTGCTAAAGACATCAGTGCTGATATCCCTTGAGGCAAGGCATGACTATTTTGGTCGGGAGCTTTGTAACTCTTTAGGAATTGAATACAAAATAAATGTTCTTTAGATGA 220
TND/S1/19801_WT ..... 220
GSA/TS7/5170_WT ..... 220
NRIV_9800521_(JX857327) .....G..... 220
NRIV_9800535_(JX857330) .....G..... 220
NRIV_DAKAR_D28542/4E_(KC608152) .....G..... 220
NRIV_DAKARD28542_(JX857318) .....G..... 220
NRIV_SUD-HKV141_(JX857324) .....C.....G..... 220
NRIV_SUD-HKV66_(JX857321) .....T.....G..... 220

ISL/TS2/5242_WT GATCATCCCTTGATGTTGTGCCAGGTGTTAACTTGTAAACTATAAACATACCCAATGTGACACCAGACAACCTATATATGGGATGGTCACCTTCTTAATAATTCCTTGACTACA 330
TND/S1/19801_WT ..... 330

```



```

NRIV_9800535_(JX857330)      .....T.....A.....G.. 880
NRIV_DAKAR_D28542/4E_(KC608152) ..... 880
NRIV_DAKARD28542_(JX857318) ..... 880
NRIV_SUD-HKV141_(JX857324) .....C.....A..... 880
NRIV_SUD-HKV66_(JX857321) .....A..... 880

ISL/TS2/5242_WT      TGATAAGGGCTGGGAATTATGAGTCAGAGAGTTTACACAGAGAGGGAAATTATAACGGATGTGACAAAACAGAAGCCGTCTATCCACTTTATTTGGGCAAAGAAATGCGG 990
TND/S1/19801_WT      ..... 990
GSA/TS7/5170_WT      ..... 990
NRIV_9800521_(JX857327) C.....T.....GC.....A.....A.....T..... 990
NRIV_9800535_(JX857330) C.....T.....GC.....A.....A.....T..... 990
NRIV_DAKAR_D28542/4E_(KC608152) C.....T.....GC.....A.....A.....T..... 990
NRIV_DAKARD28542_(JX857318) C.....T.....GC.....A.....A.....T..... 990
NRIV_SUD-HKV141_(JX857324) C.....T.....GC.....A.....A.....T..... 990
NRIV_SUD-HKV66_(JX857321) C.....T.....GC.....A.....T.....A..... 990

ISL/TS2/5242_WT      ATAGAAAGCTAATAGGTTCAACAGCAAAATTAATATACCTATCCAAATAGTTTACAAAGTATCACCGAACAGTCAACTTGGACAGATGCACTAAAAGCAATAGGAAAGAGT 1100
TND/S1/19801_WT      ..... 1100
GSA/TS7/5170_WT      ..... 1100
NRIV_9800521_(JX857327) .....G..... 1100
NRIV_9800535_(JX857330) .....G..... 1100
NRIV_DAKAR_D28542/4E_(KC608152) .....T.....G..... 1100
NRIV_DAKARD28542_(JX857318) .....T.....G..... 1100
NRIV_SUD-HKV141_(JX857324) .....T.....T.....G..... 1100
NRIV_SUD-HKV66_(JX857321) .....T.....T.....G.....G..... 1100

ISL/TS2/5242_WT      ATGGATATTTGATGGTAAAGTAGGGCAGTACGAAACCTTATGTGCTGAAAGAAAAATGATTGCCAGGTCTACTGGCAAAAAGGTAGATAACAAGAGGTTTGAAGCGGTTAA 1210
TND/S1/19801_WT      ..... 1210
GSA/TS7/5170_WT      ..... 1210
NRIV_9800521_(JX857327) .....A.....A..... 1210
NRIV_9800535_(JX857330) .....A.....A.....A..... 1210
NRIV_DAKAR_D28542/4E_(KC608152) .....A..... 1210
NRIV_DAKARD28542_(JX857318) .....A..... 1210
NRIV_SUD-HKV141_(JX857324) .....T.....A.....G..... 1210
NRIV_SUD-HKV66_(JX857321) .....T.....A.....G..... 1210

ISL/TS2/5242_WT      GATTGGCAATGCACTTGATTATGGAACCAACAATTCATCTTAGCAAAATGACTTATTTAAAAATCAAGAAAGGCAGAAGTTTATGAAGAACTTCTTTGGCATAGGGAAAC 1320
TND/S1/19801_WT      ..... 1320
GSA/TS7/5170_WT      ..... 1320
NRIV_9800521_(JX857327) .....C..... 1320
NRIV_9800535_(JX857330) .....C..... 1320
NRIV_DAKAR_D28542/4E_(KC608152) .....C..... 1320
NRIV_DAKARD28542_(JX857318) .....C..... 1320
NRIV_SUD-HKV141_(JX857324) .....C..... 1320
NRIV_SUD-HKV66_(JX857321) .....C..... 1320

ISL/TS2/5242_WT      ATAAGAGTTTTAAAGATAAGACATCCAGTGACATTGAAACAGATAAGCCTAAAACTTAGATTTCAATAACACTATAGTCTTAATGGCTGCAAGGACAAATGGTTAATAAG 1430
TND/S1/19801_WT      ..... 1430
GSA/TS7/5170_WT      ..... 1430
NRIV_9800521_(JX857327) .....G.....G.....C..... 1430
NRIV_9800535_(JX857330) .....C.....G.....C..... 1430
NRIV_DAKAR_D28542/4E_(KC608152) .....G..... 1430

```

NRIV_DAKARD28542_(JX857318)	G.....	1430
NRIV_SUD-HKV141_(JX857324)	A.....C.....G.....	1430
NRIV_SUD-HKV66_(JX857321)	C.....A.....A.....G.....	1430
ISL/TS2/5242_WT	AACAAGGCTCTACTAGCTAAGGATAACACATTGCAAGACCTACATCCTATTATCATGCAGTATGCTTCAGAAATAAAAGAGGCATCTAAAGACACATTTGATGCGCTATT	1540
TND/S1/19801_WT		1540
GSA/TS7/5170_WT		1540
NRIV_9800521_(JX857327)	C.....A.....	1540
NRIV_9800535_(JX857330)	A.....	1540
NRIV_DAKAR_D28542/4E_(KC608152)	T.....	1540
NRIV_DAKARD28542_(JX857318)	T.....	1540
NRIV_SUD-HKV141_(JX857324)	A.....T.....	1540
NRIV_SUD-HKV66_(JX857321)	A.....T.....	1540
ISL/TS2/5242_WT	AAAAATTTCCTCCAACTTGTCTTCTGGCAATGTATAGTAGATATTTCAACAATAATGAGGAATATATTAGCTGTGTCCAGTATAATAGACATAATACATTTAGAGTTGCAA	1650
TND/S1/19801_WT		1650
GSA/TS7/5170_WT		1650
NRIV_9800521_(JX857327)		1650
NRIV_9800535_(JX857330)	A.....	1650
NRIV_DAKAR_D28542/4E_(KC608152)		1650
NRIV_DAKARD28542_(JX857318)		1650
NRIV_SUD-HKV141_(JX857324)		1650
NRIV_SUD-HKV66_(JX857321)		1650
ISL/TS2/5242_WT	TGTGTGCTAATGACTCTGTCTATGCATTAGTATTTCCCTCATCTGACATAAAAACAAAAGAGCAACAGTAGTCTTTAGTATAGTTTGCATGCATAAAGAGAGAAACGAC	1760
TND/S1/19801_WT		1760
GSA/TS7/5170_WT		1760
NRIV_9800521_(JX857327)	T.....T.....T.....A.....	1760
NRIV_9800535_(JX857330)	T.....T.....T.....A.....	1760
NRIV_DAKAR_D28542/4E_(KC608152)	T.....T.....A.....	1760
NRIV_DAKARD28542_(JX857318)	T.....T.....A.....	1760
NRIV_SUD-HKV141_(JX857324)	T.....T.....T.....A.....	1760
NRIV_SUD-HKV66_(JX857321)	T.....T.....A.....	1760
ISL/TS2/5242_WT	TTGATGGATGCAGGTGCATTGTTCACTACTTTGGAATGTAAAAATAAAGAAATATATATCTATAAGTAAAGCAATTAGATTAGATAAAGAGAGGTGCCAAAGGATTGTGTC	1870
TND/S1/19801_WT		1870
GSA/TS7/5170_WT		1870
NRIV_9800521_(JX857327)	C.....A.....A.....	1870
NRIV_9800535_(JX857330)	C.....A.....A.....	1870
NRIV_DAKAR_D28542/4E_(KC608152)	C.....A.....A.....A.....	1870
NRIV_DAKARD28542_(JX857318)	C.....A.....A.....A.....	1870
NRIV_SUD-HKV141_(JX857324)	A.....A.....A.....	1870
NRIV_SUD-HKV66_(JX857321)	A.....A.....A.....	1870
ISL/TS2/5242_WT	ATCACCTGGGCTTTTCATATTAAGTTCTATGTTACTTTACAATAATAATCCAGAAGTAAACTTAGTGGATGTTCTAAATTTTACATTCTATACTAGCTTGTCTATAACAA	1980
TND/S1/19801_WT		1980
GSA/TS7/5170_WT		1980
NRIV_9800521_(JX857327)	T.....C.....	1980
NRIV_9800535_(JX857330)	T.....C.....	1980
NRIV_DAKAR_D28542/4E_(KC608152)	T.....T.....	1980
NRIV_DAKARD28542_(JX857318)	T.....T.....	1980
NRIV_SUD-HKV141_(JX857324)	T.....T.....	1980

NRIV_SUD-HKV66_(JX857321)	T.....T.....	1980
ISL/TS2/5242_WT	AAAGTATGCTTTCAGTACTGAGCCATCTAGATATATGATAATGAATTCACCTTGCCATTTCAAGTCACGTTAGAGATTATATAGCTGAGAAATTCCTCCCATACACAAA	2090
TND/S1/19801_WT		2090
GSA/TS7/5170_WT		2090
NRIV_9800521_(JX857327)	C.....	2090
NRIV_9800535_(JX857330)	G.....C.....	2090
NRIV_DAKAR_D28542/4E_(KC608152)	G.....C..T.....	2090
NRIV_DAKARD28542_(JX857318)	G.....C..T.....	2090
NRIV_SUD-HKV141_(JX857324)	.G.....G.....C.....T.....	2090
NRIV_SUD-HKV66_(JX857321)	.G.....G.....C.....T.....	2090
ISL/TS2/5242_WT	ACGCTTTTTAGTGTATACATGGTCAATTTGATAAAGAGAGGATGCGCATCTGCAATGAGCAATCATCAAAGATCCAACTGAGAAATATATATCTTTTCAGATTATGATAT	2200
TND/S1/19801_WT		2200
GSA/TS7/5170_WT		2200
NRIV_9800521_(JX857327)	..A....C.....G.....	2200
NRIV_9800535_(JX857330)	..A....C.....	2200
NRIV_DAKAR_D28542/4E_(KC608152)	..A....C.....	2200
NRIV_DAKARD28542_(JX857318)	..A....C.....	2200
NRIV_SUD-HKV141_(JX857324)	..A....C.....A.....	2200
NRIV_SUD-HKV66_(JX857321)	..A....C.....A.....	2200
ISL/TS2/5242_WT	TACACAAAAAGGTGTTAATGATGATAGGAACCTAGACTCTATTTGGTTCCCTGGCAAAGTTAACTTAAAGAATATATCAACCAAATATATCTACCATTTTACTTCAATG	2310
TND/S1/19801_WT		2310
GSA/TS7/5170_WT		2310
NRIV_9800521_(JX857327)	T.....	2310
NRIV_9800535_(JX857330)	T.....	2310
NRIV_DAKAR_D28542/4E_(KC608152)	T.....	2310
NRIV_DAKARD28542_(JX857318)	T.....	2310
NRIV_SUD-HKV141_(JX857324)	T.....	2310
NRIV_SUD-HKV66_(JX857321)	T.....	2310
ISL/TS2/5242_WT	CAAAAGGCCCTTCATGAGAAACATCAGTAAATGATTGACTTGGCAAAACTGTTCTGGAAATAGAGATGAACCAAAGAGGTGATAATTTAGGTATATGGTCTAAAGCAGAA	2420
TND/S1/19801_WT		2420
GSA/TS7/5170_WT		2420
NRIV_9800521_(JX857327)	T.....A.....	2420
NRIV_9800535_(JX857330)	T.....A.....	2420
NRIV_DAKAR_D28542/4E_(KC608152)	G.....A.....	2420
NRIV_DAKARD28542_(JX857318)	G.....A.....	2420
NRIV_SUD-HKV141_(JX857324)	A.....A.....	2420
NRIV_SUD-HKV66_(JX857321)	A.....A.....	2420
ISL/TS2/5242_WT	AAAAACAACATGTCAATCTACCAATATTAAATACACTCTATAGCAAAATCTTTAATATTGGATACATCAAGGCACAATCCTTGCGAAACCGTGTAGAAAGTAGAAATAA	2530
TND/S1/19801_WT		2530
GSA/TS7/5170_WT		2530
NRIV_9800521_(JX857327)	T.....A.....	2530
NRIV_9800535_(JX857330)	T.....A.....	2530
NRIV_DAKAR_D28542/4E_(KC608152)	C.....	2530
NRIV_DAKARD28542_(JX857318)	C.....	2530
NRIV_SUD-HKV141_(JX857324)	C.....	2530
NRIV_SUD-HKV66_(JX857321)	C.....	2530

ISL/TS2/5242_WT	TTTTAGAAGAAGCATCACAACAATAAGCACCTTTCACAAGCTCTAAATCTTGATATAAAGGTCGGTGATTTTCAGGGAAATTAAGATAAAACAAACAGAAAAATCAAAAAAAT	2640
TND/S1/19801_WT		2640
GSA/TS7/5170_WT		2640
NRIV_9800521_(JX857327)		2640
NRIV_9800535_(JX857330)		2640
NRIV_DAKAR_D28542/4E_(KC608152)		2640
NRIV_DAKARD28542_(JX857318)		2640
NRIV_SUD-HKV141_(JX857324)	T.....	2640
NRIV_SUD-HKV66_(JX857321)	T.....	2640
ISL/TS2/5242_WT	CAACTGAGAAATTTGACAAAAAGTCCGACTTTCAAATCCATTATTCTTAGAAGATGAGGAAGCTAACCTTGAGGTTCAACATTGCAATTATAAGGCTCTGATACAAAAA	2750
TND/S1/19801_WT		2750
GSA/TS7/5170_WT		2750
NRIV_9800521_(JX857327)	A.....G.....	2750
NRIV_9800535_(JX857330)	A.....G.....	2750
NRIV_DAKAR_D28542/4E_(KC608152)	A.....A.....G...T.....	2750
NRIV_DAKARD28542_(JX857318)	A.....A.....G...T.....	2750
NRIV_SUD-HKV141_(JX857324)	A.....T.....A.....G...T.....	2750
NRIV_SUD-HKV66_(JX857321)	A.....T.....A.....G...T.....	2750
ISL/TS2/5242_WT	ATTCCTAATTATAAAGACTATATTTTCAGTAAAGGTGTTTGATCGCCTATATGAATTGCTAAAAGATGGAGTCTTAACAGACAAGCCTTTTCATTGAATTAGCTATGGAAAT	2860
TND/S1/19801_WT		2860
GSA/TS7/5170_WT		2860
NRIV_9800521_(JX857327)	T.....	2860
NRIV_9800535_(JX857330)	T.....	2860
NRIV_DAKAR_D28542/4E_(KC608152)	T.....	2860
NRIV_DAKARD28542_(JX857318)	T.....	2860
NRIV_SUD-HKV141_(JX857324)	..C.....C...T.....T.....	2860
NRIV_SUD-HKV66_(JX857321)	..C.....C.....T.....	2860
ISL/TS2/5242_WT	GATGAAGAATCACAAAGAAATCTCTTTCACGTTCTTTAAATAAGGGCCAAAAGACAGCCAAAGATAGAGAGATATTGTTGGAGAATTTGAAGCTAAAATGTGTATGTATG	2970
TND/S1/19801_WT		2970
GSA/TS7/5170_WT		2970
NRIV_9800521_(JX857327)		2970
NRIV_9800535_(JX857330)		2970
NRIV_DAKAR_D28542/4E_(KC608152)	T.....	2970
NRIV_DAKARD28542_(JX857318)	T.....	2970
NRIV_SUD-HKV141_(JX857324)	T.....C.....	2970
NRIV_SUD-HKV66_(JX857321)	T.....C.....	2970
ISL/TS2/5242_WT	TAGTGGAGAGAATATCAAAGGAGAGATGCAAACCTGAACACGGACGAGATGATAAGTGAACCAGGTGATTCAAATTTGAAAAATTGGAAAAAGAAAGCAGAAGAGGAAATC	3080
TND/S1/19801_WT		3080
GSA/TS7/5170_WT		3080
NRIV_9800521_(JX857327)	A.....A.....	3080
NRIV_9800535_(JX857330)	A.....	3080
NRIV_DAKAR_D28542/4E_(KC608152)	A.....	3080
NRIV_DAKARD28542_(JX857318)	A.....	3080
NRIV_SUD-HKV141_(JX857324)	A.....T.....C.....	3080
NRIV_SUD-HKV66_(JX857321)	A.....A.....C.....	3080
ISL/TS2/5242_WT	CGCTATATTGTTGAGAGAACAAAGGACAGTATAATTAAAGGGGAATCCATCAAAGCATTGAAATTGGAAATAAATGCAGACATGTCAAAATGGAGTGCTCAAGATGTATT	3190
TND/S1/19801_WT		3190

GSA/TS7/5170_WT		3190
NRIV_9800521_(JX857327)	A.....A..G.C.....	3190
NRIV_9800535_(JX857330)	A.....A..G.C.....	3190
NRIV_DAKAR_D28542/4E_(KC608152)	A.....A..G.C.....G..	3190
NRIV_DAKARD28542_(JX857318)	A.....A..G.C.....G..	3190
NRIV_SUD-HKV141_(JX857324)	A.....A..G.C.....G..	3190
NRIV_SUD-HKV66_(JX857321)	A.....A..C.....G..	3190
ISL/TS2/5242_WT	TTACAAATATTTTTGGCTGATAGCATTGGACCCCTATACTTTATCCAGCAGAAAAACACGCATTCTGTATTTTCATGTGCAACTATATGCAAAAACACTAAATACTTCCAG	3300
TND/S1/19801_WT		3300
GSA/TS7/5170_WT		3300
NRIV_9800521_(JX857327)	A.....T.....T.....T.....G..	3300
NRIV_9800535_(JX857330)	A.....T.....T.....T.....G..	3300
NRIV_DAKAR_D28542/4E_(KC608152)	A.....T.....T.....T.....G..	3300
NRIV_DAKARD28542_(JX857318)	A.....T.....T.....T.....G..	3300
NRIV_SUD-HKV141_(JX857324)	A.....T.....T.....T.....G..	3300
NRIV_SUD-HKV66_(JX857321)	A.....T.....T.....T.....G..	3300
ISL/TS2/5242_WT	ATGATTTTAATTGCAAAATATCTTAGATCAAAAAAGACCTTATAATGATGATTTTGATCCTTGAGATGACCAATGGTCTAAATTACAATTATGTCCAAATTTAAAAGAAACTGG	3410
TND/S1/19801_WT		3410
GSA/TS7/5170_WT		3410
NRIV_9800521_(JX857327)	C.....C.....T.....T.....T.....	3410
NRIV_9800535_(JX857330)	C.....C.....T.....T.....T.....	3410
NRIV_DAKAR_D28542/4E_(KC608152)	C.....C.....T.....T.....T.....	3410
NRIV_DAKARD28542_(JX857318)	C.....C.....T.....T.....T.....	3410
NRIV_SUD-HKV141_(JX857324)	C.....C.....T.....T.....T.....	3410
NRIV_SUD-HKV66_(JX857321)	C.....C.....T.....T.....T.....	3410
ISL/TS2/5242_WT	CTCCAGGGCAATTTCAATTACATTTCTAGTTATGTGCATAGTTGTGCAATGCTTGTCTACAAGGATATCCTCAAAGAATGTATGAAGTTACTAGACGGAGACTGCTTGAT	3520
TND/S1/19801_WT		3520
GSA/TS7/5170_WT		3520
NRIV_9800521_(JX857327)		3520
NRIV_9800535_(JX857330)		3520
NRIV_DAKAR_D28542/4E_(KC608152)	T.....	3520
NRIV_DAKARD28542_(JX857318)	T.....	3520
NRIV_SUD-HKV141_(JX857324)	G.....T.....	3520
NRIV_SUD-HKV66_(JX857321)	T.....	3520
ISL/TS2/5242_WT	CAACTCAATGGTGCAATTCAGATGACAATCAAACATCGTTAGCAATTATTCAAAATAAAGTCTCTGATCAAATAGTAATTCAATATGCAGCAAACACATTTGAGTCTGTTT	3630
TND/S1/19801_WT		3630
GSA/TS7/5170_WT		3630
NRIV_9800521_(JX857327)	C.....	3630
NRIV_9800535_(JX857330)	C.....	3630
NRIV_DAKAR_D28542/4E_(KC608152)	C.....A.....	3630
NRIV_DAKARD28542_(JX857318)	C.....A.....	3630
NRIV_SUD-HKV141_(JX857324)	..T.....C.....C.....A.....	3630
NRIV_SUD-HKV66_(JX857321)	..T.....C.....C.....A.....	3630
ISL/TS2/5242_WT	GTTTGACATTTGGATGTCAGGCAAAACATGAAAAAACAATATTACTCATACATGCAAGGAATTTGTCTCACTTTTCAATTTACATGGAGAACCACATCTGTCTATGGC	3740
TND/S1/19801_WT		3740
GSA/TS7/5170_WT		3740
NRIV_9800521_(JX857327)	A.....G.....	3740

NRIV_9800535_(JX857330)	A.....G.....	3740
NRIV_DAKAR_D28542/4E_(KC608152)	G.....	3740
NRIV_DAKARD28542_(JX857318)	G.....	3740
NRIV_SUD-HKV141_(JX857324)	C.....G.....	3740
NRIV_SUD-HKV66_(JX857321)	C.....G.....	3740
ISL/TS2/5242_WT	AGATTTTATTGCTAGTGTAGGTGATTGTGCTTACATTGGGCCATATGAAGATTAGCTAGCCGTTTATCTGCAGCACAAACAGAGCTTAAAGCATGGGTGCCCTCCAAG	3850
TND/S1/19801_WT		3850
GSA/TS7/5170_WT		3850
NRIV_9800521_(JX857327)		3850
NRIV_9800535_(JX857330)		3850
NRIV_DAKAR_D28542/4E_(KC608152)	C.....	3850
NRIV_DAKARD28542_(JX857318)	C.....	3850
NRIV_SUD-HKV141_(JX857324)	A.....	3850
NRIV_SUD-HKV66_(JX857321)	A.....	3850
ISL/TS2/5242_WT	TCTAGTTTGGTTAGCAATAAGCTGTAGCCACTGGATAACATTTTTTCACCTACAACATGCTGGATGATCAAATTAATGCACCACAGCAGCATTGCGCATTCAATAATCGAA	3960
TND/S1/19801_WT		3960
GSA/TS7/5170_WT		3960
NRIV_9800521_(JX857327)	G.....	3960
NRIV_9800535_(JX857330)	G.....	3960
NRIV_DAKAR_D28542/4E_(KC608152)	G.....	3960
NRIV_DAKARD28542_(JX857318)	G.....	3960
NRIV_SUD-HKV141_(JX857324)	A.....	3960
NRIV_SUD-HKV66_(JX857321)	C.....A.....	3960
ISL/TS2/5242_WT	AGGAAATACCAGTCGAGTTAAATGGGTACTTGAATGCACCATTATATTTGATAGCATTAGTTGGCTTGGAAAGCTGGGAACCTTATGGTTTTTAATTAATATATTGAAAAA	4070
TND/S1/19801_WT		4070
GSA/TS7/5170_WT		4070
NRIV_9800521_(JX857327)	G.....A.....	4070
NRIV_9800535_(JX857330)	G.....T.....A.....	4070
NRIV_DAKAR_D28542/4E_(KC608152)	A.....	4070
NRIV_DAKARD28542_(JX857318)	A.....	4070
NRIV_SUD-HKV141_(JX857324)	C.....T.....A.....	4070
NRIV_SUD-HKV66_(JX857321)	C.....T.....A.....	4070
ISL/TS2/5242_WT	TTGGTGCCATTGGATAAACAGAGGAAGCAATATTTTACCTTATGCAATTCAATAGATAAGCTAACAGAGTCAGAAAAGTTCAAATTGAAAATATTGAG	4180
TND/S1/19801_WT		4180
GSA/TS7/5170_WT		4180
NRIV_9800521_(JX857327)	A.....A.....	4180
NRIV_9800535_(JX857330)	A.....A.....	4180
NRIV_DAKAR_D28542/4E_(KC608152)	A.....A.....A.....	4180
NRIV_DAKARD28542_(JX857318)	A.....A.....A.....	4180
NRIV_SUD-HKV141_(JX857324)	A.....A.....A.....	4180
NRIV_SUD-HKV66_(JX857321)	A.....A.....A.....	4180
ISL/TS2/5242_WT	GATCTTACTCTTGACACTGAAATGTCAGTTGATAACAACATGGGGGAGACAAGTGATATGCCAAGTAGATCACCTTTTAAACACCTCGCAAAATTTACAACATTGGGGTCCT	4290
TND/S1/19801_WT		4290
GSA/TS7/5170_WT		4290
NRIV_9800521_(JX857327)	G.....A.....C.....A.....	4290
NRIV_9800535_(JX857330)	G.....A.....G.....C.....A.....	4290
NRIV_DAKAR_D28542/4E_(KC608152)	G.....A.....C.....T.....A.....A.....	4290

NRIV_DAKARD28542_(JX857318)	A.....G.....A..A.....C.....T.....A..A....	4290
NRIV_SUD-HKV141_(JX857324)	G.....A..A.....C.....G.....A....	4290
NRIV_SUD-HKV66_(JX857321)	G.....A..A.....C.....G.....A....	4290
ISL/TS2/5242_WT	TAAATAAGCTAGTTTCCTATAATGACTTTAGATCTTCTTTGGACGACCAAGATTACTGATAATTTGAAC TTCATGCTCAATAACCCAGAATTGTTAGTTACTAAAGGT	4400
TND/S1/19801_WT		4400
GSA/TS7/5170_WT		4400
NRIV_9800521_(JX857327)	T.....C.....	4400
NRIV_9800535_(JX857330)	G.....T.....C.....	4400
NRIV_DAKAR_D28542/4E_(KC608152)	A..T.....	4400
NRIV_DAKARD28542_(JX857318)	A..T.....	4400
NRIV_SUD-HKV141_(JX857324)	C.....A..T.....	4400
NRIV_SUD-HKV66_(JX857321)	C.....A..T.....	4400
ISL/TS2/5242_WT	GAAAAATAAGAGCAATTTATGCAATCTGTCTCTTCAGATATAATTCAAAAAGATTAAAGGAAAGCCTTTCTATCCAAAAATCCAGCACAATTATTATCGAGCAGATAC	4510
TND/S1/19801_WT		4510
GSA/TS7/5170_WT		4510
NRIV_9800521_(JX857327)	G..C.....T.....A.....A.....	4510
NRIV_9800535_(JX857330)	G..C.....T.....A.....A.....	4510
NRIV_DAKAR_D28542/4E_(KC608152)	G..C.....T.....A.....C.....	4510
NRIV_DAKARD28542_(JX857318)	G..C.....T.....A.....C.....A.....	4510
NRIV_SUD-HKV141_(JX857324)	G..C.....T.....A.....C.....	4510
NRIV_SUD-HKV66_(JX857321)	G..C.....T.....A.....C.....	4510
ISL/TS2/5242_WT	ATTTTCCCATAAACCAATCATAGATTATAGCAGTATATTTGACAAATTGACTTCACCTTGACAGGCGAGACATCATTTGAGGAGTTACCGGAGATCATTGGAAGAGTTACAT	4620
TND/S1/19801_WT		4620
GSA/TS7/5170_WT		4620
NRIV_9800521_(JX857327)	G.....T.....T.....	4620
NRIV_9800535_(JX857330)	G.....T.....T.....	4620
NRIV_DAKAR_D28542/4E_(KC608152)	G.....C.....T..G.....T.....A.....	4620
NRIV_DAKARD28542_(JX857318)	G.....C.....T..G.....T.....A.....	4620
NRIV_SUD-HKV141_(JX857324)	C.....T.....T.....A.....A.....	4620
NRIV_SUD-HKV66_(JX857321)	C.....T.....T.....A.....A.....	4620
ISL/TS2/5242_WT	TTCTCAGGCATACCAAAATGATAAAATAGAGATATTGGCCAACTACCTTTAGATATAGATGATATTAAATTAATATTCCGATATTGTATATTGAATGATCCACTAATGATC	4730
TND/S1/19801_WT		4730
GSA/TS7/5170_WT		4730
NRIV_9800521_(JX857327)	C.....	4730
NRIV_9800535_(JX857330)	C.....	4730
NRIV_DAKAR_D28542/4E_(KC608152)		4730
NRIV_DAKARD28542_(JX857318)		4730
NRIV_SUD-HKV141_(JX857324)	T.....	4730
NRIV_SUD-HKV66_(JX857321)	T.....	4730
ISL/TS2/5242_WT	ACAGCTGCAAAATACCTCCTTATTATGTGTTAAAGGAACCCACAAGATAGAACTGGCCTTAGTGCAAAATCAAATGCCTGAGTTTAGGAATATGAAGCTTATTCATCATT	4840
TND/S1/19801_WT		4840
GSA/TS7/5170_WT		4840
NRIV_9800521_(JX857327)	T.....A.....	4840
NRIV_9800535_(JX857330)	T.....A.....	4840
NRIV_DAKAR_D28542/4E_(KC608152)	C.....T..C.....G.....A.....C.....	4840
NRIV_DAKARD28542_(JX857318)	C.....T..C.....G.....A.....C.....	4840
NRIV_SUD-HKV141_(JX857324)	C.....T..C.....A.....C.....	4840

NRIV_SUD-HKV66_(JX857321)	C.....A.....C.....	4840
ISL/TS2/5242_WT	CCCTGCTCTGGTTCCTTAAGGCATTTAGTAAAGGGACATCAGACATTCCTGGGGCTGATCCTATAGAATTGGAAGAAAGATCTTCACCACCTTAAATGAATTGTTGAAACAA	4950
TND/S1/19801_WT		4950
GSA/TS7/5170_WT		4950
NRIV_9800521_(JX857327)	C.....	4950
NRIV_9800535_(JX857330)	C.....	4950
NRIV_DAKAR_D28542/4E_(KC608152)	C.....T.....T.....	4950
NRIV_DAKARD28542_(JX857318)	C.....T.....T.....	4950
NRIV_SUD-HKV141_(JX857324)	C.....T.....T.....	4950
NRIV_SUD-HKV66_(JX857321)	C.....T.....T.....	4950
ISL/TS2/5242_WT	CAGCAATCAAAGAGAAGATTTTGCACAACATAGATAATCCTCCTAAGCATTTAATAGGGGAATGAAATCCTAATTTATAGAATCAGAGAGATGACCAAACTCTATCAAGTT	5060
TND/S1/19801_WT		5060
GSA/TS7/5170_WT		5060
NRIV_9800521_(JX857327)	T.....C.....C.....	5060
NRIV_9800535_(JX857330)	C.....C.....	5060
NRIV_DAKAR_D28542/4E_(KC608152)	A.....C.....C.....T.....	5060
NRIV_DAKARD28542_(JX857318)	A.....C.....C.....T.....	5060
NRIV_SUD-HKV141_(JX857324)	A.....C.....	5060
NRIV_SUD-HKV66_(JX857321)	A.....C.....	5060
ISL/TS2/5242_WT	TGTTACGATTATGTAAATCTACAGAGCATAAGGTAAATATTTATATTGCCAATGAAATCTTATACTGCAATCGACTTTTGCACATTAAATTCAGGGCAACACTATATC	5170
TND/S1/19801_WT		5170
GSA/TS7/5170_WT		5170
NRIV_9800521_(JX857327)	A.....C.....	5170
NRIV_9800535_(JX857330)	A.....C.....	5170
NRIV_DAKAR_D28542/4E_(KC608152)	T.....G.....C.....	5170
NRIV_DAKARD28542_(JX857318)	T.....G.....C.....	5170
NRIV_SUD-HKV141_(JX857324)	T.....G.....C.....	5170
NRIV_SUD-HKV66_(JX857321)	T.....G.....C.....	5170
ISL/TS2/5242_WT	TGATAATAAATGGTACACAATGCATTATTTAAAAACAGATTGCCAGCGGGTCTATCAAAGGGAATATAGTAACAACCTAGCACAAGTGAGCAAATAATAGCAAATGAGTGT	5280
TND/S1/19801_WT		5280
GSA/TS7/5170_WT		5280
NRIV_9800521_(JX857327)	G.....T.....C.....	5280
NRIV_9800535_(JX857330)	C.....G.....T.....C.....	5280
NRIV_DAKAR_D28542/4E_(KC608152)	T.....T.....	5280
NRIV_DAKARD28542_(JX857318)	T.....T.....	5280
NRIV_SUD-HKV141_(JX857324)	A.....T.....A.....	5280
NRIV_SUD-HKV66_(JX857321)	T.....T.....A.....	5280
ISL/TS2/5242_WT	TTAGAGTGCTTTGCCACTTTGCTGATTCCCTTTGTGGAAGAGGCAAGCAGATTGAGCTTTATTAATGAAGTTCTTGATAATTTACATATAAAAAACATAAGTGTTAACTCC	5390
TND/S1/19801_WT		5390
GSA/TS7/5170_WT		5390
NRIV_9800521_(JX857327)		5390
NRIV_9800535_(JX857330)	A.....	5390
NRIV_DAKAR_D28542/4E_(KC608152)	C.....	5390
NRIV_DAKARD28542_(JX857318)	C.....	5390
NRIV_SUD-HKV141_(JX857324)	C.....T.....	5390
NRIV_SUD-HKV66_(JX857321)	C.....T.....	5390

ISL/TS2/5242_WT	TTGTTTAACTCTATTAGCCAGCACTACAAGATTAGACTTTATTCCCCTATTATTTAGACTTAAAGTTTAACTCAGACAGATTTAAATAGATTTGATGCCCTTAAAAAC	5500
TND/S1/19801_WT		5500
GSA/TS7/5170_WT		5500
NRIV_9800521_(JX857327)	C.....T.....	5500
NRIV_9800535_(JX857330)	T.....	5500
NRIV_DAKAR_D28542/4E_(KC608152)		5500
NRIV_DAKARD28542_(JX857318)	T.....	5500
NRIV_SUD-HKV141_(JX857324)	T.....C.....	5500
NRIV_SUD-HKV66_(JX857321)		5500
ISL/TS2/5242_WT	TAATGAAAGAGTTTCATGGAATAACTGGCAGACAAATCGTTCCTTAAATTCAGGTCTGATTGATTGACAAATATCAGGCTATTTGAGATCAATAAGAGTTGTGGGGGAAG	5610
TND/S1/19801_WT		5610
GSA/TS7/5170_WT		5610
NRIV_9800521_(JX857327)	A.....	5610
NRIV_9800535_(JX857330)	A.....	5610
NRIV_DAKAR_D28542/4E_(KC608152)	C.....T.....A.....	5610
NRIV_DAKARD28542_(JX857318)	C.....T.....A.....	5610
NRIV_SUD-HKV141_(JX857324)	C.....A.....A.....	5610
NRIV_SUD-HKV66_(JX857321)	C.....A.....A.....	5610
ISL/TS2/5242_WT	ATAATAAACTCAAAATTGCTGAACATAACAATACCTAATTTCTATCCAAACACAGTATTCCATGCAGGGAATAAACTTTTAAATTCATAGACATGGATTAAAAATTTGAATAT	5720
TND/S1/19801_WT		5720
GSA/TS7/5170_WT		5720
NRIV_9800521_(JX857327)	G.....A.....	5720
NRIV_9800535_(JX857330)	G.....A.....	5720
NRIV_DAKAR_D28542/4E_(KC608152)	T.....G.....C.....	5720
NRIV_DAKARD28542_(JX857318)	T.....G.....C.....	5720
NRIV_SUD-HKV141_(JX857324)	G.....C.....C.....	5720
NRIV_SUD-HKV66_(JX857321)	G.....C.....C.....	5720
ISL/TS2/5242_WT	ATGGAGGAAATTATTCTAGATGAAAAATATAATTATTATATAACATACCAAAAAAGAGGGCTCATATCTATACATATCAAGTATCTACAATAGAACACATTTTGAGAAG	5830
TND/S1/19801_WT		5830
GSA/TS7/5170_WT		5830
NRIV_9800521_(JX857327)	A.....C.....	5830
NRIV_9800535_(JX857330)	A.....C.....	5830
NRIV_DAKAR_D28542/4E_(KC608152)		5830
NRIV_DAKARD28542_(JX857318)		5830
NRIV_SUD-HKV141_(JX857324)	G.....	5830
NRIV_SUD-HKV66_(JX857321)	G.....	5830
ISL/TS2/5242_WT	GAATAATGAAGGATTACAATCCAGAGGCCCTAGATATAACAAGATGGTTCTGTCTGTCCAGTTGTTTAAAGTGTTAGGGATGAATTATTAGAAATGCTCTAGAAAATG	5940
TND/S1/19801_WT		5940
GSA/TS7/5170_WT		5940
NRIV_9800521_(JX857327)	A.....C.....	5940
NRIV_9800535_(JX857330)	A.....C.....	5940
NRIV_DAKAR_D28542/4E_(KC608152)	G.....A.....G.....	5940
NRIV_DAKARD28542_(JX857318)	G.....A.....G.....	5940
NRIV_SUD-HKV141_(JX857324)	G.....A.....C.....T.....	5940
NRIV_SUD-HKV66_(JX857321)	T.....A.....C.....T.....	5940
ISL/TS2/5242_WT	TCTTTAGTCTAAATATGACAACTTTAGCATGTCTAGATTATTTGTTTCACCTGACGAAGTTGCTACTGTAAAGAAAGCTCATATGTCCAAAATGATGTCTTTTCCGGG	6050
TND/S1/19801_WT		6050

GSA/TS7/5170_WT		6050
NRIV_9800521_(JX857327)	.T.	6050
NRIV_9800535_(JX857330)	.T.	6050
NRIV_DAKAR_D28542/4E_(KC608152)	.T.	6050
NRIV_DAKARD28542_(JX857318)	.T.	6050
NRIV_SUD-HKV141_(JX857324)	.T. C. T.	6050
NRIV_SUD-HKV66_(JX857321)	.T. T. T.	6050
ISL/TS2/5242_WT	CCAA CAATAAAAGCAGGAATTATTAATTTAACATCTTTGATGAGGACCC AAGAGCTTTTAA CAATTGAATTATGATAATCTATGC AAATCTAG CA TTGTCCCGTTTGTAG	6160
TND/S1/19801_WT		6160
GSA/TS7/5170_WT		6160
NRIV_9800521_(JX857327)		6160
NRIV_9800535_(JX857330)		6160
NRIV_DAKAR_D28542/4E_(KC608152)	C.	6160
NRIV_DAKARD28542_(JX857318)	C.	6160
NRIV_SUD-HKV141_(JX857324)		6160
NRIV_SUD-HKV66_(JX857321)		6160
ISL/TS2/5242_WT	AA TATTAGAA TG CAATGGTGACGAGCAAGGAGAACTAATATTTCTCTCAGATGAGGTCATGGATTTCACAATTTCTGAGGAGATAGAATCTATGCCATTATTCACAATAA	6270
TND/S1/19801_WT		6270
GSA/TS7/5170_WT		6270
NRIV_9800521_(JX857327)	T. A. T. A. T.	6270
NRIV_9800535_(JX857330)	T. A. T. A. T.	6270
NRIV_DAKAR_D28542/4E_(KC608152)	T. T. T. A. G. T.	6270
NRIV_DAKARD28542_(JX857318)	T. T. T. A. G. T.	6270
NRIV_SUD-HKV141_(JX857324)	T. T. T. A. T.	6270
NRIV_SUD-HKV66_(JX857321)	T. T. T. A. T.	6270
ISL/TS2/5242_WT	GG TATCAGAAAAGAGGCAC TGAAAT TATGACTTATAAAAA TGCC ATAATGAAGTTAGTTGCAGCAGGGGTAGATGAGATAAAAGAAGTTTTGACTTTTCAAAACAAGGG	6380
TND/S1/19801_WT	C. T. G.	6380
GSA/TS7/5170_WT	C. T. G.	6380
NRIV_9800521_(JX857327)	C. T.	6380
NRIV_9800535_(JX857330)	C. T.	6380
NRIV_DAKAR_D28542/4E_(KC608152)	C. T.	6380
NRIV_DAKARD28542_(JX857318)	C. T.	6380
NRIV_SUD-HKV141_(JX857324)	C. T.	6380
NRIV_SUD-HKV66_(JX857321)	C. T.	6380
ISL/TS2/5242_WT	TTT TATTCAAGAAAAATCTAGGTATAATAAATACAATTTGCTCCATAATAAATATAC TAGAGACAAATGAATGG CTACAATTCATATAAATCCTTTCATATAGCAAT	6490
TND/S1/19801_WT	CT. T. T. A. C. T. C. C.	6490
GSA/TS7/5170_WT	CT. T. T. A. C. T. C. C.	6490
NRIV_9800521_(JX857327)	T. T. C. C.	6490
NRIV_9800535_(JX857330)	T. T. C. C.	6490
NRIV_DAKAR_D28542/4E_(KC608152)	C. T. C. C.	6490
NRIV_DAKARD28542_(JX857318)	C. T. C. C.	6490
NRIV_SUD-HKV141_(JX857324)	C. T. C. C.	6490
NRIV_SUD-HKV66_(JX857321)	C. T. G. C. C.	6490
ISL/TS2/5242_WT	G TTATTAGAGTCTATGGATCGAGAATTC CATATG TTACACATTACCAGGAGCCTTCTTCATAAAATGTGGCAGGTGGTATTATTAATTGGACTAAGCTGCTAAAA TTTATAA	6600
TND/S1/19801_WT	C. C. A. T. G. G. C. A. G.	6600
GSA/TS7/5170_WT	C. C. A. T. G. G. C. A. G.	6600
NRIV_9800521_(JX857327)	A. G. C.	6600

```

NRIV_9800535_(JX857330)      .....A.....G.....C..... 6600
NRIV_DAKAR_D28542/4E_(KC608152).....A.....G..... 6600
NRIV_DAKARD28542_(JX857318).....A.....G..... 6600
NRIV_SUD-HKV141_(JX857324).....A.....G.....A..... 6600
NRIV_SUD-HKV66_(JX857321).....A.....G.....A..... 6600

ISL/TS2/5242_WT      AGTCATTGCCAGTGATAGAGCGAGAGCCCTGGTCAATGATGATGTCAAGATTTGTAGAAAAAACCGTGTATTTAATAGAAAGAGAAATGAACAAAGATGTTGATTTCACT 6710
TND/S1/19801_WT      .....G.....A.....T.....T.....G..... 6710
GSA/TS7/5170_WT      .....G.....A.....T.....T.....G..... 6710
NRIV_9800521_(JX857327).....A.....T.....A..... 6710
NRIV_9800535_(JX857330).....T.....A.....T.....A..... 6710
NRIV_DAKAR_D28542/4E_(KC608152).....A.....T.....T.....A..... 6710
NRIV_DAKARD28542_(JX857318).....A.....T.....T.....A..... 6710
NRIV_SUD-HKV141_(JX857324).....A.....T.....T..... 6710
NRIV_SUD-HKV66_(JX857321).....A.....T.....T..... 6710

ISL/TS2/5242_WT      GACTTCCTAGATGAATTAGAAATTTAGTTCAGGAAAAATCTCTATTTACCTTTTTCTGAAGCATATCTTCATTGGTTTATTTAATTGGACATTCCAAAAGCCACTATGTGGC 6820
TND/S1/19801_WT      ..T..T.....G.....G.....T.....A.....A..... 6820
GSA/TS7/5170_WT      ..T..T.....G.....G.....T.....A..... 6820
NRIV_9800521_(JX857327).....T..T.....G.....A..... 6820
NRIV_9800535_(JX857330).....T..T.....G.....C.....A..... 6820
NRIV_DAKAR_D28542/4E_(KC608152).....T..T.....G..... 6820
NRIV_DAKARD28542_(JX857318).....T..T.....G..... 6820
NRIV_SUD-HKV141_(JX857324).....T..T.....G.....C..... 6820
NRIV_SUD-HKV66_(JX857321).....T..T.....G.....C.....C.....C..... 6820

ISL/TS2/5242_WT      AAAAAATGATGACAGCA-TCAAAAAAAGTACAATTTTCTTATGTAGGAGCACACTACT 6876
TND/S1/19801_WT      .....A.....-TC..... 6876
GSA/TS7/5170_WT      .....A.....-TC..... 6876
NRIV_9800521_(JX857327).....-TT..... 6876
NRIV_9800535_(JX857330).....-T.TTT..... 6877
NRIV_DAKAR_D28542/4E_(KC608152).....-TC..... 6876
NRIV_DAKARD28542_(JX857318).....-TC..... 6876
NRIV_SUD-HKV141_(JX857324).....A.....-TC..... 6876
NRIV_SUD-HKV66_(JX857321).....A.....-TC..... 6876

```

Appendix 1F: Bunyamwera virus L segment nucleotide sequence alignment

```

BUNV_(NC_001925)      AGTAGTGTA CTCTACATATAGAAAATTTAAAAATATAACCAGTAGGAGTATGGAGGACCAAGCTTATGATCAATACCTGCACAGAATCCAAGCAGCTAGAACAGCTACA 110
BUNV_(X14383)      ..... 110
GSA/S4/11232_WT      .....C.....C.....T.....C..... 110
MGD/S1/12060_WT      .....C.....T.....C..... 110

BUNV_(NC_001925)      GTTGCTAAAGACATCAGTGCCTGATATCCCTTGAGGCAAGGCATGACTATTTTGGTCGGGAGCTTTGTAACTCTTTAGGAATTGAATACAAAAATAATGTTCTTTTGGATGA 220
BUNV_(X14383)      ..... 220
GSA/S4/11232_WT      .....C.....GC.....C..... 220
MGD/S1/12060_WT      .....A.....C.....GC.....C..... 220

```

BUNV_(NC_001925) AATCATCCTTGATGTTGTGCCAGGTGTTAACTTGTTAACTATAACATACCCAATGTGACACCAGACAACCTATATATGGGATGGTCACCTTCTTGATAATTCCTTGATTACA 330
 BUNV_(X14383) 330
 GSA/S4/11232_WT G.....T.....C..T..... 330
 MGD/S1/12060_WT G.....T.....C..T..... 330

BUNV_(NC_001925) AAGTCTCAGTTGGGAATGATAGTAGTGAATTCACATATAAGAAATACACCAGTTTGATTCTCCAGTGATGTCTGAATTGGGTATAGATACAGAAATAGCTATTATTAGG 440
 BUNV_(X14383) 440
 GSA/S4/11232_WT A.....C.....C..... 440
 MGD/S1/12060_WT A.....C.....C..... 440

BUNV_(NC_001925) GCAAAATCCTGTTACATATCAGATATCTATAATTGGAGAAGAAATTCAAACAAAGATTCACCAATATACCTATACAATTAGATTTTGGTAGGTTCTTTGAACCTGAGAAAAAT 550
 BUNV_(X14383) 550
 GSA/S4/11232_WT T.....C..... 550
 MGD/S1/12060_WT T.....C..... 550

BUNV_(NC_001925) GTTGCTGGACAAGTTTGCTGATGATGAGGAATTTCTGATGATGATAGCACATGGAGATTTTCACCTTTGACAGCACCATGGTGCACATCTGACACCCCTGAGCTAGAGGAGC 660
 BUNV_(X14383) 660
 GSA/S4/11232_WT T.....C.....A.....A..... 660
 MGD/S1/12060_WT T.....C.....A.....A..... 660

BUNV_(NC_001925) ATGAAATATTTCAAGAGTTTATTAAATCCATGCCACCAAGATTTGTATCACTTTTCAAAGAAGCAGTCAATTTTAGTGACATACTCTTCAGAAAGATGGAATACATTCCTTA 770
 BUNV_(X14383) 770
 GSA/S4/11232_WT T.....C..... 770
 MGD/S1/12060_WT T.....C..... 770

BUNV_(NC_001925) TATAGAGCCAGAGCAGAGACAGAGGTGGATTATAATCAATTTCTATCAGACAAGGCACATAAGATTTTCATGCTAGAAGGAGACTATATGAGACCAACACAAGCTGAAAT 880
 BUNV_(X14383) 880
 GSA/S4/11232_WT A.....C.....G.....G..... 880
 MGD/S1/12060_WT A.....C.....G.....G..... 880

BUNV_(NC_001925) CGATAAGGGTTGGGAGCTAATGAGTCAGAGAGTTTACACAGAGAGAGAAATTAACAGATGTGACAAAACAGAAGCCTTCTATCCATTTTATTTGGGTAAAGAATGCAG 990
 BUNV_(X14383) 990
 GSA/S4/11232_WT T.....G.....C.....C.....G..... 990
 MGD/S1/12060_WT T.....G.....C.....C.....G..... 990

BUNV_(NC_001925) ATAGAAAGCTAATAGGTTCAACAGCAAAATTAATATACCTATCTAATAGTTTACAAAGTATCACTGAACAGTCAACTTGGACAGATGCACATAAAGCAATAGGAAAGAGT 1100
 BUNV_(X14383) 1100
 GSA/S4/11232_WT C.....A.....C..... 1100
 MGD/S1/12060_WT C.....A.....C..... 1100

BUNV_(NC_001925) ATGGATATTGATGGTAAAGTAGGGCAATATGAAACCTTATGTGCTGAAAGAAAAATGATTGCCAGGTCAACTTGGCAAAAAGGTAGATAACAAGAGATTGGAAGCGGTAA 1210
 BUNV_(X14383) 1210
 GSA/S4/11232_WT G.....G.....A..... 1210
 MGD/S1/12060_WT G.....G.....A..... 1210

BUNV_(NC_001925) GATTGGCAATGCACCTTGTTATGGGAACAACAATTCATCTTAGCAACGACTTATTTAAAAATCAAGAAAGGCAGAAGTTTCATGAAAACTTCTTTGGCATAGGAAAGC 1320
 BUNV_(X14383) 1320
 GSA/S4/11232_WT C.....C.....T.....G.....A..... 1320
 MGD/S1/12060_WT C.....C.....T.....G.....A..... 1320

BUNV_(NC_001925) ATAAGAGTTTAAAGATAAGACATCTAGCGACATTGAAACGGATAAGCCTAAAACTTGAATTTCAATAACTATAGTCCTGATGGCTGCAAGAACAATGGTTAATAAA 1430

BUNV_(X14383)		1430
GSA/S4/11232_WT	C.....C.....C.....C.C.....T.....C.....G.....	1430
MGD/S1/12060_WT	C.....C.....C.....C.C.....T.....C.....G.....	1430
BUNV_(NC_001925)	AACAAAGCTCTGTTAGCTAAGGATAACACATTGCAAGACCTACATCCTATTATCATGCAGTATGCTTCAGAAATAAAAGAGGCATCTAAAGACACATTGATGCGCTACT	1540
BUNV_(X14383)		1540
GSA/S4/11232_WT	C.....G.....A.....G..T.....C.....	1540
MGD/S1/12060_WT	C.....G.....A.....G.....C.....	1540
BUNV_(NC_001925)	AAAAATTTCCAAAACCTTGCTTCTGGCAATGTATAGTAGATGTTTCAACAATAATGAGGAATATATTAGCTGTGTCAATATAATAGACATAATACATTTAGAGTTGCAA	1650
BUNV_(X14383)		1650
GSA/S4/11232_WT	G.....T.....A.....A.....	1650
MGD/S1/12060_WT	G.....T.....A.....A.....	1650
BUNV_(NC_001925)	TGTGTGCTAATGACTCTGTTTATGCATTAGTATTTCCCTTCATCTGACATAAAAACAAAGAGAGCAACAGTAGTCTTTAGTATAGTTTGCATGCACAAGGAAAAAAACGAC	1760
BUNV_(X14383)		1760
GSA/S4/11232_WT	A.....T..A..G.....	1760
MGD/S1/12060_WT	A.....T..A..G.....	1760
BUNV_(NC_001925)	CTGATGGATGCAGGTGCATTATTCACACTCTTTAGAATGTAAAAATAAAGAATATATATCTATAAGTAAAGCAATTAGATTAGATAAAGAGAGGTGCCAAAGGATTGTATC	1870
BUNV_(X14383)		1870
GSA/S4/11232_WT	G.....T.....	1870
MGD/S1/12060_WT	G.....T.....	1870
BUNV_(NC_001925)	ATCACCTGGGCTTTTCATATTAAGTTCTATGTTACTTTATAATAATAATCCAGAAGTAAATTTAGTAGAGCTTCTAAATTTTACATTCTATACTAGCTTGTCTATAACAA	1980
BUNV_(X14383)		1980
GSA/S4/11232_WT	T.....C.....	1980
MGD/S1/12060_WT	T.....C.....	1980
BUNV_(NC_001925)	AAAGTATGCTTTTCGCTGACTGAGCCATCTAGATATATGATAATGAATTCGCTTGCCATTTCAAGCCACGTTAGAGATTATATAGCTGAGAAATTCTCTCCTTACACCAA	2090
BUNV_(X14383)		2090
GSA/S4/11232_WT	T.....G.....A.....	2090
MGD/S1/12060_WT	T.....G.....A.....	2090
BUNV_(NC_001925)	ACACTTTTCAGTGTATACATGGTCAATTTGATAAAGAGAGGATGCGCATCCGCAAAATGAGCAATCATCGAAGATCCAGCTGAGAAATATATATCTTTTCAGATTATGATAT	2200
BUNV_(X14383)		2200
GSA/S4/11232_WT	T.....	2200
MGD/S1/12060_WT	T.....	2200
BUNV_(NC_001925)	TACACAAAAAGGTGTTAATGATGGTAGGAACCTTAGACTCTATTTGGTTCCTTGGTAAAGTTAATTTAAAGAATATATAAACCAAAATATATCTACCATTTTACTTCAATG	2310
BUNV_(X14383)		2310
GSA/S4/11232_WT	A..A.....T.....	2310
MGD/S1/12060_WT	A..A.....T.....	2310
BUNV_(NC_001925)	CAAAAGGCCCTTCATGAGAAACATCACGTAATGATTGACTTAGCAAAGACTGTTCTGGAAATAGAGATGAACCAAGAAGTGATAATTTAGGTATATGGTCTAAAGCAGAA	2420
BUNV_(X14383)		2420
GSA/S4/11232_WT	A.....C.....	2420
MGD/S1/12060_WT	A.....C.....	2420
BUNV_(NC_001925)	AAGAAACAACATGTCAATCTACCAATATTAATACACTCTATAGCAAAATCTTTGATATTGGATACATCAAGACACAATCACTTGCGAAACCGTGAGAAAGTAGAAATAA	2530
BUNV_(X14383)		2530
GSA/S4/11232_WT	G.....C.....G..T.....T.....T.....	2530

MGD/S1/12060_WT	G.....C.....G..T...T.....T.....	2530
BUNV_(NC_001925)	TTT TAGAAGAAGCATCAACAATAAGCACTTT TACAAGCTCTAAATCTTGTAATAAGATTGGTGATTT CAGAGAAATTAAGATAAAGAAACAGAAAAATCAAAAAAT	2640
BUNV_(X14383)		2640
GSA/S4/11232_WT	C.....T.....C.....A..C.....	2640
MGD/S1/12060_WT	C.....T.....C.....A..C.....T.....	2640
BUNV_(NC_001925)	CAACTGAGAAATTTGATAAAAAGTT CAGACTTTCAAATCCATTATTTCTAGAAGATGAGGAAGCCAATCTTGAAGTTCAACATTGCAATTATAGGGCTCTGATACAAAAA	2750
BUNV_(X14383)		2750
GSA/S4/11232_WT	G.....C.....T.....	2750
MGD/S1/12060_WT	G.....C.....T.....	2750
BUNV_(NC_001925)	ATTCCTAATTATATAAGACTATATTT CAGTAAAGGTGTTTGATCGTCTATATGAGTTGCTAAAAAATGGAGTCTTAACAGACAAACCTTTCATTGAATTAGCTATGGAAAT	2860
BUNV_(X14383)		2860
GSA/S4/11232_WT	G.....C.....C.....G...T.....	2860
MGD/S1/12060_WT	G.....C.....C.....G...T.....	2860
BUNV_(NC_001925)	GATGAAGAATCACAAGGAATTCCTTTT CACATTCCTTAAATAAGGGCCAAAAGACAGCTAAAGATAGAGAGATATTCGTTGGAGAATTTGAAGCTAAAAATGTTGATGTATG	2970
BUNV_(X14383)		2970
GSA/S4/11232_WT	C.....A.....C.....T.....	2970
MGD/S1/12060_WT	C.....A.....C.....T.....	2970
BUNV_(NC_001925)	TAGTGGAGAGAATATCAAAAGAGAGATGTAAGCTGAACACGGACGAGATGATAAGTGAACCAGGTGATTCAAAAATTGAAAATATTTGGAAAAGAAAGCAGAAGAGGAAATC	3080
BUNV_(X14383)		3080
GSA/S4/11232_WT	...A.....	3080
MGD/S1/12060_WT	...A.....	3080
BUNV_(NC_001925)	CGCTATATTGTTGAGAGAACAAAAGACAGTATAATTAAAGGAGACCCATCAAAAGCATTGAAACTGGAAATAAATGCAGACATGTCAAAATGGAGTGCTCAAGATGTATT	3190
BUNV_(X14383)		3190
GSA/S4/11232_WT	T.....	3190
MGD/S1/12060_WT	T.....	3190
BUNV_(NC_001925)	TTACAAATATTTTTGGCTGATAGCAATGGACCCATATACTTTATCCAGCAGAAAAAACACGTATTCTGTATTTTATGTGCAATTATATGCAAAAACTATTAATACTTCCAG	3300
BUNV_(X14383)		3300
GSA/S4/11232_WT	T.....T.....G...C.....	3300
MGD/S1/12060_WT	T.....T.....G...C.....	3300
BUNV_(NC_001925)	ATGATTTAATTGCAAAATATCTTAGATCAGAAAAGACCTTATAATGATGATTTGATCCCTTGAGATGACTAATGGTCTAAATTATAATTATGTCCAAATTAAAAAGAACTGG	3410
BUNV_(X14383)		3410
GSA/S4/11232_WT	A..G.....C.....	3410
MGD/S1/12060_WT	A..G.....C.....	3410
BUNV_(NC_001925)	CTCCAGGGCAATTTCAATTACATTTCTAGTTATGTGCATAGTTGTGCAATGCTTGTTTACAAAGATATCCTCAAAGAAATGTATGAAGTTACTAGACGGAGACTGCTTGAT	3520
BUNV_(X14383)		3520
GSA/S4/11232_WT	C.....C.....G...T...A..	3520
MGD/S1/12060_WT	C.....C.....G...T...A..	3520
BUNV_(NC_001925)	TAACTCAATGGTGCATTTCAGATGACAATCAAACATCGTTAGCAATTATCCAAAAATAAGTCTCTGATCAAATAGTAATTCAATATGCAGCAAACACATTTGAGTCTGTTT	3630
BUNV_(X14383)		3630
GSA/S4/11232_WT	C.....G.....A.....	3630
MGD/S1/12060_WT	C.....G.....A.....	3630

BUNV_(NC_001925)	GTTTGACATTTGGATGTCAGGCAAACATGAAAAAACATATATTACTCATACATGCAAAGAATTTGCTCCTTTTCAATTTACATGGAGAACCACATCTGTCTTTGGC	3740
BUNV_(X14383)		3740
GSA/S4/11232_WT	A.....	3740
MGD/S1/12060_WT	A.....	3740
BUNV_(NC_001925)	AGATTTTTATTGCCTAGTGTAGGTGATTGTGCTTACATTGGGCCATATGAAGATTTAGCCAGCCGTTTATCTGCAGCACAACAGAGCTTAAAGCATGGGTGCCCTCCAAG	3850
BUNV_(X14383)		3850
GSA/S4/11232_WT	T.....G.....G.....	3850
MGD/S1/12060_WT	T.....G.....G.....	3850
BUNV_(NC_001925)	TCTAGTTTGGTTAGCAATAAGCTGTAGCCACTGGATAACATTTTTCACCTTACAAATGCTGGATGATCAAATTAATGCACCACAGCAGCATTGCCCATTCAATAATCGGA	3960
BUNV_(X14383)		3960
GSA/S4/11232_WT	G.....T.....T.....C.....A.....	3960
MGD/S1/12060_WT	G.....T.....T.....C.....A.....	3960
BUNV_(NC_001925)	AGGAAATACCAGTTGAGTTAAATGGGTACTTGAATGCACCATTAATTTGATAGCATTAGTCGGCTTGAAGCTGGGAACCTTATGGTTTTTAATAAATATATTGAAAAAA	4070
BUNV_(X14383)		4070
GSA/S4/11232_WT	C.....A..G.....	4070
MGD/S1/12060_WT	C.....A..G.....	4070
BUNV_(NC_001925)	TTGGTGCCATTGGATAAACAAGAAAGAACTATACAAAGCCAAATGTTTACACTTATGCAATTCAATTGATAAGCTGACAGAATCAGAAAAGTTCAAATTAATAATATTGAG	4180
BUNV_(X14383)		4180
GSA/S4/11232_WT	G.....C.....C.....	4180
MGD/S1/12060_WT	G.....C.....C.....	4180
BUNV_(NC_001925)	ATATCTTACTCTTGACACTGAGATGTCAGTTGATAACAACATGGGAGAAACAAGTGATATGCCAAGTAGATCACTCTTAACGCCTCGCAAATTTACAACTTTGGGATCCT	4290
BUNV_(X14383)		4290
GSA/S4/11232_WT	T.....A.....T.....G..G...C.....A.....T.....T.....	4290
MGD/S1/12060_WT	T.....A.....T.....G..G...C.....A.....T.....T.....	4290
BUNV_(NC_001925)	TAAATAACTAGTTTCCTATAATGACTTTAGATCTTCTTTAGACGACCAGAGATTTACTGATAATTTGAACCTCATGCTTAATAACCCAGAATTGTTAGTTACTAAAGGT	4400
BUNV_(X14383)		4400
GSA/S4/11232_WT	C.....C.....A.....C..T..T.....C.....C.....	4400
MGD/S1/12060_WT	C.....C.....A.....C..T..T.....C.....C.....	4400
BUNV_(NC_001925)	GAAAAATAAGAGCAGTTTCATGCAATCTGTCTTTTCAGATATAATTCAAAAAGATTTAAAGAAAGCCTTTCCATCCAAAACCCAGCACAATTATTTATTGAGCAGATACT	4510
BUNV_(X14383)		4510
GSA/S4/11232_WT	T.....T.....T.....T.....C.....	4510
MGD/S1/12060_WT	T.....T.....T.....T.....C.....	4510
BUNV_(NC_001925)	GTTTTCCCATAAACCAATCATAGATTACAGCAGTATATTTGATAAAATTAACCTCACCTGCAGAAGCGGATATCATTTGAAGAGCTACCAGAGATCATTGGAAGAGTTACAT	4620
BUNV_(X14383)		4620
GSA/S4/11232_WT	G..T.....A.....T.....	4620
MGD/S1/12060_WT	G..T.....A.....T.....	4620
BUNV_(NC_001925)	TTCTCAGGCATACCAGATGATAAATAGAGATATTGGCCAACACCTTTAGATATAGATGATATTAAGTTAATATTCCGGTATTGTATATTGAATGATCCACTAATGATC	4730
BUNV_(X14383)		4730
GSA/S4/11232_WT	..C.....A.....A.....T..A.....	4730
MGD/S1/12060_WT	..C.....A.....A.....T..A.....	4730
BUNV_(NC_001925)	ACAGCTGCAACACTTCCTTATTATGTGTTAAAGGAACACCACAAGATAGAACTGGCCTCAGTGCAAGTCAAATGCCCTGAATTAGAAAATGAAACTTATTCAACCATTC	4840
BUNV_(X14383)		4840

GSA/S4/11232_WT	C.....T.....G.....G.....C.....	4840
MGD/S1/12060_WT	C.....T.....G.....G.....C.....	4840
BUNV_(NC_001925)	CCCTGCTCTAGTTCTTAAGGCGTTTAGCAAAGGGACATCAGATATTCCTGGGGCTGATCCTATAGAATTGAAAAAGATCTTCATCACTTAAATGAATTTGTTGAAACAA	4950
BUNV_(X14383)		4950
GSA/S4/11232_WT	C..G.....A.....A.....C.....	4950
MGD/S1/12060_WT	C..G.....A.....A.....C.....	4950
BUNV_(NC_001925)	CAGCAATTAAAGAAAAGATTTTGCACAACATAGACAATCCTCCTAAGCATTTAATAGGGAATGAAATCCTAATTTATAGAATCAGAGAGATGACCAAACCTCTATCAGGTT	5060
BUNV_(X14383)		5060
GSA/S4/11232_WT	G..C.....	5060
MGD/S1/12060_WT	G..C.....	5060
BUNV_(NC_001925)	TGTTATGATTATGTTAAATCTACAGAGCATAAAGTTAAATATTTATATTACCAATGAAATCTTATACTGCAATTGACTTTTGCACATTGATTCAGGGCAACACTATCTC	5170
BUNV_(X14383)		5170
GSA/S4/11232_WT	C.....G.....C..T.....	5170
MGD/S1/12060_WT	C.....G.....C..T.....	5170
BUNV_(NC_001925)	TGATAATAAATGGTACACAATGCATTATTTAAAAAGATTGCTAGCGGATCTATCAAAGGGAATATAGTAACAACCTAGTACAAGCGAGCAAATAATAGCAAATGAGTGTT	5280
BUNV_(X14383)		5280
GSA/S4/11232_WT	G.....C.....T.....	5280
MGD/S1/12060_WT	G.....C.....T.....	5280
BUNV_(NC_001925)	TTAGAGTGCTCTGCCACTTTGCTGATTCTTTGTGGAAGAGGCAAGCAGATTGAGCTTTATTAATGAAGTTCTTGATAATTTACATATAAAAAACATAAGTGTTAACTCC	5390
BUNV_(X14383)		5390
GSA/S4/11232_WT	T.....T.....	5390
MGD/S1/12060_WT	T.....T.....	5390
BUNV_(NC_001925)	TTATTTAACACTCTATTAGCCAGCACTACAAGGTTAGACTTTTATTCCTCTATTATTTAGACTCAAAGTTTAACTCAGACAGATTTAAATAGATTTGATGCCCTTAAAAAC	5500
BUNV_(X14383)		5500
GSA/S4/11232_WT	C..G.....T.....T.....C.....	5500
MGD/S1/12060_WT	C..G.....T.....T.....C.....	5500
BUNV_(NC_001925)	TAAATGAAAGAGTTTCATGGAATAACTGGCAGACAAACCCTTCTTAAATTCAGGTCTGATTGATTTGACAATATCCGGCTATTTAAGATCAAATAAGGGTTGTGGGGGAAG	5610
BUNV_(X14383)		5610
GSA/S4/11232_WT	C.....C..G.....	5610
MGD/S1/12060_WT	C.....C..G.....	5610
BUNV_(NC_001925)	ATAATAAACTCAAAATTGCTGAACTAAACAATACCTAATTTCTATCCAAATACAGTGTCCATGCAGGGAACAAACTTCTAAATTCTAGACATGGATTAAAAATTGAATAC	5720
BUNV_(X14383)		5720
GSA/S4/11232_WT	C.....C.....A.....T.....T.....	5720
MGD/S1/12060_WT	C.....C.....A.....T.....T.....	5720
BUNV_(NC_001925)	ATGGAGGAAATTGTTCTAGATGAAAAATATAACTATTATATAACATACCAAAAAAGAGGGCTCATATTTATACATATCAAGTATCTACAATAGAACATATTTTGAGAAG	5830
BUNV_(X14383)		5830
GSA/S4/11232_WT	CCA.....A.....C.....	5830
MGD/S1/12060_WT	CCA.....A.....C.....	5830
BUNV_(NC_001925)	GAAATAATGAAGGATTACAAATCCAGAGGCCCTAGGTATAACAAAAATGGTTCCTGTCTGTCCAGTTGTTTTAAGTGTCAAGGATGAATTATTTAGCAATGTCTCTAGAAAAATG	5940
BUNV_(X14383)		5940
GSA/S4/11232_WT	T.....G.....G.....	5940
MGD/S1/12060_WT	T.....G.....G.....	5940

```

BUNV_(NC_001925) TTTTtagTTTAAACATGACAACTTTAGCATGTCTAGATTATTGTTTCACCTGACGAAGTTGCTACTGTAAAGAAAGCTCATATGTCCAAATGATGTTCTTTCCGGG 6050
BUNV_(X14383) ..... 6050
GSA/S4/11232_WT .....C.....C..... 6050
MGD/S1/12060_WT .....C.....C..... 6050

BUNV_(NC_001925) CCAACAATAAAAGCAGGAATTATTAATTAAACATCTTTAATGAGGACCCAAGAGCTTTTAAACATTGAATTATGATAATCTATGCAAATCTAGCATTGTCCCGTTTGTAG 6160
BUNV_(X14383) ..... 6160
GSA/S4/11232_WT ..G.....C.....G.....A..... 6160
MGD/S1/12060_WT ..G.....C.....G.....A..A..... 6160

BUNV_(NC_001925) AATATTAGAAATGTAATGGCGATGAGCAAGGAGAACTAATATTCTTTTCAGATGAAGTCATGGATTTCACAATTTCTGAGGAGATAGAATCTATGCCATTATTACAATAA 6270
BUNV_(X14383) ..... 6270
GSA/S4/11232_WT .....C.....C.....G..... 6270
MGD/S1/12060_WT .....C.....C.....G..... 6270

BUNV_(NC_001925) GGTATCAGAAAAGAGGTACTGAAATTATGACTTATAAAAAATGCTATAATGAAGTTAGTTTCAGCAGGGGTAGATGAGATCAAGAAGTTTTTGATTTTCAAAACAAGGG 6380
BUNV_(X14383) ..... 6380
GSA/S4/11232_WT .A.....C.....G..... 6380
MGD/S1/12060_WT .A.....C.....G..... 6380

BUNV_(NC_001925) TTCTATTCAAAGAAAACTTAGGTATAATAAATACAATTTGTTCTATAATAAATATACTAGAGACAAATGAGTGGTCCACAATTCTATACAATTCTTCCATATAGCAAT 6490
BUNV_(X14383) ..... 6490
GSA/S4/11232_WT .....A.....A.....T..... 6490
MGD/S1/12060_WT .....A.....A.....T..... 6490

BUNV_(NC_001925) GTTATTAGAGTCTATGGATCGAGAATTCATATGTTTCACATTACCCGAAGCCTTTTTCATAAATGTGGCAGGTGGTGTGTTAATTGGACTAAGCTGCTAAAATTTATAA 6600
BUNV_(X14383) ..... 6600
GSA/S4/11232_WT .....C.....T.....C.....A.....G..... 6600
MGD/S1/12060_WT .....C.....T.....C.....A.....G..... 6600

BUNV_(NC_001925) AGTCATTGCCAGTGATAGAGCAAGAGCCTTGGTCAATGATGATGTCAAGATTGTAGAAAAAAGCTGTGTATTGTATAGAAAGAGAAATGAACAAAGATGTTGACTTCACT 6710
BUNV_(X14383) ..... 6710
GSA/S4/11232_WT .....G.....T..... 6710
MGD/S1/12060_WT .....G.....T..... 6710

BUNV_(NC_001925) GATTTCCTTAGATGAGTTAGAATTTAGTTCAGGAAAGTCTCTATTACCTTTTTCTGAAACATATCTTCATTGGTTTATTTAATTGGACATTCCAAAAGC-ACTATGTGGC 6819
BUNV_(X14383) ..... 6819
GSA/S4/11232_WT .....A..G.....T.....C..... 6820
MGD/S1/12060_WT .....A..G.....T.....C..... 6820

BUNV_(NC_001925) AAAAAATGATAACAGCATTCAAAAAAGTACAATTTTCTTATGTAGGAGCACACTACT 6875
BUNV_(X14383) ..... 6875
GSA/S4/11232_WT .....G.....CA..... 6876
MGD/S1/12060_WT .....G.....CA..... 6876

```


Appendix 1G: Ngari virus NSs protein amino acid sequence alignment

```

NRIV_DakArD28542_(JX857316) MMSLLTPAVLLTQRSHTLTLSVSTPLGLVMTTYESSTLKDARLKLVSQKEVNGKLHLTLGACRLLYIIRIFLATGTTQFLTMVLPSTASVDSLPGTYLRRC 101
NRIV_SUD-HKV141_(JX857322) ..... 101
NRIV_SUD-HKV66_(JX857319) ..... 101
NRIV_9800521_(JX857325) ..... 101
NRIV_9800535_(JX857328) ..... 101
ISL/TS2/5242/WT (KM507342) ..... 101
GSA/TS7/5170_WT (KM507341) ..... 101
TND/S1/19801/WT (KM507343) ..... 101

```

Appendix 1H: Ngari virus N protein amino acid sequence alignment

```

NRIV_DakArD28542_(JX857316) MIELEFHDVAANTSSTFDPEVAYANFKRVYTTGLSYDHIRIFYIKGREIKTSLAKRSEWEVTNLGGWKITVYNTNFPGNRNNPVDDGLTLHRLSGFLA 100
NRIV_SUD-HKV141_(JX857322) .....H.....V..... 100
NRIV_SUD-HKV66_(JX857319) .....H.....V..... 100
NRIV_9800521_(JX857325) .....H..... 100
NRIV_9800535_(JX857328) .....H..... 100
GSA/TS7/5170_WT (KM507341) .....H..... 100
ISL/TS2/5242/WT (KM507342) .....H..... 100
TND/S1/19801/WT (KM507343) .....H..... 100

NRIV_DakArD28542_(JX857316) RYLLEKMLKVSEPEKLIISKIINPLAEKNGITWNDGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQRKEMEPKYLEKTMRQRYMGLEAATWTVSKLTE 200
NRIV_SUD-HKV141_(JX857322) ..... 200
NRIV_SUD-HKV66_(JX857319) ..... 200
NRIV_9800521_(JX857325) ..... 200
NRIV_9800535_(JX857328) ..... 200
GSA/TS7/5170_WT (KM507341) ..... 200
ISL/TS2/5242/WT (KM507342) ..... 200
TND/S1/19801/WT (KM507343) ..... 200

NRIV_DakArD28542_(JX857316) VQSALTVVSSLGWKKTNVSAAARDFLAKFGINM 233
NRIV_SUD-HKV141_(JX857322) ..... 233
NRIV_SUD-HKV66_(JX857319) ..... 233
NRIV_9800521_(JX857325) ..... 233
NRIV_9800535_(JX857328) ..... 233
GSA/TS7/5170_WT (KM507341) ..... 233
ISL/TS2/5242/WT (KM507342) ..... 233
TND/S1/19801/WT (KM507343) ..... 233

```

Appendix 1I: Ngari virus M protein amino acid sequence alignment

NRIV_DakArD28542_(JX857317)	MLLLLVLLIPCYVSASPVVTRCFHGGQLIAEKKSQTAVSEFCIKDDVSTIKSEITYEKNNTGLFAHSKVLRNWIIDWKNCPVPPTAGGSINVIEVNTDL	100
NRIV_SUD-HKV141_(JX857323)		100
NRIV_SUD-HKV66_(JX857320)		100
NRIV_9800521_(JX857326)		100
NRIV_9800535_(AY593725)		100
GSA/TS7/5170_WT(KM514677)	R.....	100
ISL/TS2/5242_WT(KM514678)	R.....	100
TND/S1/19801_WT(KM514679)	R.....	100
NRIV_DakArD28542_(JX857317)	SLTTKTYVCSRDCITIVDKEDAQIIFQTEKLNHFEVSGTTLSSGWFKTKASVTLDRICEHIKVTGCKKTLQFHACFKHHMSCIRFFHGTILPGTMTATISIC	200
NRIV_SUD-HKV141_(JX857323)		200
NRIV_SUD-HKV66_(JX857320)		200
NRIV_9800521_(JX857326)		200
NRIV_9800535_(AY593725)		200
GSA/TS7/5170_WT(KM514677)		200
ISL/TS2/5242_WT(KM514678)		200
TND/S1/19801_WT(KM514679)		200
NRIV_DakArD28542_(JX857317)	QNIELIIIIISLTLIIIFILMVILTKTYICYLLMPLFMPIAYFYGWSYNKSCCKCSCCGLAYHPFTNCGSHCVCGLKFEASDRMRIHRESGLCQGYKSLRVA	300
NRIV_SUD-HKV141_(JX857323)		300
NRIV_SUD-HKV66_(JX857320)		300
NRIV_9800521_(JX857326)	I.....	300
NRIV_9800535_(AY593725)	I.....	300
GSA/TS7/5170_WT(KM514677)		300
ISL/TS2/5242_WT(KM514678)		300
TND/S1/19801_WT(KM514679)		300
NRIV_DakArD28542_(JX857317)	RLLCKSKGSSLIISILLSMLILSFVTPIEGTLTNYPESRKYDLEEIADVLEGFIVEKGIKEYVVFYTSIFGALFLLMALVITITLNVTEYLTNINVLVC	400
NRIV_SUD-HKV141_(JX857323)		400
NRIV_SUD-HKV66_(JX857320)	A.....	400
NRIV_9800521_(JX857326)	V.....L.....	400
NRIV_9800535_(AY593725)	V.....L..I.....	400
GSA/TS7/5170_WT(KM514677)	V.....L.....	400
ISL/TS2/5242_WT(KM514678)	V.....L.....	400
TND/S1/19801_WT(KM514679)	V.....L.....	400
NRIV_DakArD28542_(JX857317)	HECSMYHKKNIKYIGDFTNKC GFCTCGELEDQEGLEKIKVSRKCIYKYQLTWSKIIMTILVCLLIAQNTILIVAASDDCWTKKSLEMECIGPLQQVDTIC	500
NRIV_SUD-HKV141_(JX857323)		500
NRIV_SUD-HKV66_(JX857320)		500
NRIV_9800521_(JX857326)		500
NRIV_9800535_(AY593725)	Y.....	500
GSA/TS7/5170_WT(KM514677)	R.....	500
ISL/TS2/5242_WT(KM514678)	R.....	500
TND/S1/19801_WT(KM514679)	R.....	500

NRIV_DakArD28542_(JX857317)	DDKASRSYSGEAKKLVRASKISDLDAAQVGLLGPTTIESAIASIRKQRTYSTMHLLSVFLGKHCDYYKTFEHNSGYSQAKWRLTAKTHHFDICSRHSTHH	600
NRIV_SUD-HKV141_(JX857323)		600
NRIV_SUD-HKV66_(JX857320)	R.....	600
NRIV_9800521_(JX857326)	R.....S.....P.....	600
NRIV_9800535_(AY593725)	R.....S.....P.....	600
GSA/TS7/5170_WT(KM514677)	S.....P.....	600
ISL/TS2/5242_WT(KM514678)	S.....P.....	600
TND/S1/19801_WT(KM514679)	S.....P.....	600
NRIV_DakArD28542_(JX857317)	FCRCISDGTKCQNGDWDFAGEMNSTYQSKKDFFEHDLKLFCTIVENAFPGTTESLFYEMLSKKNTTGKLLDKLTRKFGNNMFMVGIWKFGQYLMSLPY	700
NRIV_SUD-HKV141_(JX857323)		700
NRIV_SUD-HKV66_(JX857320)	A.....	700
NRIV_9800521_(JX857326)	F.....I.Q.....	700
NRIV_9800535_(AY593725)	L.....F.....I.Q.....	700
GSA/TS7/5170_WT(KM514677)	S.....F.....I.N.....I.....	700
ISL/TS2/5242_WT(KM514678)	S.....F.....I.N.....I.....	700
TND/S1/19801_WT(KM514679)	S.....F.....I.N.....I.....	700
NRIV_DakArD28542_(JX857317)	VNETSLTPAQVAKILEVTDQHRSISGRQESLASATPGSKSKECSHAKKVCISPRFSVPMEGLMACGDSPNYKIYKTPAKLYKSNNKGEVWCSCGDVHCS	800
NRIV_SUD-HKV141_(JX857323)	G.....	800
NRIV_SUD-HKV66_(JX857320)	G.....	800
NRIV_9800521_(JX857326)	...A.....IS.....G.....T.....	800
NRIV_9800535_(AY593725)	I.....IS.....G.....T.....	800
GSA/TS7/5170_WT(KM514677)	S.....S.....G.....	800
ISL/TS2/5242_WT(KM514678)	S.....S.....G.....	800
TND/S1/19801_WT(KM514679)	S.....S.....G.....	800
NRIV_DakArD28542_(JX857317)	QELSPASQESVDRIKQITCFLTEPEVSDDDVFSIAISTCKVQDKGVCTVNEDRWNVIKCDSGLIYYTDQRDGDGTGNDFGHEYCLSHSCRIERFPINPAIIS	900
NRIV_SUD-HKV141_(JX857323)	...T.....	900
NRIV_SUD-HKV66_(JX857320)	...T.....	900
NRIV_9800521_(JX857326)	R.....	900
NRIV_9800535_(AY593725)	R.....	900
GSA/TS7/5170_WT(KM514677)	T.....	900
ISL/TS2/5242_WT(KM514678)	T.....	900
TND/S1/19801_WT(KM514679)	A.....T.....	900
NRIV_DakArD28542_(JX857317)	DCLWEYHRSRKSKEYITSLDLENLEEFKRAISEKLSHTLIVYNFKPTANLPHIKPVYKYITVQGVENS DGVD SAYIAASMPALSGTISIGYNIMSRDNFPLFD	1000
NRIV_SUD-HKV141_(JX857323)		1000
NRIV_SUD-HKV66_(JX857320)		1000
NRIV_9800521_(JX857326)		1000
NRIV_9800535_(AY593725)		1000
GSA/TS7/5170_WT(KM514677)	S.....	1000
ISL/TS2/5242_WT(KM514678)	S.....	1000
TND/S1/19801_WT(KM514679)	S.....	1000
NRIV_DakArD28542_(JX857317)	IIIFIKSAAIKATYNHIYDTGPTIGINVMHDEHCTGQCPTDIPHKENWITFAQERTSRWGC EEF GCLAVNTGCVFGSCQDIIRPETKVYRKAVEESVLLT	1100
NRIV_SUD-HKV141_(JX857323)		1100
NRIV_SUD-HKV66_(JX857320)		1100
NRIV_9800521_(JX857326)		1100

NRIV_9800535_(AY593725)		1100
GSA/TS7/5170_WT(KM514677)		1100
ISL/TS2/5242_WT(KM514678)		1100
TND/S1/19801_WT(KM514679)		1100
NRIV_DakArD28542_(JX857317)	VCITYPGKTFCTEINAIEPKITDELELQFKTVDTKTLFNLAVQNHKLYSGQINDLGFSQCGCNIQKTNSSIIGTGAKFDYVCHGASRKDIIVRRCYN	1200
NRIV_SUD-HKV141_(JX857323)		1200
NRIV_SUD-HKV66_(JX857320)		1200
NRIV_9800521_(JX857326)	R.....	1200
NRIV_9800535_(AY593725)	R.....	1200
GSA/TS7/5170_WT(KM514677)		1200
ISL/TS2/5242_WT(KM514678)		1200
TND/S1/19801_WT(KM514679)		1200
NRIV_DakArD28542_(JX857317)	NNYESCKLLKEEQSLMFADNHETIDVANVRHLLGDLQFKLMLGDLRYKSFAENPDLEIEAKCVGCPSCFTTSYSCSFKIASNIDTVCSIEGPCTTFHNRLM	1300
NRIV_SUD-HKV141_(JX857323)	V.....	1300
NRIV_SUD-HKV66_(JX857320)		1300
NRIV_9800521_(JX857326)	T.....	1300
NRIV_9800535_(AY593725)		1300
GSA/TS7/5170_WT(KM514677)		1300
ISL/TS2/5242_WT(KM514678)		1300
TND/S1/19801_WT(KM514679)		1300
NRIV_DakArD28542_(JX857317)	ITSTKQDYGIKMSCKTKPKETEEFQICKKTYTVLFTTVEKNDKIEISTGDQTSFIQERDDRCTWLRCVRDEGISVIFEPIRAFFGSYFSIAFYVVVSII	1400
NRIV_SUD-HKV141_(JX857323)		1400
NRIV_SUD-HKV66_(JX857320)		1400
NRIV_9800521_(JX857326)	I.....	1400
NRIV_9800535_(AY593725)	I.....	1400
GSA/TS7/5170_WT(KM514677)	I.....	1400
ISL/TS2/5242_WT(KM514678)	I.....	1400
TND/S1/19801_WT(KM514679)	I.....	1400
NRIV_DakArD28542_(JX857317)	VLFLAIYIFLPMVFKLRDVLKRNEYLYLQEIKKK	1434
NRIV_SUD-HKV141_(JX857323)		1434
NRIV_SUD-HKV66_(JX857320)		1434
NRIV_9800521_(JX857326)		1434
NRIV_9800535_(AY593725)		1434
GSA/TS7/5170_WT(KM514677)		1434
ISL/TS2/5242_WT(KM514678)		1434
TND/S1/19801_WT(KM514679)		1434

Appendix 1J: Ngari virus L protein amino acid sequence alignment

NRIV_Dakar_D28542/4e_(KC608152	MEDQAYDQYLHRIQAARTATVAKDISADILEARHDYFGRELCNSLGI EYKNNVLLDEIILDVVPGVNLLNYPNVTPDNYIWDGSHFLIILDYKVS	100
NRIV_DakArD28542_(JX857318)		100
NRIV_SUD-HKV141_(JX857324)	M.....	100
NRIV_SUD-HKV66_(JX857321)	V.....	100
NRIV_9800521_(JX857327)		100
NRIV_9800535_(JX857330)		100
ISL/TS2/5242_WT(KM507334)	V.....	100
GSA/TS7/5170_WT(KM507336)	V.....	100
TND/S1/19801_WT(KM507335)	V.....	100
NRIV_Dakar_D28542/4e_(KC608152	SSEITYKKYTSLLLPVMSSELGIDTEIAIIRANPVTYQISIGEEFKQRFNPNIQIDFGRRFFELRKMLLDKFADDEEFIMMIAHGDFTLTAPWCTSDTPE	200
NRIV_DakArD28542_(JX857318)		200
NRIV_SUD-HKV141_(JX857324)		200
NRIV_SUD-HKV66_(JX857321)		200
NRIV_9800521_(JX857327)	S.....	200
NRIV_9800535_(JX857330)	S.....	200
ISL/TS2/5242_WT(KM507334)	T.....S.....	200
GSA/TS7/5170_WT(KM507336)	T.....S.....	200
TND/S1/19801_WT(KM507335)	T.....S.....	200
NRIV_Dakar_D28542/4e_(KC608152	LEDHEIFQEFINSMPPRFVSLFKEAVNFSAYSSERWNTFLYKARAETEVDYNQFLSDKAHKIFMLEGDYMRPTQAEIDKGWELMSQRVYTEREITDVTK	300
NRIV_DakArD28542_(JX857318)		300
NRIV_SUD-HKV141_(JX857324)		300
NRIV_SUD-HKV66_(JX857321)		300
NRIV_9800521_(JX857327)	D.I.....K.....	300
NRIV_9800535_(JX857330)	D.I.....K.....	300
ISL/TS2/5242_WT(KM507334)	I.....	300
GSA/TS7/5170_WT(KM507336)	I.....	300
TND/S1/19801_WT(KM507335)	I.....	300
NRIV_Dakar_D28542/4e_(KC608152	QKPSIHFIWAKNADRKLI GSTAKLIYLSNSLQSITEQSTWTDALKAI GKSMDDGKVGQYETLCAERKMIARSTGKKVDNKRLEAVKIGNALVLWEQQQFI	400
NRIV_DakArD28542_(JX857318)		400
NRIV_SUD-HKV141_(JX857324)		400
NRIV_SUD-HKV66_(JX857321)		400
NRIV_9800521_(JX857327)		400
NRIV_9800535_(JX857330)		400
ISL/TS2/5242_WT(KM507334)		400
GSA/TS7/5170_WT(KM507336)		400
TND/S1/19801_WT(KM507335)		400
NRIV_Dakar_D28542/4e_(KC608152	LANDLFKNQERQKFMKNFFGIGKHSFKDKTSSDIETDKPKILD FNNTIVLMAARTMVNKNKALLAKDNTLQDLHPIMQYASEIKEASKDTFDALLKIS	500
NRIV_DakArD28542_(JX857318)		500
NRIV_SUD-HKV141_(JX857324)		500
NRIV_SUD-HKV66_(JX857321)	I.....	500
NRIV_9800521_(JX857327)	G.....	500
NRIV_9800535_(JX857330)		500
ISL/TS2/5242_WT(KM507334)		500
GSA/TS7/5170_WT(KM507336)		500
TND/S1/19801_WT(KM507335)		500
NRIV_Dakar_D28542/4e_(KC608152	KTCFWQCIVDISTIMRNILAVSQYNRHNTFRVAMCANDSVYALVFPSSDIKTKRATVVFSSIVCMHKEKNDLMDAGALFTTLECKNKEYISISKAIRLDKE	600

NRIV_DakArD28542_(JX857318)		600
NRIV_SUD-HKV141_(JX857324)		600
NRIV_SUD-HKV66_(JX857321)		600
NRIV_9800521_(JX857327)		600
NRIV_9800535_(JX857330)	I.....	600
ISL/TS2/5242_WT(KM507334)	R.....	600
GSA/TS7/5170_WT(KM507336)	R.....	600
TND/S1/19801_WT(KM507335)	R.....	600
NRIV_Dakar_D28542/4e_(KC608152)	RCQRIVSSPGLFILSSMLLYNNNPEVNLVDVLNFTFYTSLISITKSMLSLTEPSRYMIMNSLAISSHVVDYIAEKFPYTKTLFSVYMVNLIKRGCASANE	700
NRIV_DakArD28542_(JX857318)		700
NRIV_SUD-HKV141_(JX857324)	L.....K.....	700
NRIV_SUD-HKV66_(JX857321)	K.....	700
NRIV_9800521_(JX857327)		700
NRIV_9800535_(JX857330)		700
ISL/TS2/5242_WT(KM507334)		700
GSA/TS7/5170_WT(KM507336)		700
TND/S1/19801_WT(KM507335)		700
NRIV_Dakar_D28542/4e_(KC608152)	QSSKIQLRNIYLSDYDITQKGVNDDRNLDISIWFPGKVNKEYINQIYLPFYFNAKGLHEKHHVMIDLAKTVLEIEMNQRGDNLGIWSKAEEKQHVNLPIL	800
NRIV_DakArD28542_(JX857318)		800
NRIV_SUD-HKV141_(JX857324)		800
NRIV_SUD-HKV66_(JX857321)		800
NRIV_9800521_(JX857327)		800
NRIV_9800535_(JX857330)		800
ISL/TS2/5242_WT(KM507334)		800
GSA/TS7/5170_WT(KM507336)		800
TND/S1/19801_WT(KM507335)		800
NRIV_Dakar_D28542/4e_(KC608152)	IHSIAKSLIILDTSRHNLNRVESRNNFRSITTISTFTSSKSCIKVGFREIKDKQTEKSKKSTEFDDKKFRLSNPLFLEDEEANLEVQHCHNYRALIQK	900
NRIV_DakArD28542_(JX857318)		900
NRIV_SUD-HKV141_(JX857324)		900
NRIV_SUD-HKV66_(JX857321)		900
NRIV_9800521_(JX857327)	I.....	900
NRIV_9800535_(JX857330)	I.....	900
ISL/TS2/5242_WT(KM507334)	K.....	900
GSA/TS7/5170_WT(KM507336)	K.....	900
TND/S1/19801_WT(KM507335)	K.....	900
NRIV_Dakar_D28542/4e_(KC608152)	IPNYKDYISVKVFDRLYELLKDGVLTDKPFIELAMEMMKNHKEFSFTFFNKGCQKTAKDREIFVGEFESKMCMYVVERISKERCKLNTDEMISEPGDSKLK	1000
NRIV_DakArD28542_(JX857318)		1000
NRIV_SUD-HKV141_(JX857324)	A.....	1000
NRIV_SUD-HKV66_(JX857321)	A.....	1000
NRIV_9800521_(JX857327)	A.....	1000
NRIV_9800535_(JX857330)	A.....	1000
ISL/TS2/5242_WT(KM507334)	A.....	1000
GSA/TS7/5170_WT(KM507336)	A.....	1000
TND/S1/19801_WT(KM507335)	A.....	1000
NRIV_Dakar_D28542/4e_(KC608152)	ILEKKAEEEEIRYIVERTKDSIIKGDPSKALKLEINADMSKWSAQDVFYKYFWLIAMDPILYPAEKTRILYFMCNYMQKLLILPDDLIANILDQKRPYND	1100
NRIV_DakArD28542_(JX857318)		1100
NRIV_SUD-HKV141_(JX857324)		1100

NRIV_SUD-HKV66_(JX857321)	N.....	1100
NRIV_9800521_(JX857327)		1100
NRIV_9800535_(JX857330)	L.....	1100
ISL/TS2/5242_WT(KM507334)	N.....L.....	1100
GSA/TS7/5170_WT(KM507336)	N.....L.....	1100
TND/S1/19801_WT(KM507335)	N.....L.....	1100
NRIV_Dakar_D28542/4e_(KC608152)	LILEMTNGLNynyVQIKRNLQGNFNyISSyVHSCAMLVYKDILKECMKLLDGDCLINSMVHSDDNQTSIAIIONKVSdqIvIQYAANTFESVCLTFGCQ	1200
NRIV_DakArD28542_(JX857318)		1200
NRIV_SUD-HKV141_(JX857324)	R.....	1200
NRIV_SUD-HKV66_(JX857321)		1200
NRIV_9800521_(JX857327)		1200
NRIV_9800535_(JX857330)		1200
ISL/TS2/5242_WT(KM507334)		1200
GSA/TS7/5170_WT(KM507336)		1200
TND/S1/19801_WT(KM507335)		1200
NRIV_Dakar_D28542/4e_(KC608152)	ANMKKYITHCKEFVSLFNLHGEPLSVYGRFLLPSVGDCAYIGPYEDLASRLSAAQQLKHGCPPSLVWLAISCSHWITFFTYNMLDDQINAPQQLPFF	1300
NRIV_DakArD28542_(JX857318)		1300
NRIV_SUD-HKV141_(JX857324)		1300
NRIV_SUD-HKV66_(JX857321)		1300
NRIV_9800521_(JX857327)		1300
NRIV_9800535_(JX857330)		1300
ISL/TS2/5242_WT(KM507334)		1300
GSA/TS7/5170_WT(KM507336)		1300
TND/S1/19801_WT(KM507335)		1300
NRIV_Dakar_D28542/4e_(KC608152)	NNRKEIPVELNGYLNAPLYLIAVGLVLEAGNLWFLINILKKLVPLDKQKETIQSQCLHLNCSIDKLTESEKFKILRYLTLDTEMSVDNNMGETSDMRSR	1400
NRIV_DakArD28542_(JX857318)		1400
NRIV_SUD-HKV141_(JX857324)		1400
NRIV_SUD-HKV66_(JX857321)		1400
NRIV_9800521_(JX857327)		1400
NRIV_9800535_(JX857330)		1400
ISL/TS2/5242_WT(KM507334)		1400
GSA/TS7/5170_WT(KM507336)		1400
TND/S1/19801_WT(KM507335)		1400
NRIV_Dakar_D28542/4e_(KC608152)	SLLTPRKFTTLGSLNKLVSYNDFRSSLDQRFDTNLFNMLNNPELLVTKGENKEQFMQSVLFRYNSKRFEKESLSIQNPAQLFIEQILFSHKPIIDYSSIF	1500
NRIV_DakArD28542_(JX857318)	I.....	1500
NRIV_SUD-HKV141_(JX857324)		1500
NRIV_SUD-HKV66_(JX857321)		1500
NRIV_9800521_(JX857327)	I.....	1500
NRIV_9800535_(JX857330)	I.....	1500
ISL/TS2/5242_WT(KM507334)		1500
GSA/TS7/5170_WT(KM507336)		1500
TND/S1/19801_WT(KM507335)		1500
NRIV_Dakar_D28542/4e_(KC608152)	DKLTSLEADIEELPEIIGRVTFPQAYQMINRDIGQLPLDIDDIKLIFRYCILNDPLMITAANTSLLCVKGTPODRTGLSASQMPFRNMKLIHHPAL	1600
NRIV_DakArD28542_(JX857318)		1600
NRIV_SUD-HKV141_(JX857324)	N.....	1600
NRIV_SUD-HKV66_(JX857321)	N.....	1600
NRIV_9800521_(JX857327)	N.....	1600

NRIV_9800535_(JX857330)	N.....	1600
ISL/TS2/5242_WT(KM507334)	N.....	1600
GSA/TS7/5170_WT(KM507336)	N.....	1600
TND/S1/19801_WT(KM507335)	N.....	1600
NRIV_Dakar_D28542/4e_(KC608152)	VLKAFSGKGTSDIPGADPIELEKDLHHLNEFVETTAIKEKILHNIIDNPPKHLIGNEILIYRIREMTKLYQVCYDVVKSTEHKVKIFILPMKSYTAIDFCTL	1700
NRIV_DakArD28542_(JX857318)		1700
NRIV_SUD-HKV141_(JX857324)		1700
NRIV_SUD-HKV66_(JX857321)		1700
NRIV_9800521_(JX857327)		1700
NRIV_9800535_(JX857330)		1700
ISL/TS2/5242_WT(KM507334)		1700
GSA/TS7/5170_WT(KM507336)		1700
TND/S1/19801_WT(KM507335)		1700
NRIV_Dakar_D28542/4e_(KC608152)	IQGNTISDNKWYTMHYLKQIASGSIKGNIVTTSTSEQIIANECFRVLCHFADSFVEEASRLSFINEVLNFTYKNISVNSLNFNTLLASTTRLDFIPLLER	1800
NRIV_DakArD28542_(JX857318)		1800
NRIV_SUD-HKV141_(JX857324)	I.....	1800
NRIV_SUD-HKV66_(JX857321)		1800
NRIV_9800521_(JX857327)		1800
NRIV_9800535_(JX857330)		1800
ISL/TS2/5242_WT(KM507334)		1800
GSA/TS7/5170_WT(KM507336)		1800
TND/S1/19801_WT(KM507335)		1800
NRIV_Dakar_D28542/4e_(KC608152)	LKVLQTQDLNRFDAKLTNERVSWNNWQTNRSLNSGLIDLITISGYLRSIRVVGEDNKLKIAELTIPNFYPNTVFHAGNKLLNSRHGLKFEYMEEIILDEKY	1900
NRIV_DakArD28542_(JX857318)		1900
NRIV_SUD-HKV141_(JX857324)	I.....V.....	1900
NRIV_SUD-HKV66_(JX857321)	I.....V.....	1900
NRIV_9800521_(JX857327)		1900
NRIV_9800535_(JX857330)		1900
ISL/TS2/5242_WT(KM507334)		1900
GSA/TS7/5170_WT(KM507336)		1900
TND/S1/19801_WT(KM507335)		1900
NRIV_Dakar_D28542/4e_(KC608152)	NYIITYQKRAHIYTYQVSTIEHILRRNNEGLQSRGPRYNKMVPVCPVVLVSRDELFRMSLENVFSNLMTNFSMSRFLVSPDEVATVKKAHMSKMMFFSG	2000
NRIV_DakArD28542_(JX857318)		2000
NRIV_SUD-HKV141_(JX857324)	L.....	2000
NRIV_SUD-HKV66_(JX857321)		2000
NRIV_9800521_(JX857327)		2000
NRIV_9800535_(JX857330)		2000
ISL/TS2/5242_WT(KM507334)		2000
GSA/TS7/5170_WT(KM507336)		2000
TND/S1/19801_WT(KM507335)		2000
NRIV_Dakar_D28542/4e_(KC608152)	PTIKAGIINLTSLMRTQELLTLNYDNLCSSIVPFCRILECNGDEQGEELIFLSDEVMDFTISEEIESMPLFTIRYQKRGEIMTYKNAIMKLVAAGVDEI	2100
NRIV_DakArD28542_(JX857318)		2100
NRIV_SUD-HKV141_(JX857324)	S.....	2100
NRIV_SUD-HKV66_(JX857321)	S.....	2100
NRIV_9800521_(JX857327)		2100
NRIV_9800535_(JX857330)		2100
ISL/TS2/5242_WT(KM507334)		2100

GSA/TS7/5170_WT (KM507336)		2100
TND/S1/19801_WT (KM507335)		2100
NRIV_Dakar_D28542/4e_ (KC608152)	KEVFD ^F SKQ ^G FYSK ^N LGIINT ^I CS ^I IINILE ^T NE ^W STILYNS ^F HIAM ^L LES ^M DRE ^F HMET ^L PEAFFIN ^V AGGIV ^N WTKLL ^K FKSL ^P VIE ^Q EPWS ^M MSR	2200
NRIV_DakArD28542_ (JX857318)		2200
NRIV_SUD-HKV141_ (JX857324)		2200
NRIV_SUD-HKV66_ (JX857321)		2200
NRIV_9800521_ (JX857327)		2200
NRIV_9800535_ (JX857330)		2200
ISL/TS2/5242_WT (KM507334)	G.....I.....R.....	2200
GSA/TS7/5170_WT (KM507336)	V.....	2200
TND/S1/19801_WT (KM507335)	V.....	2200
NRIV_Dakar_D28542/4e_ (KC608152)	FVEKTVY ^L IEREM ^N KD ^V DF ^T DFL ^D EL ^E FSS ^G KSL ^F TF ^F	2238
NRIV_DakArD28542_ (JX857318)		2238
NRIV_SUD-HKV141_ (JX857324)		2238
NRIV_SUD-HKV66_ (JX857321)		2238
NRIV_9800521_ (JX857327)		2238
NRIV_9800535_ (JX857330)	L.....	2238
ISL/TS2/5242_WT (KM507334)		2238
GSA/TS7/5170_WT (KM507336)		2238
TND/S1/19801_WT (KM507335)		2238

Appendix 1K: Bunyamwera virus NSs protein amino acid sequence alignment

BUNV_ (NC_001927)	MMSLLTPAVLLTQ ^R SH ^T LTLSVSTPLGLVMTTYESSTLKDARLKLVSQKEVNGKLHLLTGAGRLLYIIRIFLATGTTQFLTMVLPSTASVD ^S LP ^G TYL ^R RC	101
BUNV_BLCNNS_ (D00353)		101
BUNV_ArB29051_ (AM709778)		101
GSA/S4/11232/WT (KM507345)	L.....	101
MGD/S1/12060/WT (KM507344)		101

Appendix 1L: Bunyamwera virus N protein amino acid sequence alignment

BUNV_ (NC_001927)	MIELEF ^H HDVAANTSSTFDPEVAYAN ^F KRVHTTGLSYDHIRIFYIKGREIKTSLAKRSEWEVTLNLGGWKITVYNTNFPGNRRNPV ^P DDGLTLHRLSGFLARYLLEKMLKV	110
BUNV_BLCNNS_ (D00353)		110
BUNV_ArB29051_ (AM709778)	L.....	110

```

GSA/S4/11232/WT (KM507345) ..... 110
MGD/S1/12060/WT (KM507344) ..... 110

BUNV_(NC_001927)      SEPEKLIKSKIINPLAEKNGITWNDGEEVYLSFFPGSEMFLGTFRFYPLAIGIYKVQREMEPKYLEKTMQRQYMGLEAATWTVSKLTFVQSALTVVSSSLGWKKTNSA 220
BUNV_BLCNNS_(D00353) ..... 220
BUNV_ArB29051_(AM709778) ..... 220
GSA/S4/11232/WT (KM507345) ..... 220
MGD/S1/12060/WT      ..... 220

BUNV_(NC_001927)      AARDFLAKFGINM 233
BUNV_BLCNNS_(D00353) ..... 233
BUNV_ArB29051_(AM709778) ..... 233
GSA/S4/11232/WT (KM507345) ..... 233
MGD/S1/12060/WT      ..... 233

```

Appendix 1M: Bunyamwera virus M protein amino acid sequence alignment

```

BUNV_(NC_001926) MRILILLIIVTQLAVSSPVITRCFHGGQLIAERKSQTSISEFCIKDDVSMKSEIVYTKNDTGIFGHGSKVFRHWTITDWKACNPVVTAGGSINVIEVDKNLNLVTRNYVC 110
BUNV_(M11852) ..... 110
BUNV_(JF961341) ..... 110
GSA/S4/11232_WT .....K..G..V..... 110
MGD/S1/12060_WT .....K..G..V..... 110

BUNV_(NC_001926) TGDCTITVDRKNAQIIFQTDKLNHFVETGTTISTGWFKSKASVTLDRTCHEHIKVS CGKKTLOFHACFKQHMSCVRFLHRSILPGSMAISICQNIELIITITILALCIFIM 220
BUNV_(M11852) ..... 220
BUNV_(JF961341) .....KE..... 220
GSA/S4/11232_WT .....KE.....R..... 220
MGD/S1/12060_WT .....KE.....R..... 220

BUNV_(NC_001926) IILTNTYICYVLIPVFMPIAFAYGWAYNRSCKKCTCCGLAYHPFTNCGSSYCVGSKFETSDRMRMHRESGLCQGFKSLRVARRLCKSKGSSLIISILLSVLILSFVTPIE 330
BUNV_(M11852) ..... 330
BUNV_(JF961341) ..... 330
GSA/S4/11232_WT ..... 330
MGD/S1/12060_WT ..... 330

BUNV_(NC_001926) GTLTNYPTDQKYTLDEIADVLQAKTHEDSTKYIILYTSLFGAGLTIIFAGVALGLTIILEVLTKINVIFCNECNMYHSHKSKSIKYVGDFTNKCGFCTCGLLEDPEGVVVH 440
BUNV_(M11852) ..... 440
BUNV_(JF961341) ..... 440
GSA/S4/11232_WT ..... 440
MGD/S1/12060_WT ..... 440

BUNV_(NC_001926) KAKKSCTYSYQINWVRGIMIFVAFLFVIQNTIIMVAAEEDCWKNEELKEDCVGPLIAPKCTDKDHKTYLSEASLLATAKKITQVDAENVEILGKTMEASAIRVIERQKTY 550
BUNV_(M11852) ..... 550
BUNV_(JF961341) .....S..K.....R..... 550
GSA/S4/11232_WT .....S..K.....R..... 550
MGD/S1/12060_WT .....S..K.....E.....R..... 550

```

BUNV_(NC_001926)	HRMHLLLEAVFLNKHCDYYKMFENHSGYSQVQKWRMMIKTQHFDICALQANSFCAQCIADNSCAQGSWEFDTHMNSTYSSKVDNFKHDFSFLFLRIFEAAFPGTAYVHLLTN	660
BUNV_(M11852)		660
BUNV_(JF961341)	S.....	660
GSA/S4/11232_WT	S.....	660
MGD/S1/12060_WT	S.....	660
BUNV_(NC_001926)	IKEKKPYQAVSMIEKIKKKFPNNKLLIGYLDGKYLLGLSHASTYELQQRQLDKLYQPTELTRSGGQQTSLANSVVGQATKECKKYKDVSCLSPRFGIPLLEDLISCCDQP	770
BUNV_(M11852)		770
BUNV_(JF961341)	S.....S.....G...	770
GSA/S4/11232_WT	S.....S.....G...	770
MGD/S1/12060_WT	S.....S.....G...	770
BUNV_(NC_001926)	NYNIYKKPKKVYKAHDKEETWCINDQHCLVDFVPAEADTVEKLPKMCWLVDPGKNDDVYSIAIKTCRVVDKGVCTVNSQKWNIIKCDSGPLYSDHIPGEDTGNDIGHY	880
BUNV_(M11852)		880
BUNV_(JF961341)	I.....DL.....V.....	880
GSA/S4/11232_WT	N.....I.....DL.....V.....	880
MGD/S1/12060_WT	N.....I.....DL.....V.....	880
BUNV_(NC_001926)	CVSAGCKTD RYPINPDVVTDCVWEFTSRKSQYIGKISMQSLEDYEKALTDRLHTTLETYSFAPLENLPHIKPVYKYITAQGVENS D GIEGAFITASIPAAGGTSIGYNVR	990
BUNV_(M11852)		990
BUNV_(JF961341)	R.....K.....G.....I.....	990
GSA/S4/11232_WT	R.....K.....	990
MGD/S1/12060_WT	R.....K.....	990
BUNV_(NC_001926)	SKDGFPLLDLIVFVKSAVIKSTYNIHYDTGPTISINTKHDEHCTGQCPSNIEHEANWLTF SQERTSRWGCEEFGCLAVNTGCVFGSCQDVIRPETKVYRKAVDEVVILTV	1100
BUNV_(M11852)		1100
BUNV_(JF961341)	I.....	1100
GSA/S4/11232_WT	I.....	1100
MGD/S1/12060_WT	I.....	1100
BUNV_(NC_001926)	CITYPGHTFCTEINAIEPKITEEIELQFKTVDTKTLPIYAVAVNNHKL YSGQINDLGTFGQMC GNVQKTNSSILGTGTPKFDYTC HGASRKDIIVRRCYNNNFDSCKLLKE	1210
BUNV_(M11852)		1210
BUNV_(JF961341)		1210
GSA/S4/11232_WT		1210
MGD/S1/12060_WT		1210
BUNV_(NC_001926)	ETQLIFNDDHDTITVYNTNHLIGELAIKLLIGDIQYKLFTEITLDLQIDAKCVGCPDCEFESYSCNFQIVSNIDTICSLGPGCDTFHNRISIKAMQQNYAVKLS CQKDP RPS	1320
BUNV_(M11852)		1320
BUNV_(JF961341)	N.....G...	1320
GSA/S4/11232_WT	N.....G...	1320
MGD/S1/12060_WT	N.....G...	1320
BUNV_(NC_001926)	GTFKICNREYTVVFHTVAKDDKIEINVGDQTSFIKEKDDRCKTWLCRVRDEGISVIFEPIKAFFGSYFSIFFYIIVVVVGFLIIFYIFMPFMFKLKEVLKAN EKLYLQEI	1430
BUNV_(M11852)		1430
BUNV_(JF961341)	II.....	1430
GSA/S4/11232_WT	II.....	1430
MGD/S1/12060_WT	II.....	1430
BUNV_(NC_001926)	KQK	1433

BUNV_(M11852) ... 1433
 BUNV_(JF961341) ... 1376
 GSA/S4/11232_WT ... 1433
 MGD/S1/12060_WT ... 1433

Appendix 1N: Bunyamwera virus L protein amino acid sequence alignment

BUNV_(NC_001925)	MEDQAYDQYLHRIQAARTATVAKDISADILEARHDYFGREL CNSLGI EYKNNVLLDEIILDVVPGVNLLNYNIPNVT PDNYIWDG HFLIILDYKVS VGNDSSEITYK KYT	110
BUNV_(X14383)		110
GSA/S4/11232_WT		110
MGD/S1/12060_WT	T.....	110
BUNV_(NC_001925)	SLILPVMSELGIDTEIAIIRANPVTYQISII GEEFKQRF PNIP IQLD FGRFFELRKMLLDKFADDEEFIMMIAHGDFTLTAPWCTSDTPELEEHEIFQEFINSMPPRFVS	220
BUNV_(X14383)		220
GSA/S4/11232_WT		220
MGD/S1/12060_WT		220
BUNV_(NC_001925)	LFKEAVNFSAYSSERWNTFLYRARAETEVDYNQFLSDKAHKIFMLEGDYMRPTQAEIDKGWELMSQRVYTEREIITDVT KQKPSIHFIVWKNADRKLIGSTAKLIYLSNS	330
BUNV_(X14383)		330
GSA/S4/11232_WT	K.....A.....	330
MGD/S1/12060_WT	K.....A.....	330
BUNV_(NC_001925)	LQSITEQSTWTDALKAIGKSMIDGKVGQYETLCAERKMIAIRSTGKKVDNKRLEAVKIGNALVLWEQQFILANDLFKNQERQKFMKNFFGIGKHKSFKDKTSSDIETDKP	440
BUNV_(X14383)		440
GSA/S4/11232_WT		440
MGD/S1/12060_WT		440
BUNV_(NC_001925)	KILD FNNTIVLMAARTMVNKNKALLAKDNLTQDLHP IIMQYASEIKEASKDTFDALLKISKTCFWQCIVDVSTIMRNILAVSQYNRHNTFRVAMCANDSVYALVFPSSDI	550
BUNV_(X14383)		550
GSA/S4/11232_WT	I.....	550
MGD/S1/12060_WT	I.....	550
BUNV_(NC_001925)	KTKRATVVSIVCMHKEKNDLMDAGALEFTTLECKNKEYISISKAIRLDKERCQRIVSSPGLFILSSMLLYNNNPEVNLVDVLNFTFYTSLSITKSMLSLEPSRYMIMNS	660
BUNV_(X14383)		660
GSA/S4/11232_WT		660
MGD/S1/12060_WT		660
BUNV_(NC_001925)	LAISSHV RDYIAEFKFSPTKTLFSVYMVNLIKRG CASANEQSSKIQLRNIYLSDYDITQKGVNDGRNLD SIWFPGKVN LKEYINQIYLPFYFNAKGLHEKHHVMIDLAKT	770
BUNV_(X14383)		770
GSA/S4/11232_WT	D.....	770
MGD/S1/12060_WT	D.....	770
BUNV_(NC_001925)	VLEIEMNQ RSDNLGIWSKA EKKQH VNLPI LIHSIAKSLILDTSRHNLNRV ESRNNFRRSITTTISTFTSSKSCIKIGDFREIKDKET ESKSKSTEKFDKKFRLSNPLFL	880
BUNV_(X14383)		880
GSA/S4/11232_WT		880
MGD/S1/12060_WT	I.....	880

BUNV_(NC_001925)	EDEEANLEVQHCHNYRALIQKIPNYKDYISVKVFDRLYELLKNGVLTDPFFIELAMEMMKNHKEFSFTFFNKGOKTAKDREIFVGEFEAKMCMYVVERISKERCKLNTDEM	990
BUNV_(X14383)		990
GSA/S4/11232_WT		990
MGD/S1/12060_WT		990
BUNV_(NC_001925)	ISEPGDSKLKILEKKAEEEEIRYIVERTKDSIIKGDPSKALKLEINADMSKWSAQDVFYKYFWLIAMPILYPAEKTRILYFMCNYMQKLLILPDDLIANILDQKRPYNDD	1100
BUNV_(X14383)		1100
GSA/S4/11232_WT		1100
MGD/S1/12060_WT		1100
BUNV_(NC_001925)	LILEMTNGLNYYVQIKRNWLQGNFNYISSYVHSCAMLVYKDIKECMKLLDGDCLINSMVHSDDNQTSALAIQNKVSDQIVIQYAANTFESVCLTFGCQANMKKTYITH	1210
BUNV_(X14383)		1210
GSA/S4/11232_WT		1210
MGD/S1/12060_WT		1210
BUNV_(NC_001925)	TCKEFVSLFNLHGEPLSVFGRFLPSVGDCAIYGPYEDLASRLSAAQQSLKHGCPPSLVWLAISSHWITFFTYNMLDDQINAPQQHLPFNNRKEIPVELNGYLNAPLYL	1320
BUNV_(X14383)		1320
GSA/S4/11232_WT	Y.....	1320
MGD/S1/12060_WT	Y.....	1320
BUNV_(NC_001925)	IALVGLEAGNLWFLINILKKLVPLDKQKETIQSQCLHLCNSIDKLTSEKFKILKILRYLTLDTEMSVDNNMGETSDMRSRSLTTPRKFTTLGSLNKLVSYNDFRSSLDDQ	1430
BUNV_(X14383)		1430
GSA/S4/11232_WT		1430
MGD/S1/12060_WT		1430
BUNV_(NC_001925)	RFTDNLNFMNLNNPELLVTGENKEQFMQSVLFRYNSKRFEKESLSIQNPQOLFIEQILFSHKPIIDYSSIFDKLTSLEADIIEELPEIIGRVTFPQAYQMNRDIGQLPL	1540
BUNV_(X14383)		1540
GSA/S4/11232_WT		1540
MGD/S1/12060_WT		1540
BUNV_(NC_001925)	DIDDIKLIIFRYCIIINDPLMITAANTSLLCVKGTPODRTGLSASQMPEFRNMKLIHHSALVLKAFSGKTSDIPGADPIELEKDLHHLNEFVETTAIKEILHNIDNPPKH	1650
BUNV_(X14383)		1650
GSA/S4/11232_WT		1650
MGD/S1/12060_WT		1650
BUNV_(NC_001925)	LIGNEILIYRIREMTKLYQVCYDYVKSTEHKVKIFILPMKSYTAIDFCTLIQNGTISDNKWTMHYLKQIASGSIKGNIVTTSTSEQIANECFRVLCHFADSFVEEASR	1760
BUNV_(X14383)		1760
GSA/S4/11232_WT		1760
MGD/S1/12060_WT		1760
BUNV_(NC_001925)	LSFINEVLDNFTYKNISVNSLFNTLLASTTRLDFIPLLFRLKVLQTDLNRFDAKLTNERVSWNNWQTNRSLSGLIDLTISGYLRSIRVVGEDNKLKIAELTIPNFYPN	1870
BUNV_(X14383)		1870
GSA/S4/11232_WT		1870
MGD/S1/12060_WT		1870
BUNV_(NC_001925)	TVFHAGNKLNLNSRHGLKFEYMEEIVLDEKYNYYITYQKKRAHIYTYQVSTIEHILRRNNEGLQSRGPRYNKMVPVCPVLSVRDELFRMSLENVFSNMTNFSMSRLEVS	1980
BUNV_(X14383)		1980
GSA/S4/11232_WT	TI.....	1980
MGD/S1/12060_WT	TI.....	1980
BUNV_(NC_001925)	PDEVATVKKAHMSKMMFFSGPTIKAGIINLTSIMRTQELLTLNVDNLCKSSIVPFCRILECNGDEQGEILIFLSDEVMDFITISEEIESMPLFTIRYQKRGTETIMTYKNAIM	2090

BUNV_(X14383)		2090
GSA/S4/11232_WT		2090
MGD/S1/12060_WT	K.....	2090
BUNV_(NC_001925)	KLVSAGVDEIKEVDFSKQGFYSKKNLGIINTICSIINILETNEWSTILYNSFHIAMLLESMDREFHMFLLPEAFFINVAGGVVNWTKLLKFIKSLPVEEQEPWSMMMSR	2200
BUNV_(X14383)		2200
GSA/S4/11232_WT		2200
MGD/S1/12060_WT		2200
BUNV_(NC_001925)	FVEKTVYLIEREMNKDVFDTDFLDELEFSSGKSLFTFF	2238
BUNV_(X14383)		2238
GSA/S4/11232_WT		2238
MGD/S1/12060_WT		2238

Appendix 2: Primers used in sequencing of Kenyan Bunyamwera and Ngari virus isolates

Table 19: Primers used in sequencing of Kenyan Bunyamwera and Ngari virus isolates.

Target virus	Target gene/protein	Primer sequence pair (5'-3')	Coordinate nucleotides	Reference
Bunyamwera	S segment	BUNS1 (AGTAGTGTACTCCACACTACAACT) and BUNS9 (AGGAATCCACTGAGGCGGTGGAGG)	1-25 to 358-381	Yandoko et al, 2007
		BUNS4 (CTGGCAACCGGAACAACCCAGTT) and BUNS5 (GAGACAACTGTCAGTGCAGACTGAA)	318-340 to 687-711	Yandoko et al, 2007
		BUNS10 (TCAGTCTGCACTGACAGTTGTCTC) and BUNS2 (AGTAGTGTGCTCCACCTAAACTTA)	688-711 to 937-961	Yandoko et al, 2007
Bunyamwera	Polyprotein M segment	Bunya M14C (CGGAATTCAGTAGTGTACTACC) and Bunya M619 (GACATATGYTGATTGAAGCAAGCATG)	1-14 to 586-576	Yanase et al, 2006)
		BUNM11F (TCAGCACTGGCTGGTTTAAG) and BUNM11R (ACCTGCACCGAAGAGTGATG)	481-500 to 1159-1178	This study
		BunM12F (GAGATAGCAGATGTCCTTCAAGC) and BunM12R (CAAGCAAGTGCATTCTGTGG)	1092-1114 to 1706-1725	This study
		Bun M3F (TTCATAATAAATGTGGGTTTTG) and Bun M3R (ATGCTGACTGCCTGATAGGG)	1311-1333 to 2052-2071	This study
		Bun M4F (TCCAGGCACTGCTTATGTTC) and Bun M4R (TCTTCCCCTGGTATGTGGTC)	2003-2022 to 2652-2671	This study
		Bun M5F (TGTGATTCTGGTCCGCTCTAC) and Bun M5R (GCATCCCCATCTGCTAGTTC)	2625-2645 to 3217-3236	This study
		Bun M6F (CAAAGCATGACGAACATTGC) and Bun M6R (TCAAGGCTGCAGATTGTGTC)	3136-3155 to 3900-3919	This study
		Bunc7MF (CCAGATTGATGCGAAATGTG) BAT 3' end R (GAATTCAGTAGTGTGCTACC)	3821-3840 to 4445-4458	This study
Bunyamwera	L Protein	M13 BunL 1C Yanase (TGTAACACGACGGCCAGTAGTGTACTCCT) and BunL605R Yunase (RGTGAARTCNCCATGTGC)	1-14 to 614-597	Yanase et al, 2006)
		Bun2LF (GTTGCTGGACAAGTTTGCTG) and Bun2LR (TTGCCAATCTTAACCGCTTC)	551-570 to 1200-1219	This study
		Bun3LF (AAAATGATTGCCAGGTCAAC) and Bun3LR (TATGAAAAGCCAGGTGATG)	1152-1171 to 1870 -1889	This study
		Bun5LF (AAGAAACAACATGTCAATCTACC) and Bun5LR (TAGCGGATTTCTCTTCTGC)	2421-2443 to 3066-3085	This study
		Bunya L For JV (CAATATAATAGACATAATACATTTAGAGT) Bunya L Rev JV (CTCCATTTDGACATRTCTGCA)	1617-1645 to 3175-3154	This study

Appendix 3A

		BUNL6F (GCTGAACACGGACGAGATG) and BUNL6R (GGCCCAATGTAAGCACAAATC)	3003-3020 to 3765-3784	This study
		BUNL7F (GGAGAACCACTATCTGTCTTTGG) and BUNL7R (ATTGTGCTGGGTTTTGGATG)	3717-3739 to 4472-4491	This study
		BUNL8F (GCAGTTCATGCAATCTGTCC) and BUNL8R (TGTTGCCCTGAATCAATGTG)	4412-4431 to 5144-5163	This study
		BUNL9F (TCACAGCTGCAAACACTTCC) and BUNL9R (TCAATCTGCTTGCCTCTTCC)	4729-4748 to 5315-5334	This study
		BUNL10F (AAGCGAGCAAATAATAGCAAATG) and BUNL10R (TACCTAGGGCCTCTGGATTG)	5256-5274 to 5866-5847	This study
		BUNL11F (CCGGCTATTTAAGATCAATAAGG) and BUNL11R (TGCTCATCGCCATTACATTC)	5575-5597 to 6168-6187	This study
		BUNL12F (TCTAGCATTGTCCCGTTTTG) and BUNL12R (TTTTGCCACATAGTGCTTTTTG)	6138-6157 to 6803-6823	This study
		BUNL12F (TCTAGCATTGTCCCGTTTTG) And Bun 3'end LR (GTAAACGACGGCCAGTAGTGCTGCTCC)	6138–6157 to 6863–6875	This study
Ngari virus	Polypeptide M segment	BunyaM14C (CGGAATTCAAGTAGTGTACTACC) and TrialR2 (TGACCCGCAATTTGTAAAGG)		This study
		BATM13F (CCAAACCGAGAAGTTGAACC) and BATM13R (AATCCTTCCAGGACATCAGC)	419-438 to 1080-1099	This study
		BATM14F (TGCTCATGCTGTGGTCTAGC) and BATM14R (ACCTCCACTTTGCCTGTGAG)	798-817 to 1769-1788	This study
		BATAIM3F CCTGGGGAAGCATTGTGATTACT BATAIM3R CTAGCCAGCGACTCTTGCCTTCC	1,704–1,726 to 2,206–2,228	Jost et al, 2011
		BATAIM4F GTCGCTGGCTAGTGCTACCTCTGG BATAIM4R CTGATTATTGTCGGATTTATTGGGAACCT	2,217–2,240 to 2,698–2,726	Jost et al, 2011
		BATAIM5F AAAGGTTCCCAATAAATCCGACAA BATAIM5R CAAATTCCTCACATCCCCAACGACTA	2,696–2,719 to 3,195–3,220	Jost et al, 2011
		BATAIM6F AGAATTTGGGTGCCTTGCTGTCA BATAIM6R AGATGTTTGGTCCCCTGTGCTTATTT	3,213–3,235 to 4,061–4,086	Jost et al, 2011
		BAT 3'end F (TGTTTCGAGATAACCATGAAAC) and BAT 3'end R (GAATTCAGTAGTGCTACC)	3688-3709 to 4425-4438	This study
	L segment	NgariL6F (TTTTGAGAAGGAATAATGAAGG) and NgariL6R (CCCCTGCTGCAACTAACTTC)	5821-5842 to 6320-6339	This study

Informed Consent Agreement

Request: I wish to request for your participation in the following research project:

Project title: Tick-Borne Virus Prevalence and Diversity in Pastoral Eco-Zone of Ijara District, North Eastern Province of Kenya

Study information: We are interested in finding out causes of illness in adults and children who have fever and/or malaria like illness. We want to use new methods that can detect any germs even those that are difficult to detect usually or have not been detected before. We want to draw a small amount of blood and test it in the lab to see if you have been exposed to germs that are carried by ticks.

Expertise in the study: The study is being run by Olivia Wesula Lwande a PhD student in Medical Virology at the Department of Medical Virology, University of Pretoria (Student number:11346192) , Dr. Rosemary Sang and a team of doctors and scientists from Kenya Medical Research Institute (KEMRI), Ministry of Public Health and Sanitation (MPH&S), International Centre of Insect Physiology and Ecology (ICIPE), International Livestock Research Institute (ILRI) and Ministry of Livestock/Department of Veterinary Services (MOL/DVS).

Participation: Participation in this study is voluntary. There is no penalty for refusing to participate. We will need only one sample from you but if need arises, we may come back to you to take a second sample to confirm our finding. If you start the study you (or your child) may discontinue your (or your child's) participation at any time. The principal investigators and co- investigators from KEMRI and MOP&S may decide to withdraw you (or your child) from the study if we are unable to obtain a blood sample from you (or your child).

Study procedure: You will be asked some questions about where you live, your illness and any medications you may have taken recently. Then about a tablespoon of blood will be taken from a vein in your arm. The blood will be put into small tubes so we can test for germs that may be causing your illness. We will not test for Human Immunodeficiency Virus (HIV).

Risks involved in the study: There is the possibility of mild discomfort, bruising and very rarely infection at the site where the blood is taken. But, should you (or your child) be injured as a direct result of participating in this research project, you (or your child) will be provided medical care, at no cost to you (or your child), for that injury. You (or your child) will not receive any injury compensation, only medical care. You (your child) should also understand that this is not a waiver or release of your (your child's) legal rights. If you wish, you should discuss this issue thoroughly with the principal investigator before you (your child) enroll in this study.

Benefits from the study: The study can lead to a better understanding of the causes of acute febrile illnesses in Kenya and improve the medical care in Kenya by improving detection methods and identifying some of the hidden germs that may be causing disease. The Ministry of Health (MoH) and supporting medical community can benefit from the knowledge of the identification of new or emerging diseases as the cause of acute febrile illnesses so that they know how to care for you and others in the future. Epidemics can be more readily identified, allowing the MoH to respond in a timely manner hence reducing the number of people who get affected.

Compensation for being in the study: There is no compensation to volunteers for their participation.

Duration: This study requires only completion of a short questionnaire and one blood draw. There is no follow-up or further information needed. The questionnaire and blood draw will take about 15 minutes.

Study participants: Anyone can participate in the study if you have a fever without a source after evaluation by the clinician. If there is an obvious source of infection causing the fever, like an abscess or pneumonia, you need not (your child should not) participate.

Confidentiality: Any information about you (your child's) will remain confidential. Only the people involved in the study will be able to see your information. We will keep all files in locked cabinets when they are not in use, and all blood stored in locked freezers. Your (your child's) name will not be used in any report resulting from this study. Any report from this study will refer to you/your child

only by a study identification number and not by a name. All blood samples collected will be labeled with a study identification number; no names will be used. Your (your child's) blood will be tested for things that could cause fever. Your blood will not be tested for HIV. A sample of your blood will be kept frozen in case we want to do more testing on it in the future. These samples will be labeled with only your study number. They will be secured in freezers at KEMRI, ILRI or ICIPE facilities and only study investigators and their authorized staff will have access. All safeguards ensuring privacy and confidentiality that are in place during this study period will also continue to be in place for the long-term storage of samples and if samples are sent outside of Kenya, no personal identifiers will be included.

If we do need to use the stored blood in the future we will first get permission from the Kenya National Ethical Review Committee.

contact on information about the study or my rights as a volunteer in this research study: If during the course of this study, you have questions concerning the nature of the research or you believe you have sustained a research-related injury, you should contact either: **Mr Collins Otieno Odhiambo, International Centre for Insect Physiology and Ecology, P.O Box 30772-00100, NAIROBI Tel: 0725984059 or Dr. Rosemary Sang, Centre for Virus Research, KEMRI PO Box 54628, NAIROBI Tel. 0722 759492.**

Who should I contact if I have questions on my rights as a volunteer in this research study: If you have any question on your rights as a volunteer, you or your parent should contact: **The Secretary, National Ethical Review Committee, Kenya Medical Research Institute, P.O. Box 54840, Nairobi, Kenya Tel. 254-20-2722541.**

IF THERE IS ANY PORTION OF THIS CONSENT AGREEMENT THAT YOU DO NOT UNDERSTAND, PLEASE TALK TO SOMEONE ON THE STUDY TEAM BEFORE SIGNING.

Subject Name _____

Subject's or Parent/Guardian's Signature: _____ Date: _____

Physical Address/Home Description: _____

Family Name/Homestead Name: _____

Witness's Name: _____

Witness's Signature: _____

Date: _____

Study Number: _____

Thumbprint of of Volunteer or Volunteer's
Parent/Guardian if Unable to Sign

Person Administering Consent:

Name: _____ Signature _____

Interviewer's Name:

Stick Barcode Label here

Appendix 3B

Assent Form for Individuals above 5 through 17 Years of Age

NOTE: This form should be signed by children above 5 years of age through 17 years of age who should give their assent when a parent or guardian has given permission to enroll.

What is the study called: Circulation Reassortment and Transmission of Bunyamwera and Ngari viruses in northern Kenya

Who is running the study: The study is being run by Mr Collins Otieno Odhiambo and Dr Rosemary Sang, and a team of doctors and scientists from Kenya Medical Research Institute (KEMRI), Ministry of Public Health and Sanitation (MPH&S), International Centre of Insect Physiology and Ecology (ICIPE), International Livestock Research Institute (ILRI) and Ministry of Livestock/Department of Veterinary Services (MOL/DVS).

Introduction: We are interested in finding out what germs cause fever and/or malaria like illness. We want to draw a small amount of blood and test it in the lab to see if we can find the germ that is causing your illness. We are asking you to be in this research study because you may have signs and symptoms that may have come due to this germ.

Purpose: The purpose of this study is to find out what germs cause fever and/or malaria like illness.

Procedures: You will be asked some questions about where you live and your illness. You may participate in this study by giving only blood. About a tablespoon of blood will be taken from a vein in your arm. The blood will be put into small tubes so we that can test for germs that may be causing your illness. These samples are only for this study.

Long Term Storage of Specimens

After the tests have been performed, we will store samples that are left in a confidential manner for future testing. After this study is over, we may do new tests for germs that might have caused your illness. We will not report the results of these tests to your doctor or to you. We will not do human genetic testing or test for evidence of HIV (human immunodeficiency virus) infection of the samples that you provide. If at a later date you change your mind, you may ask to remove these samples from long term storage and destroy them. If you choose to do so, please contact: **Dr. Rosemary Sang, Centre for Virus Research, Kenya Medical Research Institute, PO Box 54628, NAIROBI, Tel. 0722 759492 or Dr. Charles Nzioka, Division of Disease surveillance and response (DDSR), Ministry of Public Health and Sanitation P. O. Box 30016-00100, NAIROBI Tel: 0721234904.**

Risks and Discomforts

Your doctor will take blood from your arm using a needle. Drawing the blood may hurt a little. It may also cause some bruising, bleeding, and slight soreness at the puncture site. There is a small chance you could get germs in the spot where the blood was taken and become infected. If the area around the spot gets red and sore, you would need to go to the clinic.

Benefits: You will not directly benefit from the study. There is a benefit to society in general, through finding the cause of germs that may be causing your illness.

Confidentiality: We will keep the data collection, informed consent/permission and assent forms in a locked filing cabinet. Only study staff will be allowed to look at them. We will keep the forms private as much as legally possible. To protect your privacy, we will keep records and samples under code numbers rather than by name. However, we will maintain a link between code numbers and the forms that we keep in locked files. Your name or other facts that might point to you will not appear when we present this study or publish its results.

Costs/Compensation: Your parent/guardian will be responsible for the routine medical costs from your visit. These are costs that you would have if you were not in the research study. You will have

no charge for collection of blood samples. You will not pay for the research tests that we will do on these samples.

Right to Refuse or Withdraw: You do not have to be in this study. We will give you the usual care for your condition whether or not you are in the study, or if you leave the study later. You may leave the study at any time.

Persons to Contact: By signing this consent form and agreeing to be in this study, you are not giving up any of your rights. If you believe that you have been harmed, please contact: **Dr. Rosemary Sang, Centre for Virus Research, Kenya Medical Research Institute, PO Box 54628, NAIROBI, Tel. 0722 759492 or Dr. Charles Nzioka, Division of Disease surveillance and response (DDSR), Ministry of Public Health and Sanitation P. O. Box 30016-00100, NAIROBI Tel: 0721234904.**

If you have any question on your rights as a volunteer, you or your parent should contact.

The Secretary, National Ethical Review Committee

C/o Kenya Medical Research Institute

P.O. Box 54840, Nairobi, Kenya

Tel. 254-20-2722541

IF THERE IS ANY PORTION OF THIS CONSENT AGREEMENT THAT YOU DO NOT UNDERSTAND, PLEASE ASK STUDY TEAM BEFORE SIGNING.

Subjects Name: _____

Subject's or Guardian's Signature: _____

Permanent Address: _____ Date: _____

Witness's Name: _____

Witness's Signature: _____

Study Number: _____ Date _____

Thumbprint of Volunteer or Volunteer's
Parent/Guardian if Unable to Sign

Person Administering Consent:

Name: _____ Signature: _____

Date: _____

Stick Barcode Label here

Appendix 3C

Parent/Guardian Permission Form for Individuals above 5 through 17 Years of Age

NOTE: This form should be signed by patients 18 years of age or older who are able to give their legal consent. Minor children ages 5 to 17 should sign this form to give their assent when a parent or guardian has given permission to enroll.

What is the study called: Circulation Reassortment and Transmission of Bunyamwera and Ngari viruses in northern Kenya.

Who is running the study: The study is being run by Mr Collins Otieno Odhiambo and Dr Rosemary Sang and a team of doctors and scientists from Kenya Medical Research Institute (KEMRI), Ministry of Public Health and Sanitation (MPH&S), International Centre of Insect Physiology and Ecology (ICIPE), International Livestock Research Institute (ILRI) and Ministry of Livestock/Department of Veterinary Services (MOL/DVS).

Introduction: We are interested in finding out what germs cause fever and/or malaria like illness. We want to draw a small amount of blood and test it in the lab to see if we can find the germ that is causing your illness. We are asking you/your child to be in this research study because you/your child may have illness that may have come due to this germ.

Purpose: The purpose of this study is to find out what germs cause fever and/or malaria like illness.

Procedures: You/your child will be asked some questions about where you live, your illness and any medications you may have taken recently. You/your child may participate in this study by giving only blood. About a tablespoon of blood will be taken from a vein in your arm. The blood will be put into small tubes so we can test for germs that may be causing your illness. These samples are only for this study.

Long Term Storage of Specimens

After the tests have been performed, we will store samples that are left in a confidential manner for future testing. After this study is over, we may do new tests for germs that might have caused your/your child's rash as these tests become available. We will not report the results of these tests to your doctor or to you. We will not do human genetic testing or test for evidence of HIV (human immunodeficiency virus) infection of the samples that you or your child provide. If at a later date you change your mind, you may ask to remove these samples from long term storage and destroy them. If you choose to do so, please contact: **Dr. Rosemary Sang, Centre for Virus Research, Kenya Medical Research Institute, PO Box 54628, NAIROBI, Tel. 0722759492 or Dr. Charles Nzioka, Division of Disease surveillance and response (DDSR), Ministry of Public Health and Sanitation P. O. Box 30016-00100, NAIROBI Tel: 0721234904.**

Risks and Discomforts

Your doctor will take blood from your/your child's arm using a needle. Drawing the blood may hurt a little. It may also cause some bruising, bleeding, and slight soreness at the puncture site. There is a small chance you/your child could get germs in the spot where the blood was taken and become infected. If the area around the spot gets red and sore, you/your child would need to go to the clinic.

Benefits: You/your child will not directly benefit from the study. There is a benefit to society in general, through finding the cause of germs that may be causing your illness.

Confidentiality: we will keep the data collection, informed consent/permission and assent forms in a locked file. Only study staff will be allowed to look at them. We will keep the forms private as much as legally possible. To protect your/your child's privacy, we will keep records and samples under numbers rather than by name. However, we will maintain a link between code numbers and the forms that we keep in locked files. Your/your child's name or other facts that might point to you/your child will not appear when we present this study or publish its results.

Costs/Compensation: You will be responsible for the routine medical costs from your/your child's visit. These are costs that you would have if you/your child were not in the research study. You will have no charge for collection of blood samples. You will not pay for the research tests that we will do on these samples.

Right to Refuse or Withdraw: You/your child does not have to be in this study. We will give you/your child the usual care for your/your child's condition whether or not you/your child are in the study, or if you/your child leave the study later. To leave the study, please contact your doctor. You/your child may leave the study at any time.

Persons to Contact: By signing this consent form and agreeing to be in this study, you are not giving up any of your rights. If you believe that you/your child have been harmed, please contact: **Dr. Rosemary Sang, Centre for Virus Research, Kenya Medical Research Institute, PO Box 54628, NAIROBI, Tel. 0722 759492 or Dr. Charles Nzioka, Division of Disease surveillance and response (DDSR), Ministry of Public Health and Sanitation P. O. Box 30016-00100, NAIROBI Tel: 0721234904.**

If you have any question on your rights as a volunteer, you or your parent should contact.

The Secretary, National Ethical Review Committee

C/o Kenya Medical Research Institute

P.O. Box 54840, Nairobi, Kenya

Tel. 254-20-2722541

IF THERE IS ANY PORTION OF THIS CONSENT AGREEMENT THAT YOU DO NOT UNDERSTAND, PLEASE ASK STUDY TEAM BEFORE SIGNING.

Subjects Name: _____

Subject's or Guardian's Signature: _____

Permanent Address: _____

Date: _____

Witness's Name: _____

Witness's Signature: _____

Study Number: _____ Date: _____

Thumbprint of Volunteer or Volunteer's
Parent/Guardian if Unable to sign

Person Administering Consent:

Name: _____ Signature: _____

Stick Barcode Label here

Appendix 4

QUESTIONNAIRE ON HUMAN EXPOSURE TO CRIMEAN-CONGO HEMORRHAGIC FEVER

Patient details:

Date of collection: _____(dd/month/yr)

Sex: 1. Male 2. Female Age: _____ years

Where is you (your child's) current residence?

Village _____ District _____

Province: _____

How long have you (your child) been living in this district?

_____ years

_____ months

During the past five days, where have you (your child) been mostly (check one)?

☐ Village of residence

☐ In the country, but not in residence, Where? _____

☐ Out of the country, Where? _____

How many times have you (your child) traveled outside of your district in the last two months:

How long ago: <2 weeks 2-4 weeks 1-2 months

Where: _____

How long ago: <2 weeks 2-4 weeks 1-2 months

Where: _____

How long ago: <2 weeks 2-4 weeks 1-2 months

Where: _____

Have you (your child) ever received a yellow fever vaccine?

1. Yes 2. No 3. Unknown

Date of vaccination (if known) _(day/month/year)

If adult: What is your occupation: _____

If child: Where do you go to school: _____

Do you have contact with any of the following species of animals?

1. Bats
2. Geese
3. Ducks
4. Chickens
5. Other- Specify _____

Indicate which birds using the codes above (1-5): _____

6. Goats
7. Cows
8. Donkeys
9. Camels
10. Monkeys

Indicate which animals using the codes above (6-10): _____

Tick Bites: Yes/No _____

Others bites

For each species checked above:

List the species using the given codes _____

2) Describe the contact, e.g., trapping, farming, slaughter, food preparation, veterinary work, casual contact (e.g., a neighbor keeps chickens, there is a slaughterhouse nearby), eating raw fowl products or drinking blood_

3. Were the animals showing signs of illness? ☐ Yes ☐ No

If **Yes** above, Specify the signs.

YOUR CURRENT ILLNESS:

Why did you (your child) come to the hospital: _____

Did you (your child) have any of the following:

Signs/Symptoms	Yes	No	Uncertain
Fever/Chills			
Rash			
Abdominal pain			
Muscle pain			
Vomiting			
Headache			

Do you (your child) have any symptoms we did not mention: If bleeding, where:

1. N/A ☐ 2. Gums ☐ 3. Nose ☐ 4. Injection sites ☐

5. Other, Specify _____

How many days have you (your child) been sick: _____

Date of Onset: _____

How many days of school or work have you (your child) missed: _____

Does anyone you know have a similar illness? Yes ☐ No ☐

Who: _____ When did they become ill _____

Who: _____ When did they become ill _____

Who: _____ When did they become ill _____

What was your temperature in the clinic: _____ °C

DIAGNOSES MADE BY MINISTRY OF HEALTH PROVIDER:

1. _____

2. _____

TREATMENT PRESCRIBED BY MINISTRY OF HEALTH PROVIDER:

1. _____

2. _____

3. _____

4. _____

Appendix 5: Permission to uses figures

From: Richard Elliott <Richard.Elliott@glasgow.ac.uk>
Sent: 13 January 2015 17:16
To: Odhiambo, Collins Otieno
Subject: RE: Permission to use Bunyaviridae genomic illustrations

Dear Collins
You are free to use any published diagrams in a thesis provided you acknowledge their source.
Best regards,
Richard Elliott

Richard M. Elliott, FRSE
Bill Jarrett Professor of Infectious Diseases and
Wellcome Trust Senior Investigator

MRC - University of Glasgow Centre for Virus Research
Henry Wellcome Building
464 Bearsden Road
Glasgow G61 1QH
Scotland (UK)

Tel: +44 (0)141-330 2876
Fax: +44 (0)141-330 4874

The University of Glasgow charity # SC00440

From: Odhiambo, Collins Otieno [codhiambo@icipe.org]
Sent: Tuesday, January 13, 2015 12:55 PM
To: Richard Elliott
Subject: Permission to use Bunyaviridae genomic illustrations

Dear Prof Elliot,

I am a PHD student working on the circulation, reassortment and transmission of Orthobunyaviruses. Thanks for your great work in the arboviral field. You have contributed greatly to our understanding of viruses of the Bunyaviridae family. I am putting up together a thesis on the same and I would like to request your permission to use figures illustrating the structure of the genomic component of these viruses.

Thank you.

Faithfully,
Collins Odhiambo

From: Patrick Masson via RT <viralzone@isb-sib.ch>
Sent: 22 January 2015 16:44
To: Odhiambo, Collins Otieno
Subject: [help #98285] [Viralzone] Request to use illustration

Dear Collins Odhiambo,

I hereby grant you permission to use the Bunyavirus viron picture you requested for your thesis. Please cite the source "ViralZone, SIB Swiss Institute of Bioinformatics".

Best regards and good luck for your thesis, Patrick Masson.

From: Brett Ellis <brettellis@mac.com>
Sent: 13 January 2015 16:37
To: Odhiambo, Collins Otieno
Subject: Re: Permission to use figure in your publication

Hi Collins, you have my permission to use the figure. I may also have a powerpoint with the original figures from the paper if you need. Just let me know. Regards, Brett.

On Jan 13, 2015, at 8:48 AM, Odhiambo, Collins Otieno <codhiambo@icipe.org> wrote:

Dear Ellis,

I am a PHD student working on the circulation, reassortment and transmission of Orthobunyaviruses. I am putting up together a thesis on the same and I would like to request your permission to use figure one on your article titled, The ecological dimensions of vector-borne disease research and control.

Thank you.

Faithfully,

Collins Odhiambo